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The most important resistance mechanism to beta -lactam antibiotics is the plasmid- 
mediated beta -lactamase and the common criterion for the epidemiology of these 
enzymes is the determination of their biochemical characteristics. Surveys of 
plasmid- encoded beta -lactamases of Gram -negative bacteria used to investigate their 
relative clinical importance have been poorly performed and rarely conducted 
outside the developed world. 
A Survey of uropathogenic strains and of Salmonellae and Shigellae, isolated in 
South India in 1984 revealed a higher incidence of ampicillin resistance (Minimum 
Inhibitory Concentration [MIC] >10mg/1) than had ever been reported before 
(Enterobacteriaceae 80.9%, Salmonellae 90 %, Shigellae 66 %). Only the 
enterobacterial strains showed any significant resistance to the first generation 
cephalosporin, cephaloridine (MIC >10mg/1). However, 65.7% of the Salmonella, 
strains were cefuroxime resistant. Cefuroxime resistance in these Salmonella, strains 
was accompanied by the widespread distribution of the novel OXA -El like enzyme 
with more hydrolytic activity against the drug, even though other resistance 
mechanisms may play subsidiary role. A small proportion of all species conferred 
resistance to third generation cephalosporins. In the individual species, there was a 
very high incidence of ampicillin resistance (E.coli 77 %; Klebsiella 69 %) and 
cephaloridine resistance (E.coli 57 %; Klebsiella 96 %). Many of the ampicillin 
resistant strains harboured either auto -transferable or mobilisable plasmids (41.8 %). 
Characterisation of the plasmid DNA from the E.coli transconjugants revealed the 
existence of 37 different plasmids types. The transconjugants from Klebsiella, 
Salmonella and Shigella possessed fewer plasmids types than those from E.coli. 
Most plasmids possessed resistance genes to aminoglycosides and to six or more 
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drugs. Beta -lactamase studies revealed that TEM -1 was the most predominant 
enzyme in all transconjugant strains followed by OXA -1, SHV -1, TEM -2, OXA -2 
and the novel enzyme SAR -2. The SAR -2 enzyme was fully characterised and had a 
higher pI (8.3) than any previously characterised plasmid- mediated beta -lactamase. It 
had a broad -spectrum activity with the molecular weight of 36000. In addition, the 
unusual observations of E.coli strains producing both the PSE -1 and PSE -2 beta - 
lactamases and strains hyperproducing the TEM -1 were made and these strains were 
studied further. 
The development and mechanisms of resistance to beta -lactam/beta -lactamase 
inhibitor combinations (ampicillin and clavulanic acid) have been performed with 
laboratory strains possessing the ampicillin resistance plasmids R1, R1010 and 
extended -broad spectrum beta -lactam resistance plasmids. The results show that 
challenge with clavulanic acid alone did not affect the expression or integrity of the 
beta -lactamase whereas challenge with the combination of ampicillin and clavulanic 
acid caused radical changes - i the expression of the beta -lactamase. In some cases 
there were multiple copies of genes which resulted in hyperproduction of TEM -1 
enzyme and this was sufficient to resist the combinations. Similarly, elevated SHV -1 
enzyme production resulted in a resistance mechanism with no concurrent 
reassortment of the plasmid R1010. Unfortunately, these variants also conferred 
resistance to second and third generation cephalosporins. The enzymes 
TEM -3, TEM -5 and TEM -7 were not hyperproduced but the corresponding strains 
were stable against the combination at higher inoculum density. Importantly, the 
SHV -1 beta -lactamase had become active against cefotaxime as it was able to 
hydrolyse the drug. Evidence of this type of resistance (hyperproduced TEM -1 and 
SHV -1 enzymes) to clavulanic acid is now emerging in clinical practice . 
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1.1 Development of Beta- lactam Family 
The beta -lactam antibiotics are widely used clinically because they have a broad 
spectrum, are well tolerated and have a high degree of safety. A 
combination which is found in few other therapeutic agents. The antibacterial 
activity of all the beta -lactams is attributed to the active beta -lactam ring. Beta - 
lactams act by binding and inhibiting the action of specific proteins (Penicillin 
Binding Proteins or PBPs) located in the cytoplasmic membrane and are 
necessary in the last stage of peptidoglycan synthesis. Beta- lactam antibiotics 
penetrate the outer membrane of the bacterial cell, enter the periplasm and finally 
reach the cytoplasmic membrane where the bacterial cell's PBPs are located 
(Tomasz, 1983). 
It is remarkable that research into beta -lactam antibiotics has continued so long after 
the first discovery of penicillin 60 years ago. This demonstrates how truly 
revolutionary and versatile the drugs were; nevertheless, the development of beta - 
lactam drugs over the years has been hampered by the evolution of beta- lactam 
resistance. 
The history of beta -lactam resistance began in 1929 with the observation of the 
penicillin resistant typhoid bacteria (Fleming,1929). In 1940 the mechanism of 
resistance was found by extraction of a penicillinase 
t (Abraham and Chain, 1940) from Escherichia coli; however, 
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Staphylococcus aureus was found to be penicillin sensitive at that time. 
Subsequently, the discovery of penicillinase production in penicillin- sensitive strain 
of Micrococcus lysodeikticus and other species of bacteria led to the conclusion that 
the penicillinase may have a metabolic function in some bacterial cells (Richmond 
and Sykes, 1973; Saz and Lowery, 1979; Medeiros, 1984). 
1.1.1 Semisynthetic Penicillins 
In 1944, penicillinase producing clinical strains of Staphylococciiwere first isolated 
(Kirby, 1944). From then until 1960, the increasing use of penicillin led to the 
rapidly increasing spread of penicillin- resistant Staphylococcus This soon reached 
I ¿.s kí tom( 
epidemic proportions and rendered the original penicillin ) (Richmond, 1965). 
The problem of the penicillinase producing Staphylococci was solved initially by the 
development of methicillin (1960) (Stewart, 1960). Penicillin G was prepared by 
conventional fermentation and the molecule was chemically modified to produce 6- 
amino- penicillinic acid. Addition of a 2,6 dimethyl phenyl group to the penicillin 
nucleus instead of the benzyl methyl group 
gave methicillin (Hoover, 1983). Methicillin was insusceptible to penicillinase attack 
but was a less effective antibiotic than penicillin G, therefore, a compromise has had 
to be made, beta -lactamase stability in favour of antibacterial efficace. Methicillin 
was the first of the semisynthetic penicillins and it spawned a series which included 
oxacillin (Kirby, Rosenfeld and Brodie, 1962), cloxacillin and finally flucloxacillin 
(Sutherland, Croydon and Rolinson, 1970) (isoxazolyl penicillins). Unfortunately, 
neither penicillin G nor any of the semi- synthetic penicillins had any effect on large 
Gram -negative rods. This problem was initially tackled by the discovery of 
ampicillin, another semisynthetic derivative, which produced significant activity 
against Gram -negative species (Rolinson and Stevens, 1961). 
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1.1.2 Introduction of First Generation Cephalosporins and Antipseudomonas 
Agents 
An important advance in the design of beta -lactam antibiotics was made in the early 
1950s. Cephalosporin C, the first of the cephalosporins as they are known today, was 
first discovered by Professor Guiseppe Brotzu from a strain of Cephalosporium 
acremonium isolated from the sea near a sewage outfall (Abraham, 1983). The first 
crude material extracted from this strain by Brotzu, was found to be active against 
both Gram- positive and Gram- negative bacteria. Later in 1953 it was purified and 
studied in detail. In 1959 it was shown to be penicillinase- stable with low toxicity 
(Abraham, 1983). Cephalosporins have an inherently greater resistance to beta - 
lactamases than the penicillins because the functional group at the C -7 position of the 
beta -lactam prevents the molecule entering the active site of many common beta - 
lactamases (O'Callaghan, 1975), in owever, the limitation was that earlier 
cephalosporins were more active against Gram -positive than the Gram- negative 
organisms. Much the same is true for the case of the first group of cephalosporins 
(cephalothin, cephapirin and cephacetrile) even though they are regarded as 
effective broad -spectrum antibiotics. In addition, they were found to be unstable in 
the body; esterases convert their ester groups to the corresponding desacetyl 
compound (O'Callaghan and Muggleton, 1963) which was formed in variable 
amounts and had low antibacterial activity. The failure of first group 
cephalosporins (cephalothin, cephapirin and cephacetrile) (O'Callaghan, 1975) 
opened the door for other semisynthetic cephalosporins cephaloridine in 1964 with a 
pyridinium as a replacement for the ester group (Muggleton, 
O'Callaghan and Stevens, 1964) and cefazolin (Nishida et al., 1969) followed by oral 
cephalosporins,cephalexin (Guttman, 1970) and cephradine (Neiss, 1973). At 
the same time new penicillins, such as amoxycillin (Sutherland, Croydon and 
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Rolinson, 1972), carbenicillin (Knudsen, Rolinson and Sutherland, 1967) and 
ticarcillin (1965) (Bergan, 1978; Neu, 1983) were brought into the chemotherapeutic 
field, the latter two drugs specifically designed for Pseudomonas spp, 
The introduction of broad -spectrum penicillins and cephalosporins during 1960s 
A 
rapidly led to the increased prevalence of ampicillin resistance among Gram - 
negative bacteria, especially E.coli, Salmonella spp, Klebsiella spp, Haemophilus spp 
and methicillin- resistant Staphylococck(review: Medeiros, 1984). This has been 
particularly well documented in the type 29 Salmonella typhimurium (Anderson, 
1968) ;" hm(k the complete development of resistance was followed from the 
introduction of the drugs to the emergence of multiple resistance. A major defect of 
all the first generation cephalosporins was their sensitivity to hydrolysis by the beta - 
lactamases of many Gram- negative bacteria. Organisms such as Enterobacter spp., 
many Klebsiella spp. and indole- positive Proteus owe much of their resistance to 
cephalosporins to the plasmid- mediated or chromosomal beta -lactamases. Resistance 
to beta -lactam antibiotics rapidly became widespread and this initially resulted from 
the transfer of the gene from one species to another. The resistance determinants 
were located on extra -chromosomal genetic elements, known as plasmids (Anderson 
and Datta, 1965; Datta and Kontomichalou, 1965; Anderson, 1968); ktowever, beta - 
lactam resistance became more ubiquitous and the main genes were found on many 
plasmid types. It was demonstrated that the resistance genes were being spread from 
one plasmid to another by transposons (Hedges and Jacob, 1974). 
1.1.3 Second and Third Generation Cephalosporins 
In order to overcome beta -lactam resistant beta -lactamases, resistant second 
generation cephalosporins such as cephamandole (Wick and Preston, 1972) cefoxitin 
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(Onishi et al., 1974) and cefuroxime (O'Callaghan et al., 1976; O'Callaghan, 1979) 
were developed. These were found to be metabolically- stable and also beta - 
lactamase stable drugs with wide antibacterial activity against many Gram- negative 
bacteria. Their activity is associated with the presence of a 7 -acyl group with a small 
amount of steric hindrance in cephamandole (Wick and Preston, 1972; Williams and 
Andrews, 1974). In cefoxitin the methoxy substituent is directly attached to the beta - 
lactam ring at position 7 (Onishi et al., 1974) and a carbamoyloxymethyl ester 
attached at position 3 in the case of cefuroxime (O'Callaghan, 1975). E ven 
these drugs did not solve the problem as the gradual selection of mutants that 
overproduce chromosomally- mediated beta -lactamase occurred. In addition, some 
of the drugs promote the induction of chromosomal beta -lactamases in clinical 
isolates (Livermore, 1987a). During the 1970s the frequent occurrence of beta -lactam 
resistances by these two mechanisms urged the introduction of a new generation of 
highly beta -lactamase resistant antibiotics, namely third- generation cephalosporins. 
The discovery of cefotaxime in 1976 (Heymes, Lutz and Schrinner, 1977) and 
ceftazidime in 1978 (O'Callaghan et al., 1980) led to their clinical use in 1978 in 
Europe and in 1982 in the USA. The third- generation cephalosporins and the 
monobactam aztreonam (Sykes et al., 1982) have considerably expanded the 
therapeutic armamentarium available for treating Gram -negative infections and even 
allowed the treatment of infections by Ps. aeruginosa. 
Before the discovery of the third- generation cephalosporins, pharmaceutical 
companies considered an alternative strategy to overcome the problem of plasmid- 
mediated beta -lactam resistance. This approach was to add a beta -lactamase 
inhibitor, clavulanic acid, to penicillin thus broadening its spectrum of activity 
against beta -lactam resistant bacteria (Fisher, Chamas and Knowles, 1978; Farmer 
and Reading, 1988). This inhibitor, first discovered in 1974, was followed by 
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another, sulbactam, in 1977 (English et al., 1978). 
both combination therapy and the third- generation cephalosporins were 
developed in order to overcome the increasing diversity of beta -lactam resistance 
problems in clinical bacteria. 
1.2 Mode of Action of Antibiotics 
1.2.1 General Antibiotic Action 
The antibiotics can, in general, be divided into three main classes according to their 
sites of attack on the cellular metabolism of bacteria (Reiner, 1982a). These are; J) 
antibiotics interfering with nucleic acid or protein synthesis (e.g. aminoglycosides, 
chloramphenicol, fusidic acid, gentamicin, quinolones, rifamycins, sulphonamide, 
t' tlacc Line 
trimethoprim ); 2) antibiotics interfering with the cell -wall bio- synthesis (e.g. 
penicillins, cephalosporins, bacitracin, fosfomycin, mecillinam, thienamycin, 
vancomycin ); 3 antibiotics affecting the function of the cytoplasmic membrane 
(e.g. amphotericin B, candicidin, gramicidins, hachimycin, natamycin, nystatin, 
polymixins, tyrocidins ). 
The antibiotics can also be sub -divided into four categories depending upon their 
bactericidal or bacteriostatic properties (Reiner, 1982b). These categories are: group 
1 bactericidal, but able to exert an effect on resting micro- organisms (e.g. amikacin, 
gentamicin, kanamycin, polymixins, streptomycin ); group 2 bactericidal, but 
only able to act on proliferating micro- organisms (e.g. penicillins, cephalosporins, 
thienamycins, bacitracin, vancomycin, rifamycins ); group 3. bacteriostatic but in 
high concentrations may also be bactericidal (e.g. chloramphenicol, erythromycin, 
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fusicid acid, novobiocin, tetracyclines) and group 4, exclusively bacteriostatic, 
even in high drug concentrations (e.g. capreomycin, d- cycloserine, viomycin etc.). 
1.2.2 Mode of Action of Beta - lactam Antibiotics 
The beta - lactam family interfere with the biosynthesis of the bacterial cell -wall by 
acting as analogues of the acyl -D- alanyl -D- alanine moiety of the lipid - linked 
disaccharide - peptapeptide substrate of the enzymes (PBPs) that catalyse the synthesis 
of cross - linked peptidoglycan; therefore, beta - lactam agents irreversibly acylate 
the PBPs resulting in an inactive penicilloyl-enzyme. This acylation is analogous to 
acyl- enzyme formed during the processing of their normal peptide substrate (Spratt, 
1989). The irreversibility of their binding ensures that beta-lactams are 
bactericidal and active against only proliferating bacterial cell. Some new beta - 
lactam agents (i.e. Mt -181), unlike the previous ones, are able to lyse non - growing 
cells of E. coli because they bind the poorly characterised low molecular- weight 
PBP 7 (Tsuruoka et al., 1985; Tuomanen and Schwartz, 1987). 
1.3 Resistance Mechanisms 
Depending upon the mode and route of action of antibiotics, different types of 
resistance mechanisms have been evolved. Both Gram -positive and Gram -negative 
bacteria fundamentally differ in their response to beta - lactam agents. This has been 
discussed in an overview by Greenwood (1986). These resistance mechanisms which 
regulate the antibacterial activity have been detailed in recent reviews (Gootz, 
1985; Piddock and Wise, 1985; Nayler, 1987). The main resistance mechanisms to 
beta - lactam antibiotics are: (1) the inability of the drug to penetrate through the 
outer membrane (Nikaido, 1989); (2) the affinity of the target PBPs for beta - lactams 
(Spratt, 1989); 
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(S) the production of enzymes which can hydrolyse the beta -lactams, the so- called 
beta -lactamases (Medeiros, 1989; Sanders, 1989) and (4-) the affinity of the drug for 
the beta -lactamases. respite the number of different types of resistant 
lechannr 
mechanisms, beta -lactamases constitute the most widely distributed in bacteria, and 
are the major single cause of beta -lactam resistance. 
1.3.1 Outer Membrane Permeability 
All bacterial cells have "permeability" barriers; however, there is a very 
considerable variation between permeabilities of different strains within a species. 
The permeability barriers are phospholipids, lipopolysaccharides and various 
proteins. Different outer membrane proteins (OMPs) or "porins" have different 
permeability characteristics (Nikaido and Vaara, 1985). Porins are acidic in nature 
(Nikaido and Rosenberg, 1983) and are considered to provide a major route of entry 
for hydrophilic molecules of anionic or zwitterionic type, including all the important 
beta -lactams (Nayler, 1987). They are peptidoglycan- associated and have molecular 
weights within the same range (30,000- 40,000) ( Nikaido, 1989); however, porin 
channels differ in their diameter and in the number of open channels. This 
considerably affects the rate of penetration of the solutes (Nikaido and Rosenberg, 
1983) through the outer membrane. Transport of low -molecular weight 
compounds into the periplasm of Gram -negative bacteria is dependent on both the 
size and the hydrophobicity of the molecule (Acar and Minozzi, 1986)j therefore, 
many factors influence the ability of a beta -lactam antibiotic to enter a Gram - 
negative organism and it is often expressed as a permeability coefficient (Acar and 
Minozzi, 1986). 
Haemophilus influenzae is very sensitive to beta -lactam antibiotics since there is 
8 
apparently no major barrier to antibiotic penetration. Indeed, this species is at least 
one order of magnitude more permeable than E.coli (Zimmermann and Rosselet, 
1977; Coulton, Mason and Dorrance, 1983); however, in their turn, E.coli strains are 
about 14 times more permeable than Enterobacter cloaceae (Vu and Nikaido, 1985). 
Most strains of Pseudomonas aeruginosa are intrinsically highly resistant because of 
the relative impermeability of their membrane to beta -lactams (Angus, et al., 1982) 
and the permeability coefficients for several beta -lactams revealed that the P. 
aeruginosa is far less permeable than E. cloacae (Nicas and Hancock, 1983). 
Reduced permeability is a widely accepted potential source of beta -lactam resistance. 
In the case of E.coli, three porin types, OMP C, OMP F and OMP E (Harder, 
Nikaido and Matsuhashi, 1981) have been identified. Of these, the first two types are 
the most important for uptake of beta -lactams. Mutational reduction in the 
expression of OMP F elevates the minimum inhibitory concentrations (MICs) of 
many beta -lactam drugs. This phenomenon is even more striking when the 
expression of both OMP C and OMP F are reduced (Harder, Nikaido and 
Matsuhashi, 1981; Komatsu, Murakami and Nishikawa, 1981; Jaffe, Chabbert and 
Semonin, 1982); and, a good example of this was an E.coli mutant resistant to 
cephalosporins (Yamaguchi et al., 1985). Another example is the OMP C and OMP 
i;n,cl. 
F deficient mutants of E. coli ( Nikaido, Rosenberg and Foulds, 1983) the 
penetration constant (C) value, characteristic to the particular organism and 
antibiotic, was decreased and led to the cephalosporin resistance. Similar results have 
been reported for other enterobacteria such as Proteus, Enterobacter, Klebsiella, 
Serratia and Salmonella spps (Sawai et al., 1982; Gutmann et al., 1985). 
crt 
Nayler (1987) reviewed that Salmonella typhimurium mutants, deficien of only two 
A 
porins of the several types normally present led to 10 -fold decrease in permeability 
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cephaloridinej however, to put this in perspective, the resistance from the 
OMPs modifications is usually very moderate in comparison with the derepressed 
cephalosporinases produced by Enterobacter cloacae (Vu and Nikaido., 1985; 
Werner et al., 1985). 
In Pseudomonas aeruginosa, it has been assumed that a single porin (protein F) 
provides a channel of two different types. These channels exist in very unequal 
proportions and there is a possibility that mere conformational change may be all that 
is required to produce significant changes in permeability to produce multi- resistant 
mutants (Woodruff et al., 1986). A diminished expression of a 52,000 dalton OMP of 
Pseudomonas aeruginosa has led to resistance to imipenem both in vivo and in vitro 
(Quinn et al., 1986; Buscher et al., 1987). There may also be other significant 
mechanisms of beta - lactam entry in some species besides the porins (Nayler, 1987; 
Livermore, 1988). 'this has been confirmed when both an E. coli and a mutant 
deficient in porins in the phospholipid bilayer were shown to be more permeable to 
penicillins than to cephalosporins (Yamaguchi, Hiruma and Sawai, 1982; Yamaguchi 
et al., 1985). Another example was the role of lipopolysaccharide layer in 
contribution to the development of resistance in P. aeruginosa (Godfrey, Hatlelid 
and Bryan, 1984). In this study, the subtle changes within the LPS were correlated 
with increased MICs of beta -lactams. The authors noted that while the interaction of 
all the outer membrane components contributed to an overall level of permeability, 
this was a major role for the LPS layer in the development of the resistance. 
The presence of an exopolysaccharide layer outside the outer membrane, 
comprised slime and capsular material (Livermore, 1988), can contribute towards 
antibiotic resistance. The slime may protect bacteria by binding antibiotic molecules; 
however, there is no significant evidence to suggest this is a resistance 
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mechanism for beta -lactams, even in the species, such as "mucoid" P.aeruginosa 
isolated from cystic fibrosis patients (Slack and Nichols, 1982; Lambert, 1983) 
In some cases it is hard to say whether high -level resistance to beta -lactam 
antibiotics can be ascribed entirely to permeability, because both very low levels of 
periplasmic beta -lactamases and extremely low rates of enzymatic hydrolysis are 
difficult to detect. It is quite evident that minimum inhibitory concentrations of 
antibiotics change in accordance with the physiocochemical characteristics of the 
bacterium. These changes may be related to alterations in diffusibility, the part 
played by beta -lactamases, the level of these enzymes in the periplasm and finally 
permeability of bacterial cell -wall (Nayler, 1987). 
1.3.2 Penicillin Binding Proteins 
The only target molecules for beta -lactam antibiotics in all bacteria are the 
penicillin binding proteins (PBPs). These proteins are bound by beta -lactam 
antibiotics by covalent bonding after the drugs have penetrated the outer membrane. 
The bacterial cytoplasmic membrane contains at least one, or more often more than 
one type of PBP (Tomasz, 1986); however, recent work with E.coli has shown that 
some PBPs are actually associated with the outer membrane although the inner 
membrane adhesion sites are considered as the major location (Barbas et al., 1986). 
Detailed studies on the biochemistry, physiology (Frere and Joris, 1985), genetics 
and structural analysis of PBPs (Waxman and Strominger, 1983) have shown that 
they are a diverse group of proteins with various peptidase functions. They have been 
most closely studied in Gram- negative bacteria (Spratt and Cromie, 1988; Spratt, 
1989). It is thought that there is distant evolutionary relationship between PBPs and 
beta -lactamases (Pollock, 1967) and this is strongly supported by recent findings, 
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such as close similarities in the amino -acid sequence of several low and high 
molecular weight PBPs and active -site serine beta -lactamases (Waxman, Amanuma 
and Strominger, 1982; Samraoui et al., 1986) by the similarities in tertiary structures 
of PBPs and beta -lactamases (Kelly et al., 1986; Samraoui et aí.,1986). 
PBPs do not all have the same function nor do they react in the same way to beta - 
lactams. In E.coli for example, there are seven PBPs, each corresponding to a 
distinct penicillin -sensitive enzyme. The main PBPs which are involved in the final 
stages of peptidoglycan biosynthesis are the high molecular weight molecules (i.e. 
PBP 1, PBP 2 and PBP 3) which were considered as the essential or physiologically 
important PBPs. On the other hand, the low molecular weight PBPs 4, 5, 6 have been 
suggested to be non -essential for cell survival and were not considered as killing 
targets for beta -lactam antibiotics (Spratt, 1983; Waxman and Strominger, 1983). 
Depending on their affinity for a particular type of PBP, beta -lactams may affect the 
host organism in one of the three ways (Spratt and Pardee, 1975; Waxman and 
Strominger, 1983): (t) rapid lysis of the bacterium (inhibition of PBP 1); (2.) change 
of the organism into a spherical shape and eventual cell lysis (inhibition of PBP 2); 
(3) inhibition of septum formation and thus cell division leading to filamentous 
growth and eventual cell death (inhibition of PBP 3). 
Beta -lactam resistance has recently emerged which has been attributed to mutational 
alterations in the PBPs. These may arise in three different ways (Malouin and Bryan, 
1986): (Í.) reduction in affinity of the normal PBPs for beta -lactams; (z.) loss in the 
level of one or more types of PBPs; (3) synthesis of additional new types with 
lower affinity for beta -lactams. Resistance in Gram- positive bacteria can also result 
from these changes. In Gram- negative organisms, resistance is mainly by reduction 
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in their affinity. Even minor changes in affinity may be of considerable importance 
with the newer, poorly hydrolysed beta -lactams such as the third generation 
cephalosporins (Spratt, 1989). 
The examples where resistance resulting from alterations of PBPs have been 
convincingly demonstrated are in three types of bacteria. The first are those 
organisms without beta -lactamases such as Streptococcus pneumoniae (Hakenbeck, 
9n 
Tarpay and Tomasz, 1980; Bryan, 1988). the second group those strains where beta - 
lactamases have recently appeared, such as Neisseria gonorrhoeae, (Dougherty, 
Koller and Tomasz, 1980; Faruki et al., 1986; Dougherty, 1986; Bryan, 1988) 
and Haemophilus influenzae (Serfass et al, 1986; Reid et al., 1987a) where 
resistance derives from an alteration of PBP 2. The third type is Clio t wF-"1"1 
beta -lactamases are of relatively little clinical significance, such as 
Staphylococcus aureus (Bryan, 1988), because beta -lactamase resistant 
antibiotics have been in use for many years. 
Recent studies have shown that some PBPs, notably the low- affinity PBP (PBP 2) 
found in methicillin- resistant Staphylococcus aureus, are also inducible (Chambers, 
Hartman and Tomasz, 1985; Ubukata, Yamashita and Konno, 1985). Indeed, the 
regulation of the PBP that determines methicillin resistance in Staphylococcus 
aureus may be linked to regulation of staphylococcal beta -lactamases (Boyce and 
Medeiros, 1987). 
The development of beta -lactam resistant PBPs in clinical strains involves the 
introduction of multiple amino -acid substitutions that restabilise the enzyme (Spratt 
and Cromie, 1988). For example, the development of cephalexin- resistant forms of 
E.coli in the laboratory (Hedge and Spratt 1985a) nescatc,l - t an an altered form of 
PBP 3 with substantial levels of resistance to beta -lactam antibiotics. 
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h ïh s wcv, au z the introduction of several amino -acid substitutions that remodel the 
active site of the enzyme to exclude beta -lactam agents without impairing its ability 
to process its normal peptide substrates (Hedge and Spratt, 1985b). The other 
examples were the isolates of Neisseria gonorrhoeae where multiple amino -acid 
substitutions had taken place within the transpeptidase domain of the enzymes 
(Faruki et al., 1985; Dougherty, 1986). With particular regard to cephalosporin 
resistance, there is clinical evidence that evolution of third- generation cephalosporin 
resistant Pseudomonas aeruginosa and Serratia marcescens can result from multiple 
substitutions of amino -acids leading to altered penicillin -binding proteins (Bryan, 
1988) 
The recently- acquired ability to study the protein crystallography of beta -lactamases 
and low molecular- weight PBPs, coupled with the likely feasibility of obtaining 
water -soluble forms of high molecular- weight PBPs, suggest that the crystallography 
of the high molecular- weight PBPs should soon be achievable. This capability should 
allow the design of potent new beta -lactam antibiotics and also provide an insight 
into the remodelling events that allow the PBPs of clinical isolates to reduce 
drastically their affinity for beta -lactam antibiotics (Spratt and Cromie, 1988). 
1.3.3 Beta- lactamases 
Beta -lactamases are ubiquitous proteins, present in almost all bacteria thj have 
structural and functional characteristics in common with the penicillin -binding 
proteins responsible for the assembly of the bacterial cell -wall and they probably 
share a common evolutionary origin (Medeiros, 1989). In all likelihood, the primary 
role of beta- lactamases is not to protect bacteria from beta -lactam antibiotics but 
rather to break transitory intermediates of beta -lactam structure bacterial 
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peptidoglycan metabolism. Indeed, beta -lactamases were produced by bacterial 
strains that were isolated before beta -lactam antibiotics were used in chemotherapy 
(Pollock, 1967; Segalove, 1974). 
Beta -lactamases are produced by various organisms, both Gram -positive and Gram - 
negative bacteria as well as Mycobacteria and Nocardia (Kasik, 1979). Many 
different beta -lactamases are known and, when produced in large quantities, they act 
as the principal resistance determinants to beta -lactam agents. The various beta - 
lactamases differ in their specificity for each type of beta -lactam antibiotic (Nayler, 
1987; Medeiros, 1989). There are a number of different enzymes that could be 
a mil 
termed beta -lactamases as they all attack beta -lactam antibiotics. Amidasesacylases 
of Gram -negative bacteria eliminate the acyl side chain of beta -lactam antibiotics. 
Cephalosporins that carry an acyl ester are sensitive to bacterial and mammalian 
esterase ( Bauernfeind, 1986); lxowever, it is the enzymes that hydrolyse the amide 
bond in the beta -lactam ring that are the most important enzymes in the bacterial 
defence system against beta -lactam drugs and these are the proteins that I shall term 
beta -lactamases. Typically they are soluble enzymes which in Gram -negative 
bacteria are confined to the periplasmic space between the inner and outer membrane; 
and in Gram -positive bacteria; they are excreted in the environment (Wiedemann, 
Kliebe and Kresken, 1989). 
Beta -lactamases are responsible for therapeutic failures where previously active 
antibiotics are no longer effective. The resistant bacterium may either acquire a beta - 
lactamase- producing plasmid and its chromosomal beta -lactamase may be induced or 
become derepressed. 
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1.3.3A Identification Methods for Beta- {actamases 
Most beta -lactamases can be easily detected by isoelectric focusing on 
polyacrylamide gels and subsequent identification with the chromogenic 
cephalosporin nitrocephin (Matthew et al., 1975). In addition, the other chromogenic 
cephalosporin, PADAC, can also be used in agar plates to detect these enzymes in 
growing bacteria. This may be achieved in the presence or absence of the inhibitor 
clavulanic acid and is considered a particularly useful tool, permitting easy, 
semiquantitative determination of beta -lactamase activity (Kobayashi et al., 1988). 
An other method is the combination of polyacrylamide -agarose gel electrophoresis 
and pH gradient electrophoresis (titration curve) which can provide a powerful 
approach to the study of the molecular structure of these enzymes. It is useful for 
rapid and easy identification of the major penicillinases in Gram -negative bacteria 
(Vedel, Paul and Picard, 1988). 
1.3.3B Classification of Beta -lactamases 
There is a great variety of beta -lactamases produced by bacteria. The diversity led to 
several classification schemes based on different criteria: substrate profile, 
inhibitor profile, molecular weight, isoelectric points, genetic determination (DNA 
homology) and amino -acid sequencing of enzymes (Richmond and Sykes, 1973; 
Matthew et al., 1975; Sykes and Matthew, 1976; Ambler, 1980; Bush, 1988a). 
None of these classification systems has achieved the ability to 
differentiate all beta -lactamases adequately. 
The grouping of beta -lactamases was described by Sawai in 1968 (Medeiros, 1989) 
.by the substrate profile of both plasmid and chromosomal enzymes in Gram- 
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negative bacteria. He listed three types of beta- lactamases; 1) inducible 
cephalosporinases; 2) cephalosporinases that had the properties of penicillinase, or 
specifically broad -spectrum beta -lactamases identified from Proteus vulgaris ; 3. 
penicillinases. Later, in 1970, this system was expanded by the addition of inhibitor 
profiles and reaction to antisera which provided an additional discriminator (Jack and 
Richmond, 1970). In 1973, Richmond and Sykes proposed one of the most widely 
used classification schemes, where five classes (1 -5) of beta -lactamases from Gram - 
negative bacteria were outlined. Class 1 enzymes were predominantly 
cephalosporinases; class 2 were penicillinases; class 3 enzymes showed broad - 
spectrum activity and were sensitive to inhibition by cloxacillin but resistant to p- 
chloromercuribenzoate (pCMB); class 4 were also broad -spectrum enzymes but 
resistant to inhibition by cloxacillin and sensitive to pCMB and the final class 5 
enzymes were penicillinases able to hydrolyse cloxacillin and resistant to pCMB 
inhibition. 
A major advance in the classification of these enzymes took place when Matthew et 
al (1975) introduced a new system of flat -bed isoelectric focusing in polyacrylamide 
gels for identification of specific beta -lactamases. This identification method was 
further developed by an alternative method i.e. application of a matrix of highly 
purified agarose for isoelectric focusing (Vecoli et al., 1983). 
jolyacrylamide gel is the most widely accepted method and this system can be 
further refined by overlaying the gel with an inhibitor prior to applying the 
nitrocephin overlay (Sanders, Sanders and Moland, 1986). The revolutionary system 
of classification by Sykes and Matthew (1976) enabled very closely related beta - 
lactamases to be distinguished. These enzymes could then be further typed by their 
molecular weights, substrate profiles and susceptibilities to inhibitors. Only Gram - 
negative bacterial beta -lactamases have been included in this scheme, for it does not 
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work well with Gram -positive beta -lactamase. The enzymes fall into two major 
groups, classes A and BI Class A enzymes are chromosomally mediated and be 
divided into the subclasses (a) penicillinases, (b) cephalosporinases and (c) broad - 
spectrum beta -lactamases. The class B enzymes are plasmid- mediated and 
subdivided into the sub -classes (a) isoxazolyl- non -hydrolysing, (b) isoxazyl- 
hydrolysing and (c) other beta -lactamases. 
A new type of taxonomy was proposed by Ambler (1980) based on the amino acid 
sequence of the active site. It has been extended by Jaurin and Grundstrom (1981) 
and Bush (1988a) and now it includes beta -lactamases from both Gram -positive and 
Gram- negative bacteria. The enzymes could be divided into three classes; I.) 
penicillinases with active serine site residue; 2) metallo enzymes, such as the 
enzyme from Bacillus cereus and related bacilli which require bivalent metal cations 
such as Zn2+ and 3) enzymes which also have an active site serine residue, but with 
rx «t 
a distinct amino -acid sequence around the active site. It has been foundkall these 
class C enzymes have substrate profiles favouring cephalosporin hydrolysis, whereas 
those beta -lactamases in class A have substrate profiles indicating either 
penicillinase or broad - spectrum activity. However, Bush (1988a) modified this 
system further. She proposed that there are three classes 1, 2 and 3 : class 1, 
cephalosporinases ; class 2, subdivided into five groups, namely a -e (a = 
cephalosporinases, b = broad -spectrum enzymes, c = carbinicillinases, d = 
cloxacillinases and e = inducible cephalosporinases); class 3, metalloenzymes. 
Many plasmid- mediated beta -lactamases which have been classified on the basis of 
their biochemical properties have now been subjected to further investigation for 
their relatedness by applying the methods of immunological cross -reactivity, DNA - 
hybridisation and nucleotide sequencing. 
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1.3.3B1 Immunological Cross -reactivity 
This technique was carried out with polyclonal antisera within, but not between, the 
classes of plasmid -mediated beta -lactamases. According to these results TEM -1, 
TEM -2 and TLE -1 are closely related. They are partially related to SHV -1 but show 
no cross -reactivity with HMS -1, OXA- or PSE- type beta -lactamases (Sykes and 
Matthew, 1979; Paul et al., 1981; Paul, Philippon and Nevot, 1985). There is also a 
close relationship between beta -lactamases from Proteus mirabilis strains N -3, N -29 
and the PSE -1, PSE -4 and CARB enzymes (Takahashi et al., 1983). Amongst the 
OXA- group, there is a considerable homology between OXA -1 and OXA -4 beta - 
lactamases (Paul, Philippon and Nevot, 1985; Philippon, Paul and Jacoby, 1986Vbut, 
there were less clear relationships between OXA -2 and OXA -3 (Holland and Dale, 
1985; Medeiros, 1989). 
Studies with monoclonal antibodies ilàvr revealed #7._. similar sort of relationship 
between TEM -1 and other enzymes (TEM -2 and TLE -1) and to a lesser extent, SHV- 
1. Different levels of cross reactivity were also observed with OXA -6, OXA -7 and 
AER -1 (Morin et al., 1987). It can be deduced from these results that biochemically 
distinct plasmid- mediated beta -lactamases share common epitopes; and, although 
rrtSnt 
there . not be any immunological relationship within the same class of enzymes, 
the enzymes can still posses structural homology in their amino -acid sequences. This 
can be demonstrated by comparing the relatedness between beta -lactamases of 
B.licheniformis and S.aureus (Pollock, 1964; Ambler, 1980). The extensive 
crossreactivity of these monoclonal antibodies is a limiting factor for using the anti - 
TEM-1 monoclonal antibodies as a tool for the identification of a given plasmid- 
mediated beta -lactamases (Morin et al., 1987). 
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1.3.3B2 DNA -Hybridisation Studies 
A 1000 base pair TEM -1 probe showed cross -hybridisation with both TEM -2 and 
OXA -2 enzymes (Cooksey, Clark and Thornsberry, 1985); however, oligonucleotide 
probes of TEM -1 and TEM -2 hybridised only with their respective beta -lactamases 
(Ouellette et al., 1987). Smaller plasmids of intragenic fragments of the TEM -1 gene 
showed cross -reactivity only with TEM -2 or TLE -1 beta -lactamases (Cooksey, Clark 
and Thornsberry, 1985). 
An intragenic probe of the OXA -1 enzyme had shown a relationship with OXA -4 
(Levesque, Medeiros and Jacoby, 1987) andGlight reactivity with OXA -2 (Ouellette 
and Roy, 1986). Four oligonucleotide probes of the OXA -1 were 
constructed by Boissinot, Mercier and Levesque (1987); three reacted only with their 
respective genes, but one did cross hybridise with the OXA -3 gene. Amongst PSE 
enzymes, a PSE -1 probe showed a relationship with PSE -4 and CARB -3 and PSE -2 
positively reacted with OXA -6 (Huovinen, Huovinen and Jacoby, 1988a, 1988b). 
These results supported the similarities revealed with the immunological assays. 
Recently it has been suggested that there may be "silent" TEM -genes that are not 
phenotypically expressed from a probing experiment conducted by Jouvenot et al 
(1987). When isoelectric focusing was compared with colony hybridisation for 122 
strains, the use of DNA probes for the detection of beta -lactamases produced by 
clinical isolates, resulted in only six strains giving false positive reactions. 
It was assumed that colony hybridisation may be useful as a screening method for 
detection of plasmid- mediated beta -lactamases (Huovinen, Huovinen and Jacoby, 
1988b). 
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1.3.3B3 Nucleotide and Amino Acid Sequencing 
Hybridisation studies can be performed with sequences as short as 12 nucleotides 
coding for four amino -acids (Ouellette, Bissonnette and Roy, 1987). So far, only five 
plasmid- mediated beta -lactamases genes have been sequenced i.e TEM -1 (Sutcliffe, 
1978), TEM -2 (Chen and Clowes, 1987), OXA -1 (Ouellette, Bissonnette and Roy, 
1987) OXA -2 (Dale et al., 1985) and PSE -2 (Huovinen, Huovinen and Jacoby, 
1988a). The two OXA enzymes share greater homology but have no significant 
homology in their amino -acid sequences with TEM enzymes. They do not show 
homology with class A or class C enzymes, except at the region adjacent to the 
active site; this is also true for same with the class B beta -lactamases. It was 
proposed by Ouellette, Bissonnette and Roy (1987) that OXA -1 and OXA -2 be 
designated as class D beta -lactamases. 
Nucleotide sequencing studies revealed that both S. aureus and B.licheniformis 
(Chan, 1986; Wang and Novick, 1987) have very low nucleotide homology despite 
ammo aLL.d 
their high degree of homology in the i - .- sequences. "The crystal 
hcue 
structures of S. aureus PC 1 
. 
similarities with tertiary structures of two other class 
A beta -lactamases (Kelly et al., 1986; Samraoui et al., 1986; Herzberg and Moult, 
1987); therefore, there might not necessarily be any structural correlations between 
nucleotide and amino -acid sequences. 
The PSE -2 shows a high degree of homology with the OXA -2 beta -lactamase but no 
homology with TEM -1 except near the active site serine. It is interesting that OXA- 
1, OXA -2 and PSE -2 share common sequences; they do nevertheless, differ in their 
substrate profile (Huovinen, Huovinen and Jacoby, 1988a). These 
nucleotide sequencing results supported the hypothesis first proposed in the late 
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1960s by Naomi Datta (Medeiros, 1989) that the TEM -1 beta -lactamase evolved 
from the beta -lactamase of K. pneumoniae, as there is great homology between 
TEM -1 and chromosomally encoded beta -lactamase of K. pneumoniae LEN 
(Arakawa et al., 1986). There is also significant homology between these enzymes 
and the SHV -1 enzyme which is encoded both by the chromosome and plasmids of 
K. pneumoniae. The outcome of these results suggest that these enzymes (SHV -1, 
TEM -1 and LEN) all have a common genetic origin. 
Thus the application of these studies (immunological, DNA -hybridisation, nucleotide 
and amino -acid sequencing) in taxonomy of the beta -lactamases will completely 
reorganise the existing and popular classification systems, which has been based on 
the biochemical properties of the enzymes (Matthew et al., 1975). Over 50 plasmid- 
encoded beta- lactamases have been identified and classified by their biochemical 
properties. Classification of these enzymes on the basis of genetics and 
molecular biology will probably reclassify some beta -lactamases into groups of 
biochemically unrelated enzymes. The new system proposed by Bush (1988a) which 
incorporates both biochemical and molecular aspects may be universally adopted and 
should prove more accurate for beta -lactamase classification, especially amongst the 
chromosomal enzymes. 
1.3.3C Chromosomal Beta -lactamases 
These beta -lactamases are present in nearly all Gram -negative bacteria (fables la, 
lb) even though the amount of enzyme endogenously present may be small (Sykes 
and Matthew, 1976). They can be either constitutive or inducible or stably 
derepressed. Induction can only occur in certain species such as Pseudomonas 



































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Chromosomal Beta -lactamases in Bacteria not mentioned in Table 2a 
Bacteria spp. Type of chromosomal Beta -lactamases* Inhibition 
by 
Cep'asea Pen'aseb Mec Indd Conste Clavf 
Morganella + - - + - - 
Shigella + - - - + - 
Salmonella + - - - + - 
Legionella pneumophilia + + - - + + 
Branhamella catarrhalis + - - - + + 
Acromobacter + - - - + - 
Flavobacterium odoratum - - + - + - 
Fusobacterium nucleotum - + - - + + 
Campvlobacter 1eiuni NK NK NK - + NK 
Providencia + - - + - - 
Aeromonas hvdrophila 
a = Cephalosprinase; b = Penicillinase; c = Metalloenzyme 
d = Inducible; e = Constitutive; f = Clavulanic acid 
NK = not known 
* = Reference, Wiedemann, Kleibe and Kresken (1989) 
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P _w Providencia, Yersinia spps., on exposure to certain beta -lactams. (Acar and 
Minozzi, 1986; Livermore, 1987b; Nayler, 1987; Bush, 1988a). These enzymes are 
classified as class 1 by the scheme of Richmond and Sykes (1973) and comprise the 
most important cephalosporinases. They can be produced constitutively and 
copiously as a result of a stable mutation in a beta -lactamase regulatory gene leading 
to derepression (Lindberg and Normark, 1986). This kind of mutation is quite 
common among beta -lactamase inducible species at a high frequency (Gwynn and 
Rolinson, 1983; Wiedemann, 1986). 
The method by which resistant mutants emerge is different in those strains where the 
genes for beta -lactamase production are inducible as in Enterobacter cloacae, 
Citrobacter freundii, Proteus vulgaris, Serratia marcescens and Pseudomonas spp. 
The genetics behind the resistance problems have been found in E. cloacae. Cloning 
experiments revealed that at least three genes are involved in the mechanism of 
induction: the a_p C gene, which codes for the beta -lactamase; the amp R gene, 
which activates the p C gene in the presence of an inducer; and the any D gene, 
which is a negative regulator for amp C gene expression (Peter, Korfmann and 
Wiedemann, 1988). In E.coli, Shigella spp., Proteus mirabilis the cephalosporinase 1 
is produced constitutively in tiny basal amounts (Livermore, 1987a). The resistant 
mutants of E.coli strains had been selected and the background of the mutation to 
beta -lactamase was overproduction of the chromosomal gene which was caused by 
promoter mutations, attenuator mutations or gene amplification (Normark et al., 
1977; Normark and Burman, 1977; Bergstrom and Normark, 1979). On the other 
hand, Klebsiella and Salmonella spps. produce constitutive enzymes of broad - 
spectrum and non -class 1 cephalosporinase beta -lactamases respectively (Livermore, 
1987; Wiedemann, Kliebe and Kresken, 1989). 
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Different beta -lactam antibiotics act as different types of inducers 
(strong/weak/labile /nonlabile). This creates the possibility of the emergence of 
resistant strains during clinical therapy and, indeed, may be the commonest and most 
important cause of emerging resistance to newer beta -lactams (Livermore, 1987a; 
Bush, 1988a). There have been recent reports of Pseudomonas aeruginosa 
(Livermore and Yang, 1987) and of Enterobacteriaceae, such as Citrobacter spp. 
(Gootz, Jackson and Sherris, 1984), Enterobacter cloacae (Sanders and Sanders, 
1983) and Serratia spp. (Sanders and Sanders, 1988) in which cephalosporins, 
monobactams and extended spectrum penicillins are resisted by inducible beta - 
lactamases. These mutants have been implicated in the emergence of multiple drug 
resistance during therapy (Collatz et al., 1984; Sanders and Sanders, 1985, 1986, 
1988; Milatovic and Braveny, 1987). Induction can also be influenced by different 
factors under laboratory circumstances, such as culture media, duration of induction, 
concentration of inducer and stability of inducer to the induced enzyme. Induction 
data can also be interpreted in different ways depending upon the concentration 
chosen for the induction studies (Gootz and Sanders, 1983; Cullmann, Dalhoff and 
Dick, 1984; Dalhoff and Cullmann, 1984). 
In contrast to the inevitable transient nature of beta -lactamase induction, selection of 
stable, derepressed mutants wif resistance to a variety of newer beta - 
lactam antibiotics can occur in both clinical strains of Enterobacter cloacae and 
Pseudomonas aeruginosa (Quinn et al., 1986; Quinn, DiVincenzo and Foster, 1987) 
and laboratory strains (Gootz, Sanders and Goering, 1982; Livermore, 1987a). 
Recently, it has been found that clinical_ Enterobacter cloacae mutants can 
produce two different but closely related beta -lactamases with different pIs. They 
have been called type -A and type -B1 and the biochemical distinction of these two 
enzymes was carried out by Then et al (1988). On the other hand, molecular studies 
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such as heterogeneity in the amp R and .amp C gene interaction, genetic control of 
beta - lactam production, impact of the amp D gene and its product on beta - lactamase 
production in Enterobacter cloacae (Goering et al, 1988; Korfmann and Wiedemann, 
1988; Peter Korfmann and Wiedemann, 1988) have recently been studied. 
In Gram -positive bacteria, chromosomal beta - lactamase production has been found in 
staphylococci, streptococci and enterococci (Wiedemann, Kliebe and Kresken, 1989). 
In the Bacillus genus (such as Bacillus cereus and Bacillus licheniformis) (Abraham 
and Waley, 1979; Collins, 1979) and in the genus Clostridium (Clostridium butyricum, 
Clostridium clostridiiforme and Clostridium ramosum) (Nord and Olsson -Liljequist, 
1984) only inducible penicillinases have been detected so far. Fortunately, no 
beta - lactamases have been found in clinically important Clostridium difficile and 
Clostridium perfringens (Nord and Olsson -Liljequist, 1984). However, Mycobacterium 
spp. have been found to produce a chromosomal enzyme which has affinity for both 
penicillin and cephalosporins (Kasik, 1979). 
1.3.3D Plasmid- Mediated Beta- Lactamases 
Bacterial plasmids are extrachromosomal molecules of circular double- stranded DNA. 
Those that mediate antibiotic resistance were first discovered in Japan in 1957 
(review: Tayler, 1989). Most resistance determinants of clinical relevance are 
encoded by plasmids which replicate independently from the chromosome. Most clinical 
plasmids can transfer to other bacterial cells and even to other species by their own 
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transfer system (conjugation). Smaller plasmids (<16 Mdal or 24 kb) cannot transfer 
but they can usually be mobilised by a transferable factor or plasmid of larger size 
(Wiedemann, 1981). R- plasmids allow rapid mobility of resistance genes enabling an 
efficient spread through bacterial populations. Twelve plasmid- determined beta - 
lactamases are known to be encoded by transposons (Table 2). These are genetic 
elements that can transfer from one plasmid to another and between plasmids and the 
bacterial chromosome (Medeiros, 1989). The existence of beta - lactamase genes on 
plasmids and transposons will ensure that a beta - lactamase originally confined to one 
group of bacteria will sooner or later appear in most other groups of bacteria. 
Until now more than 50 different plasmid- mediated beta - lactamases (Table 3) have been 
identified among Gram - negative bacteria. TEM -1 is the most predominant enzyme and is 
found in nearly all Enterobacteriaceae (Simpson, Harper and O'Callaghan, 1980; Roy 
et al, 1983, 1985; Simpson et al, 1986; Huovinen, Huovinen and Jacoby, 1988b), 
Pseudomonas aeruginosa (Jouvenot, Bonin and Michel -Briand, 1983; Huovinen, Huovinen 
and Jacoby, 1988a), Yersinia enterocolitica (Matthew, 1979), Vibrio cholerae 
(Matthew, 1979), Acinetobacter spp. (Joly- Guillo et al, 1988), H. influenzae 
(Matthew, 1979; Machka et al, 1988), N. gonorrhoeae (Roberts, Elwell and Falkow, 
1977), and in N. meningitidis (Dillon, Pauze and Yeung, 1983). The TEM -2 beta - 
lactamase is the next commonest enzyme although it has not been found in the two 
latter species (Wiedemann, Kliebe and Kresken, 1989). 
The wide variety of OXA- and PSE- enzymes are also quite common. In the group of 


















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Enterobacteriaceae (Matthew, 1979). OXA -2 has been isolated from E.coli, P. 
mirabilis, Serratia, Salmonella and even Bordetella bronchiseptica. OXA- 
4, OXA -5, OXA -6 and OXA -7 are relatively rare enzymes (Medeiros, Cohenford 
and Jacoby, 1985). OXA -3 has been found mainly in Klebsiella spp. (Simpson, 
Harper and O'Callaghan, 1980; Roy et al., 1983). The OXA enzymes, as their name 
suggests, have the specialised capability of hydrolysing the penicillinase resistant 
isoxazolyl penicillins such as oxacillin in addition to penicillins (Dale and Smith, 
1974). PSE enzymes, which were originally found in Pseudomonas and 
thought to be confined to that genus have recently been found in enterobacterial 
strains (Hedges and Matthew, 1979; Medeiros, Hedges and Jacoby, 1982; Levy et 
al., 1985; Simpson et al., 1986; Reid et al., 1988a). These enzymes have a high 
affinity for carbenicillin. The PSE -2 beta -lactamase resembles the OXA enzymes in 
having a high relative activity against oxacillin (Medeiros, 1989). The most common 
PSE enzyme, PSE -4, has recently been identified in K. pneumonia and E. cloaceae 
(Reid et al., 1988a). 
The enzyme SHV -1 is less common than the TEM -1 beta -lactamase though it has the 
same broad spectrum. However, the plasmid -borne beta -lactamase SHV -1 was 
recently found to be capable of modification to produce SHV -2 (Kliebe et al., 1985). 
The modification of SHV -1 to SHV -2 was of crucial importance because SHV -2 was 
identified in clinical strains of K. pneumoniae and Serratia marcescens in 1983 
(Knothe et al., 1983). The SHV -1 enzyme had been known for more than 10 years 
basically as an enzyme predominantly associated with a penicillinase activity and 
limited cephalosporinase activity. SHV -2 is mainly a cephalosporinase capable of 
hydrolysing third generation cephalosporins and monobactams. It is the first enzyme 
to be discovered with such an extended spectrum to the newer and active 
cephalosporins. Since then, other extended spectrum beta -lactamases, derivatives of 
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both TEM ( Bauernfeind and Horl, 1987; Brun- Buisson et al., 1987; Paul et al., 1987; 
Sirot et al., 1987; Spencer et al., 1987; Gutmann et al., 1988; Petit et al., 1988) and 
SHV (Bure et al., 1988; Jarlier et al., 1988; Gutmann et al., 1989) enzymes have 
evolved in clinical. isolateó d -. _ E.coli, E. cloacae, Citrobacter, Serratia, 
and Klebsiella spps. Each enzyme has the capability to hydrolyse one or more third 
generation cephalosporins and confer resistance to these drugs. In addition, a series 
of other, individual plasmid- mediated beta -lactamases (table 3) have been identified 
and classified under broad -spectrum type enzymes (fable 3). 
1.4 Bacterial Resistance to Beta- lactams 
The extent of antibiotic resistance mediated by a particular beta -lactamase in a 
population of bacteria is dependent on various factors. Firstly, the efficiency of the 
beta -lactamase in hydrolysing an antibiotic depends on its rates of hydrolysis 
(Vmax), conventionally expressed as a ratio relative to the rate of hydrolysis 
benzylpenicillin, ampicillin or cephaloridine. Secondly, the level of resistance Irr1 ,t 
be related to the enzyme's affinity for the antibiotic (Km), a value often difficult to 
obtain with substrates which are hydrolysed weakly (Livermore et al., 1986). A third 
rn,9ht 
factor / be the amount of beta -lactamase produced which c./.. x, affect the levels of 
susceptibility (Livermore et al., 1986; Medeiros, 1989). For example, the TEM -1 
h ch cart, 
beta -lactamase activity of clinical isolates of E. coli vary 100 -fold (Simpson et 
al., 1986; Medeiros, 1989). The elevated production of beta -lactamase has been 
associated with the enhanced resistance to cephamandole and to some third 
generation cephalosporins in an isolate of E.coli (Jacoby and Sutton, 1985). 
Enhanced levels of TEM -1 cannot be correlated to increased resistance to 
ampicillin (Reid -PhD thesis). 
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Within the bacterial cell there are two ways in which the beta -lactamases C .n 
contribute to antibiotic resistance. Firstly, in Gram- negative bacteria, there is a 
model exemplified by TEM -1 producing H. influenzae, the beta -lactamase remains 
trapped in the periplasmic space and there is no barrier to antibiotic penetration 
(Medeiros and O'Brien, 1975). In this case, the effect of inoculum size determines 
the minimum inhibitory concentration and, indeed, it was found possible to treat, the 
infection caused by H. influenzae with ampicillin when the inoculum of infecting 
bacteria was low (Moxon, Medeiros and O'Brien, 1977; Murphy and Todd, 1979). 
high level of resistance cam occur when promoter mutations occur 
which results in greater expression of beta -lactamase activity (Chen and Clowes, 
1987). 
A second model is the localisation of beta -lactamase (e.g. TEM -1 producing E.coli 
strain) between the barrier to antibiotic penetration (outer membrane) and the 
antibiotic targets (penicillin binding proteins on the cytoplasmic membrane). In this 
position the enzyme can sequentially destroy antibiotic molecules as they make their 
way through the barrier. Consequently, single bacterial cells can acquire high levels 
of resistance, unlike the previous example (Medeiros, Kent and O'Brien, 1974; Sykes 
and Matthew, 1976). 
Other types of resistance could include "trapping" of beta -lactams by beta -lactamases 
in non -covalent complexes. This suggests the removal of active antibiotic from the 
periplasm (Then and Angehrn, 1982; Sanders and Sanders, 1986). The trapping is a 
process which leads, at least temporarily, to the mutual inactivation of one molecule 
of antibiotic and one molecule of enzyme (Nayler, 1987). The operation of this 
process has been postulated under circumstances in which beta -lactamase has high 
affinity (low Ki) for a drug but little tendency to form a covalent acyl enzyme. 
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the potential for trapping of this type has been disputed on the grounds that 
some theoretically trappable substrates retain activity against enzyme - 
hyperproducing strains (Livermore, 1985). Tapping without any 
hydrolysis, could only lead to a high level of resistance if the quantity of beta - 
lactamase was very great, the organism was poorly permeable and the beta -lactam 
was poorly diffusible. In addition, it is also suggested that a beta -lactamase which is 
capable only of reversibly binding beta -lactams might promote the drug 
accumulation rather than resistance (Livermore, 1987a). Thus non -covalent trapping 
remains conceivable but has not been demonstrated convincingly (Nayler, 1987). 
In Gram- positive bacteria, plasmid- mediated beta -lactamases are predominant in 
Staphylococcus aureus. In S. aureus, about 70% show resistance to beta -lactam 
antibiotics (Wiedemann, Kliebe and Kresken, 1989), .. produce exoenzymes which 
are immunologically distinguishable (A -D) (Richmond, 1965) and are of importance 
both in community and hospital- acquired infections. The beta -lactam resistance 
genes can be located on different transposons and therefore can be integrated into the 
bacterial chromosome (Lyon and Skurray, 1987). Almost all resistant 
coagulase- negative staphylococcal strains are found to produce plasmid- mediated 
beta -lactamases ( Rosdahl, Jarlov and Knudsen, 1986). Most of them have a 
molecular weight of 28,000 and have more affinity for penicillins than 
cephalosporins. The enzymes can be inducible in some strains (Dyke, 1979). 
Constitutive synthesis occurs only occasionally in nosocomial isolates (Rosdahl, 
1973). 
Streptococctcuberies and S. faecalis also produce beta- lactamases; and S. faecalis 
produces plasmid -mediated beta -lactamase (Matthew and Harris, 1976; Murray and 
Mederiski -Samaroj, 1983; Medeiros, 1984). Recently, hybridisation analysis has 
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shown that this gene was closely related to those of S. aureus (Murray et al., 1986); 
11 evertheless, this enzyme is relatively rare and has been found in only a few strains 
(Patterson, Masecar and Zervos, 1988). 
1.5 Development and Spread of Plasmid- mediated Beta -lactamases 
The earliest emergence of penicillin resistance was in S. aureus (Kirby,1944). The 
percentage of penicillin -resistant S. aureus strains has remained unchanged over the 
years: the average has been about 70% since 1953 (Kirby and Ahern, 1953; 
Wiedemann, Kliebe and Kresken, 1989). Other common bacteria isolated 
from community and hospital -acquired infections, such as H. 
influenzae, E. coli, S. aureus, Enterobacter spps and Ps. aeruginosa have all been 
found to have the capability of possessing beta -lactamase determined resistance. 
Only S. pneumoniae remains incapable of producing a beta -lactamase- determined 
resistance (Wiedemann, Kliebe and Kresken, 1989). 
In E. coli, the development of penicillin resistance mediated by plasmid- mediated 
beta -lactamase occurred shortly after the introduction of aminopenicillins (Anderson 
and Datta, 1965). The percentage of ampicillin resistant E. coli strains stayed almost 
static, at 21.9% without any significant change during the period 1975 -1984 
(Wiedemann, Kliebe and Kresken, 1989). The TEM -1 beta -lactamase was the most 
prevalent beta- lactamasej and this did not change following the emergence of newly 
developed resistance to the recently introduced cephalosporins. Klebsiella strains 
were found to produce SHV -1 as the predominant enzyme, the next commonest 
enzyme was TEM -1. Ampicillin resistance in this species is species - 
specific. This is due to the localisation of the SHV -1 resistance gene on both 
chromosome and plasmid (Nugent and Hedges, 1979). Similarly, resistance to 
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cefoxitin and ampicillin is mainly regarded as species- specific in Enterobacter spp. 
Cefotaxime resistant strains have evolved by overproduction of the 
chromosomal enzyme, but the percentage of resistance has not increased since the 
introduction of cefotaxime in 1980 (Weinstein, 1985; Sanders and Sanders, 1988; 
Wiedemann, Kliebe and Kresken, 1989). 
The increase in the number of resistant strains among each species usually occurred 
shortly after the introduction of the respective drug into therapy. After this, the 
proportion of resistant strains remains static. This is true for all kinds of bacterial 
infections such as epidemic enteric infections, Ffie,t community - acquired and 
nosocomial infections; kowever, N. gonorrhoeae and H. influenzae seem to be the 
exceptions. It is quite obvious that the development of resistance is a continuous 
process as there are rapidly growing number of beta -lactamases causing failures 
during the therapy among clinical isolates (Bush, 1988a). 
1.6 Epidemiology of Worldwide Resistance to Beta -lactam Antibiotics 
The main reason for the development of resistance is the widespread use of 
antibiotics that fosters the selection of the resistant organisms which s Pd o mi. nirrs 
m0.y 
at a local level then spread worldwide. The introduction of the broad - spectrum 
penicillins and cephalosporins in the 1960s in Europe and USA rapidly led to the 
increased prevalence of ampicillin resistance among Gram -negative bacteria, 
especially E.coli, Salmonella, Klebsiella and Haemophilus spps (Medeiros, 1987). 
The resistance mechanisms to beta -lactam drugs were largely determined by 
plasmid- encoded beta -lactamases among Gram -negative bacilli) and, as genes on 
plasmids were freely transferable, they spread the resistance determinant rapidly 
through the bacterial population (Anderson and Datta, 1965; Medeiros, 1989). 
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Indeed, the TEM -1 beta -lactamase, common in enterobacteria, was first discovered 
in strains of H. influenzae in 1974 in the USA (Thornsberry and McDougal, 
1982). Even though it was rare at first in this species, it reached predominance 
in most regions (Thornsberry and McDougal, 1982). By 1976, TEM -1 
`v. 
appeared in/. strains of N. gonorrhoeae in England and, subsequently, in the 
USA (Perim et al., 1977). The incidence of beta -lactam resistance rapidly increased 
(1979 to 1982) by about 10 -fold in the States and similar increases occurred in other 
countries (Medeiros, 1989). 
The introduction of beta -lactamase resistant, third -generation cephalosporins led to 
the occurrence of mutations on plasmid- encoded beta -lactamases. These mutated 
genes were transferable. This is exemplified by the evolution of SHV -2 in 
Klebsiella isolates in Frankfurt, W. Germany. The SHV -2 enzyme conferring 
resistance to cefotaxime and other newer cephalosporins. It had arisen from a 
mutation in SHV -1 which involved two genetic steps in resistance gene and one 
amino -acid change in the active site of the enzyme (Kliebe et al., 1985; Barthelemy, 
1988). 
Further evolution of SHV -2 on the continent of Europe has led to the emergence of 
the more potent novel cephalosporinases, SHV -3, SHV -4 (CAZ -5) and SHV -5. 
These SHV derivatives resulted from the heavy selection pressures of third 
generation cephalosporin usage in Europe (Gutmann et al., 1988; Jarlier et al., 1988; 
Petit et al., 1988). These enzymes were identified in the isolates of K. pneumoniae 
and E. coli, some of which had cause outbreaksiosocomial infections mainly from 
r 
urinary tract infections. All these SHV- derivatives have possessed very close 
structural similarity despite the heterogeneity of their hydrolytic activities ( Vedel, et 
al., 1989). The SHV -3 differs from SHV -1 in two amino -acid residues and it is 
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assumed that SI4D-3 was a result % the substitution of ser-213 for gly,as in SHW-1 
and the replaoenntrennt of arg-1 by leu which caused decreased ;d F from 7.6 to 7.0.. 
bllaSHV-3 gene y ter»_ (92%) wifa, the chromosomal 11 d in i 
gene encoding for LEN-1 beta- actamase of -.., :3e (Nicolas et a11,, 1989). On 
the other hand SHV 44 (C 5) IilIfj1 .41 ti from S. Hw-1 by five arnnino-acid 
substitutions. The amass* mil (gm actüavíity Of SHV-4 (CAZ-5) towards ceftazidrinae 
was manifested by the substitution of a lysine ficr g3tutamâc arid at position 214 of 
the mature protein ' et a1, 19 Inem is a dispute whether both 
CAZ-4 and SHV-5 are the somme and so biochemical comparisons and genetic studies 
of the two enzymes will be necessary to resolve this (Sirot et al., 1989). 
Analogous similarities were observed between ,t t., CAZ-44 and SHV -5 and it has been 
assumed that they Rf! t be the same enzyme (Sirot et al., 19 
enzymes, only SHV -2 has e,arn uuat 
át, ). Of these new SHV- 
in more than one location i.e. in Chile and 
Greece (Metleiros, 19 ). This 7,"- reflect àt- ;; fi, u e mu , ú on from SHV-1 to SHV-2 
is quite minor compared wi t the genetic ch ges , SHV-1 to the ther SHV 4 p 
enzymes. 
titu 
ground 1987, there had been an outbreak of nosocomial cefotaxime 
resistant isolates of K. pnewnoniae and o nt, er enterobacterial strains. All strains 
produced a pI 6.3 beta- lactarnase (CTX -1), and were mainly derived from urinary 
tract isolates in several French hospitals (Brun -Buisson et al., 1987; Sìrot et al., 
1987). In the same year (1987), the other plasmìd- determined beta- lactamase CAZ -1 
was identified in K. pneumoniae strains from patients in a French hospital. This 
enzyme had more affinity for ceftazidi ne than other later generation cephalosporins 
(Sirot, Labia and Thabaut, 1987). These new enzymes CTX -1 and CAZ -1, are now 
designated as TEM -3 and TEM -5 because of their ability to hybridise with a TEM- 
gene probe. It has been shown that both these enzymes were TEM -2 derivatives 
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(Sirot et al., 1988). TEM -3 and TEM -5 enzymes arose by 
fairly minor point mutation in TEM -1 type penicillin genes (Sougakoff et al., 1988). 
Only three amino acid substitutions in TEM -1 resulted in TEM -3. For TEM -5, there 
were again three amino acid substitutions from TEM -1, jnvolvement of a second 
residue, lysine, substituted for Glu at position 237 (Philippon, Labia and Jacoby, 
1989), seems necessary to justify the unusually high rates of hydrolysis of 
ceftazidime and aztreonam by this enzyme (Sougakoff et al., 1988). Structure- 
activity relations suggest that the oxime substituent of these cephalosporins is a 
major structural factor in the catalytic process observed with the new beta -lactamases 
TEM -3 (CTX -1), TEM -5 (CAZ -1) including SHV -2 (Labia et al., 1988a). In 
addition, other TEM -type mutants such as TEM -4 (Paul et al., 1987), TEM -6 
( Bauernfeind and Horl, 1987), TEM -7 (Gutmann et al., 1988), TEM -9 ((RHH -1) 
(Spencer et al., 1987) and TEM -10 (Quinn et al., 1989) have also been identified. 
'The ceftazidimases CAZ -2 (Chanal et al., 1988) and CAZ -3 (Labia et 
al., 1988b) were also confirmed as derivatives of TEM beta -lactamase (Sirot et al., 
1989) which were isolated from the clinical strains of K. pneumoniae, in 1987 in 
fax.ii of- 
France. The TEM -7 enzyme was produced in a clinical Çitrobacter freundii M2 
isolated from the urine of a hospitalised patient in Paris (Gutmann et al., 1988). The 
beta -lactamases TEM -4, TEM -6, TEM -9 and TEM -10 were isolated from E.coli 
(TEM -4 and TEM -6) and K.pneumoniae (TEM -9 and TEM -10) in Germany, France, 
England (UK) and USA respectively. Three novel expanded -spectrum 
beta- lactamases, TEM -El, TEM -E2 (Payne, Marriott and Amyes, 1989, 1990) and 
TEM -E3 (Payne et al., 1989) isolated from E.coli, K. oxytoca and E.cloacae isolates 
from Belgium (TEM -E2) and England (TEM-El and TEM -E3) respectively, have 
been included into third generation cephalosporin (3GC) enzyme groups. 
When considering the epidemiology of beta -lactamases, and especially those that 
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confer resistance to 3GC, the contribution of the inducible chromosomally- 
determined enzyme should be taken into account (Olson et al., 1983; Sanders, 1983). 
It has been demonstrated that clinical isolates have become resistant to beta -lactam 
antibiotics while the patient was receiving appropriate therapy, a phenomenon rarely 
seen prior to the introduction of 3GC drugs (Sugarman and Pesanti, 1980; Sanders 
and Sanders, 1988). There have been recent reports which show similar results with 
the treatment of respiratory tract and soft tissue infections (Dworzack et al., 1987) 
neutropenia and cystic fibrosis (Bragman et al., 1986; Paull and Morgan, 1986; 
Pederson et al., 1986). It is possible to select mutants during clinical therapy 
(Sanders and Sanders, 1988) which overproduce the enzyme and mediate resistance 
to 3GC antibiotics when infections caused by Enterobacter, Citrobacter, indole- 
positive Proteus, Providencia, Serratia, Morganella spps and P. aeruginosa which 
produce inducible cephalosporinases (Sykes and Smith, 1979), are treated (Seeberg, 
Tolxdorff -Neutzling and Wiedemann, 1983; Gootz, Jackson and Sherris, 1984; 
Livermore and Yang, 1987). Reports on several other Gram -negative bacteria such 
as E.coli, Klebsiella, Salmonella, Shigella and, especially, Serratia, Enterobacter and 
Pseudomonas spps. which have caused resistance problems to newer cephalosporins 
have been discussed in a recent review (Sanders and Sanders 1988; Wiedemann, 
tCu. 
Kliebe and Kresken, 1989). Mutations in bacterial chromosome i.e. the mechanisms 
for an overproduction through the inactivation of the amp D gene which usually 
negatively controls the expression of the beta -lactam gene, is the main resistance 
mechanism. This can also result in the constitutive overproduction of the 
chromosomal enzyme (Medeiros, 1987; Sanders and Sanders, 1988; Wiedemann, 
Kliebe and Kresken, 1989). 
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1.7 Surveys of Beta -lactam Resistant Gram -negative Bacteria 
The incidence and type of antibacterial drug resistance has been studied in different 
nd 
regions countries. These epidemiological studies are absolutely essential in order 
to evaluate the spread of drug resistance all over the world. There have been recent 
reviews on these studies and also epidemiology of beta -lactamases (Amyes, 1989; 
Wiedemann, Kliebe and Kresken, 1989; Young, Nandivada and Amyes, 1989). 
Even though there have been several studies on beta -lactam resistance, very few 
controlled surveys have been undertaken, especially in tropical countries. Most of 
these clinical studies concentrated on plasmid- mediated (transferable) resistance in 
Gram- negative bacteria from different sources, mainly responsible for urinary tract 
infections (UTI), urinogenital tract infections, gastroenteric infections etc. in 
different regions r j Africa (Serjge1 and South Africa), Asia (Bangkok, Indonesia 
and India), Europe (England, Scotland, Germany, Italy, Paris and Spain), South 
America (Brazil) and USA (Boston and Providence) (Simpson et al., 1980, 1986; 
Jouvenot, Bonin and Michel- Briand., 1983; Roy et al., 1983, 1985; Grüneberg, 1984; 
Esposito et al., 1986; Stobberingh, Houben and Boven, 1985; Medeiros and Jacoby, 
1986; Nandivada and Amyes, 1987; Shaokat et al., 1987; Huovinen, Huovinen and 
Jacoby, 1988b; Reid et al., 1988b). From these surveys it has been shown that the 
TEM -1 beta -lactamase is the most successful with a high incidence all over the 
world. Among the other common plasmid- mediated beta -lactamases are TEM -2, 
OXA -1, OXA -2, SHV -1 and PSEs. There are also strains with combinations of 
TEM -1 with one of these common enzymes and these have been occurred 
worldwide, though in far fewer organisms than TEM -1 alone. The most common 
resistant clinical strains isolated are E.coli (18.6 %), Klebsiella spp. (20 %), 
Pseudomonas spp. (22.5 %), Proteus spp. (12.5 %), Enterobacter spp. (24.7 %) and a 
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low numbers of Citrobacter spp. (22.2 %), Salmonellae (6.1 %) and Shigellae from faecal 
specimens (Wiedemann, Kliebe and Kresken, 1989). 
Apart from frequently obtained common plasmid- mediated beta - lactamases (TEMs, OXAs, 
PSEs and SHV), there has also been a new series of enzymes identified in the surveys; 
for example TLE -2, SAR -1, the broad- spectrum penicillinases BRO -1 and CARB enzymes. 
The latter carbenicillinases have each been found on only one occasion. These new 
enzymes may be species- specific and give a particular advantage to those particular 
organisms under antibiotic challenge. Another beta - lactamase OHIO -1 is a good 
example of an endemic enzyme confined to a geographic region (Shales et al., 1986). 
It was isolated from various species of Enterobacteriaceae from two hospitals in 
Ohio, one in Columbus and the other in Cleveland. The resistance gene for the OHIO -1 
beta -lactamase, located on different plasmids, was found to have common genetic 
origin in all strains producing this enzyme (Rron et al., 1987). 
It is obvious from available data that the occurrence of the expanded - spectrum beta - 
lactamases, the TEM and SHV derivatives are not widespread yet, except in some 
outbreaks in France and Germany. There have only been isolated cases both in England 
and West India (Bombay). The first cephalosporinase present in an Indian clinical 
isolate has just been found (D.J. Payne personal communication). The genetic 
background still has to be investigated in order to find out the origin of the 
resistance gene. 
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1.8 Combination Therapy 
Binding of beta -lactam to beta -lactamase does not always result in hydrolysis. In 
fact, a number of beta -lactam molecules act as potent inhibitors, or inactivators, for a 
variety of beta -lactamases. Beta -lactamase inhibitors may fall into several distinct 
classes: i) metal ion chelators such as EDTA or 0- phenanthroline (Sabath and 
Abraham, 1966); 2) amino -acid modifiers such as p- chloromercuribenzoate or the 
boronic acids (Jack and Richmond, 1970; Beesley et al., 1983; Carwright and Waley, 
1984); 3) active site directed irreversible inhibitors such as the suicide inactivator/ 
clavulanic acid (Brown et al., 1976; Fisher et al., 1981) ) beta -lactam antibiotics 
that have very low kcat values such as aztreonam, moxalactam and cefoxitin (Bush, 
Freudenberger and Sykes, 1982; Bush et al., 1985; Bush and Sykes, 1986). 
Even though beta -lactamases are major determinants of bacterial resistance, the 
introduction of new beta -lactamase- resistant cephalosporins has only marginally 
influenced the epidemiological situation. After the introduction of the third - 
generation cephalosporins (3GC), there has been a constant proportion (18 -20 %) of 
E. coli strains which overproduce the chromosomally mediated beta -lactamases. 
More importantly, the introduction of the 3GC has resulted in the evolution of new 
plasmid- mediated beta -lactamases capable of destroying these newer beta -lactam 
agents. An alternative strategy to combat resistance problems has been combination 
therapy, the combination of beta -lactam and beta -lactamase inhibitor, which has 
recently been perceived as an alternative strategy to overcome very stable beta - 
lactamases. 
In fact, the therapeutic use of beta -lactam antibiotic combinations that were intended 
to exploit the beta -lactamase- inhibition principle enjoyed a short vogue in the late 
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1960s (Greenwood, 1986). It was not until the appearance of clavulanic 
acid (Reading and Cole, 1977; Neu and Fu, 1978) and sulbactam (English et al., 
1978) that the idea became a viable therapeutic prospect. Penicillin -inhibitor 
combinations have two main advantages in overcoming stable beta -lactamases. 
girstly, they have the attraction of providing the option of oral therapy, if necessary 
with appropriate prodrugs (Greenwood, 1986) and, these combinations are far less 
expensive than other later generation beta -lactams. These combined antibiotics are 
exemplified by (i .) amoxycillin + clavulanic acid (augmentin); (2) ampicillin + 
clavulanic acid (sultacillin); and (3) ticarcillin + clavulanic acid (Timentin) which 
all are in clinical practice at present. Sultacillin was introduced in 1980 (Wise, 
Andrews and Bedford, 1980), augmentin in 1981 (Jackson et al., 1983) and timentin 
in 1985 (Roselle et al., 1985). 
aw 
Clavulanic acid is a potent inhibitor with a beta -lactam structure but has j oxygen in 
the ring instead of sulphur (Nayler, 1987). It is a naturally available penem. It is 
active against many of the plasmid- mediated beta- lactamases of Gram -negative 
bacteria, including the widely distributed TEM- type, SHV -1, OXA -1 and OXA -3 
enzymes produced by clinical isolates (Roy et al., 1989; Rubio et al., 1989). Very 
significantly, these inhibitors (clavulanic acid and sulbactam) also act against the 
novel extended spectrum enzymes of TEM and SHV derivatives (Jarlier et al., 1988; 
Sirot et al., 1988). 
Some chromosomal beta -lactamases of obligate anaerobes such as many Bacteroides 
spp. and of the class 4 beta -lactamases of Klebsiellae are also inhibited by clavulanic 
acid (Roy et al., 1989; Werner et al., 1989) and sulbactam (Lees et al., 1986; Nord, 
1986). -They have little activity against the class 1 beta -lactamases that are 
produced by most Gram -negative aerobes (Livermore et al., 1989). Clavulanic acid 
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can potentiate labile beta -lactams such as amino- and carboxypenicillins against 
these stable beta -lactamases (Reading and Slocombe, 1986; Bush, 1988b). The 
spectrum áctivity of timentin also includes staphylococci and Pseudomonas 
aeruginosa (Fuchs et al., 1984).. It has been noted that clavulanic acid can 
antagonise ticarcillin action against some beta -lactamase inducible isolates. It should 
be emphasised that whilst induction of class 1 beta -lactamases by clavulanate may 
cause a temporary impairment of the activity of the ticarcillin, the phenomenon is not 
a potential source of permanent resistance (Livermore, et al., 1989). 
Several studies to evaluate the clinical efficacy, safety and pharmacokinetics of 
clavulanic acid (Adam et al., 1989; Claes, Vandeursen and Baert, 1989; Cox, 
Meewis and Horton, 1989; Franz et al ., 1989; Fricke et al., 1989; Meier, Adam and 
Heilmann, 1989; Nord, Bergan and Thorsteinsson, 1989; Obwegeser et al., 1989; 
Weismeier et al., 1989) and sulbactam (Lees et al., 1986) in the presence of 
penicillins have been conducted both in vivo and in vitro for both prophylactic and 
therapeutic use and have proven to be very effective. These combined drugs can be 
ar 
administered either by oral or parental route (Aronoff et al., 1986) for various kinds 
of infections' 'gynaecological (Giamarellou et al., 1986); abdominal surgical 
(Study group of intraabdominal infections, 1986; Menzies et al., 1989); soft tissue) 
bone and joint (Leffler et al., 1986; Weismeier et al., 1989); cartilage (Meier, Adam 
and Heimann, 1989); urinary tract (Kim et al., 1986; Naber and Wittenberger, 1986; 
Fischbach et al., 1989); intra cerebral (Hanninen and Rossi, 1986; Stahl et al, 1986; 




are also quite useful as prophylactic agents in surgery (Dieterich H -J et al., 
1989; Friese et al., 1989; Hall et al., 1989; Menzies et al., 1989). 
the united action of ampicillin and clavulanic acid combinations have 
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been proven to be compatible with other effective drug combinations such as 
metronidazole + gentamicin (Hall et al., 1989), metronidazole + cefuroxime (Friese 
et al., 1989), metronidazole + netilmicin (Schmitt et al., 1989), clindamycin + 
gentamicin (Fink et al., 1989), cefoxitin (Dieterich H -J et al., 1989), cefotaxime 
(Fischbach et al., 1989), ciprofloxacin (Schmidt et al., 1989) and mezlocillin 
(Menzies et al., 1989). For sulbactam, the combination with the beta -lactam is 
comparable with the efficacy of other drug combinations; gentamicin + 
clindamycin (Study group of intraabdominal infections, 1986); chloramphenicol + 
ampicillin (Rodriguez et al., 1986); metronidazole + cefotaxime (Foster et al., 1986); 
and cefotaxime (Loff ler et al., 1986). 
Recently, another combined drug (YTR -830H or tazobactam + piperacillin) has been 
introduced and is now under study (Marunaka et al., 1988). This beta -lactamase 
inhibitor binds PBP 2 of Gram- negative bacteria and has poor antibacterial activity 
like the previous ones (Moosdeen, Williams and Yamabe 1988). In addition, another 
new inhibitor (6 -AMPA) has been tested in vitro with ampicillin and found to have 
excellent inhibiting properties with isolated enzymes but is less useful with intact 
organism (Chin, McElrath and Neu, 1988). 
Despite the fact that combined drugs are very effective both in vivo and in vitro 
against many beta -lactamase producing bacteria, especially enterobacterial strains 
(English et al., 1978; Retsema, English and Girard, 1980; Labia, Morand and 
Peduzzi, 1986; Brook, 1989; Roy et al., 1989; Rubio et al., 1989; Werner et 
aí.,1989), there have been recent reports that beta -lactam/clavulanic acid resistant 
bacteria which produce the TEM -1 (Martinez et al., 1987, 1988; Sanders et al., 1988; 
Williams et al., 1988) and SHV -1 (Sanders et al., 1988) enzymes have emerged. The 
resistance derives from hyperproduction of the beta- lactamase,and,very recently, the 
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genetic base for this hyperproduction was found in 10 resistant E, coli clinical 
strains isolated in Spain (Martinez et al 1989). It was found, by transformation 
experiments, that very small plasmids, ranging in size from 2.5 to 7.0 kb, were 
providing 10 copies per bacterial chromosome. This gave an increased production of 
the TEM -1 beta -lactamase. It was also observed that a large plasmid (55 kb) was also 
present in one to two copies per chromosome. Thus it appeared that the large plasmid 
had yielded smaller plasmids. They had become multi -copy and thus boosted TEM -1 
production. There was one other exceptional circumstance in which resistance results 
from the production of low levels of PSE -1 enzyme in five E, coli clinical strains 
seemed to be responsible for the rapid hydrolysis of ticarcillin rather than 
inhibition by potassium clavulanate (Sanders et al, 1988). This was proven as the 
susceptibility to potassium clavulanate was reflected by the ability of this 
inhibitor at higher concentrations to reduce the MIC of ticarcillin against the E 
coli to clinically achievable concentrations (Sanders et al, 1988). 
Since these reports, there have not been any published data detailing resistance 
problems of beta-lactam /clavulanate in clinical isolates. The increasing clinical 
use of these drugs has resulted in an increasing demand for in vitro susceptibility 
tests with these agents. In addition, there is a lack of agreement as to whether MIC 
tests with these combinations should be performed in the presence of constant or 
variable concentrations of the beta - lactamase inhibitor (Dance et al., 1989). False 
conclusions can be drawn if beta - lactamase inhibitor concentrations in vitro are 
considerably different from those encountered in vivo as the effect of beta - lactamase 
inhibitor concentrations on the results of MIC tests varies considerably from one 
species to another (Fuchs et al, 1984; Simonet et al, 1989). 
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The Aims of This Thesis 
tiv " 
The main objectes of the first part of this thesis were: 
(A). To study the epidemiology of the beta -lactam resistance in South India, among 
Gram -negative pathogens. 
(B). To investigate the biochemical and genetical mechanisms involved in beta- 
lactam resistance. 
The second part of this project was aimed at: 




MATERIALS and METHODS 
2.1 Bacterial Strains 
The Gram -negative clinical isolates studied in this thesis were collected from India 
during a three month period in 1984, by Dr. Hilary-Kay Young (Young et al., 1986). 
All strains were maintained at -70 °C in nutrient broth containing 10% glycerol v/v 
(Analar). Details of the individual strains are presented in the appendix. 
The standard bacterial strains used in this thesis are in table 4 and standard bacterial 
plasmids are detailed in table 5. The standard beta -lactamase producing strains are 
listed in table 6. 
2.2 Information Storage and Retrieval 
Information concerning each bacterial isolate was recorded on a computer data form 
and stored on the database program dBASE III (Ashton -Tate, Milton Keynes). Care 
was taken to ensure that no repeat specimens were included in the study with the 
help of the database system. 
2.3 Materials 
2.3.1 Antimicrobial Agents 
All antimicrobial agents used during this study were supplied sterile. The antibiotics 
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Table 4 
Standard Bacterial Strains 
Bacterial Strain Markers Reference 
E. coli K12 J62 his -pro trplac- Bachmann (1972) 
E. coli K12 J62 -1 his pro trp lac NaR Bachmann (1972) 
E. coli K12 J62 -2 his pro trplac RfR Bachmann (1972) 
E. coli K12 J53 met pro Bachmann (1972) 
E. coli K12 (X +) Obtained from K.B. Sharma 
E. coli K12 J53 -2 met pro RfR Given by Dr H -K. Young 
E.coli Mc 1022 Sm R Obtained from Dr S.G.B. Amyes 
X - ThiS Ì& A p lcU m.k, r( 
Aee pc'sc S Í 
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Table 5 
Standard Bacterial Plasmids 
Plasmid 
designation Markers Mr (kb) Reference 
R1 Ap Cm Km Sm Su IncF2 90 Meynell & Datta (1966) 
RP4 Ap Km Tc IncPl 52 Datta et al. (1971) 
R6K Ap Sm IncX 38 Kontomichalou et al (1970) 
R1010 Ap Cm Sm Sx Inc N 54 Nugent & Hedges (1979) 
Sa Cm Km Sm Su Sp IncW 33 Watanabe et al. (1968) 













































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































and their suppliers are listed in table 7. The non -chemotherapeutic agent nitrocephin 
(87/312) was provided by Glaxo Group Research Ltd. For assays beta -lactam 
solutions were made up aseptically adding sterile sodium phosphate buffer (pH 7.0, 
25mM). For preparation of the agar plates, beta -lactams were suspended in sterile 
distilled water. Preparations of sulphamethoxazole and nalidixic acid were made by 
dissolving the compound in 0.1N NaOH and the solution was then made up 
aseptically with sterile distilled water. Solutions of rifampicin and chloramphenicol 
were made by first dissolving these drugs in a minimum volume of absolute ethanol 
and then the solution was made up with distilled water. Water soluble rifampicin was 
also used in the latter experiments. Nitrocephin was dissolved with the aid of 
dimethyl sulphoxide (DMSO) (Analar, BDH Chemicals Ltd., Poole) and made up in 
sodium phosphate buffer (pH 7.0, 25mM). All other compounds listed were 
dissolved directly in sterile distilled water. Compounds, with the exception of 
nitrocephin stock solution (500mg/1) which could be stored at -20 °C for up to more 
than one month in the dark, were prepared when required. 
2.3.2 Buffers 
The most commonly used buffer during this study was sodium phosphate (pH 7.0, 
25mNi). This was prepared as described in Data for Biochemical Research (Oxford 
University Press, 1974) (30.5mis of 0.5M Na2HPO4 and 19.5mls of 0.5M 
Na2H2PO4 were mixed and made up to one litre in order to get 25mM sodium 






































Non Chemotherapeutic Agents 
Beecham Research Laboratories, Middlesex 
E.R. Squibb & Sons, Middlesex 
Glaxo Laboratories Ltd., Greenford, Middlesex 
Beecham Research Laboratories, Middlesex 
Dista Products Ltd., Basingstoke 
Eli Lilly and Co. Ltd., Basingstoke 
Roussel Laboratories Ltd., Middlesex 
I.C.I. Ltd., Macclesfield 
Merck, Sharp and Dohme Ltd., Herts 
Ciba-Geigy Laboratories, Horsham 
Glaxo Laboratories, Greenford, Middlesex 
Glaxo Laboratories Ltd., Greenford, Middlesex 
Glaxo Laboratories Ltd., Greenford, Middlesex 
Eli Lilly and Co. Ltd., Basingstoke 
E.R. Squibb & Sons, Middlesex 
Glaxo Laboratories Ltd., Greenford, Middlesex 
Parke- Davis, Pontypool, Gwent 
Glaxo Laboratories Ltd., Greenford, Middlesex 
Beecham Research Laboratories, Middlesex 
Roussel Laboratories Ltd., Middlesex 
Bristol Laboratories Ltd., Middlesex 
Beecham Research Laboratories, Middlesex 
Sterling Winthrop Laboratories, Surrey 
Glaxo Laboratories Ltd., Greenford, Middlesex 
Sigma Chemicals Ltd., London 
Lederle Laboratories Division, Hants 
Le Petite, Milan, Italy 
Upjohn Ltd., Crawley, Sussex 
Glaxo Laboratories Ltd., Greenford, Middlesex 
Wellcome Foundation Ltd., Kent 
Wellcome Foundation Ltd., Kent 
Nitrocephin Glaxo Laboratories Ltd., Greenford, Middlesex 
para -chloromercuric benzoic 
acid Sigma Chemicals Ltd., London 
Sodium chloride 
All antimicrobial concentrations are expressed in terms of the base. 
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2.4 Media 
2.4.1 Complex Media 
The complex media used were as follows: 
Nutrient Broth No. 2 (CM67) (Oxoid, Basingstoke, Hants) 
Isosensitest Broth (CM473) (Oxoid, Basingstoke, Hants) 
Diagnostic Sensitivity Test Agar (CM216) (Oxoid, Basingstoke, Hants). 
Columbia Agar Base (CM331) (Oxoid, Basingstoke, Hants) 
MacConkey Agar (CM76) (Oxoid, Basingstoke, Hants). 
2.4.2 Minimal Media 
Table 8 
Preparation of Double Strength Davis and Mingioli (DM) Basal Medium 
K2HPO4 14.0g 
KH2PO4 6.0 
Tri- sodiumcitrate 0.9g 
MgSO47H2O 0.2g 
(NH4)2SO4 2.0g 
A one litre solution containing the above compounds was made up with distilled 
water in the order given and then 50m1 quantities of base were distributed and 
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autoclaved at 15psi for 15 minutes. 
Media (DM) was diluted to single strength before use by adding supplements and 
molten agar (Bacteriological Agar No 1). The supplement solutions for incorporation 
in the minimal medium are given in table 9. 
2.4.3 Preparation of Plates 
2.4.3A Plates Containing DM Minimal Media 
Plates containing minimal media were prepared by adding supplements (table 9) 
aseptically to 50mis double - strength DM base. Antimicrobial drugs were added 
aseptically where necessary to give the required concentrations. Finally, 1.4mls of a 
20% glucose solution were added and the volume made up to 60mis by the addition 
of sterile distilled water. This was mixed and added to 40mis of molten 
Bacteriological Agar No 1 (1.5g/100 mls) (Oxoid). After rolling gently to mix, the 
plates were poured and once set, dried inverted at 55 °C for 10 -15 minutes. In 
addition, plates (with no antibiotics) were also made up with and without one of 
the supplements (auxotrophic requirements of the standard recipient strain) in order 
to confirm the positive conjugation results. All plates were used within 7 -10 days of 
manufacture. 
2.4.38 Complex Media Plates 
Agar plates with complex media were made up by following the instructions given 
by the manufacturers. These solutions were sterilised at 15psi for 15 minutes and 




Solution Source Strength Final Mode of 
prepared Concentration Sterilisation' 
D- glucose BDH 200 mg /L 2.8 mg /ml Aucoclaving/ 
filtration 
L- histidine BDH 5 mg /L 50 mg /L Steaming 
L- methionine Sigma 5 mg /L 50 mg /L Steaming 
L- proline BDH 5 mg /L 50 mg /L Steaming 
L- tryptophan Sigma 2.5 mg /L 50 mg /L Steaming 
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required concentration of antibiotic solution to the molten Oxoid Diagnostic 
Sensitivity Test Agar (DSTA) maintained at 55 °C. Poured plates were left for setting 
and then dried inverted at 55 °C for about 10 -15 minutes. Similarly, Nutrient and 
MacConkey agar plates were poured with or without antibiotics as required 
according to the manufacturer's instructions. 
2.5 Methods 
2.5.1 Identification of Bacterial Species 
All enterobacterial pathogens isolated from the patients, were classified to the genus 
level by standard biochemical characterisation and catalogued by Dr. Hilary -Kay 
Young. 
2.5.2 Viable Counts 
Bacterial cultures were diluted to a series of concentrations in single strength DM 
base. The appropriate diluted suspensions were vortexed (Rotary Mixer, 
Gallenkamp) and 0.1m1 amounts spread with a sterile glass spreader onto solid 
media. 
All plates were incubated inverted at 37 °C for 18 to 24 hours and for 66 hours in the 
case of DM medium. 
2.5.3 Sen54b4of Ampicillin and Cephaloridine Resistant Strains 
An overnight nutrient broth cultures of each organism was diluted to 10 -4 by serial 
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dilutions in single strength DM base medium with no supplements. This diluted 
suspension (105cfu /m1) was placed on to the surface of DSTA plates containing 
ampicillin or cephaloridine at 10mg/1. 
2.5.4 Susceptibility Tests against Antimicrobial Agents 
The susceptibility of each isolate was also determined against a selection of 
antibacterial drugs (table 7), other than ampicillin and cephaloridine, by inoculating 
similar dilutions (10 -4 ) onto Oxoid DSTA plates containing 10mg/1 of drug, 
except for sulphamethoxazole and spectinomycin where 100mg/1 was used and 
rifampicin where 25mg/1 was used. A series of beta -lactam antibiotics also were 
des Lae4 against the strains at different fixed concentrations (Results, tables 14, 28, 
35). 
Each plate was inoculated with one negative control either E.coli J62 or E.coli J62.2. 
(Rifr) as required. A DSTA plate containing no antibiotic was also inoculated as a 
positive control. Plates were inverted and incubated for 18 hours at 37 °C. Presence 
of growth at the point of inoculation resistance 
2.5.5 Determination of Minimum Inhibitory Concentrations (MICs) on Solid 
Media 
The MICs of ampicillin and cephaloridine (or other beta -lactams where required) for 
each organism was tested by diluting an overnight broth culture 10,000 -fold in single 
strength DM and 2111 (105cfu) of this was inoculated as before onto the surface of 
DSTA plates containing antimicrobial agents. The MICs of ampicillin in the 
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presence of a fixed concentration of clavulanic acid (8 mg /1) was also measured. 
Drugs were incorporated into the plates, two -fold concentrations ranging from 1 to 
1250 mg /1. The MICs were expressed as the lowest concentration of drug permitting no 
visible growth. The negative control strain was included as before to ensure the 
reproducibility of sensitivity testing results. 
2.5.6 MICs in Liquid Media 
The MICs of oxacillin were tested by the broth dilution method in Iso- Sensitest broth 
(ISTB) ( Oxoíd). A series of test tubes containing ISTB with decreasing two-fold 
concentrations (broth dilutions) ranging from 20 to 0.625 mg /1 of the antibiotic were 
inoculated with 2 pl of 10 -4 dilution of an overnight culture (approximately 105 
cfu /ml). These inoculated tubes were vortexed briefly to make sure the culture was 
mixed evenly in the nutrient broth and incubated statically for 18 hours at 37 °C. 
After incubation, the concentration at which ISTB test tube showed no visible growth 
was taken as MIC. 
2.5.7 Mutation Studies 
Overnight cultures (4.5 ml) of standard bacteria in nutrient broth were centrifuged 
(4,500 rpm, 20 minutes) to harvest the cells. They were resuspended in the same 
amount of single strength DM base and washed (4,500 rpm, 20 minutes). The pellet was 
resuspended again in 4.5 ml of single strength DM base. Hundred microlitres 
quantities of appropriate diluted suspensions were spread onto the surface of Oxoid 
DSTA plates containing different concentrations of the required antibiotics on which 
resistant mutants were selected. 
One hundred microlitres of 10 -4 and 10 -6 dilutions of these strains were plated onto 
60 
MacConkey agar plates without any antibiotics as positive controls. All plates were 
incubated at 37 °C for 24 hours or 72 hour The count of colony forming unit on the 
MacConkey agar plates was noted to indicate the original bacterial concentration of 
the nutrient broth. Colonies grown on the DSTA plates containing antibiotics were 
also counted in order to evaluate the mutational frequency. The mutational frequency 
to a particular antibiotic was taken as the ratio of the number of mutants to the 
original concentration of bacteria in the culture. 
2.5.8 Plasmid DNA Transfer 
Conjugation experiments were performed by inoculating both donor and recipient 
paa, c 
cells from fres 
h 
MacConkey agar plates separately into 4.5mls of Nutrient Broth No. 
ovx gnl' 
2 (Oxoid). Cultures were incubated statically at 37 °C. Following incubation, 
0.1m1 of - . the donor was mixed with lml of 
the recipient strain in 4.5ml of fresh pre -warmed nutrient broth (Amyes 
and Gould, 1984). This mixture was then incubated at 37 °C for 18 -24 hours. After 
an overnight incubation this mating mixture was mixed on a Whirlmixer to separate 
the donor and the recipient cells which were then collected by centrifugation at 
4,500rpm for 20 minutes (Heraeus Christ Bactifuge). The pellet was washed with 2 
volu,ues (9.9m11of single strength DM base without supplements and again the 
pellet was collected (4,500rpm for 20 minutes). The pellet was resuspended in 5.6ml 
(or 0.56m1 i.e. 10 -fold increased concentration when required) of DM base without 
supplements (equivalent to the volume of the original mating mixture). This 
(ID NJ) 
resuspended mixture was streaked out on the surface of selective DM agar plates 
which would allow only for the growth of a plasmid- containing recipient strain. 
Controls were made by inoculating the washed donor and recipient cells onto the 
same selective plates. The plates were incubated for 24 -72 hours. Resultant 
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transconjugant colonies were purified by streaking out on identical DM selective 
plates. The purified transconjugants were checked for their auxotrophic requirements 
on DM medium without antibiotics in them. 
2.5.9 Plasmid Mobilisation 
In bacteria where no self -transmissible plasmids could be demonstrated, plasmid 
DNA was mobilised with the transfer factor X+ (Sharma, Sharma and Prakash 1984). 
A 0.1m1 amount of an overnight culture of the donor strain ( E.coli) containing the 
transfer factor X+ was added to lml of recipient in 4.5ml of 
pre - warmed nutrient broth. Conjugation was allowed for 24 hours at 37 °C by 
incubating statically. Following the incubation, lml of this mixture was mixed with 
lml of an 18 hour broth culture of the recipient E.coli strain J62.2 in 4.5ml of pre - 
warmed nutrient broth. After further incubation at 37 °C for 24 -48 hours, 
transconjugants were selected on suitable media containing rifampicin and the 
selective antibiotics. The resultant transconjugants were purified on the same 
selective plates. The purified transconjugants were tested for possession of the gene 
from the original culture by plasmid isolation and testing for the resistance markers 
present in the original clinical strain. 
2.5.10 Transformation of Plasmid DNA 
Plasmids of interest which were found to be neither self -transferable nor 
mobilisable were subjected to transformation experiment (Saunders, Docherty and 
Humphreys, 1984). 
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2.5.10A Preparation of Competent Cells 
A lml of an overnight culture of E.coli MC 1022 grown statically for 18 hours at 
37 °C was added to a 100 ml of pre -warmed nutrient broth in a 250m1 conical flask. 
This culture was incubated at 37 °C with aeration (Gallenkamp orbital shaker at 160 
rpm) until the bacterial density reached 0.15 -0.2 OD at A660 n1 a Bausch and 
Lomb spectrophotometer. The culture was then chilled on ice for 5 -10 minutes. The 
cells were harvested at 12,000g for 5 minutes at 4 °C. The pellet was resuspended 
in 25m1s of 10mM calcium chloride solution and washed by centrifugation (12,000g 
for 5ininutes at 4 °C). The pellet was resuspended in 5m1 of 75mM calcium chloride 
which contained 0.5% w/v glucose and 3- (N- morpholino) propane sulfonic acid 
(MOPS) at pH 6.5. The final product waS a suspension of competent cells 
containing 2.5- 5.0x109. The competent cells were kept stored at -70 °c until they 
were required. 
2.5.10B Transformation of Extracted Plasmid DNA into Competent Cells 
The plasmid DNA to be transformed was extracted by the method of Takahashi and 
Nagano (1984) and analysed by agarose gel electrophoresis to estimate the plasmid 
DNA content (see below). Once sufficient plasmid DNA was obtained, it was 
used for the transformation. A 0.2ml amount of competent cells in a sterile 
Eppendorf (polypropylene) tube was added to the plasmid DNA (0.01 -10µg) and 
the, mixture was made up to 0.5ml with 75mM calcium chloride solution containing 
0.5w /v glucose and 10mM MOPS at p46.5. This mixture was kept on ice for 45 
minutes. The tubes wereetransferred to a 42 °C water bath for 10 minutes. At the end 
of 10 minutes, the tubes were taken out and 0.5m1 of nutrient broth was added to it. 
This was followed by incubation at 37 °C for 2 hours. 
63 
After incubation, the transformation mixture was diluted and a 0.1m1 amount of 
appropriate dilutions were spread onto the surface of nutrient agar plates containing 
antimicrobial agents to select for plasmid transformants. Control plates 
of nutrient agar with no antibiotics were also inoculated by the mixture of 
transformation to quantify the number of viable cells surviving the procedure. 
Concomitantly, MacConkey agar plates were also used as control plates to r .red.- 
' contaminants_ in the transformation mixture. 
2.5.11 Isolation of Plasmid DNA 
A small scale method was followed for the isolation of plasmid DNA throughout the 
thesis. This method was described by Takahashi and Nagano (1984). Cells were 
grown shaking in 4.5mls nutrient broth overnight at 37 °C and harvested by 
centrifugation (4,500k-pm, 20 minutes, Heraeus Christ Bactifuge). The method 
suggested by the authors was then followed exactly. 
All extracted plasmid DNA solutions were either analysed directly by agarose gel 
electrophoresis or were stored at 4 °C after b+- te.i..ltat.hi at 66 °C for 5 minutes. 
2.5.12 Plasmid DNA Preparation for Restriction Endonuclease Digest 
Preparation of plasmid DNA for restriction endonuclease digest was performed as 
described by Takahashi and Nagano (1984) with a minor modification as s 
To the extracted plasmid DNA pellet wag added 350111 of 10mM Tris - 
CT 
acetate, 2mM disodium EDTA, pH8.0 buffer and 50111 of acetate buffer (91mM 
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sodium acetate, 10mM Tris- acetate, 2mM disodium EDTA, pH 8.0), and the;c- 
solutions . mixed. The DNA solution was ethanol precipitated with 2 volumes of 
cold ( -20 °C) absolute ethanol for 20 -30 minutes on ice or at -20 °C and collected by 
centrifugation (2874g, 5 minutes, 4 °C, MSE Microcentaur),._ .lhe pellet was dried 
in a vacuum dessicator (30 -60 minutes). The pellet was dissolved in 50µ1s of sterile 
distilled water and a DNAase -free RNAase solution (Sigma) was added to the DNA 
solution to give a final concentration of 50mg/1 or 1mg/1 of the RNAase. This 
mixture was incubated at 37 °C for 15 minutes. 
Ten microlitres of the plasmid DNA solution was removed to a sterile Eppendorf 
tube. To this were added 2µls of the appropriate restriction enzyme buffer (10x 
strength, supplied by NBL Enzymes Ltd., Northumberland) 7µ1s of sterile distilled 
water followed by 5 -10u of the required restriction endonuclease (Hind 111 or ECO 
R1). The tube was incubated at 37 °C for 1 -3 hours or overnight and the reaction was 
terminated by cooling to 4 °C and adding 71.1,1s of loading buffer (0.1% SDS, 0.05% 
bromophenol blue, 25% sucrose and 5mM sodium acetate (Sigma) or 0.1% 
bromophenol blue plus 50% glycerol in distilled water). The sample was analysed by 
0.7% agarose gel electrophoresis in parallel with Hind III (Murray and Murray, 
1975) or other appropriate enzyme -digested lambda DNA as molecular weight 
markers. 
2.5.13 Agarose Gel Electrophoresis 
Plasmid DNA was electrophoresed by horizontal slab gel electrophoresis by the 
method of Meyers et al. (1976). A 30µ1s volume of plasmid DNA was mixed with 
1Oµls of loading buffer and placed into the wells of a horizontal slab gel (14 by 25 x 
0.5cm) consisting of 0.5% or 0.7% agarose (Sigma) in Tris- acetate buffer (40mM 
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Tris -acetate, 2 mM disodium EDTA, pH 8.0). Similarly, the 27 pl of restriction 
endonuclease digested DNA samples were loaded into a gel of 0.7% or 1% agarose. 
The DNA samples were electrophoresed initially at about 200 V to allow the DNA to 
enter the gel from the wells and then both plasmid DNA and restriction endonuclease- 
digested DNA were electrophoresed overnight at 60 V. The agarose gels were run 
submerged in Tris- acetate buffer (40 mM Tris- acetate, 2 mM disodium EDTA, pH 8.0). 
The gels were stained with a solution of ethidium bromide (0.5 mg /1) either in 
distilled water or in the Tris- acetate buffer for a minimum of 30 minutes. Plasmid 
DNA was visualised over a long -wave ultra -violet light source (330 nm) (Ultra -violet 
Products Inc., Cambridge) after destaining the gel with distilled water. The 
distance travelled by DNA through the gel is inversely proportional to the logarithm 
of its molecular size. The sizes of the sample DNA were measured from the sizes of 
the standard plasmid DNA which were run concurrently with the samples. The stained 
agarose gels could be kept submerged in the ethidium bromide solution for up to 
10 days without any significant diffusion of the plasmids into the gel. 
Photographs of the DNA agarose gel were taken with a Polaroid camera with an orange 
filter. The gels were exposed to the film for 3 minutes (f8 and shutter speed B). 
2.5.14A Beta - lactamase Studies 
2.5.14A1 Spot Test for Beta - lactamase Activity with Nitrocephin 
Nitrocephin spot test was performed on separated single colonies of bacteria with a 
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nitrocephin solution (50 mg /L) (O'Callaghan et al., 1972) for beta - lactamase 
activity. The intact substrate is yellow but becomes red when the beta-lactam bond is 
broken. A colour change of the nitrocephin from yellow to red within 5 minutes was 
taken as positive reaction. Beta - lactamase production in individual colonies was 
also identified by incorporating nitrocephin (50 mg /1) in the agar. Bacterial 
colonies with high production of beta - lactamase were distinguished by discolouration 
of the nitrocephin present in the plates. 
2.5.14B Preparation of Beta - lactamases 
2.5.14B1 Extraction of Crude Beta - lactamases on Large Scale 
The method followed to extract beta - lactamases was described by Simpson, Harper and 
O'Callaghan (1980). One litre volumes of nutrient broth were inoculated and incubated 
overnight with shaking at 37 °C. Cells were harvested at 6,000 rpm for 15 minutes at 
4 °C (Sorvall RC -5B Refrigerated Superspeed Centrifuge, Du Pont Instruments). The 
pellet was washed in 120 ml of 25 mM, sodium phosphate buffer (pH 7.0) and the pellet 
was again collected (6,000 rpm, at 4 °C for 15 minutes). The pellet was resuspended 
in 5 or 10 ml of 25 mM sodium phosphate buffer (pH 7.0). This suspension was 
disrupted in small volumes by 2 cycles of ultrasonication with constant cooling (6 -8 
pm, 30 seconds, MSE Soniprep 150, MSE Instruments, Crawley). Cell debris was removed 
by centrifugation at 16,000 rpm for 40 -60 minutes at 4 °C (Sorvall). The supernatant, 
crude enzyme preparation, was stored at -20 °C until required. 
For standard beta - lactamase preparations either 100 ml or one litre cultures were 
used for the enzyme extraction. Hundred millilitre cultures were harvested and 
washed 
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and finally resuspended in 1 or 2mls of phosphate buffer in order to get the required 
concentration. They were stored at -20 °C in small aliquots for sequential use in order 
to avoid the protein loss. 
2.5.14B2. Extraction of Crude Beta -lactamases on Small Scale 
Beta -lactamases in small amounts were extracted by the method described by 
Livermore, Maskell and Williams (1984). Either 2 or 5m1 nutrient agar slopes were 
inoculated with the appropriate beta -lactamase producing strain and incubated for 18 
hours at 37 °C. Cells from the surface of the slopes were removed by addition of lml 
of sodium phosphate buffer (25mM, pH7.0) and thoroughly resuspended. The cells 
were then sonicated (6 -811m, 15 seconds x 2, Soniprep). The lysate was cleared by 
centrifugation (MSE Microcentaur centrifuge, 11,500g 20 minutes, 4 °C) and the 
supernatant was stored at -20 °C until required. 
Small amounts of beta -lactamases were also prepared from 10mis of nutrient broth 
by harvesting (4,5 m, 20 minutes) the cells and washing them in the phosphate 
buffer. This was followed by collecting the pellet and resuspending it in the same 
buffer ready forrsonication (6 -811m, 15 seconds, Soniprep). The sonicated culture 
was centrifuged (11,500g, 20 minutes, 4 °C) and cleared supernatant was collected 
and stored at -20 °C. 
2.5.14C Induction Studies on Beta -lactamase Production 
Induction studies were carried out on the cefuroxime resistant Salmonellae. 
Nutrient broth was inoculated with a single colony from a fresh MacConkey plate 
and incubated overnight at 37 °C. One hundred mls of pre -warmed nutrient broth was 
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inoculated with 1 ml of this overnight culture and shaken for 2 hours at 37 °C. 
Cefuroxime was then added to the growing culture at one - quarter of the MIC and 
incubation was continued for a further 2 -3 hours. At the end of the incubation 
period, the beta - lactamase was extracted as previously described for large -scale 
preparation of crude enzyme extracts. These enzyme extracts were measured for their 
protein concentration and specific activities. These were compared with the 
uninduced control strain. 
2.5.14D Assessment of Beta - lactamase Activity of Crude Enzyme 
Preparations 
The presence of beta - lactamase activity was indicated by a colour change of 
nitrocephin and the length of time this took (Simpson, Harper and O'Callaghan, 1980). 
This assessment was performed by mixing crude enzyme samples (30 pl) to 100 pl of 
nitrocephin solution (50 mg /1) in a microtitre tray (Cooke Microtitre System, 
sterline). Time taken for reaction was noted for each enzyme preparation. The 
reaction time (in seconds) was converted into amount (in pl) of the respective enzyme 
to be loaded on the gel. Previous experiments in this laboratory have shown this 
procedure delivers the correct quantity of the enzyme onto the gel (Reid, 1986). 
2.5.14E Concentration of Beta - lactamases 
One litre of overnight culture (nutrient broth) was harvested (6,000 rpm, 15 minutes, 
4 °C) and the cells were resuspended in sodium phosphate buffer (25 mM, pH 7.0) and 
washed at 6,000 rpm for 10 minutes at 4 °C. The pellet was resuspended in 5 ml of the 
same buffer and sonicated for 2 cycles (6 -8 pm, 30 seconds) The sonicated extract 
was separated by high -speed centrifugation (18,000 rpm, 60 minutes, 4 °C). 
The volume of the supernatant was measured and its specific activity was estimated 
(specific activity = enzyme activity /protein concentration). Then ammonium sulphate 
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was slowly added to 50% saturation (i.e 29.1g ammonium sulphate for 100m1 of 
enzyme preparation) and left to precipitate by constant stirring for 30 minutes. 
This mixture was centrifuged (6,000 rpm, 30 minutes, 4 °C) to collect the pellet. 
The pellet was resuspended in 0.8 ml of sodium phosphate buffer (25mM, pH 7.0). 
Pr C.iv, ( tC t: .l- n 
The ( of this suspension was measured and its specific activity also estimated. 
This concentrated enzyme preparation was used for further assays. 
2.5.14F Analytical Isoelectric Focusing 
Isoelectric focusing of beta -lactamases was carried out according to the method 
described by Matthew et al. (1975). The crude beta -lactamase extracts were focused 
on thin layer polyacrylamide gels containing carrier ampholines supported by a 
glass plate. Details of the preparation of the IEF gels are given in Matthew et al. 
(1975). The composition of the polyacrylamide gel mixture is shown in table 10. 
2.5.14F1 Application of the Beta -lactamase Samples on the IEF Gels 
The amount of beta -lactamase loaded on the IEF gel was equalised with regard to the 
enzyme activity (see section 2.5.14D). Samples of the beta -lactamase enzymes 
(maximum of 100µ1s) were applied on the surface of the gel near the anode. 
Isoelectric focusing was carried out at 1 watt (maximum voltage 500V) for around 
18 hours (LKB 10 -2000V Power Pack). At the end of each run, the pH of the gel was 
read with a miniature flat -ended combined glass electrode (Pye- Unicam 403, 
30M8E07) at 0.5 or 1.0cm intervals from the cathode to the anode. After pH 




































































































































































































































































































































































































































































2.5.14F2 Visualisation of Beta -lactamases on IEF Gel with Nitrocephin Stain 
With the aid of nitrocephin, the chromogenic cephalosporin, beta -lactamase activity 
was detected on the gels. The IEF gel was over -laid with a sheet of Whatman No. 54 
paper which had been dipped in a solution of nitrocephin (500mg/1). Care was taken 
to avoid allowing any air bubbles to be trapped between the gel and the staining 
paper. The focused bands of beta -lactamase activity appear red on a yellow 
background. 
2.5.14F3 Photography of Analytical IEF Gels 
The gradual revelation of the beta -lactamase bands occurred on the focused gel after 
treatment with the nitrocephin iNowever, by the time the weakest bands were visible, 
the strongest bands had diffused. Tn order to obtain a complete record, a 
series of photographs were taken. The gel was photographed with a polaroid camera 
with transmitted light and a Wratten 58 green filter (f8 and shutter speed 1/8 of 
second). 
2.5.14F4 Beta -lactamase Identification on the Analytical IEF Gels 
A maximum of 12 beta -lactamase enzyme samples could be loaded on each gel 
plate. A primary identification of all test enzyme extracts was performed on 
polyacrylamide gel containing a broad range ampholine (3.5 -10.0) and compared 
with the standard beta -lactamases (TEM -1, TEM -2 and SHV -1 or OXA -2) of 
different isoelectric points (pIs). Subsequently, both the beta -lactamases of interest 
and the ambiguous or indistinct enzymes were checked for identity by running side - 
by -side with the suitable standard enzymes (table 6) of similar pIs. This was usually 
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performed on gels containing an appropriate mixtures of ampholines to provide a 
narrower pH range than had been used previously in order to increase sensitivity. 
2.5.14G Assays of Beta -lactamase Activity 
2.5.14G1. Hydroxylamine Assay System 
The hydroxylamine assay system was as described by Smith (1976). This method 
was followed during this thesis for the substrates like oxacillin and methicillin 
without any modification. 
2.5.14G2 Spectrophotometric Assay of Beta -lactamase Activity 
Beta -lactam compounds generally give characteristic absorption spectra in the ultra- 
violet (UV) region of the spectrum. A detectable shift in the ultraviolet absorption 
spectrum of penicillins and cephalosporins occurs upon hydrolysis of the cyclic bond 
in the beta -lactam ring. The wavelength at which maximum decrease in absorption 
occurs following hydrolysis is termed Amax (lambda maximum). This is determined 
by comparing intact and fully hydrolysed substrate. The rate of substrate hydrolysis 
is assessed by measuring the rate of decrease in optical density (OD) at lambda 
maximum. 
The basic method employed in this thesis, for spectrophotometric assays was that of 
O'Callaghan, Muggleton and Ross (1968). During this project the assays were 
performed on a Perkin -Elmer Lamda 2 uv /vis spectrophotometer which had a 
thermostatically controlled cell carrier with a chart recorder. 
Different molar concentrations of penicillin and cephalosporins were used in the 
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assays. Penicillin substrates were prepared at 10 -2M and cephalosporin substrates 
were made up at 10 -3M in 25mM phosphate buffer (pH 7.0). Test cuvettes 
(containing 0.3m1 substrate and 2.6mls sodium phosphate buffer (25mM, pH 7.0)) 
and blank cuvettes (containing 2.9mls buffer) were prepared and equilibrated at 
37 °C. Beta- lactamase enzyme preparation (0.1m1) was then added to each cuvette 
and monitoring of the decrease in OD at Xmax(lambda) was begun immediately. The 
decrease in the optical density in the initial linear part of the reaction curve was taken 
to obtain a value for change in OD per minute. 
calculation: R = A OD x N x enzyme dilution 
OD1 x time 
where 
R = µmoles of substrate hydrolysed minute-lm1 -1 of 
enzyme 
/1OD = change in optical density 
N = µmoles substrate in cuvette 
(0.3 for cephalosporins, 3.0 for penicillins) 
OD1 = optical density of intact substrate 
Protein concentrations of crude beta -lactamase enzymes were estimated as described 
in a further section and the specific activities of enzymes were expressed per mg 
protein. 
2.5.14G3 Estimation of the Protein Concentration 
Protein estimations of beta -lactamase enzymes and outer membrane proteins were 
carried out by diluting the samples 1 in 1000 in sodium phosphate buffer 
the method described by Waddell (1956). The protein concentrations 
(mg/ml in the original preparation) of the diluted samples were read at two different 
wavelengths (215 and 225nm) and calculated as follows: (OD at 215nm - OD at 
225nm) x correction factor. This method was fully described by Hesslewood (1973). 
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It was found to be a more accurate and sensitive method than that the more 
widespread method of Lowry et al (1951). 
2.5.14G4. Specific Activities of Beta -lactamases 
Specific activities of the required enzymes were measured as follows: 
Specific activity = Enzymic activity against nitrocephin 
protein concentration 
Total enzymic activity = Enzymic activity x total volume of enzyme. 
2.5.14G5 Michaelis Menton Kinetics Determination 
The Km and Vmax values were obtained by measuring the rate of hydrolysis at 
limiting substrate concentrations and plotting the reciprocal of the substrate 
concentration against the reciprocal of the rate by the Lineweaver -Burk method 
(1934). The intercept on the abscissa gives the negative of the reciprocal of the 
Michaelis constant (Km), the Km value being the substrate concentration at which 
half the maximal velocity occurs (Dixon and Webb, 1958). 
The Vmax values were normalised with respect to benzyl penicillin, i.e.: 
Relative Vmax = (Vmax per .tl of enzyme) of substrate x100 
(Vmax per .i1 of enzyme) of benzyl penicillin 
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2.5.14G6 Inhibition Studies on Beta -lactamase Activities 
The effect of beta -lactamase inhibitors on the enzymic activity was examined by 
spectrophotometric assay system as described above (O'Callaghan, Muggleton and 
Ross, 1969). Inhibition profiles of the enzymes were carried out with nitrocephin 
(0.1mM) as substrate. The potential inhibitor was added at the start of the assay to 
both the test and blank cuvettes at various concentrations ranging from 10mM to 
100nM. The effect of the inhibitors was expressed as the concentration required to 
inhibit the 50% activity of the beta -lactamase. The value of the inhibitor 
concentration was termed as ID50. 
The inhibitor constants (Ki) of the enzyme were calculated by repeating the assays in 
limiting substrate concentrations in the presence of required enzyme inhibitor 
(clavulanic acid). Again double reciprocal plots of 1/S against 1/V were plotted. 
Clavulanic acid inhibition of beta -lactamases is competitive and the: reciprocal 
plot intercepts the ordinate at the same point as the Km line. However, the plots in 
ei 
the presence of inhibitor intercept the abscissa nearil the origin than the lines obtained 
without inhibition. If the distance to the origin from the intercept is -1/Kp then: 
Ki = 
Kp/Km 1 
Where "i" is the concentration of the inhibitor (Dixon and Webb, 1958). 
2.5.14H Molecular Weight Determination of Beta -lactamase Enzymes 
The method followed was described by Andrews (1964). The proteins ovalbumin, a- 
chymotrypsinogen and cytochrome C (all Sigma) were all dissolved at 12mg/m1 in 
sterile distilled water and 1ml was applied to the Sephadex G -75 column (section, 
2.5.14H1). The position of the peaks of the protein markers was established by 
i` 1/S represents the reciprocal of the substrate concentration and 1/V 

































































































































































































































































































































































































































































































































































































































































































































































































studied in further detail in order to investigate the resistance mechanisms involved. 
3.2 Beta -lactam Resistance in E.coli Population 
A significant proportion (77 %) of the E.coli were ampicillin resistant and over half 
of them were highly resistant to the drug (table 13). The incidence of cephaloridine 
resistance was also high (57 %) amongst these strains, although none of them had 
high MICs to cephaloridine ( >1280 mg/1) (table 13). In addition, five E.coli isolates 
were able to resist all the beta -lactam antibiotics tested in this survey. 
Even though the combination of ampicillin and clavulanic acid showed a dramatic 
effect on the MICs of ampicillin (table 13), some E.coli strains (36) were moderately 
resistant (MIC 40- 160mg/1). Only one strain possessed increased resistance to 
ampicillin (MIC 60mg/1) when the inhibitor was present (MIC for ampicillin, 
160mg/1). This might result either from reduced permeability of the bacterial cell 
wall or, more likely, antagonism between the beta -lactam and the beta -lactamase 
inhibitor in that particular organism. 
The ampicillin- resistant E.coli were examined further for the transferability of the 
resistance genes. 
3.2.1 Self- transferable and Mobilisable Beta -lactam Resistance in E.coli 
ce 
Each resistant strain was tested for its ability to transfer the resistan determinant. It 
was mixed in nutrient broth with an E.coli J62.2 recipient as described in the 
Materials and Methods. The conjugation results showed that about 53% (56/106) of 
the ampicillin- resistant clinical isolatespossessed auto -transferable resistance 
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plasmids carrying beta -lactam resistance genes. The results showed that 21.7% 
(23/106) of the strains transferred cephaloridine resistance. Ampicillin and 
cephaloridine determinants were independently transferred by 14 isolates, For 
further analysis there was a total of 28 transconjugants (14 ampicillin and 14 
cephaloridine resistant transconjugants) (table 15). 
Thirty -three clinical isolates possessed self -transferable resistance to ampicillin, but 
not to cephaloridine. Similarly, there were nine transconjugants selected on 
cephaloridine which were not resistant to ampicillin (10mg/1). Therefore, 70 
transconjugants were taken for further study. Most of the ampicillin resistant 
transconjugants were moderately resistant to ampicillin (MIC <1280 mg/1), although 
three transconjugants strains exhibited high level resistance (MIC >1280 mg/1). 
The remaining E.coli clinical isolates which did not ¡ to have self -transferable 
resistance genes were retested. Overnight broth cultures of clinical strains and E.coli 
K -12 (X +) were mixed in a ratio of 1 to 10 and incubated for 24 hours for 
conjugation. Following the incubation, lml of this mixture was mixed with 1ml of 
the recipient E.coli J62.2 for further incubation. 
A further 15 E.coli isolates showed positive mobilisation of 
resistance genes in the presence of the transfer factor X +. Eight isolates transferred 
resistances to both ampicillin and cephaloridine and six were found to have 
mobilisable resistance only to ampicillin. A single isolate was able to transfer a 
cephaloridine R- plasmid into the standard recipient strain, without the co- transfer of 
ampicillin resistance (table 15). 
to 
Attempts made either to transfer or h mobilise the resistances to the second 
(cefuroxime) and third generation (ceftazidime and cefotaxime) cephalosporins from 
those E.coli strains which were resistant to them failed. However, these strains 
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Table 15 
Transfer of Ampicillin and Cephaloridine Resistances in E. colt Isolates 
(138) 
Total number of ampicillin resistant strains = 106/138 





















Total transconjugants 23 
a Amp, Ampicillin (10 mg /L) 
b Cer, Cephaloridine (10 mg/L) 
This experiment was performed on two separate occasions and the result shown 
is representative of that found on each occasion. 
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ti(o.41,51-eirla ampicillin resistance. This implied that the 
resistances to the later generation cephalosporins are probably chromosomally- 
mediated. 
3.2.2 Characterisation of R- plasmids in the E.coli Transconjugants 
Each transconjugant from E.coli was examined for its plasmid content and the 
plasmids were characterised by their size and resistance profile. Plasmid DNA was 
extracted from each transconjugant and analysed by 0.5% agarose gel electrophoresis 
along with the standard plasmids as described by Takahashi and Nagano (1984) and 
the plasmid sizes were estimated from the standard curve (Materials and Methods). 
The proportion of beta -lactam- resistant E.coli carrying R- plasmids had been high 
(67 %). These results revealed that a large number of different plasmid types (37) 
were present in the E.coli population as no plasmid was found on more than five 
occasions. From this it can be deduced that very few plasmid types were responsible 
for direct cross -infection in the population. The different plasmids are shown in table 
16. If the same plasmid was found in the recipient after separate selection with 
ampicillin and cephaloridine, it was only counted once in the table 16. There were a 
further 18 different plasmids identified among the mobilisable R- plasmids (table 17). 
The sizes of plasmids in most of the transconjugants were large, a few of 
them were greater than 100 kb and some were greater than 150kb. On 13 
occasions (8 for the auto -transferable plasmids and 5 for the mobilisable 
plasmids) no plasmid DNA could be detected, which probably reflects their 
large size. Most of the plasmids of these transconjugants were shown to have 
resistance genes to more than five non -beta -lactam antibiotics and almost all 
of them were resistant to aminoglycosides. 
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Table 16 
Characteristics of R- plasmids from Isolates of E. coli 
No. Resistance pattern Size (kb) 







5 Ap Ce Cm Km Sm Sx Tc Tp 
5 Ap Ce Cm Sm Sx Tc Tp 
5 Ap Sx 
3 Ap Ce Cm Gm Km Sm Sp Sx Tc Tp 
3 Ap Ce Cm Km Sm Sx Tc Tp 
3 Ap Ce Km Sm Sx Tp 
2 Ap Ce Cm Gm Km Sm Sp Sx Tp 69.6 
2 Ap Ce Gm Km Sm Sx Tp 81.5 
1 Ap Ce Cm Gm Km Sm Sp Sx Tc Tp 123.3 
1 Ap Ce Gm Km Sm Sp Sx Tc Tp - 
1 Ap Ce Cm Gm Km Sm Sp Sx Tp - 
1 Ap Ce Cm Gm Km Sm Sp Sx Tc 50.3 
1 Ap Ce Cm Gm Km Sm Sp Sx Tp 45.3 
1 Ap Ce Cm Km Sm Sp Sx Tc Tp 18.9 
1 Ap Ce Cm Gm Km Sm Sx Tc Tp 62.0 
1 Ap Ce Cm Gm Km Sm Sp Sx Tp 91.5 
1 Ap Ce Cm Km Sm Sp Sx Tc 51.4 
1 Ap Ce Gm Km Sm Sp Tc 49.1 
1 Ap Ce Km Sm Sx Tc Tp 232.0 
1 Ap Ce Cm Sm Sx Tc Tp 76.1 
1 Ap Ce Cm Sm Sx Tc Tp 112.5 
1 Ap Ce Cm Km Sm Sx Tc 89.5 
1 Ap Ce Cm Km Sm Sx Tc 43.8 
1 Ap Ce Cm Km Sm Sx Tc 104.9 
1 Ap Ce Cm Sm Sx Tp 55.1 
1 Ap Ce Km Sm Sx Tp 72.7 
1 Ap Ce Cm Sx Tc 51.4 
1 Ap Ce Cm Sx Tp 268.3 
1 Ap Ce Cm Sx Tp 52.2 
1 Ap Gm Sm Sx Tp 76.7 
1 Ap Ce Sx Tc 109.9 
1 Ap Ce Sx Tp - 
1 Ap Ce Sx Tp 56.4 
1 Ap Ce Sm Sx 89.8 
1 Ap Sm Sx Tp 72.6 
1 Ap Ce Km Sx 74.4 
1 Ap Ce Sx 83.4 
1 Ap Ce Sx 22.5 
This result was confirmed on two separate occasions. 
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Table 17 
Characteristics of R- plasmids Mobilised from Isolates of E. coli 
Size Resistance pattern size (kb) 
Mobilised from 15 isolates 
4 Ap Ce Cm Gm Km Sm Sp Sx Tc Tp 38.3 
2 Ap Ce Cm Gm Km Sm Sp Sx Tc Tp 81.75 
2 Ap Ce Sp Sx Tc - 
1 Ap Ce Cm Gm Km Sm Sp Sx Tc Tp 57.6 
1 Ap Ce Cm Km Sm Sp Sx Tc Tp 33.0 
1 Ap Ce Cm Gm Km Sm Sp Sx Tc 91.5 
1 Ap Ce Gm Km Sm Sp Sx Tc Tp 78.0 
1 Ap Ce Gm Km Sm Sp Sx Tc 73.5 
1 Ap Ce Cm Gm Km Sm Sx Tp 33.6 
1 Ap Ce Cm Km Sm Sp Sx Tc 97.5 
1 Ap Ce Gm Km Sp Sx Tc Tp 82.5 
1 Ap Ce Cm Sp Sx Tc Tp 103.5 
1 Ap Ce Sm Sx Tc 27.0 
1 Ap Ce Sp Sx Tc 82.5 
1 Ap Ce Sm Sx Tc 
1 Ap Ce Sm Sp Sx 
1 Ap Ce Sp Sx 
1 Ap Ce Sx Tc 61.5 
Total transconjugants obtained - 23 
This result was confirmed on two separate occasions. 
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3.2.3 Non - beta- lactam Resistance among the Urinary Pathogens and the 
Transconjugants of E.coli 
Almost every ampicillin resistant clinical isolate (214/230: 93 %) and virtually every 
transconjugant (92/93: 99 %) of the E.coli isolates were sulphamethoxazole resistant 
(table 18). Most sulphamethoxazole resistant strains were also resistant to 
trimethoprim, as this drug has been exclusively co- administered with 
sulphamethoxazole in India for the treatment of urinary tract infections. The next 
most common resistance determinant associated with ampicillin resistance was 
streptomycin which might result from the treatment of tuberculosis or leprosy 
infections, as these infections are common in most areas of India amongst the poorer 
populations. The resistance genes for gentamicin and spectinomycin were associated 
with ampicillin resistance genes in less than 50% (80/230, gentamicin and 83/230, 
spectinomycin) of the clinical isolates; 54% (50/93) of the R- plasmids from 
E.coli were spectinomycin resistant; and ' less than 50% (32/93) of the R- 
plasmids were gentamicin resistant. 
3.2.4 Distribution of Beta- lactamases in Ampicillin - Resistant E.coli and in their 
Transconjugants 
3.2.4A Beta -lactamases in E.coli Transconjugants 
The beta -lactamases produced by the transconjugants of E.coli obtained from both 
mating and mobilisation experiments were identified and categorised by isoelectric 
focusing of crude enzyme extracts by comparison of their migration against standard 
beta -lactamases. The vast majority of transconjugant strains (71.9 %) encoded the 
TEM -1 beta -lactamase in spite of the diversity of plasmid types on which the gene 
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Table 18 
Types and Proportion of Non -beta -lactamase 
Resistant Urinary Pathogens Including 
Trans con jugants 
Resistances among Ampicillin 
Clinical Strains /and Their 
G3 
Antibiotics 
Percentages of resistant strains 
Urinary 




Ap 100 100 100 
Ce 80 75 91 
Cm 77 77 66 
Gm 35 21 34 
Km 43.5 53 64.5 
Sm 87 96 78.5 
Sp 36 18 54 
Sx 93 92 99 
Tc 85 97 73 
Tp 77 78 68 
Tp + Sx 76 76 66.7 
Total number of urinary pathogens tested (including E. coli), 230; total 
number of E. coli clinical strains tested, 106; total number of 
transconjugants of E. coli tested, 93; (transfer and mobilisation 
positive). 
This result represents the average of two separate determinations 
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was carried. Amongst the remaining types of beta -lactamases identified, five 
previously well characterised enzymes were also represented, although in 
far fewer strains. These beta -lactamases were TEM -2, OXA -1, OXA -2, SHV -1 and 
PSE -1 beta -lactamases (table 19). In a few strains two or more enzymes were 
encoded. In addition, TEM -1 like enzymes and also a novel enzyme with a high pI 
were observed in the transconjugants and their discoveries are discussed in the 
sections 3.2.4A1, 3.2.4A2 and 3.2.4A3. 
The transconjugants obtained by mobilisation had plasmids encoding only two types 
of beta -lactamases, TEM -1 and OXA -1. Once again, the most prevalent beta - 
lactamase was TEM -1 as it was produced by 20 of a total of 23 transconjugants 
(table 19). OXA -1 was found in only 3 of the 23 transconjugants. 
3.2.4A1 Hyperproduction of TEM -1 Beta- lactamase 
The specific activity range of TEM -1 in all but three of the strains was between 1 and 
35µM. However, in three E.coli transconjugants, the TEM -1 beta -lactamases were 
hyperproduced (11,M -1 + +). Their hyperproduction was revealed by measuring their 
specific activities which were much higher than that for the normal TEM -1 enzyme. 
In strain 1 the specific activity was 102.2µM, in strain 2 the specific activity was 
271.4µM and in strain 3 it was 191.7µM. All three of these specific activities were at 
G St tc nC_ul'c'_n.n 
least 5 -10 fold more than the average TEM -1 enzyme expression of plasmid Rl. 
The expression of these beta -lactamases on the polyacrylamide gel 
0.1- 
was so prominent they were considerably darker with more satellite bands (fig 1). 
These hyperproduced enzymes were determined by large plasmids, all greater than 
100kb. The biochemical properties of these enzymes were the same as those of the 
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measuring the optical density of the fractions at 278nm by the method of Waddell 
(1956). Beta -lactamase enzyme samples were then applied to the calibrated column 
and the molecular sizesof the proteins were determined from the standard curve (i.e. 
log molecular weight verses fraction Nos of the peaks of the protein markers). 
2.5.14H1 Preparation of Sephadex G -75 Column: Gel Filtration 
Sephadex G -75 (Pharmacia, Uppsala, Sweden) was swollen in a hot water bath at 
100 °C for 3 hours in sodium phosphate buffer (25mM, pH 7.0). The concentration of 
the Sephadex was about 84mg/m1 and a total amount of 300m1 of the suspension was 
made up. The slurry was allowed to cool and then poured carefully into an LKB 
(Bromma, Sweden) gel filtration column (2cm2 x 90) avoiding any air bubbles 
getting into the column. When the column was full, the top was connected and flow 
started in a downward direction ca't tc, a peristaltic pump. The flow rate was adjusted 
to between 8 and 12mis per hour and the column was washed with sodium phosphate 
buffer (25mM, pH 7.0) for 48 hours. 
2.5.14H2 Separation by Sephadex Gel Filtration 
The concentrated bacterial sonicates were used for separation. . These 
Ct\l 
samples\were applied slowly through the sample applicator (LKB) and eluted with 
phosphate buffer. Fractions were collected by an LKB ultrorac fraction collector. 
Elution was continued (overnight) until a volume of buffer equivalent to the total 
column volume had passed through (180m1s). The fractions containing the beta - 
lactamase activity were determined first by testing samples from each fraction with a 
nitrocephin solution (50mg/1). The peak of activity was quantified by assaying at 
fractions shown to possess beta -lactamase activity. The fraction containing the peak 
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activity was compared on the standard curve to establish the molecular weight of the 
particular sample (section, 2.5.14H) 
The column was washed with sodium phosphate buffer for about 12 hours between 
each run. In addition, column was kept clean from any contamination by adding 
sodium azide as a preservative in the running buffer when it was not in use. 
2.5.15 Isolation of Outer Membrane Proteins 
One hundred mis of an overnight nutrient broth culture, grown with aeration, was 
harvested (6,000g, 10minutes, Sorvall) to obtain cells from which outer membrane 
proteins (OMPs) could be prepared. The cells were washed once in sodium 
phosphate buffer (25mM, pH 7.0) and the pellet was resuspended in lOmis of the 
same buffer. The . cells were disrupted by sonication (81.tm, 2 minutes, soniprep) 
z u1 constant cooling. This was followed by centrifugation (2,500g, 10 minutes, 4 °C, 
Sorvall) to remove large debris from the lysate. The supernatant containing the 
OMPs was decanted and n -lauryl sarcosine (Sigma) was added to give a final 
concentration of 1 -2% w /v. This was incubated at room temperature for 30 minutes. 
Sarcosyl- insoluble OMPs were sedimented by centrifugation (100,000g, 60 minutes, 
4 °C) ( Sorvall,Ultra- Centrifuge (Du Pont) OTD 65B). The clear pellet was then 
resuspended in 0.5 or 1.0m1 of sodium phosphate buffer (25mM, pH 7.0) and the 
protein concentration was measured. The protein concentration was adjusted 
(minimum 20- 30ng/µ1, loaded up to 214/µ1) according to the specifications given by 
the manufacturcrs of the Phast System (The Phast System, Pharmcia, LKB 
Biotechnology). The samples were subjected to the Phast System mini SDS- 
polyacrylamide (discontinuous buffer system) gel electrophoresis. Molecular weight 
markers (Pharmacia, LKB, 17- 0446 -01) were included on each gel (range 14,400 to 
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94,000), provided by Electrophoresis Calibration Kit. 
2.5.15A The Phast Gel Electrophoresis (SDS -Polyacrylamide) of Outer 
Membrane Proteins 
The Phast System Gradient gels (8 -25 i.e. 6,000 -300,000) were used to separate the 
outer membrane proteins, in discontinuous buffer system. The composition of ready 
made gradient gels and buffer (SDS) strips were as follows: The gels had continuous 
8 to 25% gradient zone with 2% crosslinking. The gels were approximately 0.45 mm 
thick and the buffer system in the gels was 0.112M acetate (leading ion) and 0.112M 
Tris, pH 6.4. The gradient gels enhance the band sharpness of the proteins. 
The buffer system in Phast Gel SDS Buffer Strips was 0.20M tricine (trailing ion), 
0.20M and 0.55% SDS (analytical grade), pH 8.1. The buffer strips were made of 2% 
agarose IEF. 
The molecular weight marker proteins provided by the Pharmacia MW Calibration 
Kit (17- 0446 -01), were within the range of 14,400 -94,000. 
2.5.15B Sample Treatment 
The sample treatment4-e-Zc -cr, the procedure given by the Phast 
System manufacturers. To the suspension of outer membrane proteins in sodium 
phosphate buffer (25mM, pH 7.0) was added sample buffer (final concentrations of 
10mM Tris/Hcl, 1mM EDTA, pH 8.0), SDS to 2.5% and beta -mercaptoethanol to 
5.0 %. This mixture was boil.r.d for 5 minutes. Bromophenol blue (0.1 %, 
2.21.4.1) (loading buffer) was then added to the treated samples at the final 
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concentration of 0.01%. Protein markers were directly suspended in the sample 
buffer, SDS and beta -mercaptoethanol solution according to the instructions of the 
manufacturers and treated in the same way as the samples. 
2.5.15C Loading the Samples and Running the Gels 
The gradient (8 -25) gel was placed gently on the flat surface of the Phast System 
Separation Unit. Then the sample applicator with the samples (2µ1 or 411.l) was 
placed on the surface of the gel. The running of the gel (samples) was immediately 
started according to the running conditions which were devised following the 
instructions given by the manufactures and preprogrammed by myself (table 11). The 
samples were then applied to the gel automatically. The time taken for the separation 
of the protein samples and markers was about 30 -40 minutes. 
Table 11 
The Gel Running Conditions 
Sample application. Down at 1 Vh 
Sample application. Up at 10Vh 
Separation (1st Step) 250V 10.0mM 30W 15 °C 65Vh1 
Separation (2nd Step) 50V 0.1mM 0.5W 15 °C OVh2 
2.5.15D Developing the Phast System Gel 
The gradient gel (8 -25) was stained and destained by Co- o-massie blue according to 
the instructions in the Development Unit of the Phast System. The development 
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procedure took about 40 minutes. The solutions used were listed in table 12 below. 
The stained gels were photographed and could also be preserved by using the 
preserving solution. 
Table 12 
Solutions Used for Developing the Phast Gels 
(A) Stain 0.1% Phast Gel Blue R solution or 0.1% 
*Coitomassie blue solution in 30% 
methanol and 10% acetic acid 
in distilled water (100m1) 
(B) Destain : 30% and 10% acetic acid in distilled 
water (3:1:6) (100m1) 
(C) Preserving 
solution : 10% glycerol and acetic acid in 
water (100m1) 
The patterns of the OMPs were compared with the standard sample and molecular 
mass of the proteins were estimated from the calibrated curve of the protein markers 
used. 
44 Coomassie blue, rather than silver stain, was used to stain the gel because 





3.1 Survey of Beta -lactam Resistant Urinary Pathogens Isolated in South India 
3.1.1 Introduction 
There have been very few controlled studies on the incidence of beta -lactam 
resistance among enterobacterial strains isolated in tropical countries. In 1984, an 
intensive field study for bacterial resistance in hospital isolates was undertaken in 
South India. Urinary pathogens (284) responsible for significant bacteriuria were 
collected and catalogued at the Christian Medical College Hospital at Vellore. These 
284 clinical enterobacterial isolates were originally tested for their trimethoprim 
resistance (minimum inhibitory concentrations >10 mg/1) which was found to be as 
high as 64% (Young et al., 1986). 
These Indian pathogens had been widely exposed to common penicillins such as 
ampicillin and amoxycillin but had hardly been challenged by cephalosporins. The 
same Indian isolates (284) have now been further investigated for their beta -lactam 
resistance employing ampicillin and cephaloridine as resistance markers (break point 
of 10 mg/1). The results showed that the proportion of ampicillin resistant strains was 
230/284 and the the proportion of cephaloridine resistance was 185/284 (table 13). 
-There was a very high incidence of ampicillin resistance (80.9 %) and 
cephaloridine resistance (65.1 %). E.coli accounted for 48.6% of the strains of 
Eli erobacteriaceae studied. The remaining strains in this study were mainly 
































































































































































































































































































































































































































































































































































































































































































































































































































































spp (5.6 %) and other species were also included in this study. 
3.1.2 Minimum Inhibitory Concentrations of Ampicillin and Cephaloridine for 
Urinary Pathogens 
The ampicillin- resistant urinary pathogens were retested for their MICs of ampicillin 
at a series of doubling concentrations from 10mg/1 upwards (10 -1280 mg/1). There 
was a very high incidence of high -level ampicillin resistance (MIC >1280mg/1) 
(121/230 strains: 52.6 %) (table 13). High level ampicillin resistance was found in 
42.6% of all the enterobacterial strains (284) tested . The large proportion of highly - 
resistant strains was not a result of particular bacterial species, which are inherently 
resistant to ampicillin, -the proportion of highly resistant strains among 
individual species (E.coli (39 %), Klebsiella x(57 %) and Proteus(29 %)) showed that 
there was no P,{` 
ci 0;r,n,- nc ,in any one species of highly resistant strains. For 
cephaloridine, the break- points showed that a significant percentage of the 
population (185 strains, 65 %) were resistant but the MIC results showed that 
virtually none of them were able to resist the drug at the high concentration level 
(1280 mg/1) (table 13). A few Klebsiella (8 strains) and Enterobacter (3 strains) spp 
were highly resistant to cephaloridine (table 13). 
On the other hand, there was a widespread resistance (250/284: 88 %) to piperacillin 
(8mg/1) and half (126/250) 50 %) were resistant to the higher concentration 
(32 mg/1) of the drug. 
3.1.3 Effect of Clavulanic Acid in Association with Ampicillin 
Clavulanic acid is a potent inhibitor of many of the plasmid- mediated beta - 
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lactamases of Gram -negative bacteria, especially broad-spectrum penicillinases. 
When all the ampicillin resistant strains were tested against ampicillin in the 
presence of a subinhibitory concentration of clavulanic acid (8 mg /1), the MICs of 
ampicillin were greatly reduced in over 95% of the highly resistant bacteria (Table 
13). This indicated the involvement of beta - lactamases in the resistance mechanisms 
of these strains. Some bacteria remained highly resistant to the drug combination 
(Table 13). This was exemplified particularly by certain strains amongst the 
Klebsiella and Proteus spp. 
3.1.4 Sensitivity Testing to Cephalosporins 
Susceptibility tests to the first generation (cephradine and cefazolin) and second 
generation (cephamandole, cefoxitin) cephalosporins showed that about 25% of the 
strains were resistant to each drug, except for cephradine where 50% were resistant 
(Table 14). The majority of the population tested had increased susceptibility to 
two other second generation cephalosporins (cefuroxime and cefotetan) as only 18% an 
3.5% were able to grow in the presence of each drug respectively, at the 
concentrations tested (8 mg /1 for cefuroxime and cefotetan) (Tables 13 and 14 
respectively). 
Only a few strains were able to resist the third generation cephalosporins 
ceftazidime (13 strains), cefotaxime (15 strains) and the monobactam aztreonam 
(15 strains) (Table 13). The proportions of the beta - lactam resistant strains 
amongst each individual species were varied irrespective of their inherent 
resistances to beta - lactam antibiotics (Tables 13, 14). E. coli strains are 
naturally sensitive to beta-lactam antibiotics examined. This was not the case in 
this survey as there was a high incidence of ampicillin resistance within the E. col: 




























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































A B C D E 
PI 
5.4 
This experiment was performed on four separate occasions and the result shown 
is representative of that found on each occasion. 
Figure 1 
Isoelectric Focusing Pattern of TEM -1 Beta- lactamase of 
(121) and TEM -144 Beta -lactamases of Three E, coli J62 -2 
Transconjugants of E, coli Clinical Isolates. 
Track A - F. cols K -12 (TEM -1) 
Track B - LN19 (TEN -144) 
Track C - LN35 (TEM -144) 
Track D - LN37 (TEM -144) 
Track E - B. cola K -12 (TEM -1) 
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coli K-12 
normal TEM -1 beta -lactamase (table 20) and their activities were inhibited by 
clavulanic acid (ID50 and Kls fig 2a, 2b). It is particularly noteworthy that the host 
strains that produced these TEM -1 ++ were resistant to the combination of ampicillin 
and clavulanic acid (MIC 40 +8 mg/1 amp +clav). 
3.2.4A2 Ceftazidime Hydrolysing TEM -1 Beta -lactamase 
A beta -lactamase which hydrolysed the third generation cephalosporin, ceftazidime, 
was also identified. This enzyme had exactly the same pI as TEM -1 (pI 5.4) and 
some similar satellite banding. The rate of hydrolysis of ceftazidime for this enzyme, 
( _ TEM (CazrAwas low (0.03 %); butait was significantly higher than a control 
TEM -1 enzyme (unmeasurable). Despite this, the corresponding host strain remained 
sensitive to ceftazidime. 
3.2.4A3 A Novel Enzyme of High pI 7.4 
A novel enzyme of pI 7.4 was identified in an E.coli transconjugant strain which had 
been selected on cephaloridine. The gene for this enzyme was not stable and required 
the presence of a beta -lactam antibiotic to maintain it. This enzyme had very poor 
activity against nitrocephin but was more active against carbenicillin on the basis of 
its substrate profile than the TEM -1 enzyme had been. It did not co- migrate with 
either OXA -1 or OXA -2 beta -lactamases nor with any enzyme from the SHV group, 
all of which have pIs in this range. This enzyme was classified as CARB -6 based on 
its preferential carbenicillin hydrolysis (table 21). 
Another novel enzyme with a high pI of 8.3, designated SAR -2, was also 
identified. This enzyme has been fully characterised and is described in section 3.3. 
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Table 20 
Biochemical Properties of TEM -1 ++ and the Standard TEM -1 Beta -lactamases 
Relative rates of hydrolysisa'b Inhibitiond by clavulanic 
acid 






100 72 12 4 1.0 60.0 9.5 x 10-8 
100 104.5 12 3 16.8 14.0 8.5 x 10-7 
100 93 14 0.97 0.6 11.9 0.8 x 10-7 





a = Spectrophotometric assay method 
b = Expressed as a percentage of the value for benzyl penicillin 
c = Hydroxylamine assay method 
d = Nitrocephin (0.1 mM) as substrate 
ND = Not done 
This result represents the average of three separate determinations 
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This experiment was performed on three separate occasions and the result 
shown is representative of that found on each occasion. 
Figure 28 
Lineweaver -Burk Plot of the Strain LN19 Producing TIIM-144 Beta - 
lactamase. 
A = with clavulanic acid 





I/S (mM I 1 
120 140 
Lineweaver -Burk Plot of The Strain LN35 Producing TQ1 -1 Beta - 
lactamase. 
A = with clavulanic acid 
B = without clavulanic acid (substrate nitrocephin) 
This experiment was performed on three separate occasions and the result 
shown is representative of that found on each occasion. 
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Table 21 
Rates of Hydrolysisa of the Novel Beta- lactamase (CARB -6) Isolated 
from E. cola J62 -2 Transconjugants of An E. colt Clinical Strain 
Substrate b,c Relatived 
Vmax 
Benzyl penicillin 0.039 100 
Ampicillin 0.039 100 
Carbenicillin 0.0597 153.8 
Cephaloridine 0.0075 19.2 
Cefotaxime 0.00262 6.72 
Ceftazidime 0.012 30.8 
Nitrocephin 0.0053 13.6 
a = Spectrophotometric assay method 
b = Vmax , pm substrate hydrolysed minute -lml enzyme -1 
c = Vmax values for these substrates were obtained from the initial 
reaction rates at maximal substrate concentration 
d = Expressed as a percentage of the value for benzyl penicillin 
This result represents the average of two separate determinations 
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3.2.4B Beta -lactamases in the Rest of the E.coli Clinical Isolates 
plus tri,cl 
The rest of the clinical E.coli isolates (35) I n which transferable resistance could 
r 
not be cicnt .-,mwere also screened for beta -lactamase production. Again, the TEM- 
1 enzyme was present in the majority of isolates (60 %) (table 19), which suggested 
that the plasmid gene Inviht have transposed onto the bacterial chromosome. Four 
other " plasmid- mediated" beta -lactamases were also identified, these were OXA -1, 
OXA -2, PSE -1 and PSE -2 (table 19). It is an infrequent event to find the PSE beta - 
lactamases in E.coli and it was surprising to see both PSE -1 and PSE -2 in one of the 
E.coli clinical isolates tested. _ Tn five isolates which were found to be 
resistant to second and third generation cephalosporins (sections 3.2 and 3.2.1), no 
new beta -lactamases were detected and it was presumed that the resistance to those 
drugs might be derived from other resistance mechanisms such as altered outer 
membrane porins or penicillin binding proteins. 
3.3 SAR -2: Characterisation of A Novel Plasmid- mediated Beta -lactamase 
3.3.1 Introduction 
In E.coli strains, many different types of plasmid- determined beta -lactamases have 
been found. The commonest is TEM -1 enzyme and the rest are TEM -2, TLE -1, 
OXA -1, 2 novel OXA enzymes, PSE -1, PSE -2, PSE -4, SHV -1 and now these 
include extended - spectrum beta- lactamases (cephalosporinases) the TEM beta - 
lactamase derivatives (Medeiros, 1984, 1989; Bush, 1989). 
In the survey of beta -lactam resistance among urinary pathogens (Gram- negative 
rods) isolated in South India (results, section 3.2), a high proportion of E. 
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coli (77%) was found to be resistant to ampicillin. The majority of the ampicillin 
resistance genes were freely transferable to the standard recipient strain and most of 
these genes encoded the ubiquitous TEM -1 beta -lactamase. Amongst these 
transconjugants, one strain was discovered to produce a novel high pI beta - 
lactamase. 
3.3.2 Results 
One clinical strain, E.coli 146, was highly resistant to ampicillin (MIC >1280 mg/1) 
but only moderately to cephaloridine (MIC 20mg/1). The other antibacterial drugs to 
which this strain was resistant were trimethoprim, streptomycin, tetracycline and 
nalidixic acid (measured at 10mg/i) as well as sulphamethoxazole (measured at 100 
mg/1). 
3.3.3 Conjugation Experiments 
When strain E.coli 146 was used as a donor in a conjugation experiment, 
cephaloridine resistance (10mg/1) could be transferred to the standard recipient 
(E.coli J62.2) which has only a chromosomally -mediated rifampicin resistance. 
When selection was made for ampicillin resistance 
with the same recipient strain, no transfer could be detected. 
3.3.4 Plasmid Analysis of E.coli 146 and its Transconjugant 
Both the original clinical strain E.coli 146 and the transconjugant were examined for 
their plasmid content and their resistance profiles. Both the original and 
transconjugant contain a single large plasmid of approximately 118kb. The 
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expression of these plasmids was very poor on the agarose gel (Materials and 
Methods) and, therefore, plasmids were detectable as faint bands. The plasmid in the 
transconjugant was designated as pUK734. The transconjugant with plasmid 
pUK734, acquired resistances to sulphamethoxazole (MIC >100 mg/1) and 
tetracycline (MIC >10 mg/1). 
3.3.5 Isoelectric Focusing 
Sonicated extracts were prepared (Materials and Methods) from both E.coli 146 and 
the transconjugant E.coli J62.2 @UK 734). The beta -lactamases were examined by 
analytical IEF employing a broad -range ampholine (pH 3.5 -10). Both extracts 
produced a beta -lactamase with a high pI. The extracts of the cephaloridine- resistant 
transconjugant was re- examined by IEF with a 1:1 mixture of pH 7 -9 and 3.5 -10 
ampholines to increase the resolution at higher pHs. The beta -lactamase band did not 
co -focus with any other known beta -lactamase and had a higher pI (8.3) than either 
the CEP -1 and CEP -2 beta -lactamases (fig 3); therefore the enzyme was considered 
as novel and was designated as SAR -2. It was found by IEF that the 
original clinical isolate also produced the TEM -1 enzyme, in addition to the novel 
enzyme SAR -2. The novel enzyme was weakly expressed in the original 
clinical isolate. These findings implied that the .9 ,cyce 
h. 
the E.coli 146 was either chromosomal,or it might be located on a different plasmid 
of a large size which was not easily extractable intact. 
3.3.6 Molecular Weight Determination 
The crude extract from the cephaloridine resistant transconjugant was applied to a 
Sephadex G -75 column calibrated with the standard proteins ovalbumin, a- 
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This experiment was performed on three separate occasions and the result 
shown is representative of that found on each occasion. 
Figure 3 
Isoelectric Pattern of SAR -2, A Novel Beta -lactamase Encoded by 
Plasmid pUK 734, Compared with the CEP -1 and CEP -2 Beta -lactamases. 
Track A - CEP -1 
Track B - SAR -2 (E. cola J62 -2 transconjugant) 
Track C - CEP -2 
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chymotrypsinogen and cytochrome C (fig 4). In comparison with known molecular 
weight markers the size of the SAR -2 beta -lactamase was 36000 (fig 5). 
3.3.7 Substrate Profile 
This novel enzyme was concentrated by ammonium sulphate precipitation as detailed 
in Materials and Methods. One litre overnight broth culture was harvested and 
washed in sodium phosphate buffer (pH 7.0). The washed pellets were resuspended 
in small (5m1s) quantity of the same buffer and sonicated extract was separated by a 
high speed centrifugation. After measuring the specific activity of the enzyme, 
ammonium sulphate was added to 50% saturation to the extract, This 
mixture was stirred constantly for 30 minutes then centrifuged to 
collect the pellet. The pellet was resuspended in 0.8ml of the same phosphate buffer 
and again the specific activity of this suspension was estimated. This enzyme was 
assayed in the presence of fixed concentrations of various beta -lactams (Simpson, 
Harper and O'Callaghan, 1980) and the rates related to the hydrolysis of benzyl 
penicillin. It was impossible to measure the Km values of beta -lactam antibiotics as 
these substrates were hydrolysed very slowly by this novel enzymeftherefore Vmax 
values for the substrates were obtained from the initial reaction rates at maximal 
substrate concentrations. Besides benzyl penicillin, the SAR -2 beta -lactamase 
hydrolysed ampicillin, carbenicillin, oxacillin, methicillin, cefotaxime, nitrocephin 
and cephaloridine (table 22). _ The enzyme showed a greater ability to 
hydrolyse oxacillin and methicillin than most broad -spectrum beta -lactamases. 
3.3.8 Inhibition Studies 
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This experiment was performed on two separate occasions and the result shown 
is representative of that found on each occasion. 
Figure 4 
Elution Profile of The SAR -2 Beta -lactamase Separated by Sephadex G-75 
Gel Filtration 
A = ovalbumin (MW 45,000) 
B = SAR -2 beta- lactamase (MW 36,000) 
C = aC -chymotrypsinogen (MW 25,500) 
















This graph was drawn for both the gel filtration separations represented by 
figure 4. The values shown in this figure are for the separation detailed in 
figure 4. The molecular sizes from the two runs were comparable. 
Figure 5 
Molecular Weight Determination of the Novel Beta- lactamase (SAR -2) as 
Measured by Gel Filtration on Sephadex G-75 
A = ovalbumin (MW 45,000) 
B = SAR-2 (MW 36,000) 
C = dC -Chymotrypsinogen (MW 25,500) 
D = Cytochrome-C (MW 12,384) 
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Table 22 
Relative Rates of Hydrolysisa of SAR -2 Beta- lactamase Encoded by pUK 734 in 
E. colt J62 -2 Transconjugant 
Substrate b,c Relatived 
Vmax 
Benzylpenicillin 0.39 100.0 
Ampicillin 0.395 101.25 
Carbenicillin 0.186 48.1 
Oxacillin 0.25 64.2 
Methicillin 0.395 100.2 
Cephaloridine 0.1053 27.0 
Cefotaxime 0.0762 19.6 
a = Spectrophotometric assay method 
b = Vm uM substrate hydrolysed minute -1ml enzyme -1 
c = V max values for these substrates were obtained from the initial 
reaction rates at maximal substrate concentration. 
d = Expressed as a percentage of the value for benzyl penicillin 
This result represents the average of two separate determinations 
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highly inhibited by cloxacillin (ID50 <10 -9M). However, it was not sensitive to 
inhibition by clavulanic acid (ID50 >10 -4) or para- chloro mercuribenzoic acid (ID50 
>104) (table 23). 
3.3.9 Comparison between the Novel Enzyme and Other Plasmid- mediated 
Beta -lactamases 
The SAR -2 has a higher pI than all previously described plasmid -mediated beta - 
lactamases and can easily be distinguished from them by isoelectric focusing. Its 
molecular mass of 36000 suggests that the SAR -2 enzyme is similar to the CEP -2 
beta -lactamase found in Achromobacter (Levesque et al., 1982); h owever, SAR -2 
has a different substrate profile from CEP -2 and focuses above it. The SAR -2 beta - 
lactamase has greater affinity for penicillins than CEP -2 which would classify it as a 
"broad- spectrum" enzyme. On the other hand, it also hydrolyses oxacillin and 
methicillin more efficiently than any of the other "broad- spectrum" plasmid- 
mediated beta -lactamases. It is not as efficient as other oxacillin- 
hydrolysing (OXA) enzymes at hydrolysing these two substrates. 
3.4 Beta -lactam Resistance among Klebsiella spp. 
The second largest population of the enterobacterial strains (284) studied in this 
survey after E.coli (results, section 3.2) were Klebsiella spp. (26.4%). Ampicillin 
resistance in Klebsiella spp. is species -specific (Sawai, Yamagishi and Mitsuhashi, 
1973; Sykes and Matthew, 1976; Sirot et al., 1988). _ 'These strains isolated 




Inhibition Profile of the Novel Beta- lactamase (SAR -2) 
Potential Inhibitor a ID50 Value (M) 
Clavulanic acid > 1 x 10 -4 
Cloxacillin < 1 x 10-9 
pCMBb > 1 x 10 -4 
a = Nitrocephin, 0.1 mM as substrate 
b = para -chloro- mercuribenzoic acid 
This result represents the average of two separate determinations 
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3.4.1 Resistance to Ampicillin and Cephalosporins 
Ampicillin resistance in Klebsiella spp. (75) was almost universal (96 %), and more 
than half of them (43) were highly resistant to the drug (1280 mg/1) (table 13). On the 
other hand, cephaloridine resistance was found in only 52 strains (69 %) and high 
level resistance to this drug was observed in only 8 strains (MIC >1280 mg/1) (table 
13). Most of these strains were sensitive to clavulanic acid, as their MICs to 
ampicillin were drastically reduced in the presence of the beta -lactamase inhibitor 
(8mg/1) (table 13). This result indicated the possible involvement of clavulanic acid 
sensitive beta -lactamases in the strains conferring resistance to ampicillin. 
When these strains were tested against other cephalosporins (table 13), a small 
proportion (17 strains) were resistant to cefuroxime (table 13) while a few strains 
were able to overcome the activity of the third generation cephalosporins such as 
cefotaxime (7 strains) and ceftazidime (5 strains) (table 13). These latter five strains 
were also able to resist the monobactam aztreonam (table 13). 
The outcome of sensitivity testing to the series of beta -lactam drugs tested revealed 
that the Klebsiella spp. were predominantly resistant to ampicillin rather than to 
cephalosporins. The ampicillin resistant strains were investigated for transferable 
beta -lactam resistance. 
3.4.2 Plasmid- determined Beta - lactam Resistance among Klebsiella spp. 
The results obtained showed that about 50% (37/75) were able to transfer their beta - 
lactam resistance genes freely into the recipient strain E.coli J62.2 (table 24). Only 7 
strains transferred both ampicillin and cephaloridine resistance genes. Thirty strains 
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Table 24 
Transfer of Ampicillin and Cephaloridine Resistances in gletslella 
islates (75), 






7 + + 14 
30 
Total transconjugants 
a = Ampicillin (10 mg/L) 
b = Cephaloridine (10 mg/L) 
This experiment was performed on two separate occasions and the result shown 
is representative of that found on each occasion. 
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were discovered to have only transferable ampicillin resistance without co- 
transferable resistance to cephaloridine (table 24). The transconjugant strains of 
Klebsiellae were further investigated for their plasmid content. 
3.4.3 Plasmid DNA Characterisation of the Transconjugants 
All plasmids of the Klebsiella transconjugants (44) were characterised for their 
resistance genes that they carried. A representative group of 24 were examined for 
their plasmid DNA sizes. From the information on the resistance patterns, there were 
22 different plasmid types in the 44 transconjugant strains. Among the Klebsiella 
transconjugants (24) for which plasmid sizes were determined 11 different plasmid 
types were distinguished (table 25a) on the basis of their plasmid sizes and resistance 
profiles. In the second group of Klebsiella transconjugants (20) (table 25b), 11 
different resistance patterns were observed based only on resistance profile. 
In the first group Klebsiella transconjugants (24), the plasmid sizes were large 
( >80kb) and seven plasmids appeared on more than two occasions. Interestingly, in 
this group, four plasmids had the same molecular size (116kb) but with different 
resistance genes (table 25a). 
In the second group Klebsiella transconjugants (20), 4 resistance patterns were 
exhibited by the transconjugants on more than one occasion (13 strains) (table 25b). 
These 4 resistance patterns might indicate the presence of more than 4 types of 
plasmids. In the second group of Klebsiella transconjugants, there were seven 
different resistance profiles conferred on one occasion each by seven different strains 
which suggested the presence of 7 different plasmid types. 
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Table 25a 
Plasmid DNA Profile of Klebsiella Transconjugants (24)a 
No. Resistance patterns Size (Kb) 
6 Ap Ce Cm Km Sm Sp Sx Tc Tp 116 
4 Ap Cm 87.1 
2 Ap Cm Gm Km Sm Sp Tc Tp 251 
2 Ap Cm Gm Km Sm Sx Tc Tp 116 
2 Ap Cm Sm Sx Tc 116 
2 Ap Cm Gm Sx Tp 95.5 
2 Ap Cm Gm 83.2 
1 Ap Cm Gm Km Sm Sc Tp 113.4 
1 Ap Cm Gm Km Tp 87.1 
1 Ap Ce Cm Tc 100 
1 Ap Cm Tc 116 
a - Total Klebsiella transconjugants = 44 
Total transconjugants tested for plasmid sizes = 24 
This result was confirmed on two separate occasions. 
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Table 25b 
Plasmid Resistance Profile of the Rest of the Klebsiella 
iransconjugants (20) a 
No. Resistance patterns 
4 Ap Cm Km 
3 Ap Cm Sm Sx Tp 
3 Ap Cm Sm 
3 Ap Cm Gm Km Sm Sp Sx Tc Tp 
1 Ap Cm Gm Km Sm Sp Tc Tp 
1 Ap Cm Gm Km Sm Sp Sx Tp 
1 Ap Cm Gm Km Sm Sp Tp 
1 Ap Cm Gm Km Sx Tp 
1 Ap Cm Km Sm Sx 
1 Ap Cm Tc Tp 
1 Ap Gm Sm Tc 
a - Total Klebsiella transconjugants = 44 
Total transconjugants tested only for resistance patterns = 20 
This result was confirmed on two separate occasions. 
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Therefore, Klebsiella transconjugants possessed a minimum of 18 plasmid types (tables 
25a, 25b). Most of them (24 strains) harboured resistance genes for five or more 
antibiotics and were found to be resistant to aminoglycosides (tables 25a, 25b). 
3.4.4 Plasmid Resistance in the Transconjugants 
The proportion of cephaloridine resistance in the clinical isolates of Klebsiella 
spp. was 72 %. This percentage fell to 15.9% in the transconjugants (table 26). On 
the basis of this result, it appears that cephaloridine resistance in the clinical 
isolates must generally be non - plasmid mediated. Sulphamethoxazole resistance linked 
to the ampicillin resistance was less than 50% in the transconjugants; whereas, it 
had been notable that in their corresponding clinical isolates it was as high as 
70.8 %. In the urinary pathogens, as a whole, the linkage of sulphamethoxazole and 
ampicillin resistance was 93 %. 
Resistances to chloramphenicol, trimethoprim and streptomycin were widely spread 
(table 26) in all the strains (urinary pathogens, Klebsiella spp.) including in the 
transconjugants of Klebsiella spp. A remarkable proportion of the ampicillin 
resistant R- plasmids also coded for chloramphenicol resistance (97.7 %). On the other 
hand, ampicillin resistant strains encoded linked resistance to spectinomycin was 
less than 50% in all the strains (table 26). The proportion of linked gentamicin and 
kanamycin resistant genes with ampicillin resistant genes was over 50% in the 
Klebsiella and their transconjugant strains. These resistances were less significant 
in enterobacterial (284) strains as a whole. Linkage of ampicillin resistance to 
trimethoprim on R- plasmids was about 57% whereas this had been well over 60% in the 
original (284) strains. The combination of sulphamethoxazole and trimethoprim 
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Table 26 
Types and Proportion of Non -beta- lactam Resistances among Ampicillin 
Resistant Urinary Pathogens Including Klebsiella Clinical Isolates and 
Their Transconjugants 
Percentages of resistant.. strains 
Antibiotics Klebsiella spp. Transconjugants 
of Klebsiella spp. 
Urinary 
pathogens 
Ampicillin 100 100 100 
Cephaloridine 72 15.9 80 
Chloramphenicol 70.8 97.7 77 
Gentamicin 51.4 52.3 35 
Kanamycin 56.9 54.5 43.5 
Streptomycin 75 61.4 87 
Spectinomycin 40.3 31.8 36 
Sulphamethoxazole 70.8 47.7 93 
Tetracycline 66.7 47.7 85 
Trimethoprim 68.1 56.8 76 
Trimethoprim + 
Sulphamethoxazole 68.1 38.6 76 
Total number of urinary pathogens tested (including Klebsiella) = 230 
Total number of Klebsiella isolated tested = 72 
Total number of transconjugants of Klebsiella tested = 44 
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resistance genes on ampicillin resistance R- plasmids was only 38.6% and it was 
considerably higher in the Klebsiella spp. Less than 40% of the plasmids carried 
resistance genes to tetracycline and this was notably higher in the both Klebsiella 
spp. and the urinary pathogens (table 26). 
The ampicillin resistant transconjugants of Klebsiella spp. were screened for the 
production of plasmid- mediated beta -lactamases. 
3.4.5 Beta -lactamases Produced in Klebsiella Transconjugants 
There were only two types of beta -lactamases produced in the Klebsiella 
transconjugants (table 27). The TEM -1 beta -lactamase was predominant as it was 
appeared in most of the transconjugants (80 %). The second beta -lactamase was 
SHV -1 beta -lactamase which is commonly found in these strains (Roy et al., 1985). 
The SHV -1 enzyme was identified alone in only 3 transconjugant strains and in 6 
strains where it was co- produced with TEM -1 enzyme (table 27). Despite the 
presence of broad - spectrum beta -lactamases such as TEM -1 and SHV -1, the 85% of 
transconjugants remained sensitive to cephaloridine ( <10 mg/1) (table 26). 
3.5 Incidence of Beta -lactam Resistance in Salmonella and Shigella spps. 
Isolated from Gastrointestinal Infections 
During the survey for collection of urinary pathogens from significant bacteriuria 
(results, section 3.1), over 200 Salmonella and Shigella spps., were also isolated from 
gastrointestinal infections, at the Christian Medical College Hospital, Vellore, South 
India, in 1984. Even though beta -lactam resistance among Salmonella and Shigella 
spps. is not inherent, the prevalence of ampicillin resistance has gradually become 
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Table 27 
Distribution of "Plasmid- encoded" Beta- lactamases among Klebsielld 
Transconjugants Selected on Ampicillin and Cephaloridine 
Number and proportion of beta -lactamases 
Transconjugant TE I -1 + 
strains TEM -1 SHV -1 SHV -1 NBa Totalb 
Number 34 3 6 1 44 
(77.3) (6.8) (13.6) (2.3) 100 
a, total transconjugants selected = 44 
b, NB - No beta -lactamase could be detected 
This experiment was performed on two separate occasions and the result shown 
is representative of that found on each occasion. 
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common among these species. The Salmonella and Shigella isolates in the present 
study were examined in detail for the spread of beta -lactam resistance. 
3.5.1 Beta -lactam Resistance Profile in salmonellae 
Ampicillin resistance in salmonellae was quite significant because as many as 90% 
of the strains (92/102) were resistant to the drug (table 28); however, less than half 
of them were highly resistant to ampicillin ( >1280 mg/1). Conversely, these strains 
were very sensitive to the first generation cephalosporin, cephaloridine. Only 7 
strains were able to grow in the presence of this antibiotic ( >10 mg/1) and none of 
them highly resistant to the drug ( >1280 mg/I). The proportion of ampicillin 
resistance was decreased when isolates were challenged with clavulanic acid (56% of 
the strains remained resistant). The beta -lactamase inhibitor was used at the at 
subinhibitory concentration (8mg/1) in conjunction with ampicillin (table 28). The 
salmonellae were more resistant to the action of clavulanic acid than they had been 
to cephaloridine as they retained high MICs (160 +8mg /1) of the combination of 
ampicillin and clavulanic acid. Resistance to this combination may result from the 
presence of beta -lactamases which were stable to inhibition by clavulanic acid. 
Surprisingly, a significant proportion (65.7 %) of the strains were resistant to 
cefuroxime, the second generation cephalosporin (table 28). This was remarkable 
because of their sensitivity to cephaloridine. Apart from this, all Salmonella strains 
remained sensitive to other second and third generation cephalosporins (table 28) and 
this included the monobactam, aztreonam. 
The ampicillin and cefuroxime resistant strains were taken further to investigate the 
resistance mechanisms involved. 
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Table 28 
Proportion of Clinical Salmonella Isolates (102) Resistant to Beta - 
lactam Antibiotics 
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a = Minimum inhibitory concentrations of ampicillin in the presence of 
subinhibitory concentration of clavulanic acid (8 mg /L) 
The other cephalosporins employed were Cefazolin (8 and 100 mg /L); 
Cefamandole (8 mg /L); Cefoxitin (8 mg /L); Cefotetan (4 mg /L) and 
Ceftriaxone (4 and 32 mg /L). In each case, about 2% of the total 
population were resistant to them. 
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3.5.1A Selection of Ampicillin and Cefuroxime Resistant 
Transconjugants 
It was inferred from the results, the degree (15 %) of transferability of ampicillin 
resistance was very low. Of these 92 ampicillin resistant strains, only 14 could 
transfer by conjugation their resistance genes into the standard recipient (table 
29). All transconjugants were selected on ampicillin as none of the original 
isolates were cephaloridine resistant and, therefore, no cephaloridine resistant 
transconjugants were obtained when selection was made for it. 
Attempts were made to select the cefuroxime resistant transconjugants both by 
conjugation and by mobilisation with transfer factor X. Both these methods failed. 
It was assumed the prevalence of cefuroxime resistance among these isolates was 
mediated either by chromosomal beta - lactamases or by reduced outer membrane 
permeability. Both ampicillin resistant transconjugants and cefuroxime resistant 
clinical isolates were studied in detail to examine their resistance mechanisms. 
3.5.1b Plasmid DNA of the Ampicillin- resistant Transconjugants 
Plasmid DNA of the Salmonella transconjugants was characterised by the sizes and the 
resistance genes which they carried. There were ten different plasmid sizes with 
different resistance patterns (table 30). Only two types of plasmids were found on 
more than one occasion. The interesting feature was the presence of the smallest 
plasmid (11.5 kb) alone in one transconjugant carrying resistance genes for 9 
antibiotics. Occurrence of auto - transferable small plasmids (<25 kb) is unusual. 




Transfer of Ampicillin Resistance in Salmonella Isolates (102) 
Total ampicillin resistant isolates = 92/102 






Total transcon jugants 
+ - 14 
14 
a, Amp = Ampicillin (10 mg /L) 
b, Cxm = Cefuroxime ( 8 mg/L) 
This experiment was performed on two separate occasions and the result shown 
is representative of that found on each occasion. 
125 
Table 30 
Characteristics of Resistance Plasmids in Salmonella Transconjugants 
Number Resistance pattern Size (kb) 
4 Ap Sm Sx 78 
3 Am Cxm* Cm Gm Km Sm Sp Sx Tc Tp 84.8 
1 Ap Sm Sx 90.0 
1 Ap Cm 57.5 
1 Ap Cm 135.0 
1 Ap 65.25 
1 Ap 160.5 
1 Ap Cxm* Cm Km Sm Sp Sx Tc Tp 11.5 
* see text 
This result represents the average of three separate determinations 
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could not be isolated and identified by the plasmid extraction and separation 
techniques available. This hypothesis is supported by the fact that when 0-a_ 
resistance genes were transferred from E.coli J62.2 to E.coli J53, only the 
11.5kb plasmid could be visualised in the transconjugant. It is extremely 
unlikely that the small plasmid would have sufficient available DNA to 
account for the resistance genes and it would certainly be unable to carry 
sufficient information for auto -transferability. The rest of the plasmid 
sizes were within the range of 57- 90kb (table 30) except for two plasmids 
which were 135 and 160 kb respectively. 
There were five different resistance genes patterns on the plasmids. Only two 
plasmids carried resistance genes more than five antibiotics and they conferred 
resistance to aminoglycosides. 
3.5.1C Comparison of Beta -lactam Resistance Levels of Transconjugants 
and their Respective Original Salmonella Strains 
In most of the transconjugants, the level of ampicillin resistance was considerably 
higher than it had been in the original clinical strains. In some,the MICs of ampicillin 
were the same as their original clinical isolates (table 31). None of the R- plasmids 
were cephaloridine resistant (MIC <10 mg/1), although some of their original 
Salmonella isolates were resistant to this drug (MIC >10 mg/1). When the 
transconjugants were tested against cefuroxime, all were sensitive to the drug except 
for four of them. This comparison was made with the sensitive strain E.coli K -12, 
J62.2 (table 31). High inocula of these cultures (1x109 cfu) elevated their MICs of 
cephaloridine (table 31) but nck for cefuroxime. However, four ampicillin and 
cefuroxime resistant transconjugants were found to have a high MIC to cefuroxime 









































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































The beta - lactamases produced by the transconjugants were extracted and identified by 
isoelectric focusing to establish their resistance mechanism. 
3.5.1D Plasmid- determined Beta - lactamases in the Transconjugants 
Beta - lactamases from the transconjugants were identified on polyacrylamide gel by 
analytical IEF; and, as expected, the TEM -1 enzyme was by far the most common 
(10/14) (table 32). In addition, on two occasions, there was a second beta - lactamase 
in the transconjugants besides TEM -1, and this was found to be an OXA -1 like enzyme. 
There were two other transconjugants which also produced this OXA -1 like enzyme, but 
in the absence of the TEM -1. 
Only those transconjugants which had plasmids encoding for OXA -1 like enzymes 
possessed resistance to the drug cefuroxime (tables 31 and 32); therefore, all the 
cefuroxime- resistant Salmonella clinical isolates were screened for this type of 
beta - lactamase production in order to establish the resistance mechanism to 
cefuroxime. 
3.5.1E A Detailed Study on Cefuroxime Resistant Salmonella, 
Strains 
3.5.1E1 Mobilisation of Cefuroxime Resistance 
The plasmid- carriage of the cefuroxime resistance genes were once again tested by 
conjugation on the plates containing lower concentrations of cefuroxime (2 mg /1) as 
four of the ampicillin resistant E, coli J62.2 transconjugants of Salmonella strains 
were found to be cefuroxime resistant (MIC 4 mg /1); but these attempts failed. 
Consequently, when the mobilising plasmid X+ (E. coli) was employed to transfer the 
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Table 32 
Types and Proportion of Beta- lactamases in Salmonella Transconjugants 





TEM-1 OXA-1 OXA-1 
10 + - - 71.4 
2 - + - 14.3 
2 - - + 14.3 
14 = Total transconjugants 100.0 
This experiment was performed on two separate occasions and the result shown 
is representative of that found on each occasion. 
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cefuroxime resistance; but none of the clinical isolates showed any plasmid 
transfer. Original clinical isolates were investigated to determine whether the 
source of cefuroxime resistance can be attributable to the type of beta - lactamase 
production. 
3.5.1E2 Identification of OXA -like Enzyme in Cefuroxime Resistant 
Salmonella Clinical Isolates 
The sonicated concentrated beta - lactamase extracts of the four Salmonella strains 
were identified by isoelectric focusing on polyacrylamide gel composed of 6 -8 and 
3.5 -10.0 ampholines in a ratio of 1.5:0.5 respectively and compared to the standard 
OXA -1 beta - lactamase. Both beta - lactamases had the same main bands which co- focused 
at a pI of 7.4; however, two satellite bands were absent in the OXA -1 like enzyme 
whereas they were clearly visible in the standard OXA -1 enzyme (fig. 6). 
As the standard OXA -1 enzyme is both plasmid and transposon mediated, it is possible 
that these resistance genes encoding OXA -1 like beta - lactamase could be located on 
the chromosome. To confirm this hypothesis, two of the cefuroxime resistant 
Salmonella strains were tested by induction studies. 
3.5.1E3 Induction of Beta -Lactamases 
Induction of beta - lactamases was carried out as described in Materials and Methods. 
The bacterial cells from 100 ml broth cultures in exponential phase of the growth 
cycle, grown in the presence or absence of cefuroxime (1/4 mg /1 of their MICs) were 
harvested and disrupted. The disrupted cell debris was discarded and supernatant was 
collected. The specific activities of 
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The result shown compares one of the OXA-1 like beta -lactamase taken from one 
of the Salmonella strains directly with the original OXA-1 enzyme. The 
banding patterns and pIs of the beta -lactamases from the three other 
Salmonella strainswere identical. All these enzyme extracts were tested by 





Isoelectric Focusing of OXA -1 and OXA -1 -like Beta- lactamases Extracted 
from a Standard F, coli and a Salmonella, Clinical Strains. 
Track A - OXA -1 like enzyme Track B - OXA -1 enzyme 
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these supernatants were measured and it was revealed the OXA -1 like enzymes were not 
inducible as they had similar specific activities as control OXA -1 like enzyme. 
According to these results this enzyme might be plasmid- mediated; therefore, all 
these cefuroxime resistant clinical strains were subjected to plasmid DNA studies. 
3.5.1E4 Inspection of Plasmid DNA 
Plasmids possessed by these cefuroxime resistant Salmonellae clinical isolates were 
isolated and electrophoresed in 0.5% agarose gel by the method of Takahashi and 
Nagano (1984). These results showed that every clinical isolate harboured a minimum 
of 3 plasmids with a wide range of sizes (>35- 88kb). As none of these plasmids was 
either transferable or mobilisable, in order to determine that OXA -1 like enzyme is 
indeed plasmid- encoded, an attempt was made to cure the isolates of the plasmid. This 
experiment failed, leading to the assumption that these OXA -1 like genes might be 
either plasmid- mediated or, alternatively, could be on the chromosome and produce the 
enzyme constitutively. The characteristics of the OXA -1 like enzyme from each of the 
four Salmonella strains were compared with the standard OXA-1 beta-lactamase. The 
biochemical properties of both enzymes were examined to establish the differences 
between them. 
3.5.1E5 Activity of OXA -1 like Beta - lactamase against Different 
Substrates and Inhibitors 
The rates of hydrolysis of various substrates at fixed concentrations by the OXA -1 
like and OXA -1 enzymes were analysed under the same experimental conditions. The 
results are presented in table 33. The rates were related to the hydrolysis of 
penicillin G (i.e. 100 %). The OXA -1 like and OXA -1 enzymes hydrolysed ampicillin 
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Table 33 
Substrate Profilea of OXA -1 -like and the Standard OXA -1 Beta- lactamases 
OXA-1-like OXA-1 
Substrate Vmb Relativec VmaXb Relativec 
V(%) 
vmax (50 
Penicillin 0.376 100 1.015 100 
Ampicillin 2.845 756.6 5.825 573.9 
Carbenicillin 0.405 107.7 2.64 260.0 
Cephradine 0.001248 0.33 0.032 3.2 
Cephalothin 0.049 13.0 0.0399 5.8 
Cephaloridine 0.1865 49.6 0.324 46.9 
Cefuroxime 0.047 12.5 0.015 1.5 
Cefoxitin 0.007 1.9 NH - 
Cefamandole 0.148 39.4 0.1597 15.7 
Cefotaxime 0.0691 18.4 0.0854 12.4 
Ceftazidime NH NH NH NH 
Nitrocephin 2.46 654.3 2.54 250.0 
a = Spectrophotometric assay method 
b = Vmax , um substrate hydrolysed minute -lml enzyme -1 
c = Vmax values for these substrates were obtained from the initial 
reaction rates at maximal substrate concentration 
d = Expressed as a percentage of the value for benzyl penicillin 
NH = No hydrolysis 
The velocity constants for the OXA-1 like enzyme are the average of two 
determinations for one of the Salmonella strains. Concurrent tests with the 
enzyme preparations from the other three Salmonella strains showed no obvious 
variation from the results presented. 
134 
(755% and 573% respectively), cephaloridine (49.6% and 46.9 %) and cefotaxime (18.4% 
and 12.4 %) to similar extents. The OXA -1 like enzyme had a considerably higher 
activity (8 -fold) against cefuroxime than OXA -1. Moreover, the OXA -1 like enzyme 
could hydrolyse cefoxitin whereas OXA -1 could not (table 33). In addition, the OXA -1 
like enzyme had higher activity (>2 -fold) than the OXA -1 like enzyme against the 
substrates such as cephalothin, cephamandole and nitrocephin (table 33). On the 
other hand, the OXA -1 like enzyme was less effective than OXA -1 against cephradine 
and carbenicillin (table 33). The relative rates of hydrolysis of oxacillin and 
methicillin of these enzymes could not be determined spectrophotometrically as the 
lambda maximum for these antibiotics were very low. 
The enzymes shared common inhibitor profiles (table 34) as they were resistant to 
clavulancic acid (dose for 50% inhibition (ID50 >1mM), cloxacillin, p- Chloromercuri- 
benzoic acid, sodium chloride, cefoxitin, cefotetan and cefuroxime in the presence of 
nitrocephin as a substrate (table 34). 
Cefuroxime resistance in these Salmonella strains was accompanied by the widespread 
distribution of the novel OXA -1 like enzyme, even though other resistance mechanisms 
may also play a subsidiary role. This must be true as four of the ampicillin 
resistant transconjugants had different MICs of cefuroxime (MIC 4mg /1 at 105cfu and 









Clavulanic acid > 1.0 > 1.0: 
Cloxacillin 0.1 0.1 
Cefuroxime > 0.1 > 0.1 
Cefoxitin > 1.0 > 1.0 
Cefotetan > 1.0 > 1.0 
Sodium chloride >10.0 >10.0 
p-CMB > 1.0 > 1.0 
a = Nitrocephin (0.1mM) as substrate 
pCMB = para- chloromercuribenzoic acid 
The inhibitor constants for the OXA-1 like enzyme are the average of twn 
determinations for one of the Salmonella strains. Concurrent tests with the 
enzyme preparations from the other three Salmonella strains showed no obvious . 
variation from the results presented. 
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3.5.2 Study of Clinical Isolates of Shigella spp. 
3.5.2A Introduction 
A total of 101 Shigella strains were also isolated from gastrointestinal infections at 
the same time as the Salmonella strains (results, section 3.5). These strains were also 
assessed for their beta -lactam resistance and for the resistance mechanisms involved. 
3.5.2B Sensitivity Testing to Beta -lactam Antibiotics 
The Shigella isolates were examined for their minimum inhibitory concentrations of 
different beta -lactam antibiotics (table 35). It was found that a remarkable proportion 
of them (66 %) was ampicillin resistant; however, only one strain was highly 
resistant to the drug (MIC >1280 mg/1). Unlike the Salmonella isolates, the shigellae 
were extremely sensitive to the combination of ampicillin and the beta -lactamase 
inhibitor clavulanic acid (table 35) as their MICs of ampicillin in most strains 
dropped to <10 mg/1 in the presence of the inhibitor. Only 7 strains were able to 
resist this combination. 
Virtually, none of the strains were able to withstand the antibacterial activity of 
cephaloridine (10 mg/1) except a single strain (MIC >1280 mg/1). This strain was 
more resistant to cephaloridine than to ampicillin. The shigellae were sensitive even 
to drugs (table 35) such as cephradine and piperacillin which were beta -lactamase 
unstable antibiotics. On the other hand all other species examined so far in this study 
(urinary pathogens and salmonellae) 
antibacterial agents. 











































































































































































































































































































































































































































































































































































































































































































































































































































































































































For second and third generation cephalosporins, a few strains had grown in the 
presence of them (table 35). These results clearly showed that resistance to 
cephalosporins was very insignificant despite the wide spread ampicillin resistance 
amongst Shigella spp. The ampicillin resistant strains were studied further to locate 
the genetic location of the ampicillin resistance genes. 
3.5.2C Transfer of Ampicillin Resistance from Shigella Isolates 
The study of transferable beta -lactam resistance in these strains had shown that only 
20 (20/67) of ampicillin resistant strains could transfer the ampicillin resistance 
genes alone (table 36). The percentage of transferable resistance amongst these 
isolates was 2 -fold higher (30%) than in Salmonella isolates. The ampicillin 
resistance genes did not seem to confer any resistance to cephaloridine as no 
transconjugant could be isolated when the selection was made on cephaloridine 
(table 36). Indeed the clinical strain that could transfer genes for cephaloridine 
resistance freely into the standard recipient strain (table 36) was the only strain which 
conferred resistance to cephaloridine (MIC >1280 mg/1) from the total shigellae 
population. 
3.5.2D Resistance Determinants on R- plasmids of Shigella Transconjugants 
Characterisation of the plasmids of the Shigella transconjugants revealed that all the 
transconjugant strains possessed ampicillin resistance genes. There were a total of 7 
different plasmid types characterised by their plasmid sizes and resistance genes that 
they acquired (table 37). All the plasmids were about the same size (about 80kb) 
(table 37), expect one plasmid which was as large as 135.8kb in size. There were 7 
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Table 36 
Transfer of Ampicillin and Cephaloridine Resistances in $higella 
Isolates (101). 
Total number of ampicillin resistant strains = 67 
Total number of cephaloridine resistant strains = 1 
Selecting antibiotic 
Strains ,)-q, Transcon jugants 
-CI anst -z Jc.hi. Ptl .V1,-c{5 Ampa Cerb 
20 + - 20 
1 - + 1 
Total transconjugants = 21 
a = Ampicillin (10mg/L) 
b = Cephaloridine (10mg/L) 
This result was confirmed on two separate occasions. 
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Table 37 
Characteristics of Transferable Resistance Plasmid of Shigella 
Transconjugants 
Number Resistance patterns Size (kb) 
6 Ap cm Sm Sp Sx Tc 83 
6 Ap Cm Sm Sx Tc Tp 88.9 
3 Ap Cm Gm Km Sm Sp Sx Tc Tp 91.5 
2 Ap Cm Sm Sx Tc Tp 135.8 
1 Ap Cm Gm Km Sm Sx Tc 88.5 
1 Ap Cm Sm Sp Sx Tc Tp 84.0 
1 Ap 75.0 
1 Ce 
This result represents the average of two separate determinations 
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different plasmid resistance patterns, conferring resistance to all common 
antibiotics. Almost all of them harboured genes for aminoclycosides and each plasmid 
was resistant to a minimum of five drugs. There was one exception where the plasmid 
was resistant to ampicillin alone (table 37). Resistance patterns revealed that only 
one of them was cephaloridine resistant. In this respect, Shigella transconjugants 
were similar to the transconjugants of Salmonella. 
Resistance determinants to chloramphenicol, sulphamethoxazole, streptomycin and 
tetracycline were remarkably common among the ampicillin resistant transconjugants 
(95%) (fig 7). R- plasmids coding for ampicillin resistance were also associated with 
the genes encoding trimethoprim and spectinomycin resistances separately in 50% of 
the transconjugants. A small proportion (20 %) of the R- plasmids possessed linked 
resistance to gentamicin and kanamycin in each case (fig 7). Only half of the 
ampicillin resistant transconjugants showed linked resistance to the combination of 
trimethoprim and sulphamethoxazole. This association between ampicillin resistance 
genes and the combination of trimethoprim and sulphamethoxazole resistance genes was 
found to be common, as it had been in isolates tested in the general survey (urinary 
and gastroenteric pathogens). 
3.5.2E Identification of Plasmid- encoded Beta - lactamases of 
R-plasmids 
The identification of beta - lactamases produced in the Shigella transconjugants once 
again showed the prevalence of the TEM -1 beta-lactamase, which was found in 90% of 
the transconjugants (table 38). The only other beta - lactamase found in the 
transconjugants was OXA -1. On two occasions TEM -1 enzyme was co- produced with OXA -1 
enzyme. In only one transconjugant OXA -1 beta - lactamase alone was responsible for 






Ap Cm Gm Km Sm Sp Si Tc Tp TpSi 
ANTIBIOTICS 
Figure 7 
Types and Proportions of Non- beta -lactam Resistance Genes on 
Ampicillin Resistant Plasmids of Shigella J62 -2 Transconjugants. 
Ap = 100%; Cm = 90.5%; Gm = 19.0%; Km = 19.0%; Sm = 90.5%; 
Sp = 47.6%; Sx = 90.5%; TC = 90.5%; Tp = 57.0%; Tp + Sx = 57.0% 
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Table 38 
Plasmid- encoded Beta -lactamases of R- plasmids in $higelld Transconjugants 




TEM-1 OXA-1 TEM-1 + 
OXA-1 NBIa 
17 + - - - 80.9 
2 - - + - 9.5 
1 - + - - 4.8 
1 - - - + 4.8 
Total 21 100.0 
a NBI = No beta- lactamase identified 
This experiment was performed on two separate occasions and the result shown 
is representative of that found on each occasion. 
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Table 38 
Plasmid- encoded Beta- lactamases of R- plasmids in Shigel13 Transconjugants 




TßM-1 OXA-1 TIIM-1 + 
OXA-1 NBIa 
17 + - - - 80.9 
2 - - + - 9.5 
1 - + - - 4.8 
1 - - - + 4.8 
Total 21 100.0 
a NBI = No beta -lactamase identified 
This experiment was performed on two separate occasions and the result shown 
is representative of that found on each occasion. 
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was detectable in the transconjugant selected on cephaloridine (table 38). 
Although this resistance gene was also transferable from E. coli J62.2 to 
E. coli J53, no plasmid DNA could be detected in the latter transconjugant. 
It appears that this transferable cephaloridine resistance might be mediated 
by a mechanism other than a beta -lactamase. 
3.5.2F Minimum Inhibitory Concentrations of Ampicillin for the Shigella 
Transconjugants 
The results of these susceptibility tests to ampicillin showed that all the Shigella 
transconjugants possessed approximately the same MIC levels as their corresponding 
original clinical strains (table 39). The interesting feature was that there was an 8- 
fold increase in the MIC of ampicillin in four transconjugants and it was doubled on 
one occasion (table 39). Only one transconjugant occurred which had a reduced MIC 
level to ampicillin compared to its original clinical isolate. Despite the 
elevated MICs of ampicillin, after transfer of the respective resistance genes into the 
standard recipients, all the transconjugants remained cephaloridine sensitive, even 
though they all produced TEM -1, the broad -spectrum beta -lactamase. 
3.6 Mutation Studies on Resistance to the Combination of Ampicillin and 
Clavulanic Acid 
3.6.1 Introduction 
Surveys of ampicillin resistant enterobacterial strains from different countries 
showed some variation in the distribution of beta -lactamases, with TEM -1 always the 
commonest. The results of this present study have demonstrated that this is true in 
India as well. The TEM -1 beta -lactamase gene has proved highly successful as a 
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Table 39 
Comparison between Ampicillin Resistance Levels of Shigella 
Transconjugants and Their Corresponding Clinical Isolates 
Number of 
transconjugants 
MICs of Ampc 
for 'T'a 
(mg /L) 
MICs of mpc 
for 'C' 
(mg /L) 
13 160 160 
3 1280 160 
2 320 320 
1 > 1280 160 
1 320 160 
1 160 320 
Total 21 transconjugants 
a, 'T' = transconjugants 
b, 'C' = corresponding clinical isolates 
c, Amp = Ampicillin 
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major contributor to the high incidence of ampicillin resistances and it is responsible 
for the spread of ampicillin resistance world -wide. This beta -lactamase 
is capable of acquiring mutational modification of its active site 
in order to meet the challenge of new beta -lactam antibiotics. There are many 
examples of this, in particular the evolution of extended -spectrum beta -lactamases of 
the TEM -1 derivatives which can destroy the highly potent later generation 
cephalosporins. 
There are fewer examples of clinical resistance to beta -lactamase inhibitors and, 
therefore, the ob 
ject'óf 
the mutation studies, described below weato establish the 
efficacy of the combination of enzyme labile beta -lactam and beta -lactamase 
inhibitor (ampicillin and clavulanic acid) and to determine the emergence of 
possible resistance mechanisms that effect the antibacterial activity of beta -lactam 
and beta -lactamase inhibitors in E.coli. 
The TEM -1 enzyme producing plasmid R1 was used for these studies. TiNe R1 
plasmid containing E.coli strain K -12 was challenged with a mixture of ampicillin 
(100 mg/1) and clavulanic acid (20 mg/1). In parallel, the same strain harbouring one 
each of the extended spectrum beta -lactamases (i.e. TEM -3, TEM -5 and TEM -7) 
were also challenged. This experiment was also performed on the same 
E.coli strain harbouring R1010 plasmid which encodes SHV -1 beta -lactamase. 
SHV -1 is another common broad -spectrum penicillinase but is, like TEM -1, sensitive 
to the combination of ampicillin and clavulanic acid. 
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3.6.2 Mutants of R -1 Plasmid Harbouring and TEM -1 Enzyme 
3.6.2A 
Producing E. coli Strain 
Selection of A Mutant "A" Resistant to Ampicillin and 
Clavulanic Acid and Mutants "B" Resistant to Clavulanic 
Acid Alone 
Mutants resistant to both the combination (ampicillin and clavulanic acid) and 
clavulanic acid were obtained on the Oxoid diagnostic sensitivity test agar (DSTA) 
plates containing the selective antibiotics. The selected mutants were purified on 
the same selective plates. Mutant "A" was obtained from a R1 plasmid containing, TEM 
1 beta - lactamase producing strain E. coli K -12 challenged with the combination of 
ampicillin and clavulanic acid at the concentration levels of 100 and 20 mg /1 
respectively. Mutant "A" was re- exposed (fig 8) to clavulanic acid alone at two 
different concentration levels (64 and 128 mg /1). In this case, two types of II B II 
mutants were selected: Mutants B1 and B2 were obtained from agar plates containing 
64 mg /1 clavulanic acid and mutants B3 and B4 were obtained at 128 mg /1 of clavulanic 
acid. The mutants "A" and "B" were then rigorously tested for their beta - lactam 
resistance profiles. The mutation rates are shown in table 39a. 
3.6.2A1 Antibiotic Sensitivity Testing for Mutant "A" and 
Mutants "B" 
The minimum inhibitory concentrations of ampicillin, clavulanic acid, combination of 
ampicillin + clavulanic acid and augmentin (amoxycillin and clavulanic acid) were 
investigated for these mutants. In addition, all these mutants were tested for their 
resistance patterns to cefuroxime, the second generation cephalosporin, and third 


































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































The results showed that mutant "A" had increased resistance a 100 -fold to the 
combination of ampicillin and clavulanic acid (table 40) in comparison with the 
original E.coli K -12 strain. Concurrently, resistances to ampicillin (2560 mg/1) and 
augmentin (40 +8 mg/1 of amoxycillin and clavulanic acid) had also increased 
compared to the parent strain. Mutant "A" was also able to resist ampicillin in the 
presence of 32 mg/1 of clavulanic acid; h.;,zv u, the MIC of ampicillin was 
drastically reduced for the mutant in the presence of the higher concentration level of 
clavulanic acid (5 +32 mg/1 of amp+clav). 
The other mutants "B" (1 -4) obtained from mutant "A" (fig 8) showed an even 
further increase in the MICs of ampicillin ( >2560 mg/1) (table 40) than the parent 
strain "A ". The MICs of clavulanic acid for these mutants were doubled'and, for B1 
and B2, there was a 4 -fold increase over their parent strain (table 40). _ -These 
mutants (B 1 -B4) lost their resistances to ampicillin in the presence of higher 
concentration level of clavulanic acid (32 mg/1) and to augmentin (table 40). 
Interestingly, one of each of these mutants ( "A" and "B ") had acquired resistance to 
cefuroxime at the concentration level of 4 mg/1. Apart from this, no mutants had 
acquired any resistances to any other of the cephalosporins tested (ceftazidime and 
cefotaxime). 
3.6.2A2 Resistances to Non - beta -lactam Antibiotics of the Mutants "A" and 
The mutants "A" and "B" were examined for their resistance profile to all other 
common non - beta -lactam antibacterial agents at fixed concentrations. The results 
(table 40) showed that the mutant "A" had the same resistance pattern as its parent 
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strain E.coli K -12 strain. iie clavulanic acid resistant mutants B1 -B4 
differed from their parent strain "A "; they lost the resistances to antibiotics such as 
chloramphenicol, streptomycin, spectinomycin and sulphamethoxazole after 
exposure to the beta -lactamase inhibitor, clavulanic acid. 
3.6.2A3 Examination of Synergy between Ampicillin and Clavulanic Acid as A 
"Combination" against the Mutants "A" and "B" 
The Fractional Inhibitory Concentrations (FICs) of ampicillin (1.25 -2560 mg/1) in 
the presence of clavulanic acid (0.312 -320 mg/1), were measured for the mutants "A" 
and "B" and the original E.coli K -12 strain. This was performed to evaluate the 
synergy between the beta -lactam (ampicillin) and the beta -lactamase inhibitor 
(clavulanic acid). The results are presented in table 40 and1 they indicated that there 
was a decrease in the synergy between ampicillin and clavulanic acid in the mutants. 
The FIC indices of original strain E.coli K -12 strain was 0.029 whereas the values 
for the mutants ( "A" and "B") were 0.156 i.e. about a 6 -fold increase in the mutants. 
The outcome of this experiment suggests that there was a strong synergism between 
ampicillin and clavulanic acid in the original E.coli strain; nevertheless, this 
synergism declined as the strain became resistant to the combination of ampicillin 
and clavulanic acid. 
3.6.2A4 Exploration of the Resistance Mechanism in Mutant "A" 
Firstly, beta -lactamase produced by this mutant was extracted and identified, 
primarily to see whether it was different from the normal TEM -1 enzyme. The TEM- 
1 beta -lactamases produced by both the mutant and the parent were identified on 
polyacrylamide gel by analytical IEF (Materials and Methods) with a 1 :1 mixture of 
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ampholines (pH 4 -6 and 3.5 -10) to increase the resolution at the lower pH range. 
Even though the TEM -1 enzyme from the mutant appeared similar to the normal 
TEM -1 enzyme with respect to its pI and banding on the gel, it differed from the 
original enzyme, . let produced much more prominent bands with nitrocephin 
(Materials and Methods) and also had increased satellite banding on the gel (fig 9). 
The darkened bands of TEM -1 beta -lactamase from the mutant "A" suggested that 
there was a higher level of enzyme production than in the parent strain. However, a 
detailed study on the biochemical properties of these beta -lactamases were 
performed to check whether the mutant did indeed produced the same TEM -1 
enzyme as the parent strain. 
3.6.2A4a Comparison of Biochemical Properties of the Mutant "A" to its 
parent E.coli K -12 Strain 
Beta -lactamases of both the mutant and its parent strain were analysed for their 
hydrolysis capability, protein concentrations and, therefore, their specific activities 
(Material and Methods) against nitrocephin as a substrate. The specific activities 
showed that there was about a 12 -fold increased activity in the mutant comparing to 
that of the original TEM -1 enzyme (table 41) 
"The substrate profile of the enzymes with different beta -lactam antibiotics 
revealed that the increased specific activity did not alter the relative rates of 
hydrolysis of TEM -1 beta -lactamase produced in the mutant. $ espite the 
increased specific activity in the mutant, the substrate profile was the same as the 
original TEM -1 beta -lactamase. 





This experiment was performed on four separate occasions and the result shown 
is representative of that found on each occasion. 
Figure 9 
Isoelectric Focusing of Beta- lactamases from R1 Plasmid Containing 
Standard Strain and its Mutant 'A'. 
Track A - F. coli K12 (R1) 
(TEM -1 enzyme) 
154 




Specific Activities and Inhibition Properties of the Mutant 'A' and 
Its Parent Strain E. coli K -12 
Strain Specific activitya ID50b Kmc Kid 
Clay (NM) (PM) 
Parent strain 
B. coli K -12 219.1 
17.3 
9.5 x 10-8 




0.36 Mutant 'A' 
a, Specific activity = Enzymic activity against nitrocephin 
Protein concentration 
(u moles nitrocephin hydrolysed min -1 mg protein -1) 
b, ID50 = Concentration of clavulanic acid required to inhibit 50% of 
enzymic activity against nitrocephin 
c, Km = Michaelis constant (the Km value is the substrate 
concentration at which half the maximal velocity occurs) 
d, Ki = The inhibitor constant for clavulanic acid (inhibition of 
the enzyme is competitive and the double reciprocal plot 
intercepts the ordinate at the same point as the Km line, 
see graphs l0a and 10b) 
Ki = i 
KP - 1 
Km 
i = concentration of the inhibitors in uM 
This result represents the average of three separate determinations 
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that both the original TEM -1 and the mutant's enzyme were inhibited by clavulanic 
acid to the same extent. Their ID50 and Ki values were similar (table 41 and fig 10a, 
b) as there were no significant differences. Therefore, the difference in the mutant 
appears to derive entirely from increased production of the enzyme. The genetic 
basis for the increased production of the TEM -1 enzyme of the mutant was found out 
by analysing the plasmid DNA. 
3.6.2A4b Genetic Background for the Hyperproduction of the TEM -1 Enzyme 
in the Mutant "A" 
The plasmids in the mutant "A" was extracted and analysed by 0.5% agarose gel 
electrophoresis as described by Takahashi and Nagano (1984), -(hc plasmid size was 
determined from a calibration curve and compared to the original R1 plasmid. The 
characterisation of the plasmid DNA showed that there had been a plasmid 
rearrangement in the mutant. The plasmid R1 containing strain possessed a single 
plasmid of 90kb. In the mutant, in addition to the original plasmid R1 (90kb), there 
were two small plasmids with the sizes of 48 and >10kbases (fig 11). This 
observation indicates that the mutant had acquired beta -lactamase determinants on 
small multicopy plasmids in addition to the original large plasmid which had been 
present in its parent strain. Further experiments were carried out in order to test what 
effect this rearrangement had on the transferability of resistance to the combination 
of ampicillin and clavulanic acid from the mutant strain. 
3.6.2A4c Transconjugants of the Mutant "A" 
The results c A conjugation experiments demonstrated that the acquired 
resistance to the drug combination in the mutant was not transferable. 
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Figure loa 
Lineweaver -Burk Plot of the TF S -1 Beta- lactamase 
A = with clavulanic acid 
B = without clavulanic acid (substrate nitrocephin) 
This experiment was performed on three separate occasions and the result 





Lineweaver -Burk Plot of the Mutant 'A' TEE -1 Beta -lactamase. 
A = with clavulanic acid 
B = without clavulanic acid (substrate nitrocephin) 
This experiment was performed on three separate occasions and the result 
shown is representative of that found on each occasion. 
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This experiment was performed on five separate occasions and the result shown 
is representative of that found on each occasion. 
Figure 11 
DNA Profile of Plasmid R1 and Plasmids from its Mutant 'A'. 
Track A - Plasmid R6k 
Track C - Plasmid R1 
'C' - chromosomal DNA 
Track B - Plasmid R1010 
Track D - Plasmids from the mutant 'A' 
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ampicillin resistance alone was transferred into the standard strain by conjugation. 
Study of this transconjugant showed that it was exactly as same as the original E.coli 
K -12 strain in all respects (table 42, fig 12). The transconjugant possessed only a 
single large plasmid (R1) and produced the normal TEM -1 beta -lactamase (fig -12). 
The other resistance determinants that it possessed were also identical to the R1 
plasmid of E.coli K12 strain (table 42). 
From these observations made on the transconjugant selected on ampicillin, it was 
clear that the genetic location of the resistance to the combined drug (amp+clav) 
must be on one of the small plasmids. The Amp +Clav resistan5 determinant was 
present in the mutant "A" but it could not transfer into the recipient with the large 
R1 plasmid, and so the transconjugant was resistant to ampicillin only. There might 
be an involvement of non -beta -lactamase resistance mechanism such as diminished 
permeability preventing the entry of antibiotic combination. To establish the possible 
resistance mechanisms involved, outer membrane proteins of both the mutant E.coli 
strain and original strain were extracted and analysed. The results are presented in 
section 3.6.2A8. 
3.6.2A5 Resistance Mechanisms Involved in the Mutants "B" 
A complete study was also performed on the clavulanic acid resistant mutants "B". 
Beta -lactamases from the mutants were extracted and identified by IEF. The TEM -1 
beta -lactamases produced in the mutants "B" were no different from the enzyme 
produced in their parent strain, mutant "A" (fig 13). This showed clearly that these 
beta -lactamases, TEM -1, were also hyperproduced in the "B" mutants. 
Specific activities of these enzymes were determined and only one mutant 
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Table 42 







Ap Clay Ap + clavb Ap + clavc Augd Sp.acte 
E. coli K12 (R1) - 480 40 < 2.5 + 8 < 2.5 + 32 20 +4 17.3 
J62 -2 transe of 
E,_2211 K12 (R1) - 480 40 < 2.5 + 8 < 2.5 + 32 20 +4 17.0 
E. coli K12 (R1) 'A' 2560 40 160 + 8 10 + 32 40 +8 219.1 
J62 -2 transe of 
Mutant 'A' - 490 40 < 2.5 + 8 < 2.5 + 32 20 +4 18.3 
a = Minimum inhibitory concentrations (mg /L) 
b = Ampicillin + clavulanic acid (8 mg /L) 
c = Ampicillin + clavulanic acid (32 mg /L) 
d = Augmentin (Amoxycillin + clavulanic acid) (2.5/0.5 - 160/32 mg /L) 
e = Specific activity (uM nitrocephin hydrolysed /min /mg protein 
f = J62 -2 transconjugant 
All strains shown in this table are resistant to Chloramphenicol, 
Streptomycin, Spectinomycin, Sulphamethoxazole. 
This experiment was performed on two separate occasions and the result shown 
is representative of that found on each occasion. 
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I 
A B C 
pi 
5.4 
This experiment was performed on five separate occasions and the result shown 
is representative of that found on each occasion. 
Figure 12 
Isoelectric Focusing of TEM -1 Beta- lactamases from R1 Plasmid 
Containing Standard Strain, Mutant 'A' and the Transconjugant of 
Mutant ' A' . 
Track A - E. coli K12 (R1) Track B - Mutant 'A' (LN182) 
Track C - Transconjugant of mutant 'A' (LN 286) 
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A B C D E F 
PI 
5.4 
This experiment was performed on five separate occasions and the result shown 
is representative of that found on each occasion. 
Figure 13 
Isoelectric Focusing of TEM -1 Beta- lactamases from R1 Plasmid 
Containing Standard Strain, Mutant 'A' and Mutants B1 - B4. 
Tracks A,B - Mutants B1, B2, Track C - E. Coli K12 (R1) 
(LN281, 282) 
Tracks D,E - Mutants B3, B4 Track F - Mutant 'A' (LN182) 
(LB284,285) 
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was found to have increased activity (table 43). There was a variation 
between the enzymic activities of the mutants "B ". Two mutants B2 and B4, selected 
on 64 and 128 mg/1 of clavulanic acid respectively, had the same activity of TEM -1 
enzyme as their parent strain. The mutant B3 showed decreased beta -lactamase 
specific activity while the other mutant, B1, produced TEM -1 enzyme with a 3 -fold 
increased activity in comparison with the parent TEM -1 beta -lactamase from the 
mutant "A" (table 43). 
From these clavulanic acid resistant mutants (B1-4), no resistances could be 
transferred, not even the resistance determinant to ampicillin. When attempts were 
made to transfer the resistances with a mobilising plasmid X +, no transfer was 
possible. Some rearrangements of the plasmids were taking place. So 
the following study analysed the plasmid DNA of these mutants in order to 
determine the presence and types of plasmids in them. 
3.6.2A6 Plasmids in the Mutants "B" 
The interesting feature among these "B" mutants was loss of the large plasmid R1, 
which had been present both in their parent strain "A" and in the E.coli K -12 strain 
(fig 14). . The "B" mutants retained the other two small plasmids (38 and 
>10kbases), which were also harboured by the mutant "A ". 
As these plasmids were neither self -transferable nor mobilisable, these small 
plasmids were transformed into a sensitive strain (E.coli MC 1022) to 
J í , .l C `4 c G u.. 
resistance to clavulanic acid \ these 
Outer membrane proteins of the mutants were also examined 
to a-s,sc any contribution of non -enzymic resistance mechanism 




Specific Activities of Beta- lactamases Produced by the 'B' Mutants and 
Their Parent Mutant 'A' 
Parent strain Mutant No. Specific activities* 
E. coli K12 (R1) A 219.1 
A B1 645.7 
A B2 213.8 
A B3 83.8 
A B4 218.0 
* ¡1 moles of nitrocephin hydrolysed /min /mg protein 








This experiment was performed on four separate occasions and the result shown 
is representative of that found on each occasion. 
Figure 14 
DNA Profiles of Plasmids from Mutants B1 - B4, Standard F, coli R1 and 
Mutant ' A' . 
Track A - Mutant B1 (LN281) 
Track C - Standard E. coli (R1) 
Track E - Mutant B3 (LN284) 
Track G - Plasmid R6k 
c = chromosomal DNA 
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Track B - Mutant 'A' (LN182) 
Track D - Mutant B2 (LN282) 
Track F - Mutant B4 (LN285) 
Track H - Plasmid R1010 
in these mutants "B ". 
3.6.2A7 Transformation of Small Plasmids into a Sensitive Strain 
]n order to establish the location of the gene for acquired resistances to clavulanic 
acid, to augmentin and to cefuroxime in one mutant and elevated resistances to 
<mpicillin, the small plasmids present in one of the "B" mutants (Cxmr MIC 4mg /1) 
which were nontransferable and nonmobilisable were transformed into a sensitive E 
çoli MC1022 (smr) strain. The competent cells of E, coli MC 1022 were made as 
described in the Materials and Methods. After transformation, competent cells were 
spread out on the surface of the MacConkey plates containing suitable selective 
antibiotics (Ap +Sm and Sm at 10mg /1). 
The frequency of the transformation was calculated (table 44). 
Table 44 
Dilution of the recipient strain (E. coli) MC 122 = 10 -3 
used for the calculation of the frequency rate 
Viable count on control plates = 1000 
Count of transformants obtained on selective plates = 50 
Frequency of transformation = 5x10 -2 
This result was confirmed on two separate occasions. 
The results suggested the rate of transformation was very high as 50 colonies out of 
1000 control colonies could grow on the selective plates after transformation (table 
i4) . 
Then these 50 presumed transformants were tested for their MICs for ampicillin and 
cugmentin, all of them were shown to be highly resistant to ampicillin (MIC 
167 
>2560mg/1) and augmentin (MIC > 80mg /1 of amoxycillin+ 16 mg /1 of clavulanic acid) 
but not to cefuroxime. When these transformants were investigated for their plasmid 
content none of them was found to contain plasmid DNA. Consequently, the same 
transformants were checked for the production of beta - lactamase and all were found to 
produce the enzyme. 
On the basis of these results, the small plasmids of the mutants "A" and "B" seem to 
be responsible for hyperproduction of the TEM -1 beta -lactamase, leading to the 
acquired resistance to the drug combination and high level MICs to ampicillin. On 
the other hand, these small plasmids did not seem to possess any resistance genes for 
cefuroxime and clavulanic acid alone. 
The inability to detect plasmid DNA in the transformants might be a result of the 
incorporation of resistance genes into the chromosomal DNA of the recipient strain E. 
coli MC 1022. Such incorporation is a rare event and the inability to detect the DNA 
may have resulted from problems in the plasmid preparation technique. It is unlikely 
that mutation was the cause because of the high level of resistance and the 
sensitivity to clavulanic acid combinations. 
These mutants "A" and "B" were also examined to establish if there were any 
modifications in their outer membrane protein offering contribution towards 
clavulanic acid and cefuroxime (in one mutant) resistances. 
3.6.2A8 Outer Membrane Proteins of the Mutants "A" And "B" 
In E. coli, porins are one of the most abundant proteins and present in approximately 
100,000 copies for cell. They usually have molecular weights between 30,000 and 
40,000 (Nikaido, 1989). E. coli K -12 produce two types, OMP F (outer membrane 
protein "F ") and OMP C (outer membrane protein "C "). These two porins ( "F" and 
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"C ") are the main channels for the beta -lactam antibiotic passage into the cells and 
have the molecular weights of 36K and 40K respectively (Nikaido, 1989). The OMP 
"F" is a main channel for beta- lactaras , especially cephalosporins. 
Mutants "A" and "B" were examined for porin modification by 
extracting their OMP proteins (Materials and Methods) and analysing them by the 
Phast System on an SDS -PAGE gel (Materials and Methods). As it can be seen in fig 
15, all the mutants "A" and "B" possessed unaltered OMP "F" and OMP "C" porins 
when compared to their control parent strain E.coli K -12 (R1). The 
expression of these two porins was found to be the same in comparison with their 
parent porins. It can be deduced from these resultsas there were no alterations in the 
porin proteins of the mutants, there was no involvement of the outer membrane 
proteins sharing resistance mechanism to clavulanic acid and cefuroxime. 
From the previous experiments it was confirmed that the hyperproduction of TEM -1 
beta -lactamase was the main resistance mechanism among these mutants 
responsible for high MIC levels to ampicillin and resistance to augmentin, even 
though the resistance mechanisms for clavulanic acid alone and cefuroxime were not 
clarified 
3.6.2B Selection of Clavulanic Acid Resistant Mutants "C" And "D" Directly 
from the E.coli K -12 Strain 
The second part of these mutation studies was to investigate the possible resistance 
tit 
mechanisms 3-teawc , is. hip. j o clavulanic acid resistant mutants "C"and "D" selected 
directly from the R1 plasmid- containing E.coli K -12 strain (fig 8). In the first stage, 
the mutants "C" were selected on 64 mg/1 of clavulanic acid. At the second stage, 
some of the "C" mutants obtained from the first stage, including the original E.coli 
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SDS -PAGE (The Phast System) of Outer Membrane Proteins Extracted from 
Standard E. coli (R1) Strain, Mutants A and B1 - B4. 
Track A - E. coli K12 (R1) Track B - Mutant 'A' (LN182) 
Track C - Mutant B1 (LN281) Track D - Mutant B2 (LN282) 
Track E Mutant B3 (LN284) Track F - Mutant B4 (LN285) 
Track G Molecular weight proteins 
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K -12 strain, were further exposed to a higher concentration of clavulanic acid (128 
mg /1). The strains obtained here were designated "D" mutants (fig 8). Mutation 
rates are shown in table 39a. 
3.6.2B1 Antibiotic Susceptibility Tests for the Mutants "C" 
The minimum inhibitory concentrations of ampicillin, clavulanic acid, the combination 
of ampicillin and clavulanic acid and augmentin of these mutants were determined 
(table 45). In addition, each mutant was tested against cefuroxime, cefotaxime and 
ceftazidime, second and third generation cephalosporins. The monobactam aztreonam 
was also included in these susceptibility tests. Resistance patterns for the mutants 
against non -beta- lactam antibiotics at fixed concentrations were also determined 
(table 45). 
The group "C" mutants were divided into two subgroups Cl -C4 and C5 -C8 on the basis of 
their ampicillin resistance levels (table 45). The subgroup Cl -C4 had increased 
resistances to both ampicillin (MIC 1280 mg /1) and clavulanic acid (MIC 80 mg /1). 
these mutants had also acquired resistance to augmentin when compared with the 
original E. coli strain. The second subgroup (C5 -C8 mutants) was the same as their 
parent strain apart from their elevated resistance level to clavulanic acid (MIC 80 
mg /1) (table 45). 
As with mutant "B ", there were some "C" mutants that became resistant to the second 
generation cephalosporin cefuroxime (>4mg /1) (table 45). This was regardless of 
their (cl-C4 and C5 -C8) differences in the MICs to ampicillin. 
The important observations made from the sensitivity testing indicated that the 






























































































































































































































































































































































































































































































































































































































































































































































































































enable the mutants "C" to become resistant to the combination of amp +clav, although 
the subgroup C1 -C4 did show some increased MICs to augmentin (table 45). When 
the mutants, tested against all common antibiotics (table 45), they had exactly 
thame resistance profile as their parent strains. 
3.6.2B2 Fractional Inhibitory Concentration Indices 
The Fractional Inhibitory Concentration Indices (FIC) to ampicillin (1.25 -2560 mg/1) 
and clavulanic acid (0.312 -320 mg/1) for the mutants "C" suggested there was no 
antagonism between those two drugs as there was no significant change in the FIC 
Index values of the combination for the mutants in comparison with that of the 
original E.coli strain (table 45). 
3.6.2B3 Resistance Levels and Patterns of Mutants "D" 
This set of mutants selected on clavulanic acid at 128 mg/1 were also divided into 
four subgroups: The first two subgroups, D1 and D2 were selected from the mutants 
Cl (ampicillin MIC 1280 mg/1) and C7 (ampicillin MIC 480 mg/1) respectively (fig 8 
and Table 46) and the second two subgroups were, D3 and D4 mutants which were 
selected directly from the original E.coli K -12 (fig 8 and table 46). 
The first subgroup mutants "D 1" had no change in their resistance levels either to 
ampicillin or to augmentin when compared to their parent strain, mutant "Cl'J 
ijowever, one of the mutants in this group did became more resistant to cefuroxime 
(MIC >8 mg/1) than its parent mutant had been. These mutants had a 4 -fold increased 
































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































The subgroup "DT did not show any changes in the resistance levels from their 
parent mutant "C7" (table 45) to the antibiotics tested (table 46), apart from the 
resistance to clavulanic acid (MIC 160 mg/1)f however, they lost resistance to 
cefuroxime which was present in their parent strain, mutant "C7" (table 45). 
The subgroup "D3" mutants, derived directly from E.coli K -12 strain, became 
significantly resistant to both ampicillin and clavulanic acid separately. The results 
are presented in table 46. Similarly, they became highly resistant to augmentin, 
reaching MIC of amoxycillin of 320 mg/1 of in the presence of 64 mg/1 of clavulanic 
acid. These were the mutants which possessed resistances to both cefuroxime ( >8 
mg/1) and cefotaxime ( >8 mg/1) (table 46). The last subgroup "D4" mutant which was 
also directly obtained from E.coli K -12 strain was found to be different from the 
"D3" mutants. Except for possessing high levels of resistances to both ampicillin and 
clavulanic acid separately, no other special features were observed for mutants "D4" 
(table 46). 
The common characteristics among these "D" mutants (D1 -D4) were that they did 
not acquire resistance to the combination of ampicillin and clavulanic acid on 
exposure to clavulanic acid alone. Furthermore, they all retained the same resistance 
patterns to other common antibiotics (table 46) as their parent strains. In addition, the 
differences in the FIC indices of drug combination (amp +clav) for these mutants 
were negligible, as there was a slight variation between them and the FIC index of 
the original E.coli K -12 strain (table 46), confirming the presence of a synergetic 
effect produced by the combination of ampicillin and clavulanic acid against these 
mutants. 
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3.6.2B4 Possible Resistance Mechanisms amongst Clavulanic Acid Mutants 
"C" And "D" 
Beta- lactamases produced in these mutants "C" and "D" were identified and 
compared to the normal TEM -1 of their parent strain E.coli to determine their part of 
contribution to acquired resistance to clavulanic acid. The results of 
analytical isoelectric focusing with a narrow range ampholine (a 1:1 mixture of pH 
4 -6 and pH 3.5 -10) showed that TEM -1 enzymes from the mutants were very similar 
to the normal TEM -1 enzyme (fig 16). 
Unlike the previous mutants, "A" and "B ", the IEF results 6 the enzymes produced 
by these mutants did not suggest that they have hyperproduced TEM -1 beta - 
lactamase. 'The specific activities of beta- lactamases of the mutants "C" and 
"D" were measured and compared to the normal TEM -1 beta -lactamase. There were 
considerable differences between the specific activities of TEM -1 beta -lactamases 
amongst the mutants (table 47). The mutants "Dl" and "D3" produced TEM -1 
enzyme with a 6 and an 8 -fold increased activities respectively. Conversely, there 
were not any noticeable differences between the specific activities of TEM -1 
fF.ey 
enzymes produced by the mutants "D2" and "D4'; and were similar to that of the 
I 
normal TEM -1 enzyme (table 47). 
The results provided by the plasmid -DNA characterisation revealed that the 
plasmids harboured by the mutants had no plasmid rearrangement. The sizes and the 
number of plasmids isolated from the mutants were exactly the same as the original 




A B C 
This experiment was performed on three separate occasions and the result 
shown is representative of that found on each occasion. 
Figure 16 
Isoelectric Focusing of TEK -1 Beta -lactamases from Mutants 'C' and 'D' 
Groups and their parent E. col. Strain. 
Track A - Group 'C' mutants Track B - Group 'D' mutants 
Track C - E. coli K12 (R1) 
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Table 47 
Specific Activities of the Mutants 'C' and 'D' 
Parent strain Mutant No. Specific activities* 





17.0 - 18.9 E, Coll K12 
(1 -4) 
E, coli K12 (R1) C 15.0 - 17.0 
(5 -8) 
Mutant C1 D 113.0 
(a,) 
Mutant C7 D2 18.0 - 20.0 
(a -f) 
E. coli K12 (R1) D 
(a,g) 
158.9, 277.0 
E, coli K12 (R1) D 115.0 
(al 
* u moles nitrocephin hydrolysed /min /mg protein 
This result represents the average of two separate determinations 
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This experiment was performed on two separate occasions and the result shown 
is representative of that found on each occasion. 
Figure 17 
Plasmid DNA Profile of Mutants 'C' and 'D' Groups with the Standard R1 
Plasmid. 
Track A - Plasmid R6K 
Track C - Plasmid R1 
Track B - Plasmid R1010 
Track D - Mutants 'C' 
(LN249, 251 -256) 
Track E - Mutants 'D' 
(LN268- 275,277 -279) C = chromosomal DNA 
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3.6.2B5 Transferability of the Clavulanic Acid Resistance from 
the Mutants "C" and "D" 
The acquired resistances to clavulanic acid and other antibiotics (table 45 and 46) 
in the mutants "C" and "D" were investigated to see whether the resistance 
determinants were associated with the plasmid. All mutants IICH and "D" were 
subjected to conjugation with the standard recipient strain E, coli J62.2, to select 
the resistances for ampicillin and clavulanic acid alone. Overnight broth cultures 
of both donor and recipient strains were mixed in a ratio of 1:10 in a pre-warmed 
nutrient broth and incubated statically for another 18 hours as described in the 
Materials and Methods. As with the previous results obtained for the mutants "A" and 
"B ", no other resistances were transferable from mutants "C" and "D" except the 
ampicillin resistance determinants. The transconjugants from these mutants selected 
on plates containing ampicillin were examined and compared to their parent strains. 
The transconjugants were different from their parent mutant strains but they were 
exactly the same as the original R1 plasmid containing E. coli strain in all 
respects. 
The study of the mutants "C" and "D" revealed that the prime factor responsible for 
the acquired resistances to clavulanic acid, augmentin, cefuroxime and cefotaxime and 
also an increased resistance to ampicillin might have been diminished permeability of 
the drugs. This may have been in association with a high amount of beta - lactamase in 
some of the mutants obtained on exposure to clavulanic acid alone. 
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3.6.3 Factors Influencing the antibacterial activity of Beta - 
Lactams Plus Beta - lactamase Inhibitor in E. coli Strains 
Producing Extended - spectrum Beta - lactamases 
Studies were performed to determine the relationship between beta-lactamase and 
antibacterial activity of the combination of ampicillin and clavulanic acid against 
TEM -3, TEM -5 and TEM -7 beta - lactamases produced in E, coli J53. 
3.6.3A Effect of the Inoculum Size 
Mutants of TEM-3, TEM-5 and TEM -7 enzymes which were resistant to ampicillin in 
combination with clavulanic acid (amp +clav) were selected at different antibiotic 
concentrations (12.5 +2.5; 25 +5 and 50 +10 mg /1 of amp +clav). During the attempts to 
select the mutants, it was revealed that these strains producing extended - spectrum 
stable beta - lactamases were able to overcome the effect of the combination of 
amp +clav provided the inoculum size was high (1x109cfu). 
The effect of the bacterial density of these strains in relation to their resistance 
to amp +clav was observed in two different ways. Bacterial cultures were diluted from 
1x109 cfu into a series of dilutions and each dilution was spread onto the plates 
containing increasing concentrations of amp +clav (table 48). These results suggested 
that the bacterial strains showed increased sensitivity as the inoculum size was 
reduced to amp +clay. No growth was seen at the higher concentrations of the drug 
combination (50 +10 mg /1 of amp +clav) against the lowest dilution (1x103cfu) of the 
bacterial cultures (table 48); however, the MICs of a bacterial culture 105cfu (the 

























































































































































































































































































































































































































































































































































































































































comparison with a concentration of 109cfu of bacterial culture. 
In similar way, even at the highest inoculum (1x109cfu) of each bacterial culture, 
it was clear that the E.coli strains became sensitive as the concentration of amp +clav 
increased (12.5 +2.5 < 25 +5 < 50 +10 mg/L) (table 48). 
Some strains which seemed to be mutants grew at the highest concentration of 
the combined drug (50 +10mg /1 of amp+clav) after long exposure (6ührs) to the 
combination. It is possible, however, that the long exposure destroyed the 
beta -lactam antibiotics in the selection plates and that the strains that 
emerged were not resistant mutants. Despite this, two "mutants" were obtained 
from each E. coli strain producing TEM-3, TEM-5 and TEM-7 beta -lactamases. 
The presumed mutants were designated as 1M to 6M (mutants 1M-2M; 3M-4M; 5M-6M 
obtained from TEM-3, TEM-5 and TEM-7 producing E. coli strains 
respectively)(table 48). 
3.6.3B Sensitivity Testing of Mutants "1M " -"6M" 
They were maintained on the plates containing amp+clav as they seemed to be 
unstable mutants. These mutants were examined for their MIC levels to beta -lactams 
(ampicillin, clavulanic acid, amp +clav and augmentin) and also other non -beta- 
lactam antibiotics. The results revealed that none of the mutants "1M " -"6M" acquired 
a stable resistance to the antibiotic -inhibitor combination as they could not grow 
even at lowest concentration of ampicillin in the presence of clavulanic acid 
( <10 +8mg/1) (table 49). On the other hand, all of them,including the corresponding 
parent strains,grew on plates containing augmentin (table 49). 
some other changes were noticed among these 
presumed mutants "1M -6M ". The mutants 3M and 4M were the only ones which had 
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Table 49 
Resistance Levels and Patterns of Mutants 1M - 6M 




No. Amp A + C Aug 
Resistance 
patterns 
F. coli K12b - >2560 - 20 + 4 Ap Ce Cm Km Sm Sp Tc Tp 
(J53) 
E, coli Kl2b 1M >2560 - 20 + 4 Ap Ce Cm Km Sm Sp Tc Tp 
(J53) 
E, coli K12b 2M >2560 - 20 + 4 Ap Ce Km Sm Sp Tc Tp 
(J53) 
E. coli K12c - 640 - 20 + 4 Ap Ce Cm Km Sm Sx Tc 
(J53) 
E. coli K12c 3M 2560 - 20 + 4 Ap Ce Cm Km Sm Sx Tc 
(J53) 
E, coli K12c 4M 2560 - 20 + 4 Ap Ce Km Sm Sx Tc 
(J53) 
E. coli K12d - >2560 - 40 + 8 Ap Ce Gm Km Sx Tc 
(J53) 
E. coli K12d 5M 1280 - 10 + 2 Ap Ce Gm Km Sx Tc 
(J53) 
E. coli K12d 6M 1280 - 10 + 2 Ap Ce Gm Km Sx Tc 
(J53) 
a = Minimum inhibitory concentrations 
b = TEM -3 beta -lactamase producing E. coli K12 (J53) strain 
c = TEM -5 beta- lactamase producing E. coli K12 (J53) strain 
d = TEM -7 beta -lactamase producing E. coli K12 (J53) strain 
A+C = Ampicillin + clavulanic acid (8 mg /L) 
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(4 -fold) elevated MICs of ampicillin compared to their parent strain E.coli. the TEM- 
5 enzyme producing organism. A particularly interesting feature in the mutants 5M 
and 6M, obtained from TEM -7 enzyme producing E.coli strain, was drop of its MIC 
levels both to ampicillin and augmentin (table 49). 
The common feature among these mutants ("1M-6M") was that loss of resistance to 
chloramphenicol in some mutants and retention of other resistances compared to 
their parent strains (table 49). 
3.6.3C Comparison between Resistances to Augmentin and Ampicillin/ 
Clavulanic acid among the Mutants and their Parent Strains 
It was observed that the strains producing TEM -3, TEM -5 and TEM -7, the extended - 
spectrum beta -lactamases, were more resistant to augmentin than to ampicillin in 
association with clavulanic acid. Both parents and their mutants (" 1M -6M ") were 
able to grow in the presence of amoxycillin and clavulanic acid ( MIC 20 +8 mg/1 for 
1M -4M mutants and their parent strains and 40 +8 mg/1 for TEM -7 producing E.coli 
strain) (table 49). But the same strains with the same inoculum (1x105cfu) were not 
able to grow in the same concentration level of amp +clay. j;s.espite their 
high levels of resistance to ampicillin and resistance to augmentin that they already 
possess, this did not enable them to acquire resistance to the combination amp +clay. 
However, the mutants 5M and 6M had 2 -fold decrease in their resistance levels to 
both ampicillin and augmentin (table 49) after being exposed to ampicillin and 
clavulanic acid. 
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3.6.4 Mutants Resistant to the Combination of Ampicillin and 
Clavulanic Acid from the R1010 Plasmid- containing 
Standard E. coli K12 Strain 
The beta - lactamase encoded by the plasmid R1010 of the standard strain E. cQli is 
SHV -1 enzyme, a broad - spectrum beta -lactamase, sensitive to inhibition by clavulanic 
acid. This enzyme is similar to TEM-1 beta-lactamase in its substrate profile. Thi 
clavulanic acid sensitive strain was exposed to a fixed combination of ampicillin 
(50 mg /1) and clavulanic acid (8 mg /1, a subinhibitory concentration). The resistan 
mutants were selected on the Oxoid DSTA plates with the incorporated antibiotics and 
purified on the same selective media. The calculation of mutational frequencies too 
place by counting the viable colonies on the purified plate and referring them to 
the total viable count of bacterial colonies on the control plates of MacConkey agar 
(see Table 50): 
Table 50 
Bacterial Strain 
Viable counts on 
= E. coli K12 J53 (R1010) 
control plates = 1.98 x 108 
Viable counts on 
antibiotic plates = 1.57 x 103 
Mutational frequency = 7.9 x 10-5 
This result was confirmed on two separate occasions. 
Of these mutants, six well grown and separated colonies were randomly selected and 
again purified. These mutants were designated as "S1 -S6" and studied in detail. 
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3.6.4A Susceptibility Patterns of the mutants "S1 -S6" 
The selected mutant strains (S1-S6) concurrently with their parent strain E. coli 
K -12 J53 (R1010) were examined for their MICs of beta-lactam antibiotics (table 51). 
This sensitivity testing also included the second and third generation cephalosporins 
such as cefuroxime, cefotaxime and ceftazidime, and the monobactam aztreonam (table 
51). 
The results showed that all the mutants ( "Sl -S6 ") had raised MICs (>2560mg/1) of 
ampicillin (an 8 -fold increase) (table 51). The MICs of ampicillin in the presence 
of clavulanic acid were not significant, even though these were mutants resistant to 
the drug combination. This can be shown by the fact that at a bacterial density of 
105 there was only a 2 -fold increase in resistance to the drug combination and even 
more elevated MICs were noticed with the increased bacterial inoculum (109) (table 
51). On the other hand, all the mutants possessed a significant MIC (i.e. 80mg /1 of 
amoxycillin and 16mg /1 of clavulanic acid) to the drug augmentin compared to amp +clav 
combination (table 51) even at lower inoculum sizes (105cfu). In summary, the 
mutants acquired 2 -fold increases in MIC for amp +clav and 4 -fold increases in MIC for 
augmentin at a bacterial density of 105cfu in comparison with the standard parent 
strain. 
In addition, the mutants became more resistant to the second and third generation 
cephalosporins and also the monobactam aztreonam (table 52). There was a 2 -fold 
increased resistance to cefuroxime. The striking features were the resistance levels 
to ceftazidime which was about an 18 -fold increase and a 4-fold increase in MIC 
levels of cefotaxime compared to the parent strain. The resistance to the drug 









MICs (mg /L) 
Ampa 
(105 cfu)e 
A + Cb A + Cc 
(105 cfu)e (109 cfu)e 
AAugd 
(10 cfu)e 
F, coli K12 - 320 10 + 8 10 + 8 20 + 4 
(R1010) 
E. coli K12 S1 >2560 20 + 8 80 + 8 80 + 16 
(R1010) 
E. coli K12 S2 >2560 20 + 8 80 + 8 80 + 16 
(R1010) 
E. coli K12 S3 >2560 20 + 8 80 + 8 80 + 16 
(R1010) 
E. coli K12 S4 >2560 40 + 8 80 + 8 80 + 16 
(R1010) 
E. coli K12 S5 >2560 40 + 8 80 + 8 80 + 16 
(R1010) 
E. coli K12 S6 >2560 20 + 8 80 + 8 80 + 16 
(R1010) 
a = Ampicillin 
b = A + C, Ampicillin in the presence of 8mg /L of Clavulanic acid, 
c = A + C, Ampicillin in the presence of 8 mg /L Clavulanic acid 
d = Augmentin (Amoxycillin + Clavulanic acid; 2.5/0.5 - 160/32 mg /L) 
e = bacterial density, cfu /ml. 
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Table 52 
Resistance Levels and Resistance Patterns of Mutants Si - S6 
Resistance levels to 




No. Cima Ctxb Cazc Azd 
Resistance 
patterns 
E. coli K12 - 8 0.06 0.5 0.5 Ce Cm Sm Sx 
(R1010) 
E, coli K12 S1 >8 0.5 >8.0 1.0 Ce Cm Sm Sx 
(R1010) 
E. coli K12 S2 >8 0.5 >8.0 1.0 Ce Cm Sm Sx 
(R1010) 
E, coli K12 S3 >8 0.5 >8.0 1.0 Ce Cm Sm Sx 
(R1010) 
F. colt K12 S4 >8 0.5 >8.0 4.0 Ce Cm Sm Sx 
(R1010) 
E. coli K12 S5 >8 0.5 >8.0 1.0 Ce Cm Sm Sx 
(R1010) 
E. coli K12 S6 >8 0.5 >8.0 1.0 Ce Cm Sm Sx 
(R1010) 
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strain (S4) was shown to be significantly resistant to this drug (an 8 fold increase). 
Both the mutants and standard E.coli strain had the same resistance 
patterns to other non -beta -lactam antibiotics (table 52). 
It can be deduced from these results that the exposure to the combination of 
amp+clav diminish` the bacterial sensitivity to the later generation 
cephalosporins whatever their resistance mechanisms might be) therefore, firstly, 
beta -lactamases produced by the mutants were investigated as a possible resistance 
mechanism. 
3.6.4B Comparison of Beta -lactamases from Both the Mutants (S1 -S6) and 
Original Parent Strain E.coli K12 (R1010) 
Beta- lactamases produced by the mutants were identified by analytical isoelectric 
focusing. The comparison of the mutant enzymes and the standard SHV -1 enzyme 
was made on a polyacrylamide gel with a 1:1 mixture of 6 -8 and 3.5 -10.0 
ampholines ¿,y a high resolution. The critical comparative studies 
revealed one of the main satellite bands disappeared in the mutant beta -lactamases 
which was prominently present in the standard SHV -1 enzyme (fg 18). Apart from 
this observation, mutant beta- lactamases were identical to their parent enzyme with 
respect to their band patterns. The effect of these mutant beta -lactamases, 
was tested against selected substrateswhich the mutant strains became resistant. 
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This experiment was performed on four separate occasions and the result shown 
is representative of that found on each occasion. 
Figure 18 
SHV -1 Beta - lactamases Extracted from the Standard Strain E. coli K12 
and from its Mutants S1 - S6 
Tracks A -F - Mutants S1 - S6 
Track G - F. cols K12 (R1010) 
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3.6.4c Biochemical Properties of the Beta -lactamases Produced by the Mutants 
"S1 -S6" 
The protein concentration and, subsequently, specific activities of the beta -lactamases 
of the cell -free extracts of the mutants were measured and compared to the standard 
SHV -i enzyme (table 53). The results showed that there was anincrease in the 
specific activities of the mutant enzymes with some variation between them. There 
1cÁ11í ;nt cci 
was a 3 -5 fold increased activity in 4 mutants ktheir parent strain. The other 
two mutants (S1 and S4) produced enzymes with a significant 17 -fold and a 32 -fold 
increased activities respectively, compared to = the parent 
enzyme. Despite the increased specific activities, all the enzymes remained sensitive 
to clavulanic acid in the presence of nitrocephin as a substrate (ID50 >10 -7M) like 
their parent enzyme. 
The substrate profiles (table 53) of these enzymes (S 1 -S6 mutants) showed that they 
had a rate of hydrolysis (penicillin 100 %) against ampicillin similar to SHV -1 beta - 
lactamase, kowever, they had less effect on cephaloridine (3.4 -fold) than the 
standard enzyme. They differed from SHV -1 by hydrolysing cefotaxime. Even 
though the hydrolysis of cefotaxime was clearly detectable, the relative rate of 
hydrolysis of this antibiotic became less significant (0.031 %) when this activity was 
referred to the activity against penicillin (table 53). Following this, all the mutant 
strains ( "S 1 -S6 ") were subjected to conjugation to examine the transferability of the 
resistances that they acquired. 
3.6.4D Experiments on the Feasibility of the Transferable Resistances 
Conjugation experimentswert conducted employing the standard recipient strain 
E.coli J62.2; and an attempt was made to select on the DM plates 
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Table 53 







Relative ratesa of 
hydrolysis ( %) 
Pen Amp Cer Ctx 
E, coli K12 - 0.700 100 212 56 NH 
(R1010) 
E. coli K12 S1 12.19 ND ND ND ND 
(R1010) 
E. coli K12 S2 2.2 ND ND ND ND 
(R1010) 
E, coli K12 S3 3.32 ND ND ND ND 
(R1010) 
E. coli K12 S4 22.7 100 143.9 16.6 0.031 
(R1010) 
E. coli K12 S5 2.24 ND ND ND ND 
(R1010) 
E. coli K12 S6 3.6 ND ND ND ND 
(R1010) 
a = Spectrophotometric assay method (expressed as a percentage of the 
value for benzyl penicillin) 
Specific activities = u moles hydrolysed /min /mg protein 
ND = not done 
NH = no hydrolysis 
This result represents the average of two separate determinations 
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containing appropriate (ampicillin 10mg/1; cefuroxime, ceftazidime, cefotaxime and 
aztreonam 0.7mg/1) antibiotics. The results were negative showing no transferability 
even of ampicillin resistance. 
Attempts to transfer. resistances were continued with the mobilising 
factor X. The method is described in the Materials and Methods section. 
No resistances were mobilisable from these mutants; therefore, further investigation 
was carried out for characterisation of the plasmid- content of the mutants "S1-S6" 
which must be the genetic basis for the hyperproduction of the beta- lactamases. 
3.6.4E Characterisation of Plasmid DNA 
The extra -chromosomal DNA of the mutants ( "S1 -S6 ") was isolated and analysed by 
agarose gel (0.5 %) electrophoresis according to the method described by Takahashi 
and Nagano (1984). The molecular mass of plasmids from the mutants were 
observed as slightly larger in their sizes with respect to the standard R1010 plasmid 
(fig 19). The uncertainty of the result suggest that a plasmid restriction digest might 
evaluate the plasmid size and if there had been any plasmid rearrangement. The 
plasmids were restricted by Hind III restriction enzyme (Materials and Methods). A 
single restricted fragment was detected in all the mutants and that included the 
standard plasmid R1010. All the restricted fragments migrated the same distance in 
the 0.7% agarose gel (fig 20). The sizes of these restricted fragments were calculated 
from the calibrated graph of known sizes of the lamda DNA which co- migrated 
in the gel with the sample DNA fragment. 
The ..Cz I.r a plasmid rearrangement 
in the form of "up mutations" of the promoter on the plasmids of the mutants, in 
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This experiment was performed on four separate occasions and the result shown 
is representative of that found on each occasion. 
Figure 19 
Plasmid DNA Profile of the Standard E, coli K12 (21010) and of its 
Mutants S1 - S6. 
Track A - Plasmid R6K 
Track C - Plasmid R1 
c = chromosomal DNA 
Track B - Plasmid R1010 
Tracks D -I - Mutants S1 - S6 
(LN306 -311) 
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Bind III Digestion of the Plasmids from the Standard E, coli K12 
(R1010) and its Mutants S1 - S6. 
Track A -ADNA 
Tracks B-G - Mutants Si - S6 (LN306 -311) 
Track H - E. coli K12 (R1010) 
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which case it was not possible to detect any changes in the plasmid. As it appeared 
that hyperproduction of beta-lactamases in the mutants was not sole resistance 
mechanism for their acquired resistances to the drug combination (amp +clav) and 
cephalosporins, the outer membrane proteins of the mutants were examined as a 
possible resistance mechanism. 
3.6.4F Analysis of Outer Membrane Proteins of the Mutants "S1 -S6" 
The OMPs were extracted from 100 ml overnight cultures as described in Materials and 
Methods. The final OMP pellets were resuspended in 0.5 ml of 25 mM sodium phosphate 
buffer to increase the protein concentration. The protein concentrations were 
adjusted to 20-30 ng /pl. The Phast System Gradient gels (SDS -PAGE, 8-25) were used 
to focus the OMP bands. Molecular weight markers were also run simultaneously. 
The profile of the outer membrane proteins of the mutants S1 -S6 were no different 
from their parent strain E. coli K12 (R1010) with respect to the porins OMP "F" and 
OMP "C" (Fig. 21). These two porins are considered as important channels for beta - 
lactam antibiotics into the E. coli K12. The molecular weight of these porins are 
36K (OMP "F ") and 40K (OMP "C "). 
There was no alteration of these porin proteins in the mutants conferring resistances 
to the combination of ampicillin +clavulanic acid, the second (cefuroxime) and the 
third (cefotaxime and ceftazidime) generation cephalosporins, and also the monobactam 
aztreonam (Fig. 21). 
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This experiment was performed on two separate occasions and the result shown 
is representative of that found on each occasion. 
Figure 21 
SDS -PAGE (the Phast Sytem) of Outer Membrane Proteins 
Standard F. coli (R1010) Strain and Mutants S1 - S6. 
Track A - 
Track C- 
Track E - 
Track G - 
Molecular weight proteins 
Mutant S2 (LN307) 
Mutant S4 (LN3O9) 
Mutant S6 (LN311) 
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Extracted from 
Track B - Mutant S1 (LN306) 
Track D - Mutant S3 (LN308) 
Track F - Mutant S5 (LN310) 
Track H - E. cola K12 (R1010) 
The resistance to the drug combination (amp+clav), augmentin and high 
level ampicillin resistance must be the hyperproduction of SHV -1 beta -lactamase. 
Furthermore, this SHV -1 enzyme from the mutants was able to hydrolyse the third 
generation cephalosporin cefotaxime but not the other cephalosporins (cefuroxime 
or ceftazidime) and the monobactam aztreonam. It was difficult to ekeIroontrahe 
genetic location of resistances to these antibiotics (cefuroxime, ceftazidime and 
aztreonam) as the SHV -1 encoding plasmid R1010 from these mutants was neither 
transferable nor mobilisable. It could be argued that resistances to cefuroxime 
ceftazidime and aztreonam resulted from the hyperproduced SHV -1 beta - 
lactamase; but this hyperproduced enzyme could not break down these antibiotics as 
it had done with ampicillin +clavulanic acid and augmentin.. ,1t appears that 
mutated SHV -1 beta -lactamase is responsible for the hydrolysis of cefotaxime like 




4.1 Beta -lactam Resistance in South India 
Bacterial evolution and the emergence of antibacterial drug resistance continue to 
interfere with the successful treatment of both community and nosocomial infections. 
Large amounts of antibiotics, especially tetracyclines, broad - spectrum 
penicillins /cephalosporins and sulphamethoxazole -trimethoprim, are being used 
throughout the world (Col and Conner, 1987). In most cases, the epidemiology is not 
studied and the spread of drug resistance not only goes unchecked but can also 
remain largely unnoticed. Almost all controlled surveys on beta -lactam resistance 
had been performed in Europe and North America (Medeiros, et al., 1980; Simpson, 
Harper and O'Callaghan, 1980; Medeiros, Gilleece and O'Brien, 1981; Roy et al., 
1983, 1985; Gruneberg, 1984; Stobberingh, Houben and Van Boven, 1985; Simpson 
et al., 1986; Huovinen, Huovinen and Jacoby, 1988b; Reid et al., 1988b; 
Wiedemann, Kliebe and Kresken, 1989; Morfin -Otero et al., 1990) but not in 
developing countries. The first part of this thesis studied the incidence and 
type of beta -lactam resistance among enterobacterial pathogens isolated from 
significant bacteriuria, as well as Salmonella and Shigella isolates obtained from 
gastro -intestinal infections, over a three month period from the Christian Medical 
College Hospital, Vellore, South India (Young et al., 1986). In addition, biochemical, 
genetical and molecular biological aspects of the resistance mechanisms were 
investigated. 
Ampicillin, amoxycillin and some cephalosporins had been in use for the 
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treatment of most infections (Urinary tract and gastro -intestinal) at the Christian 
Medical College Hospital in Vellore during the period over which the survey was 
conducted. These . results revealed that there was a high incidence of 
ampicillin resistance (80.9 %), and more than half of them were highly resistant to the 
drug (MIC >1280mg/1). The high proportion of the highly ampicillin resistant strains 
indicated the presence of plasmid -associated beta -lactamases among this resistant 
population. There have been different surveys on the epidemiology of plasmid- 
mediated beta -lactamases in Gram -negative bacteria isolated from different sources 
(faecal and urinary); .but some surveys did not state the total number of strains 
obtained and source of the isolates (Roy et al., 1983, 1985; Simpson et al., 1986; 
Huovinen, Huovinen and Jacoby, 1988; Wiedemann, Kliebe and Kresken, 1989). 
.fie high incidence of ampicillin resistance of the present study had never 
been found before in similar surveys of urinary isolates of Enterobacteriaceae. Even 
in the recent Scottish multicentred survey (Reid et al., 1988b) where ampicillin 
resistance was believed to be unprecedented in the UK, the level of resistance was 
only 52.1 %. In other surveys, E.coli had been the prevalent species (Gruneberg, 
1984; Simpson et al., 1980, 1986) followed by Klebsiella spp (Simpson et al., 1980, 
c -} 1-k;1 
1986). The 
survey 
w tesimilar in that E.coli was the most common pathogen. 
These Indian pathogens had hardly been exposed to cephalosporins (Collee and 
Amyes, 1986). Despite the lower usage of cephalosporins, most (65.1 %) of the 
enterobacterial pathogens derived from urinary infections were resistant to 
cephaloridine; this included the E.coli strains (57.2 %). This high proportion of 
resistance was even greater than in the earlier survey reports, i.e., 34% in London and 
28.8% in Scotland (Gruneberg, 1984; Reid et al., 1988b).. In this survey, 
only a very few isolates were highly resistant to cephaloridine (MIC >1280mg/1) 
which might indicate the lower cephalosporin usage. In the population of gastro- 
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intestinal pathogens (Salmonella and Shigella spp), only a few strains were resistant 
to cephaloridine. 
The resultsof this thesis suggest . that the high incidence of beta -lactam resistance 
among these Indian pathogens was derived from the general acquisition of the 
resistance genes by naturally sensitive bacteria (E.coli, Salmonella, Shigella spps) 
and was unbiased by the undue presence of intrinsically resistant species. As beta - 
lactam resistance has become prevalent among these sensitive bacteria (E.coli, 
Salmonella and Shigella spps), this has caused clinical resistance problems in India. 
In conclusion, the results for the incidences of ampicillin resistance in India were the 
highest in the world as previous surveys have shown variation in ampicillin 
resistance with the incidences range from 17 -72% (Shales and Currie - 
McCumber,1989). 
Resistance to later generation cephalosporins can also be a major problem in 
clinical situations and one of the main reasons for antibiotic research in this area. 
In most cases in this survey, only a small proportion of isolates (both 
urinary and gastro -intestinal) were shown to be resistant to either the second czar 
third generation cephalosporins tested. A noticeable proportion of urinary pathogens 
(18 %) and a remarkable percentage of Salmonella isolates (65.7 %) were identified as 
cefuroxime resistant (MIC >8mg/1). No previous surveys have reported incidences 
reaching these levels. In addition, there were five E.coli isolates which were resistant 
to the whole series of cephalosporins tested; h owever, the resistances were not 
transferable and resistance mechanisms were assumed to be alterations in the 
membrane permeability (NB. TEM -1 was the only beta -lactamase produced by these 
bacteria). The same resistance mechanism was very likely to be responsible in the 
cefuroxime resistant urinary isolates. Usually, resistances to later generation 
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cephalosporins (3GC) are manifested by inducible chromosomal beta -lactamases 
(Quinn, DiVincenzo and Foster, 1987) or by slow hydrolysis of antibiotics mediated 
b 
by beta -lactamase (Vu and Nikaido, 1985) orpiminished penetration of these agents 
across the bacterial outer membrane (Bush et al., 1985; Nikaido, 1989). To this list 
may now be added active and stable plasmid- mediated beta -lactamases, which 
inaLb.y : 3GC drugs (Philippon, Labia and Jacoby, 1989; Bush, 1989; Payne, Marriott 
and Amyes, 1989; Payne et al., 1989). These new enzymes now occur frequently 
(Philippon et al., 1989; Bush and Singer, 1989). The widespread 
cefuroxime resistance amongst Salmonellae, was found to be associated with R- 
plasmid mediated OXA -1 like enzyme and this is further discussed below. 
The ampicillin susceptibility of the urinary pathogens, in the presence of the beta - 
lactamase inhibitor clavulanic acid had dropped to 41.5% (MIC of ampicillin >10- 
1280mg/1) and only 7 strains of Klebsiella, Proteus and Enterobacter spp. were 
highly resistant to this combination (MIC of ampicillin >1280mg/1). In contrast, a 
large proportion of salmonellae (62.7 %) were resistant to this drug combination. On 
the other hand, very few isolates of shigellae were shown to resist ampicillin in the 
presence of clavulanic acid. The resistance to the combination of ampicillin and 
clavulanic acid can result (a) from changes in the cell wall, (b) from the production 
of new types of beta -lactamases and (c) most probably from the hyperproduction 
of the certain plasmid- mediated beta -lactamases such as TEM -1 or SHV -1 (Sanders 
et al., 1988; Martinez et al., 1988). Indeed, in the present study, three E.coli clinical 
isolates were found to produce the high quantities of R- plasmid- encoded TEM -1 
beta -lactamases required to overcome the combination. 
The most common mechanism by which clinically important bacteria become 
resistant to beta -lactam antibiotics is by acquisition of plasmid encoded beta- 
203 
lactamases. It is evident that R- plasmids evolve by a series of events that are 
initiated in many cases by the association of resistance determinants with 
transposable DNA sequences. Transfer of the resulting transposons to conjugative or 
nonconjugative mobilisable plasmids can lead to the spread of the determinants to 
other members of the species or closely, or even distantly, related species (Saunders, 
Hart and Saunders, 1986), and, thus, a worldwide spread of antibiotic resistance 
occurs. Transferable resistances in clinical isolates should be txamna)in 
epidemiological studies to evaluate the genetics of resistance determinants 
and their potential to disseminate. This is most comprehensively performed in 
parallel with biochemical investigations (e.g. beta -lactamase evaluation). Most 
previous studies in the literature only concentrated on biochemical analysis i.e. 
designation of plasmid- mediated beta- lactamases was made purely on the basis of 
biochemical results and no plasmid analysis was performed (Medeiros et al., 1980; 
Simpson, Harper and O'Callaghan, 1980; Medeiros, Gilleece and O'Brien, 1981; Roy 
et al., 1983, 1985; Simpson et al., 1986; Wiedemann, Kliebe and Kresken, 1989; 
Morfin -Otero et al., 1990) f From the results in this thesis, it has been shown that 
many clinical isolates produced typical plasmid- mediated beta -lactamases, but the 
resistance genes encoding these enzymes were neither transferable or mobilisable. 
This result implies that determination of the genetic location of the beta -lactamases 
on the basis of biochemical evidence is not reliable. In a recent report, a new beta - 
lactamase (CMY -1), with a high pI 8.0 appeared to be chromosomally- determined. 
This was based on biochemical characteristics (isoelectric focusing and sensitivity 
testings) but conjugation experiments determined that it was a plasmid- mediated 
extended - spectrum beta -lactamase ( Bauernfeind, Chong and Schweighart, 1989). 
As it is possible to be misled by the employment of certain biochemical 
criteria, only a full characterisation of enzymes and the genetics of the gene will 
reveal the true nature of beta -lactam resistance. 
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A large number of ampicillin resistant clinical E. coli isolates (66.9 %) possessed 
R- plasmids. This includes both autotransferable and mobilisable plasmids. The 
incidence of transferability was lower in other species of ampicillin resistant 
strains (Klebsiella spp, 51.4 %; Shigella spp, 31%; and Salmonella spp, 15%). These 
data indicate only the self-transferable plasmids in those species. On most 
occasions transferability was found only in those strains which had high MICs of 
ampicillin (>1280 mg /1). This was true in all isolates except Shigella strains. 
Some transconjugants of shigellae showed higher MIC levels of ampicillin than their 
corresponding clinical isolates. This might result from better expression of 
resistance genes in the transconjugant strains than in their host strains. Certain 
plasmids sometimes are known to be expressed more efficiently in some host strains 
than others (Reid et al, 1988a). 
On the other hand, resistance to cephaloridine was freely transferable from the 
strains of E, coli and some Klebsiella species despite the low MICs of the drug. 
Cephaloridine resistance was not transferable from the salmonellae. One interesting 
finding was that transferable resistance to ampicillin was often not accompanied by 
the transfer of resistance to cephaloridine (E. coli, Klebsiella, Salmonella and 
Shigella spp.) and vice versa (E. coli). This observation was made in the strains 
which produced the broad - spectrum TEM -1 and the penicillinase OXA -1 beta-lactamases 
and, amongst the Klebsiella spp., another broad-spectrum enzyme, SHV-1. Even though 
in some transconjugant strains TEM -1 was present in association with either OXA -1 or 
SHV -1, this combination did not enhance activity against cephalorídine in the intact 
cells. 
These observations strongly suggest that the permeability of the clinical strains, in 
addition to the production of the beta-lactamases, might be a very important factor 
in the development of resistance. This can be explained as follows: in E. coli K12, 
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ampicillin permeates two to three fold more slowly than the cephaloridine which can 
be predicted from the differences in hydrophobicity. Penicillins have about a four 
times higher partition coefficient in octanol /water than the corresponding 
cephalosporins (Yoshimura and Nikaido, 1985). The relative rate of diffusion 
constant of cephaloridine is 167 whereas the equivalent for ampicillin is 46 
(Yoshimura and Nikaido, 1985). These values indicate that ampicillin enters the 
periplasmic space of bacteria rather more slowly than cephaloridine. The TEM -1 
enzymes have a much lower affinity for cephaloridine (16 -20 fold) than for ampicill: 
(Medeiros, Kent and O'Brien, 1974; Bush and Sykes, 1984); therefore, for TEM -1 
producing strains, the differences in permeability to cephalosporins and penicillin; 
in addition to differences in the TEM -1 affinity for the substrates might explain tl 
differences in the susceptibilities to cephaloridine and ampicillin in the E. coli 
K12 J62.2 transconjugants. This also explains why, although in vitro the Vmax value 
for the hydrolysis of cephaloridine are high, they are not rapid enough to inactivat 
sufficient beta - lactam and thus the amount of cephaloridine soon reaches a level 
which is lethal for E, coli K12. 
In all individual bacterial spp. (E, coli, Tlebsiella, Salmonella and Shigella) a 
wide variety of R- plasmid types were identified (minimum 8 types - maximum 38 types) 
This variation of plasmid type suggests that high -level beta - lactam resistance was 
not a consequence of the spread of a single or even a few plasmid types cross - 
infecting the whole bacterial population. Almost all the R- plasmids possessing beta 
lactam resistance genes also carried genes for other antibiotics; and, alarmingly, 
most of them conferred resistance to six or more drugs. 
There are various factors interfering with plasmid transfer in vivo. The 
experimental models have revealed two major factors: 1) in general, there is a 
reduction of growth rate of 
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plasmid bearing bacteria in the mammals' digestive tract. This is a result of general 
dominance of antibiotic susceptible bacteria, 2)1he efficiency of in vivo plasmid 
transfer does not differ from that occurring in vitro (Corpet,1986); however, very 
low rates of in vivo plasmid transfer are possible, 11% are related mainly to the 
population densities of E.coli in the gut (Corpet, 1986). These reports indicate the 
importance of the investigation of transferable resistances in the clinical isolates and 
to take account of the variation under different clinical conditions. 
Plasmids in general vary in size up to greater than 400kb (Timmis et al., 1986). In 
the present study, there was considerable variation in the size of plasmids, ranging 
from as small as 11.5kb and as large as >200kb. Even though small (<16Md or 
<24kb) transferable plasmids are unlikely to occur (Wiedemann, 1981), there was a 
report Gt a plasmid (erythromycin, clindamycin and streptogramin resistant) as 
small as 10Md (15kb) found to be transmissible in Bacteroides fragilis (Jacoby, 
1985). Some of these small plasmids could be transferable though it is not clear 
what the mechanism of transfer is. 
In relation of ampicillin resistance to other common antibiotic resistances, the 
association of combined resistance genes of trimethoprim and sulphamethoxazole 
with the ampicillin resistance genes was widespread. This might rk. 1ec:+t the high 
usage of co- trimoxazole in Vellore, South India, for the treatment of urinary 
infections (Young et al., 1986). 
The distribution of beta -lactamases in the transconjugants of E.coli, Klebsiella spp, 
Salmonella spp and Shigella spp and the rest of the E.coli isolates from which 
resistance genes could not be transferred (t_itxir transfer or mobilisation) was 
studied by the isoelectric focusing (IEF) method. Isoelectric focusing has proved a 
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extremely useful tool for the detection of beta -lactamases in cell -free extracts, and 
has been used successfully in a number of previous surveys (Medeiros, 1984, 1989; 
Roy et al., 1983, 1985; Simpson et al., 1980, 1986; Reid et al, 1988b). This method 
has been one of the most sensitive for epidemiological purposes as it 
is able to produce very reproducible pIs and satellite banding patterns. This feature 
provides the capability to distinguish enzymes even if they differ by only a single 
amino acid residue. . New enzymes can easily be, .(44eiaä i.from known 
beta -lactamases by IEF;and thus, only new beta -lactamases need be subjected to full 
biochemical characterisation. 
In this study, the TEM -1 beta -lactamase was pre -eminent amongst the rest of the 
beta -lactamases identified in all individual species ( E.coli, Klebsiella spp, 
Salmonella spp and Shigella spp). This is similar to previous surveys. The 
percentage of the TEM -1 enzyme was greater than 70% in all species. The 
distribution of the rest of the beta -lactamases types encountered in this study was 
not similar to the previous studies as the next commonest enzyme was the OXA -1 
beta -lactamase. This was not so among Klebsiella isolates where SHV -1 enzyme is 
the second commonest. Indeed, the predominant enzyme in Klebsiella spp is 
usually the SHV -1 beta -lactamase (Roy et al., 1985). Overall, SHV -1 in Klebsiellae 
and OXA -1 in salmonellae and shigellae were the only other types of enzymes 
found besides TEM -1 enzyme. Amongst the E.coli population, a number of other 
previously documented enzymes TEM -1, OXA -1, OXA -2, SHV -1, PSE -1 
and PSE -2 -were also found; but most of them were found on only a few 
occasions. In the previous literature, the largest number of different types of beta - 
lactamases were found in Pseudomonas aeruginosa (16) and E.coli (12), Klebsiella 
spp. (10), Proteus mirabilis (9), Salmonella spp. (6) and Providencia spp. (6) 
(Medeiros, 1989). Ihese numbers have increased recently because of the 
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evolution of new broad -spectrum enzymes in the populations of E.coli, Klebsiella 
and Salmonella strains (Philippon, Labia and Jacoby, 1989; Bush, 1989). 
in two transconjugant strains selected on a plate containing cephaloridine, 
no beta -lactamase was detected with the chromogenic cephalosporin nitrocephin. 
This might be because of either their poor or no. activity against the substrate 
nitrocephin as it has bean. cabs '.zc two plasmid- mediated beta -lactamases. 
One of them, an enzyme (pI 8.0), produced by Haemophilus influenzae, was found to 
be non -reactive with nitrocephin (Rubin et al., 1981), The other enzyme (pI 5.7- 
5.9) from Enterobacter cloacae and Klebsiella pneumoniae gave a slow nitrocephin 
reaction (Corkill, Hart and Shears, 1989). These findings raise the possibility of beta - 
lactam treatment failure because of infections caused by apparently beta -lactamase 
negative clinical strains. Indeed, this did happen with the H. influenzae strain which 
produced the beta -lactamase non -reactive with nitrocephin (Rubin et al., 1981). 
It was found in this study. b.1dt 34.2% of the E.coli clinical isolates which 
neither transferred nor mobilised their resistance genes produced the TEM -1 beta- 
lactamase. This indicates that resistance genes encoding TEM -1 enzyme have 
probably been located. It has been noted that the migration of certain 
plasmid- associated antibiotic resistance genes into the bacterial chromosome has 
occurred, most notably, with trimethoprim resistance (Amyes, Doherty and Young, 
1986). Uniquely, one E.coli strain produced both PSE -1 and PSE -2 beta- lactamases; 
and, although both have been found in members of the Enterobacteriaceae before 
(Medeiros, Hedges and Jacoby, 1982; Roy et al., 1983; Livermore, Maskell and 
Williams, 1984), they have nct- been found together in the same strain. The 
Uß.1 
interesting feature of the strain producing these two PSEs was it remained sensitive 
to a combination of clavulanic acid and ampicillin even though biochemical studies 
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have shown these enzymes were not sensitive to inhibition by clavulanic acid (Reid, 
A.J., Ph.D. Thesis). Another unusual E. coli isolate produced the PSE -1 enzyme in 
conjunction with the TEM -1 enzyme. 
In the E. coli population, two other unusual plasmid- mediated enzymes and a further 
two novel beta - lactamases were identified. The two unusual enzymes were 1) hyper - 
produced TEM -1 beta - lactamase (TEM -1 + +) which conferred resistance to the combination 
of ampicillin and clavulanic acid (MIC 40 +8mg /1 of Amp and Clay). This hyperproduced 
enzyme was encoded by plasmids of greater than 100kb. Hyperproduction is often a 
consequence of multiple copies of the plasmid or a more active resistance gene. 
Multiple copies almost invariably occur with small plasmids (<24kb) (Timmis et al., 
1986). Hyperproduction by large plasmids often results from tandem repeats of the 
gene (gene amplification). In this case, it is likely that tandem repetitions of the 
ampicillin resistance genes or up mutations in the promoter region of the gene are 
responsible for hyperproduction (Korfmann, Kliebe and Wiedemann, 1986). The 
biochemical properties of the TEM -1 ++ enzyme were identical to those of the normal 
TEM -1 beta - lactamase and, therefore, the resistance to ampicillin /clavulanic acid 
most probably derives from the high production of the enzyme. 
The second unusual beta - lactamase was TEM -1 (Caz1) which could hydrolyse ceftazidime 
at a much higher rate than the normal TEM -1 enzyme could. This enzyme had a similar 
pI and banding pattern on IEF to TEM -1 enzyme; however, TEM-1 (Cazl) focused with 
marginally higher pI on IEF with narrow range ampholines than the standard TEM -1. 
The TEM derived plasmid mediated extended - spectrum beta - lactamases currently being 
isolated in Europe and the USA 
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TEM -5, TEM -7, TEM -9, TEM -E 1 and TEM -E2, have very similar pIs which 
lie between pI5.4 (TEM -1) and p15.6 (TEM -2) (Sirot, Labia and Thabaut, 1987; 
Gutmann et al., 1988; Spencer et al., 1987; Payne, Marriott and Amyes, 1989; Payne 
et al., 1989). This feature has made it confusing to identify these enzymes unless 
they run side -by -side on a narrow range ampholines lEF gelj therefore, it is very 
easy to miss this type of enzyme on IEF gels with broad range ampholines under 
quick screening procedures. 
Finally, the further two novel beta -lactamases identified among the E.coli 
transconjugants were CO K'-- b avvi EAg - z . 
CARB -6 i s carbenicillin hydrolysing enzyme of high pI. Although this enzyme 
had a broad- spectrumactivity, it had shown more activity towards carbenicillin. 
the plasmid encoding this enzyme was not stable in the strain and 
required antibiotic pressure to maintain it. Some previous studies indicated instability 
of plasmids may be observed after transfer to another host such as a laboratory strain 
of E.coli (Richmond and Sykes, 1972; Timmis, et al., 1986). This instability v J of 
result from certain circumstances such as inefficient expression of plasmid genes and 
host systems where the DNA polymerases are not suitable. Most plasmids 
are well adapted to the hosts in which they are found (Bennett and Linton, 1986). 
The original E.coli clinical strain which produced CARE -6 also harboured resistance 
genes for TEM -1 production. These TEM -1 resistance genes could not transfer or 
mobilisedinto a recipient, indicating their presence might be either on a different 
plasmid or the chromosome. . The expression of this CARB -6 was very poor 
on an lEF gel compared with TEM -1 beta -lactamase from the original clinical 
isolate. Comparing the biochemical properties, it does not appear that the production 
of these two enzymes in the same strain has any additional advantages over other 
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isolates. 
,The other novel enzyme was SAR -2 (Nandivada and Amyes, 1989). SAR -2 beta - 
lactamase had a higher pI (at 8.3) than any previously characterised plasmid encoded 
beta -lactamases including CEP -1 (Bobrowski et al., 1976) and CEP -2 (Levesque et 
al., 1982). The classification of beta -lactamases is largely dependent on their 
substrate and inhibitor profile (Richmond and Sykes, 1973; Sykes and Matthew, 
1976), therefore, this enzyme was classified as a broad -spectrum beta -lactamase as 
it could hydrolyse a series of antibiotics such as benzyl penicillin, ampicillin, 
carbenicillin, oxacillin, methicillin, cephaloridine and cefotaxime. The rates of 
hydrolysis revealed that it had more affinity for penicillins;and,it was different from 
other broad -spectrum beta -lactamases . ,o,tP . higher rates of hydrolysis against 
¿tL'1Y.rt 
methicillin and oxacillin. The ma o n ,k between the SAR -2 and the rest of the 
broad -spectrum enzymes was its inhibition profile. It was not sensitive to inhibition 
e b,z clavulanic acid c( p- chloromercuribenzoic acid; however, its activity 
was restricted by the inhibitor cloxacillin. 
Amongst salmonellae populations, the spread of an OXA -1 like enzyme was 
responsible for a high incidence of cefuroxime resistance (65.7 %) even though these 
strains were susceptible to cephaloridine. Of these strains, only four clinical isolates 
could transfer the resistance genes encoding this OXA -1 like enzyme. In 
susceptibility patterns to ampicillin, oxacillin, cephaloridine and cefuroxime, there 
were no significant differences between the strains producing the standard OXA -1 
and the new OXA -1 like enzymes. "These two enzymes showed 
noticeable differences biochemically, i.e.; band pattern on IEF and substrate profile 
pattern. These beta -lactamases co- focused at pI7.4, the main differences were two 
satellite bands which were absent in the OXA -1 like enzyme but were clearly visible 
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with the standard OXA -1 enzyme. 
When the rates of hydrolysis of various substrates by both the OXA -1 like and 
OXA -1 enzymes were analysed under the same experimental conditions, there were 
some dissimilarities, especially for cefuroxime hydrolysis. When the rates were 
related to the hydrolysis of penicillin G (100 %), OXA -1 like and OXA -1 hydrolysed 
cephaloridine (49.6% and 46.9% respectively), cefotaxime (18.4% and 12.4 %) and 
ampicillin (755% and 573 %) to similar extents. significantly, the 
OXA -1 like enzyme had a considerably higher activity (8 -fold) against cefuroxime 
than OXA -1 (12.5% and 1.5% respectively). The OXA -1 could hydrolyse 
cefoxitin (1.9 %) whereas OXA -1 like enzyme could not. The OXA -1 like enzyme 
had higher activity ( >2 -fold) than OXA -1 against cephalothin (13.0% and 5.8% 
respectively), cephamandole (39.3% and 15.7 %) and nitrocephin (654% and 250 %). 
On the other hand, the OXA -1 like enzyme was less effective than the OXA -1 
enzyme against substrates such as cephradine (0.33% and 3.2 %) and carbenicillin 
(107% and 260 %). 
Inez 
With respect to inhibitor profile, both \enzymes share common properties_ 
They were resistant to clavulanic acid, cloxacillin, p- chloromercuribenzoic acid, 
sodium chloride, cefoxitin and cefotetan. It was previously reported that a 
characteristic feature of all the members of OXA family of enzymes was the 
sensitivity to inhibition by sodium - chloride and this was the main c10 r .n c 
between these enzymes and rest of the plasmid mediated beta -lactamases (Medeiros, 
1989). This result what was not obtained in this study. The occurrence of 
the OXA -1 enzyme is not an unusual event in species of Salmonellae. This 
enzyme was previously isolated from different epidemic strains (Styphimurium from 
Iran, S, typhi from Algeria, typhimurium from UK and 5: lvien from Paris) of 
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ampicillin resistant salmonellae (Medeiros, 1984). The OXA-1 was also identified it 
ampicillin resistant E. coli clinical isolates from different countries: Thailand, 
Brazil, S. Africa and UK; and, in F. mirabilis and Salmonella St Paul from the USA 
associated with the TEM -1 beta-lactamase (Medeiros, 1984) similar to the findings of 
this study. A high incidence of OXA-1 like enzymes in Salmonella isolates was 
unknown before this present study. A parallel could be drawn between the prevalence 
of TEM -1 enzyme among the ampicillin resistant salmonellae (81%) (Medeiros, 1984) 
from the USA and the results obtained in the Indian Salmonella strains (85.7 %). 
The necessity for the increased activity of OXA -1 like enzymes for cefuroxime was 
unclear as cephalosporins were used little at the time these strains were collected 
in Vellore, S. India in 1984. It has recently been shown that higher usage of 
penicillins and aminoglycosides could lead to cefuroxime resistance. This has 
happened among the isolates obtained from urinary infections and also from intensive 
care patients in the Edinburgh Royal Infirmary (John Hood, personal communication). 
Even though cefuroxime resistance in the Salmonella strains was accompanied by the 
widespread distribution of novel OXA -1 like enzymes, there must be other resistance 
mechanisms playing a subsidiary role. The most probable additional resistance 
mechanism could be a membrane permeability barrier. Theoretically, the outer 
membrane proteins of Salmonella strains are similar to those of E, coli. Both OMP 
"F" and OMP "C" porin proteins are important for influx of beta-lactam antibiotics; 
and OMP "F ", a larger channel provides a good passage for cephalosporins (Medeiros gt 
21, 1987). Zwitterionic compounds (cephaloridine) diffuse more rapidly than 
monoanionic compounds (cefuroxime) (Nikaido, 1989); therefore, the cephaloridine 
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quickly enters the bacterial periplasm in large amounts and so that the quantity of 
bacterial enzyme might be insufficient to destroy the drug in the intact cells. This 
would explain bacterial sensitivit, s to cephalosporins (e.g. 
cephaloridine and cefuroxime) in permeability mutants (Medeiros et al., 1987; 
Nikaido, 1989). In Salmonella isolates there must be an involvement of the outer 
membrane in addition to the OXA -1 like enzyme. This would explain why so many 
transconjugants of these isolates had low MICs of cefuroxime. 
This problem with cefuroxime resistance is now particularly poignant following the 
release of cefuroxime axetil. Cefuroxime axetil (an oral compound) has been proven 
to be efficient in treating upper and lower ),tract infections, soft tissue infections and 
sexually transmitted infections (Emmerson, 1988). This drug's efficacy has been 
found to be compaïabk- with that of beta -lactam combinations (augmentin) 
(Emmerson, 1988) in terms of beta -lactamase stability and wide - spectrum activity. It 
is recommended as a valuable therapy for the treatment of urinary tract infections, 
particularly those resulting from beta -lactamase producing bacteria (Leigh et al., 
1989). In order to keep the efficacy of this drug, the other common 
penicillins and cephalosporins which are still in use for common and uncomplicated 
infections must not be misused; otherwise, this could lead to cross -resistance 
problems by selective pressure as has happened in S.India and in the Edinburgh 
Royal Infirmary (John Hood, personal communication). 
The results of the present study on both urinary and gastro -intestinal pathogens 
clearly indicates that the incidence of antimicrobial resistance was considerably 
higher in Vellore, South India than in the UK. The widespread resistance is probably 
a reflection of either intensive use of antibiotics or their uncontrolled availability. 
The comparison was made between the antibiotic usage given to inpatients in the 
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Christian Medical College Hospital, in Vellore in 1984, and antibiotic distribution 
to similar patients in the Royal Infirmary, Edinburgh, at the same time. The 
hospital sizes are similar (about 1000 beds). The official consumption in the 
Vellore hospital of ampicillin /amoxycillin was 2.8 kg /month and of cephalosporins O. 
kg /month. The sum of this was approximately half the equivalent consumption of the 
sum of these two groups of drugs in the Edinburgh Royal Infirmary where the usage of 
ampicillin /amoxycillin was 2.2 kg /month and of cephalosporins was 4.3 kg /month 
(Collee and Amyes, 1986). Despite the higher usage of beta - lactams in Edinburgh, the 
incidence of beta - lactam resistance was just over half that found in Vellore, South 
India (Reid et al, 1988b). The recorded consumption of beta - lactam antibiotics does 
not explain the high incidence of beta - lactam resistance at the Christian Medical 
College, Vellore. The possible explanation might be given considering other factors: 
ampicillin /amoxycillin are poorly absorbed by the gut, and residual antibiotic 
provides a selective environment for the emergence of resistant strains from 
commensal gut bacteria (Knudsen, Rolinson and Stevens, 1961; Garrod, Lambert and 
O'Grady, 1981); and ampicillin and amoxycillin remain in widespread clinical use 
outside the hospital. 
In addition to conducting surveys on clinically associated pathogens, studies on 
commensal gut flora should be performed on normal healthy volunteers as they 
represent a "gene pool" from which future infections involving beta - lactamase 
producing isolates might arise. The first survey on ampicillin resistant E. coli 
(17 %) in the community was conducted in the UK in 1966 (Smith and Halls, 1966), 
followed by another study in 1969 among children in the general community 
(Moorehouse, 1969). It was found that ampicillin-resistant E. coli in the children 
was high (62 %), as children, in general, are less hygienic than their elders, and 
this was taken as a reason for this high proportion of resistant E. coli isolates. 
The first survey on ampicillin 
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resistant E.coli from nosocomial infections in UK was held in 1969 (Datta, 1969). 
Recently, surveys on ampicillin resistant enterobacterial strains from healthy 
volunteers have been carried out in the UK, South India and Mexico (Simpson et al., 
1986; Tait et al ., 1990 ; Morfin -Otera et al., 1990). In addition to these 
studies, the assessment of qualitative and quantitative factors of the principal 
resistance mechanisms, especially beta -lactamase types responsible for resistance in 
clinical populations must be combined with the establishment of the range of 
activities (e.g. spectrum of resistance) associated with each. This information is 
valuable in assessing the relative merits of new antibiotics (Simpson et al., 1986). 
4.2 Combinations of Ampicillin and Clavulanic Acid 
The second part of this thesis involved the investigations on the efficacy of the 
antibiotic combination ampicillin + clavulanic acid as this combination and later 
generation cephalosporins are amongst the main current strategies to overcome 
widespread bacterial beta -lactam resistance (Turck, 1988). The broad - 
spectrum activities of the later generation cephalosporins (3GC) and the 
monobactams are being hampered by extended -spectrum plasmid mediated beta - 
lactamases derived from the common TEM and SHV enzymes (table 54). Within the 
past seven years a group of multiresistant Gram- negative bacteria have been 
identified with resistance patterns that include aminoglycosides and extended 
spectrum beta -lactam antibiotics. There have recently been several reports on the 
genetics ( Philippon, Labia and Jacoby, 1989), biochemical characteristics (Bush and 
Singer, 1989) and epidemiology of these extended spectrum beta -lactamases 
(Philippon et al., 1989). 
All extended -spectrum beta -lactamases have been identified among nosocomial 
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Table 54 
Country ( *species) 
in which the enzyme 
was first found 
f3- lactamase pI Reference 
France1,2 TEM -3 (CTX -1) 6.3 Sirot et al 
(1987) 
France3 TEM -4 5.9 Paul et al 
(1987) 
Francel TEM -5 5.55 Petit et al 
(1988) 
F.R. Germany3 TEM -6 5.9 Bauernfeind 
and Horl (1987) 
France4 TEM -7 5.41 Gutmann et al 
(1988) 
Englandl TEM -9 (RI-H -1) 5.5 Spencer et al 
(1987) 
U.S.A1 TEM -10 5.57 Quinn et al 
(1989) 
F.R. Germany6'2 SHV -2 7.6 Knothe et al 
(1983) 
Francel SHV -3 7.0 Jarlier et al 
(1988) 
Francel CAZ -2 5.9 Chanal et al 
(1988) 
France' CAZ -3 5.2 Labia et al 
(1988b) 
Francel SHV -4 (CAZ -5) 7.75 Bure et al 
(1988) 
Chile 1 SHV -5 (CAZ -4) 8.2 Gutmann et al 
(1989) 
France' CAZ -6 6.5 Channal et al 
(1989) 




Country ( *species) 
in which the enzyme 
was first found 
ß-lactamase pI Reference 
Belgiuml CAZ lo 6.5 Vuye et al 
(1989) 
Belgiuml CAZ hi 6.5 Vuye et al 
(1989) 
USA1 PMG 25 5.55 Jacoby et al 
(1988) 
CMY -11 8.0 Bauernfeind 
et al (1989) 
France? MJ -1 5.53 Deschaseaux 
et al (1988) 
France5 MJ -2 5.55 Deschaseux 
et al (1988) 
Belgiuml FUR 7.5 Vuye et al 
(1989) 
Japan3 FEC -1 Matsumato et al 
(1988) 
UK8 UN 5.7 Corkill et al 
(5.9) (1989) 
Belgium3 TEM -El 5.4 Payne, Marriott 
and Amyes (1989) 
UK1 TEM -E2 5.3 Payne, Marriott 
and Amyes (1990) 
England3 'l'EM -E3 5.55 Payne et al 
(1989) 
*, 1, Klebsiella pneumoniae; 2, Serratia marcescens; 3, Escherichia coli; 4, 
Citrobacter freundii; 5, Citrobacter amalonaticus; 6, Klebsiella azaenae; 7, 
Klebsiella oxytoca; 8, Enterobacter cloacae. UN, unnamed 
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isolates of Enterobacterial strains (urinary, blood, wound, sputum cultures), mostly 
from intensive care units (Philippon et al., 1989). The broad - spectrum beta - 
lactamases TEM and SHV are efficient in controlling the activities of a wide variety 
of new potent beta - lactams because they are able to produce mutations capable of 
dealing with these drugs and this has resulted in therapeutic failures. Thus, this 
part of the thesis was directed towards the potential of the TEM and SHV enzymes to 
produce resistance to ampicillin and clavulanic acid. 
The TEM -1 and SHV -1 beta - lactamases producing E. coli K12 (R1) and E. coli K12 
(R1010) standard laboratory strains were chosen for challenge with the drug 
combination (ampicillin and clavulanic acid). Simultaneously, mutation experiments 
were also carried out with E. coli K12 (J53) producing the extended - spectrum beta - 
lactamases TEM -3, TEM -5 and TEM -7 to evaluate the efficacy of these drug combinations 
against these enzymes. In the clinical situation, beta-lactam combination therapy 
has not yet been compromised by bacterial resistances despite some minor resistance 
problems. These experiments were carried out to see what type of mutations occurred 
which could confer resistance to various combinations of the beta - lactam (ampicillin) 
and beta - lactamase inhibitor (clavulanic acid). 
Challenge of the original E. coli strain producing the original TEM -1 enzyme with the 
combination (amp +clav, 100 +20mg /1 respectively) resulted in mutant "A" in which there 
was a rearrangement of plasmid R1 to give small, multicopy non - transferable plasmids. 
In this mutant, there were copies of the original R1 plasmid as well. Wiedemann 
(1981) showed that under selective presure (e.g. antibiotic stress), several natural 
manipulations could occur in plasmids such as insertion of IS elements, insertion of 
transposons, general recombination, mutations, formation of multicopy plasmids, 
amplification, and perhaps deletion. Therefore he had postulated that one or two big 
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plasmids fall apart into a coaggregated status of small plasmids, which can under 
certain circumstances, reaggregate to a big molecule. It is this type of 
rearrangement that has produced the genetic background in the present experiment 
which resulted in mutant "A" which contained two small additional plasmids. This 
rearrangement increased the level of enzyme produced resulting in 12 -fold elevation 
in specific activities. Despite the hyperactivity of the enzyme, the beta - lactamase 
itself possessed similar biochemical properties to the normal TEM -1 enzyme. It also 
had similar ID50 values of clavulanic acid with nitrocephin as a substrate. However, 
despite the apparently identical nature of the enzyme, the hyperproduction of the 
enzyme resulted in the acquisition of resistance to the combination (MIC 160 +8mg /1, 
amp +clav) and elevated MIC of ampicillin (mix 2560 mg /1). 
The genetic basis for the development of resistance in mutant "A" was found to be 
much the same as that in resistant clinical strains. There have been recent reports 
of beta - lactam /clavulanic acid resistant bacteria of Enterobacteriaceae in England 
(Williams et al., 1988), Spain (Martinez et al., 1987, 1988; Rodriguez - Creixems gt 
ál., 1988) and USA (Medeíros et al., 1988; Sanders et al., 1988; Cooksey et al., 
1990). In all these cases resistance to the combination had been based on 
overproduction of TEM -1 enzyme. In addition to TEM -1 enzyme, SHV -1 and class IV 
beta - lactamases were also reported to be hyperproduced in the clinical strains 
isolated from the patients at the University of Texas M.D. Anderson Cancer Hospital 
(Sanders et al., 1988). In one exceptional circumstance resistance resulted from the 
rapid hydrolysis by PSE -1 with low level enzyme production in Klebsiella pneumoniae 
strain at the same Cancer Hospital. 
Later the genetic basis of beta - lactamase hyperproduction was found in ten 
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resistant E. coli clinical strains in Spain (Martinez et al., 1989). They found fro( 
transformation experiments that very small plasmids with sizes ranging from 2.5 t1 
7.0kb with 10 copies per chromosome were responsible for hyperactivity of the TEM- 
beta- lactamase. They also observed a conjugative plasmid in the same cell with 
size of 55kb with one to two copies per chromosome. All these small plasmids were 
found to be mainly non -conjugative, even though some could be mobilised (Martinez g 
a1., 1989). No positive association between the large and small plasmids was shown. 
Further challenge of mutant "A" by clavulanic acid alone resulted in the loss of the 
R1 plasmid (mutants "B "). The small multi -copy plasmids were retained but they wen 
unable, of course, to transfer ampicillin resistance alone even with the aid of 
mobilising factor X. Smaller plasmids (>24kb) usually cannot auto - transfer but ar( 
often capable of mobilisation by unknown mechanisms. Homology between the mobilised 
and the mobilising plasmid is necessary in order to obtain transfer (Olsen, 1978). 
Mutant "B" had further increased ampicillin resistance but the loss of the R1 plasmic 
had led to the loss of the other antibiotic resistance determinants associated witl 
this plasmid, namely chloramphenicol, streptomycin, spectinomycin anc 
sulphamethoxazole. This suggests that small plasmids carried resistance genes onl) 
to ampicillin or beta -lactams. Similar observations had been made in a previous 
study that plasmid R1767 S. typhimurium had been split into and gave several plasmid; 
under antibiotic pressure. Some plasmids with a molecular weight as low as SMc 
(7.5kb) coded for resistance to only one drug while others carried quite a lot of 
resistance genes (Wiedemann, 1981). 
Mutants "B 11 were almost exactly the same as their parent strain with respect tc 
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sensitivity to inhibition by clavulanic acid alone regardless of their furthe] 
elevated resistance to ampicillin. This can be explained because both mutants "A' 
and "B" produced elevated levels of enzyme (increased number of molecules) which car 
easily overcome the inhibition by clavulanic acid. Additional interpretation ma} 
come from the fact that clavulanic acid, even though Michaelis-Menton kinetic; 
suggest it to be a competitive inhibitor, functions 75% as a competitive and 25% as 
suicidal inhibitor (D.M. Livermore, personal communication). The inhibitor is 
disadvantaged when challenged with an overproduced enzyme as the number of clavulanic 
acid molecules are insufficient to bind all the enzyme molecules. Sanders et al it 
studies (1988) with PSE -1 enzyme and 10011M of nitrocephin as a substrate determined 
that clavulanic acid is irreversible once saturing concentrations of the inhibitor 
are achieved. This suggests that any mechanism (such as overproduction) that 
prevents saturation of beta - lactamases by clavulanic acid is likely to be an 
efficient mechanism to overcome the combination. 
The kinetic parameters (Vmax and Km values for substrate and Ki values for inhibitor 
profiles) should be determined in the evaluation of new antibiotics against beta - 
lactamases (Bush and Sykes, 1986). The TEM -1 enzyme from mutant "A" did have a 
slightly lower Km for nitrocephin and Ki values of clavulanic acid than the normal 
TEM -1 enzyme though these differences are probably not significant. In a recent 
report on clinical isolates of E. coli (amp +sulbactam resistant), hyperproduced TEM -1 
beta - lactamase has been found to be the resistance mechanism; and this enzyme 
appears to hydrolyse nitrocephin more efficiently (Vmax, 1.000 for hyperactive TEM -1 
and 0.725 for normal TEM -1) but with decreased affinity for the substrate (2 -fold 
increase in Km value) and to be less susceptible to sulbactam inhibition 
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(Cooksey et al., 1990). Differences in susceptibilities of hyperproduced TEM -1 
enzymes to different inhibitors such as clavulanic acid and sulbactam might indicate 
differences in the efficiencies of the inhibitors. From these results it can be 
deduced that clavulanic acid is more stable to the hyperproduced beta -lactamases. 
Indeed, it has been postulated before that clavulanic acid is a more efficient 
inhibitor than sulbactam (Bush, 1988b). 
The increased level of enzyme production must be the main resistance mechanism in the 
mutants "A" and "B" as there were no alterations in the outer membranes of these 
mutants when compared with their parent strain E. coli K12. Both the OMP F and OMP 
C, the channels for beta -lactamas, were produced in the mutants to the same level as 
in the parent E, coli strain. As reported earlier, it is possible to see 
transferable plasmids affecting the permeability of the outer membrane (Iyer et al., 
1978; Rossouw and Rowbury, 1984). 
For the mutant "A ", as only the large plasmid (R1) was transferable into the 
transconjugants, the recipient strains were identical to the original parent strain 
E. coli. This confirms the involvement of the small plasmids of the mutant "A ", in 
bacterial resistance to the combination (amp +clav) and elevated resistance to 
ampicillin because these features were not transferable. In conclusion, the small 
multi -copy plasmids (<10kb (mutants "A" and "B "), 38kb ( "B" mutants) and about 48kb 
(mutant "A ")) were responsible for hyperproduction of the enzyme. Unlike their 
laboratory counterparts, the multi -copy small plasmids (2.5kb to 10.0kb) found in 
clinical isolates of E, coli which encoded the greater amount of TEM -1 beta - lactamase 
were either mobilisable or transformable (Martinez et al., 1989); and, this 
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augurs badly for the future. 
Like non - transferable small plasmids in the mutant "A ", the small plasmids of mutant 
"B" were also neither self - transferable nor mobilisable; they could be transformed 
into a sensitive strain E, coli MC 1022 (streptomycin resistant). The transformants 
that were obtained were highly resistant to ampicillin (MIC >2560mg/1) and augmentin 
(>80 + lómg /1, amoxycillin + clavulanic acid). Although these transformants acquired 
the correct resistances, it was difficult to visualise the transformed plasmids. It 
is possible the plasmids might have been integrated into the host bacterial 
chromosome. In the conjugation process, a plasmid with a host range for conjugation 
that exceeds its range for replication is a potential "suicide" vector. It is able 
to introduce resistance genes which can only survive if they can integrate into the 
host chromosome or another plasmid (Jacoby, 1985). It is unlikely to be with the 
plasmids as this transformation was performed between two similar E. coli strains. 
Another explanation might be that TEM -1 encoding resistance genes are on transposons. 
The small plasmids or transposons which possessed only multicopy ampicillin 
resistance genes might have been unstable and have difficulty in existing as 
individual plasmid forms. During the procedure of transformation, these DNA units 
might have been incorporated into the chromosome. On the other hand, the technique 
used might simply not have detected these plasmids. In a recent report, non- 
transferable small plasmids (2.5kb to 10.0kb), responsible for resistance to 
agumentin in the clinical strains were identified following transformation. The 
plasmids in the transformants were clearly detectable (Martinez et al., 1989). In 
conclusion, the resistance mechanisms resulted from small multicopy plasmids (>10kb 
(mutants nAit and "B "), 38kb (mutants "B ") and 48kb (mutant "A ")) 
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producing a very active TEM -1 enzyme. In the Spanish study, the genetic basis for 
hyperproduction of the enzymes in clinical strains of E. coli was shown to result 
from the emergence of small, multicopy plasmids (Martinez et al., 1989). In other 
clinical studies, hyperproduction of the enzyme has been shown to be a resistance 
mechanism but, in these cases, the genetic basis was not established (Williams 
g1., 1988; Rodriguez -Creixems et al., 1988; Sanders et al., 1988; Cooksey et al., 
1990). 
Challenge of the original TEM -1 producing strain with a lower concentration of 
clavulanic acid (64mg /1) alone produced "C" mutants (MIC 80mg /1). Mutant "C" had an 
elevated MIC of ampicillin (>1280mg/1) and combined drug (amoxycillin +clavulanic 
acid, MIC 40 +8mg /1) resistances. In these mutants neither the plasmid nor the level 
of enzyme produced was altered. Regardless of the resistance levels to ampicillin, 
some of the "C" mutants had become resistant to cefuroxime (MIC >4mg /1); but none of 
these resistance genes, except for ampicillin, were transferable. The ampicillin- 
resistant transconjugants were found to be no different from the standard TEM -1 
producing strain. This finding indicates that the resistance mechanisms of these 
mutants are unlikely to be beta-lactamase derived; and they probably result from 
alterations of the outer membrane permeability of clavulanic acid. It is unlikely to 
come from alterations of penicillin binding proteins which are potent mechanisms of 
resistance in Gram -positive organisms which have no membrane barriers; but this is 
unusual in these types of Gram - negative organisms (Spratt, 1989). 
Challenge of some of the mutants "C" as well as the original E. coli K12 strain with 
higher clavulanic acid concentrations (128 mg /1) had the effect of increasing the 
resistances to beta - lactam drugs in the resultant mutant "D "; however, it did not 
affect plasmid integrity. Most of the "D" mutants produced elevated levels of TEM -1 
beta -lactamase. Of these "D" mutants, only those directly derived from the strain 
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E. coli K12 had very high MICs of ampicillin, clavulanic acid and augmentin (in one 
mutant) and two of them also conferred resistance to cefuroxime and cefotaxime 
(>8mg /1). 
The results suggest that exposure to clavulanic acid alone brings about changes in 
the bacterial cells yielding resistant mutants. It had been reported that the 
elimination rate of clavulanic acid from patients with different degrees of renal 
insufficiency varied and took longer time than in the patients with normal renal 
function (Muench, Luethy, and Siegnthaler, 1981). When two drugs are administered 
together, it is possible that some parts of the body may only be exposed to one of 
the drugs at either higher or lower concentrations. It was because of this reason 
that attempts were made to select the resistant mutants to clavulanic acid at 
concentrations above the MIC. It had been postulated that this would demonstrate the 
effect that the pharmacokinetics of this inhibitor might have on the development of 
bacterial resistance. Most pharmacokinetic studies of this inhibitor, in conjunction 
with the beta - lactam antibiotic, have shown that it can penetrate through all 
tissues, eventually achieving the required concentrations as a combination in each 
part of the body (Cox, Meewis and Horton, 1989; Meier, Adam and Heilmann, 1989; 
Weismeier et al., 1989). Amoxycillin, ampicillin and clavulanic acid do have 
different penetration rates and there are times during therapy when high 
concentrations of clavulanic acid are achieved in the absence of the penicillin. It 
has been suggested that employment of antibiotics that display their additive or 
synergic activity for a broad range of concentrations would counter balance the 
possible variations in drug level that can take place in vivo due to differences in 
pharmacokinetics, distribution and metabolism (Grassi, 1981). 
As with the previous mutants ( "A ", "B" and "C "), in mutant "D" only the ampicillin 
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resistance gene was transferable. Pls there were no 
additional acquired small multicopy plasmids, the hyperproduction in some mutants 
( "D1 ", "D2" and "D3 ") is probably the result of mutation in the promoter region of 
beta -lactamase bla gene and not from plasmid rearrangement to small plasmids. 
Mutants ( "S1 -S6 ") selected from SHV -1 beta -lactamase producing and R1010 
plasmid harbouring E.coli strain by exposure to the combination (50 + 8 mg/1, amp + 
clay) also exhibited similar results to that of the E.coli K12 (R1 plasmid) mutants. 
The main resistance mechanism among these mutants ( "S 1 -S6 ") had been the 
enzyme hyperproduction (SHV -1 beta -lactamase). The important and interesting 
feature of these mutants was the acquisition of resistances to cefuroxime, cefotaxime, 
ceftazidime and aztreonam in addition to their significantly increased resistance to 
ampicillin and moderately acquired resistance to the drug combination (amp+clav). 
The mutants ( "S 1 -S6 ") had shown in c J no-/ MICs of the combination 
with increased bacterial density. The increased MICs of the drug combinations 
a ss c with increased inoculum size is possible only with those strains 
producing beta -lactamases, especially, in larger amounts of the enzyme (Martinez, et 
al., 1988). , These mutants were found to be more 'le .. st ant t. the 
combination of amoxycillin and clavulanic acid than the combination of ampicillin 
and clavulanic acid at the same inoculum size. 
Although the genetic basis for these resistances was hyperproduced, plasmid- 
mediated beta -lactamase SHV -1, the plasmid encoding the enzyme could not transfer 
resistance genes even to ampicillin resistance. As it was difficult to 
establish the genetic basis for the resistances of the mutants, biochemical 
characterisation of the enzyme produced by these mutants ( "S1 -S6 ") was carried out. 
The results revealed that the SHV -1 enzyme from the mutant could hydrolyse 
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cefotaxime, but not cefuroxime, ceftazidime and aztreonam to which the intact 
bacterial cells were resistant. From a few mutational steps only, the SHV -1 beta - 
lactamase has been converted into the new enzyme SHV -2 and the strain producing 
this enzyme became cefotaxime resistant (Korfmann, Kliebe and Wiedemann, 1986). 
This concept may be applicable to the mutated SHV -1 enzyme of the present study, 
R lthough the enzyme is not identical to SHV -2 -a certainly had become capable 
of hydrolysing cefotaxime. Analytical isoelectric focusing clearly 
revealed that the SHV -1 enzyme from all the mutants differed from the standard 
SHV -1 by loss of one satellite band. This might imply some structural change in the 
SHV -1 which would enable it to hydrolyse cefotaxime. 
the enzyme could hydrolyse ampicillin and cephaloridine at rates similar 
to that of the original SHV -1 enzyme.. the inhibitor profile with clavulanic 
acid showed its unchanged sensitivity to inhibition by this inhibitor in comparison 
with the standard SHV -1 enzyme (ID50 >10 -7), despite its high specific activity and 
the resistance to the drug combination. Sanders et al., (1988) found in her study 
hyperproduction of SHV -1 enzyme with different specific activities in Klebsiella 
pneumoniae was responsible for resistance to ticarcillin- potassium clavulanate. 
One Klebsiella strain produced SHV -1 in association with TEM -1 beta - 
lactamase. In all strains there was a correlation between the amount of enzyme 
produced and the resistance level to the combination even though major differences 
in permeability might have masked the true relationship between quantity of enzyme 
produced and resistance (Sanders et al., 1988). Some studies showed a lack of 
correlation between the specific activity of the beta -lactamase present in the cell and 
the beta -lactam resistance level (Richmond and Curtis, 1974; Medeiros, 1984; Reid. - 
Ph. D thesis). This has been contrary to the situation of resistance to beta -lactam 
combination. , 'These clinical isolates remained sensitive to inhibition by 
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clavulanic acid (ID50 0.02211M) which is lower than the value obtained for the 
mutants "S 1 -S6" of this study (ID50 0.111M). 
As the biochemical properties of the enzyme from the mutants ( "S 1 -S6 ") showed no 
activity against some cephalosporins, the outer membrane proteins (OMPs) of the 
mutants were extracted and analysed by SDS -PAGE electrophoresis concurrently 
with the OMPs of the standard E.coli. The pattern and the expression of the beta - 
lactam porins OMP "F" and OMP "C" of the mutants (S1-S6) showed no 
differences from the porin proteins of the standard E.coli. On the basis of the results 
it could be determined that hyperproduction of the enzyme must have been the 
main resistance mechanism even for resistances to cefuroxime, ceftazidime and 
aztreonam, even though there might be other resistance mechanisms such as 
permeability through lipopolysaccharide layer (LPS) (Nikaido, 1989). However, the 
LPS barrier has been recognised to be a suitable passage for penicillins because they 
can pass through easily. . This barrier can not be considered as a potential 
resistance mechanism as it can not be a channel for cephalosporins' influx 
(Yamaguchi, Hiruma and Sawai, 1982). Attention should perhaps be focused on the 
hyperproduced beta -lactamase which might be able to trap the cephalosporins, even 
though they have an inability to destroy them. The large amounts of the enzyme in 
the periplasm of the bacterial cells could trap low numbers of antibiotic molecules 
and confer resistance to them. This kind of resistance mechanism could be possible 
for the antibiotics such as cephalosporins. Similar findings have been found 
elsewhere in Pseudomonas aeruginosa and Enterobacter cloacae which became 
resistant to cephalosporins because of the trapping mechanism (Then and Angern, 
1982). In another report latamoxef- resistance in beta -lactamase derepressed 
Pseudomonas aeruginosa was seen by "covalent- trapping" (Livermore, 1987c). 
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The plasmid analysis of these mutants "S 1 -S6" showed that even though the mutants 
apparently had slightly larger plasmids than the original plasmid R1010, the 
digestion of these plasmids with Hind III restriction enzyme revealed that there was 
no difference between the patterns of the restricted plasmid fragments of the mutants 
and the standard E.coli strain. n'-vtbe "up" mutations in the 
promoter region of the beta -lactamase gene giving rise to high amounts of enzyme 
production. In general, under continuing antibiotic stress, a plasmid could 
extend its molecular weight by selectively multiplying those DNA segments 
responsible for that particular antibiotic resistance. w 4!ct form duplications within 
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the molecule resulting ins increased ability to withstand higher concentrations of the 
drugs it was exposed to. This was the case with plasmid pBP11 (encoding OXA -2 
enzyme) when exposed to ampicillin (Wiedemann, 1981). Another plasmid pBP10 
(encoding TEM -1 enzyme) showed an overproduction of the whole plasmid 
molecule under antibiotic exposure (multicopy plasmid with no change in the 
plasmid size) (Wiedemann, 1981) 
The outcome of these mutation experiments revealed that exposure to the drug 
combination and also to clavulanic acid alone could select mutants but only at a low 
frequency rate. These mutants conferred resistance not only to the drug combination 
but also to later generation cephalosporins. Mone of these third generation 
cephalosporin resistance determinants was transferable. Although there have been 
reports of clinically isolated strains which are resistant to the drug combination by 
hyperproduction or reduced membrane permeability, the reports did not identify 
concurrent conferment of resistance to later generation cephalosporins (Williams et 
al., 1988; Martinez et al., 1987, 1989; Rodriguez -Creixems et al., 1988; Medeiros et 
al., 1988; Sanders et al., 1988; Cooksey et al., 1990). ji appears this is 
likely to arise and may become epidemic during beta -lactam combination therapy if 
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care is not taken during dosage (i.e. correct concentrations and correct combination 
of beta - lactam and beta-lactamase inhibitor to be included in a combined drug) and 
compliance. 
It has been postulated that strains with beta - lactamase determinants in small 
multicopy plasmids or strains with hyperproduced TEM -1 enzyme might have existed long 
before the introduction of amoxycillin in clinical therapeutics (Sanders et al., 
1988; Martinez et al., 1989). This must be true, as there were three E. coli 
isolates that produce hyperactive TEM -1 beta - lactamases among the Indian urinary 
pathogens of this study in the absence of exposure to the beta - lactam combinations in 
clinical therapy. These drug inhibitor combinations still prove to be effective 
against clinical isolates producing very stable extended - spectrum beta - lactamases of 
the TEM and SHV types. All these beta - lactamases are inhibited well by clavulanic 
acid with ID50 values ranging from 4.3 to 12nM compared with 130nM for TEM -2. 
Inhibition by sulbactam was also found to be better for the extended broad - spectrum 
beta - lactamases than for the TEM -2 beta - lactamase with ID50 values of 12 -940nM for 
the extended broad-spectrum enzymes compared to 1600nM for the TEM -2 beta-lactamase 
(Bush and Singer, 1989). 
When E, coli strains producing TEM-3 (hydrolyses cefotaxime preferentially), TEM -5 
(hydrolyses ceftazidime preferentially) and TEM -7 (more resistant to ceftazidime) 
enzymes were challenged with different concentrations of ampicillin and clavulanic 
acid combinations, they could overcome the combined drugs, only the bacterial density 
was high. MICs for these enzyme- producing strains of the combination were 
progressively reduced as the concentrations of both the beta - lactam and the inhibitor 
were increased. 
To treat the infections with the pathogens producing expanded - spectrum beta- 
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lactamases, it may be necessary to use higher concentrations of the antibiotic 
combination. It is impossible to find a fixed ratio that can be valid for all 
bacterial species to achieve the adequate dosage for the treatment of severe 
infections (Muench, Luethy and Siegenthaler, 1981). However, it is important that 
the components are present in the most appropriate ratio to develop their 
antibacterial activity. 
Six well -grown colonies of strains producing TEM -3, TEM -5 or TEM -7 beta - lactamases (2 
colonies from each type of beta - lactamase producing strain) were chosen from the 
plate containing higher concentrations of ampicillin and clavulanic acid. Studies 
carried out on these strains ( "1M -6M ") to determine if there were any mutations 
leading to modified resistance patterns or hyperproduced beta - lactamases revealed 
that they had not significantly differed from their parent strains. On exposure to 
the combination, mutants 3M and 4M (from TEM -5 producing strain) had highly increased 
MICs of ampicillin and 4M mutant lost its resistance to chloramphenicol. Mutants 5M 
and 6M (from the strain producing TEM -7) surprisingly dropped their resistance level 
to ampicillin in comparison with their parent strain. Mutants 1M and 2M (from the 
strain producing TEM -3 beta-lactamase) were similar to their parent strain; but the 
mutant 2M lost its resistance to chloramphenicol. Apart from these observations, 
none of these strains acquired resistance to the drug combinations such as 
ampicillin /clavulanic acid or elevated resistances to amoxycillin in combination with 
clavulanic acid. 
From the results, it can be deduced that combined beta - lactam antibiotics would be 
useful against the extended - spectrum beta -lactamases. Not only the concentrations of 
the antibiotics but also the type of the beta-lactam to be included in a combination 
might be of considerable importance, depending on the type of bacteria to be 
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treated. Beta - lactams such as ampicillin, amoxycillin and early cephalosporins 
(Livermore, 1987a) are often strong inducers of chromosomal beta - lactamases at levels 
below their MICs; and they are labile to the class 1 beta - lactamases that they 
induce. The achievement of the required concentrations of the beta - lactam and beta - 
lactamase inhibitor at the site of infection is vital, especially in the treatment of 
bacteria capable of producing inducible beta -lactamases. The inducible enzymes can 
lead to an antagonism between beta - lactam (i.e. ticarcillin) and beta - lactamase 
inhibitor (clavulanic acid) as has happened in Pseudomonas clinical strains 
(Livermore, 1987b). In one study, induction of chromosomal beta - lactamases by 
ticarcillin in combination with clavulanic acid did not result in any decrease in 
ticarcillin susceptibility in four clinical strains (Stobberingh, 1988). The other 
tests conducted on non - inducible beta - lactamase producing bacteria with different 
combinations of beta - lactams and beta - lactamase inhibitors demonstrated no antagonism 
except between cefotaxime and clavulanic acid (Kitiz et al., 2989). 
On the basis of the literature available and the data obtained from this thesis, it 
can be concluded that beta - lactamases play an important role in beta - lactam 
resistance and the TEM -1 beta-lactamase is the most prevalent in Gram -negative 
bacteria worldwide. Strains producing the TEM -1 beta - lactamase are likely to be 
dominant even over the bacterial strains harbouring genes for extended - spectrum beta - 
lactamase production. Both TEM -1 and SHV -1 beta-lactamases are responsible for 
current beta - lactam resistance problems, as they have been shown to be highly 
efficient in their ability to mutate. Structural changes in their enzymes overcome 
newer beta - lactam antibiotics. The prime cause of the evolution of new potent beta - 
lactamases is the antibiotic cefotaxime which has been widely used (Casellas and 
Goldberg, 1989; Philippon, Labia and Jacoby, 1989) in the treatment of complicated 
and hospital 
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acquired urinary tract infections because of its wide spectrum (Naber, 1989) 
antibacterial activity. It has been postulated that the extensive use of other newer 
antibiotics also contributes to the emergence of the new beta - lactamases (Philippon 
et al., 1989). The continued success of combination therapy in the clinical 
situation is only threatened by the same enzymes (TEM -1 and SHV -1) if these are 
hyperproduced. Hyperproduction of these enzymes does not change their sensitivity to 
clavulanic acid and they retain their activity against beta-lactam antibiotics. The 
inhibitory effect of clavulanic acid for all kinds of plasmid- mediated beta - 
lactamases shows that combination therapy could be well chosen for different types of 
infections. Indeed, the extended - spectrum enzymes remain sensitive to inhibitors 
such as clavulanic acid, sulbactam and tazobactam (Philippon, Labia and Jacoby, 
1989). Along with increased affinity for cephalosporin substrates goes enhanced 
affinity for these beta - lactamase inhibitors so that combinations of an inhibitor 
with a hydrolysable beta - lactam should prove effective against infections by bacteria 
with new enzyme production (Philippon, Labia and Jacoby, 1989). 
Recently, it has been documented that the potentiation effect of clavulanic acid or 
sulbactam, in combination with third - generation cephalosporins against 46 Klebsiella 
nnaeumoniae strains from Argentina producing expanded - spectrum enzymes has been shown 
to be positive synergy (Casellas and Goldberg, 1989). 
Although generalisations can be made about the appropriate use of agents on the basis 
of published susceptibility patterns, significant regional, demographic, and 
institutional variables exist that require each hospital to establish its own 
antibiotic data base and antibiogram (Parry, 1989). It is necessary to monitor 
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carefully the development of resistance to new beta -lactams. Even though advances in 
the chemistry of beta - lactams should offer solutions to these real problems, it seems 
likely that enzymes will be found wherever antibiotics are used which will favour 
their appearance, either by promoting the emergence of novel beta - lactamase or the 
interplay between the various mechanisms of resistance which can be reflected in the 
emergence of resistance to a new antibiotic. 
236 
REFERENCES 
ABRAHAM, E.P. & CHAIN, E. (1940). An enzyme from bacteria able to destroy 
penicillin. Nature, 146, 837. 
ABRAHAM, E.P. & WALEY, S.G. (1979). (3- lactamases from Bacillus cereus. In 
Beta -lactamases (HAMILTON- MILLER J.M.T. and SMITH, J.T. Eds), pp.311 -338. 
Academic Press, London. 
ABRAHAM, E.P. (1983). History of 3- lactam antibiotics. In Antibiotics Containing 
the Beta -lactam structure, Part I. Handbook of Experimental Pharmacology, Vol. 
67/I ( DEMAIN, A.L. & SOLOMON, N.A. Eds), pp.1 -14. Springer -Verlag. 
ACAR, J.F. & MINOZZI, C. (1986). Role of (3- lactamases in the resistance of Gram - 
negative bacilli to ß- lactam antibiotics. Rev Infect Dis., 8 (suppl 5), 5482 -5486. 
ADAM, D., 1,ELLNER, P.R., KOEPPE, P. & WESCH, R. (1989). Pharmacokinetics 
of ticarcillin/clavulanate in severely burned patients. J Antimicrob Chemother., 24 
(suppl B), 121 -129. 
AMBLER, R.P. (1980). The structure of (3- lactamases. Philos Trans R Soc Lond 
(Biol)., B289, 321 -331. 
AMYES, S.G.B. & Gould, I.M. (1c,84). Trimethoprim resistance plasmids in faecal 
bacteria. Ann Microbiol., 135B, 177 -186. 
AMYES, S.G.B., DOHERTY, C.J. & YOUNG, H -K (1986). Changes in high level 
trimethoprim resistance in haspital strains. In abstracts of 14th International 
congress of Chemotherapy, Abstract No. S84 -10. International Society of 
Chemotherapy, Kyoto, Japan. 
AMYES, S.G.B. (1989). The sucess of plasmid- encoded resistance genes in clinical 
bacteria. J Med Microbiol., 28, 73 -83. 
ANDERSON, E.S. & DATTA, N. (1965). Resistance to penicillins and its transfer in 
Enterobacteriacae. Lancet, 1, 407 -409. 
ANDERSON, E.S. (1968). The ecology of transferable drug resistance in the 
Enterobacteria. Annu Rev Microbiol., 22, 131 -180. 
ANDREWS, P. (1964). Estimation of the molecular weights of proteins by Sephadex 
Gel- filtration. Biochem J., 91, 222 -233. 
ANGUS, B.L., CAREY, A.M., CARON, D.A., KROPINSKI, A.M.B. & 
HANCOCK, R.E.W. (1982). Outer membrane permeability in Pseudomonas 
aeruginosa: Comparison of a wild -type with an antibiotic - supersuceptible mutant. 
Antimicrob Agents Chemother., 21, 299 -309. 
ARAKAWA, Y., OHTA, M., KlDO, N., FUJII, Y., KOMATSU, T. & KATO, N. 
(1986). Close evolutionary relationship between the chromosomally encoded beta - 
lactamase gene of Klebsiella pneumoniae and the TEM beta- lactamase gene 
mediated by R plasmids. FEBS Lett., 207, 69 -74. 
ARONOFF, S.C., SCOLES, P.V., MAKLEY, J.T., JACOBS, M.R., BLUMER, J.L. 
237 
& KALAMCHI, A. (1986). Efficacy and safety of sequential treatment with parental 
sulbactam/ampicillin and oral sultamicillin for skeletal infections in children. Rev 
Infect Dis., 8 ( suppl 5), S639 -S643. 
BACHMANN, B.J. (1972). Pedigree of some mutant strains of Escherichia coli K- 
12. Bact Rev., 36, 525 -557 
BARBAS, J.A., DIASZ, J., RODRIGUEZ -TEBAR, A. & VAZQUEZ, D. (1986). 
Specific location of penicillin -binding proteins within the cell envelope of 
Escherichia coli. J Bacteriol., 165, 269 -275. 
BARTHELEMY, M., PEDUZZI, J., BEN YAGHLANE, H. & LABIA, R. (1988). 
Single aminoacid substitution between SHV -1 13- lactamase and cefotaxime- 
hydrolyzing SHV -2 enzyme. FEBS Lett., 231, 217 -220. 
BAUERNFEIND, A. (1986). Classification of (3- lactamases. Rev Infect Dis., 8 
( suppl 5), S470 -S481. 
BAUERNFEIND, A. & HORL, G. (1987). Novel R- factor borne 3- lactamase of 
Escherichia coli conferring resistance to cephalosporins. Infection, 15, 257 -259. 
BAUERNFEIND, A., CHONG, Y. & SCHWEIGHART, S. (1989). Extended broad 
spectrum (3- lactamase in Klebsiella pneumoniae including resistance to cephamycins. 
Infection, 17, 316 -321. 
BEESLEY, T., GASCOYNE, N., KNOTT-HUNZIKER, V., PETURRSON, S., 
WALEY, S.G., JAURIN, B. et al. (1983). The inhibition of class C ß-lactamases by 
boronic acids. Biochem J., 209, 229-233. 
BENNETT, P.M. & LINTON, A.H. (1986). Do plasmids influence the survival of 
bacteria? J Antimicrob Chemother., 18 (suppl C), 123 -126. 
BERGSTROM, S. & NORMARK, S. (1979). Beta -lactam resistance in clincal 
isolates of Escherichia coli caused by elevated production of the ampC- mediated 
chromosomal beta -lactamase. Antimicrob Agents Chemother., 16, 427 -433. 
BERGAN, T. (1978). Penicillin. In Antibioitcs and Chemotherapy Pharmacokinetics, 
Vol. 25 (Schonfeld, H. Ed), pp.1 -102. Karger, Basel. 
BOBROWSKI, M.M., MATTHEW, M., BARTH, P.T., DATTA, N., GRINTER, 
N.J., JACOB, A.E. et al. (1976). Plasmid- determined 3- lactamase indistinguishable 
from the chromosomal ß- lactamses of Escherichia coli. J Bacteriol., 125, 149 -157. 
BOISSINOT, M., MERCIER, J. AND LEVESQUE, R.C. (1987). Development of 
natural and synthetic DNA probes for OXA -2 and TEM -1 (3- lactamases. Antimicrob 
Agents Chemother., 31, 728 -734. 
BOYCE, J.M. & MEDEIROS, A.A. (1987). Role of beta -lactamase in expression of 
resistance by methicillin- resistant Staphylococcus aureus. Antimicrob Agents 
Chemother., 31, 1426 -1428. 
BRAGMAN, S., SAGE, R., BOOTH, L. & NOONE, P. (1986). Ceftazidime in the 
Pseudomonas aeruginosa sepsis. Scand J Infect Dis., 18, 425 -429. 
BROOK, I. (1989). The concept of indirect pathogenicity by P- lactamase production, 
238 
especially in ear, nose and throat infection. J Antimicrob Chemother., 24 (suppl B), 
63 -72. 
BROWN, A.G., BU 1"lERWORTH, D., COLE, M., HANSCOMB, G., HOOD, J.D. 
READING, C. et al. (1976). Naturally- occuring ß- lactamase inhibitors with 
antimicrobial activity. J Antibiot (Tokyo)., 20, 668 -671. 
BRUN -BUISSON, C., LEGRAND, P., PHILIPPON, A., MONTRAVERS, F., 
ANSQUER, M. AND DUVAL, J. (1987). Transferable enzymatic resistance to third - 
generation cephalosporins during nosocomial outbreak of multiresistant Klebsiella 
pneumoniae. Lancet, 2, 302 -306. 
BRYAN, L.E. (1988). General mechanisms of resistance to antibiotics. J Antimicrob 
Chemother., 22 (suppl A), 1 -15. 
BURE, A., LEGRAND, P., ARIET, G., JARLIER, V., PAUL, G. & PHILIPPON, A. 
(1988). Dissemmination in five French hospitals of Klebsiella pneumoniae serotype 
K25 harboring a new transferable enzymatic resistance to a third generation 
cephalosporins and aztreonam. Eur J Clin Microbiol., 7, 780 -782. 
BUSCHER, K -H., CULLMANN, W., DICK, W. & OPFERKUCH, W. (1987). 
Imipenem resistance in Pseudomonas aeruginosa resulting from diminished 
expression of an outer membrane protein. Antimicrob Agents Chemother., 31, 703- 
708. 
BUSH, K., FREUDENBERGER, J.S. & SYKES, R.B. (1982). Interaction of 
azthreonam and related monobactams with ß- lactamases from Gram -negative 
bacteria. Antimicrob Agents Chemother., 22, 414 -420. 
BUSH, K. & SYKES, R.B. (1984). Interaction of ß- lactam antibiotics with [3- 
lactamases as a cause for resistance. In Antimicrobial Drug Resistance (BRYAN, LE. 
Ed), pp.1 -31. Academic Press, New York. 
BUSH, K., TANAKA, S.K., BONNER, D.P. & SYKES, R.B. (1985). Resistance 
caused by decreased penetration of 13- lactam antibiotics into Enterobacter cloacae. 
Antimicrob Agents Chemother., 27, 555 -560. 
BUSH, K. & SYKES, R.B. (1986). Methodology for the study of ß- lactamases. 
Antimicrob Agents Chemother., 30, 6 -10. 
BUSH, K. (1988a). Recent developments in ß- lactamase research and their 
implications for the future. Rev Infect Dis., 10, 681 -690. 
BUSH, K. (1988b). Beta -lactamase inhibitors from labortory to clinic. Clin 
Microbiol Rev., 1, 109 -123. 
BUSH, K. (1989). Excitement in the ß- lactamase arena. J Antimicrob Chemother., 
24, 831 -836. 
BUSH, K. & SINGER, S.B. (1989). Biochemical characteristics of extended broad 
spectrum 13- lactamases. Infection, 17, 429 -433. 
CARTWRIGHT, S.J. & WALEY, S.G. (1984). Purification of ß- lactamases by 
affinity chromatography on phenylboronic acid -agarose. Biochem J., 221, 505 -512. 
239 
CASELLAS, J.M. AND GOLDBERG, M. (1989). Incidence of strains producing 
extended spectrum ß- lactamases in Argentina. Infection, 17, 434 -436. 
CHABERS, H.F., HARTMAN, B.J. & TOMASZ, A. (1985). Increased amounts of a 
novel penicillin- binding protein in a strain of methicillin- resistant Staphylococcus 
aureus exposed to nafcillin. J Clin Invest., 76, 325 -331. 
CHAN, P.T. (1986). Nucletide sequence of the Staphylococcus aureus PC1 ß- 
lactamase gene. Nucleic Acids Res., 14, 5940. 
CHANAL, C.M., SIROT, D.L., LABIA, R., PETIT, A., MORAND, A., SIROT, J.L. 
et al. (1988). Comparative study of a novel plasmid- mediated ß- lactamase, CAZ -2, 
and the CTX -1 and CAZ -1 enzymes conferring resistance to broad -spectrum 
cephalosporins. Antimicrob Agents Chemother., 32, 1660 -1665. 
CHANAL, C., SIROT, D., LABIA, R. & SIROT, J. (1989). Identification of two 
novel TEM- derivative ceftazidimases, CAZ -6 and CAZ -7, from Klebsiella 
pneumoniae isolates. J Antimicrob Chemother., 24, 86 -87. 
CHEN, S -T. & CLOWES, R.C. (1987). Nucleotide sequence comparisons of 
plasmids pHD131, pJB1, pFA3, and pFA7 and ß- lactamase expression in 
Escherichia coli, Haemophilus influenzae, and Neisseria gonorrhoeae. J Bacteriol., 
169, 3124 -3130. 
CHIN, N.X., McElrath, M.J. & NEU, H.C. (1988). Beta -lactamase inhibition by 
acetylmethylene penicillanic acid compared to that of clavulanate and sulbactam. 
Chemotherapy., 34, 318 -325. 
CLAES, H., VANDEURSEN, R. & BAERT, L. (1989). Amoxycillin/ clavulanate for 
extracorpeal shock wave lithotripsy -a comparative study. J Antimicrob Chemother., 
24 (suppl B), 217 -220. 
COL, N. F. & O'CONNER, R.W. (1987). Estimating worldwide current antibiotic 
usage: report of task force 1. Rev Infect Dis., 9 (Supp13), S232 -S243. 
COLLATZ, E., GUTMANN, L., WILLIAMSON, R. & ACAR, J.F. (1984). 
Development of resistance to ß- lactam antibiotics with special reference to third - 
generation cephalosporins. J Antimicrob Chemother., 14 (suppl B), 13 -21. 
COLLEE, J.G. & AMYES, S.G.B. (1986). Relevance of bacteriú.l resistance for 
clinical and community medicine: point of view of the bacteriologist. In Resistance 
and Development of Resistance. Possible Implications for Antimicrobial Policy 
(MICHEL, M.F. AND VAN DER MEER, JW.N. Eds), pp.67 -73. BRL London. 
COLLINS, J.F. (1979). The Bacillius licheniformis ß- lactamase system. In Beta - 
lactamases (HAMILTON- MILLER, J.M.T. AND SMITH, J.T. Eds), pp.351 -368. 
Academic Press. London. 
COOKSEY, R.C., CLARK, N.C. & THORNSBERRY, C. (1985). A gene probe for 
TEM type ß- lactamases. Antimicrob Agents Chemother., 28, 154 -156. 
COOKSEY, R., HILL, B., GAY, E. & THORNSBERRY, C. (1990). 
Characterisation of ampicillin /sulbactam resistance in clinical isolates of Eschirichia 
coli. In Abstracts of the 90th Annual Meeting of the American Society, Abstract No 
A86, Anaheim, California. 
240 
CORKILL, J.E., HART, C.A. & SHEARS, P.(1989). Plasmid mediated ceftazidime 
resistance associated with a b- lactamase giving a slow nitrocephin reaction. J 
Antimicrob Chemother., 24, 467 -470. 
CORPET, D.E. (1986). Ecological factors influencing the transfer of plasmids in vivo 
and in vitro. J Antimicrob Chemother., 18 ( suppl C), 127 -132. 
COULTON, J.W., MASON, P. & DORRANCE, D. (1983). The permeability barrier 
of Haemophilus influenzae type b against ß- lactam antibiotics. J Antimicrob 
Chemother., 12, 435 -449. 
COX, A.L., MEEWIS, J.M.J.M. & HORTON, R. (1989). Penetration into lung tissue 
after intravenous administration of amoxycillin/ clavulanate. J Antimicrob 
Chemother., 24 (suppl B), 87 -91. 
CULLMANN, W. DALHOFF, A. & Dick, W. (1984). Nonspecific induction of beta - 
lactamase in Enterobacter cloacae. J Gen Microbiol., 130, 1781 -1786. 
DALE, J.W. AND SMITH, J.T. (1974). R- factor -mediated ß- lactamases that 
hydrolyse oxacillin: Evidence for two distinct groups. J Bacteriol., 119, 351 -356. 
DALE, J.W., GOODWIN, D., MOSSAKOWSKA, D., STEPHENSON, P. & WALL, 
S. (1985). Sequence of the OXA -2 ß- lactamase: comparison with other penicillin - 
reactive enzymes. FEBS Lett., 191, 39 -44. 
DALHOFF, A. & CULLMANN, W. (1984). Specificity of ß-lactamase induction in 
Pseudomonas aeruginosa. J Antimicrob Chemother., 14, 349-357. 
DANCE, D.A.B., WUTHIEKANUN, V., CHAOWAGUL, W. & WHITE, N.J. 
(1989). The activity of amoxycillin/clavulanic acid against Pseudomonas 
pseudomallei. J Antimicrob Chemother., 24, 1012 -1014. 
DATTA, N. & KONTOMICHALOU, P. (1965). Penicillinase synthesis controlled 
by infectious R factors in Enterobacteriaceae. Nature, 208, 239 -241. 
DATTA, N. (1969). Drug resistance and R factors in the bowel bacteria of London 
patients before and after admission to hospital. Br Med J., 2, 407 -411. 
DATTA, N., HEDGES, R.W., SHAW, E.J., SYKES, R.B. AND RICHMOND, M.H. 
(1971). Properties of an R factor from Pseudomonas aeruginosa. J Bacteriol., 108, 
1244 -1249. 
DESCHASEAUX, M.L., JOUVENOT, M., ADESSI, G.L. & MICHEL- BRIAND, Y. 
(1988). Two presumed novel ß- lactamases in members of the family 
Enterobacteriaceae. J Antimicrob Chemother., 21, 133 -135. 
DIETERICH, H -J, GROH, J., BEHRINGER, K., LAUTERJUNG, L. & MARTIN, 
E. (1989). The prophylactic activity of amoxycillinlclavulanate and cefoxitin in 
vascular surgery-a randomized clinical study. J Antimicrob Chemother., 24 (suppl 
B), 209 -211. 
DILLON, J.R., PAUZE, M. & YEUNG, K.M. (1983). Spread of penicillinase- 
producing and transfer plasmids from the gonococcus to Neisseria meningitidis. 
Lancet, 1, 779 -781. 
241 
DIXON, M. & WEBB, E.C. (1958). Enzyme techniques. In Enzymes, pp.8 -35. 
Academic Press, London. 
DOUGHERTY, T.J., KOLLER, A.E. & TOMASZ, A. (1980). Pencillin- binding 
proteins of penicillin -susceptible and intrinsically resistant Neisseria gonorrhoeae. 
Antimicrob Agents Chemother., 18, 730 -737. 
DOUGHERTY, T.J. (1986). Genetic analysis and penicillin- binding protein 
alterations in Neisseria gonorrhoeae with chromosomally mediated resistance. 
Antimicrob Agents Chemother., 30, 649 -652. 
DWORZACK, D.L., PUGSLEY, M.P., SANDERS, C.C. & HOROWITZ, E.A. 
(1987). Emergence of resistance in gram- negative bacteria during therapy with 
expanded -spectrum cephalosporins. Eur J Clin Microbiol., 6, 456 -459. 
DYKE, K.G.H. (1979). 13- lactamases of Staphylococcus aureus. In Beta -lactamases 
(HAMILTON -MILLER, J.M.T. AND SMITH, J.T. Eds), pp. 291 -310. Academic 
Press, London. 
EMMERSON, A.M. (1988). Cefuroxime axetil. J Antimicrob 
104. 
ENGLISH, A.R., RETSEMA, J.A., GIRARD, A.E., LYNCH, 
(1978). CP- 45,899, a beta -lactamase inhibitor that extends the 
of beta -lactams: initial bacteriological characterization. 
Chemother., 14, 414 -419. 
Chemother., 22, 101- 
J.E. & BARTH, W.E. 
antibacterial spectrum 
Antimicrob Agents 
ESPOSITO, S., GALANTE, D., BARBA, D., PENNUCCI, D. & LIMAURO, D. 
(1986). Correlation of beta -lactamase stability and antibacterial activity of beta - 
lactams in beta -lactamase producing bacteria and respective transconjugants. Drugs 
Exp Clin Res., 12, 329 -333. 
FARMER, T.H. & READING, C. (1988). The effects of clavulanic acid and 
sulbactam on beta -lactamase biosynthesis. J Antimicrob Chemother., 22, 105 -111. 
FARUKI, H., KOHMESCHER, R.N., McKINNEY, W.P. & SPARLING, P.F. 
(1985). A community -based outbreak of infection with penicillin- resistant Neisseria 
gonorrhoeae not producing penicilinase (chromosomally mediated resistance). N 
Engl J Med., 313, 607 -611. 
FINK, M.P., HELSMOORTEL, C.M., AROUS, E.J., DOERN, G.V., MORIARTY, 
K.P., FAIRCHILD, P.G. et al. (1989). Comparison of the safety and efficacy of 
parenteral ticarcillin /clavulanate and clindamycin/gentamicin in serious intra- 
abdominal infections. J Antimicrob Chemother., 24 ( suppl B), 147 -156. 
FISCHBACH, M., SIMEONI, U., MENGUS, L., JEHL, F., MONTEIL, H., GEISET, 
J. et al. (1989). Urinary tract infections with tissue penetration in children: 
cefotaxime compared with amoxycillin/clavulanate. J Antimicrob Chemother., 24 
(suppl B), 177 -183. 
FISHER, J., CHARNAS, R.L. & KNOWLES, J.R. (1978). Kinetic studies on the 
inactivation of Escherichia coli R TEM P- lactamase by clavulanic acid. 
Biochemistry, 17, 2180 -2184. 
FISHER, J., CHARNAS, R.L., BRADLEY, S.M. & KNOWLES, J.R. (1981). 
242 
Inactivation of the R TEM ß- lactamase from Escherichia coli. Interaction of penem 
sulfones with enzyme. Biochemistry, 20, 2726 -2731. 
FLEMING, A. (1929). On antibacterial action of cultures of a penicillum with 
special reference to their use in isolation of B. influenzae. Br J Exp Pathol., 10, 226- 
235. 
FLEMING, P.C. GOLDNER, M. AND GLASS, D.G. (1963). Observations on the 
nature, distribution and significance of cephalosporinase. Lancet, 1, 1399 -1401. 
FOSTER, M.C., KAPILA., L., MORRIS, D.L. AND SLACK, R.C.B. (1986). A 
randomized comparative study of sulbactam plus ampicillin vs metronidazole plus 
cefotaxime in the management of acute appendicitis in children. Rev Infect Dis., 8 
( suppl 5), S634 -S638. 
FRANZ, P., VON ROSEN, F., GARNER, C., SWOZIL, U., SCHMIEDEK, P., 
EINHAUPL, K. et al. (1989). Cerebrospinal fluid penetration after single or multiple 
dosage with ticarcillin/ clavulanate. J Antimicrob Chemother., 24 (suppl B), 107 -110. 
FRERE, J.M. AND JORIS, B. (1985). Pencillin- sensitive enzymes in peptidoglycan 
biosynthesis. CRC Crit Rev Microbiol., 11, 299 -396. 
FRICKE, G., DOERCK, M., HAFNER, D., HORTON, R. AND KRESKEN, M. 
(1989). The pharmacokinetics of ticarcillin/clavulanate acid in neonates. J 
Antimicrob Chemother., 24 ( suppl B), 111 -120. 
FRIESE, S., WILLEMS, F.T.C., LORIAUX, S.M. & MEEWIS, J.M.J.M. (1989). 
Prophylaxis in gynaecological surgery: a prospective randomized comparison 
between single dose prophylaxis with amoxycillin/clavulanate and the combination 
of cefuroxime and metronidazole. J Antimicrob Chemother., 24 ( suppl B), 213 -216. 
FUCHS, P.C., BARRY, A.L., THORNSBERRY, C. AND JONES, R.N. (1984). In 
vitro activity of ticarcillin plus clavulanic acid against 632 clinical isolates. 
Antimicrob Agents Chemother., 25, 392 -394. 
FURTH, A.J. (1975). Purification and properties of a constitutive ß- lactamase from 
Pseudomonas aeruginosa strain Dalgleish. Biochim Biophys Acta., 377, 431 -443. 
GARROD, L. P., LAMBERT, H.P. & O'GRADY,F. (1981). Cephalosporins. In 
Antibiotic and Chemotherapy, 5th Edn., pp.94 -114. Churchill Livingston, Edinburgh. 
GIAMARELLOU, H., TROUVAS, G., AVLAMI, A, ARAVANTINOS, D. & 
DAIKOS, G.K. (1986). Efficacy of sulbactam plus ampicillin in gynecologic 
infections. Rev Infec Dis., 8 ( suppl 5), 5579 -S582. 
GODFREY, A.J., HATLELID, L. AND BRYAN, L.E. (1984). Correlation between 
lipopolysaccharide structure and permeability resistance in beta -lactam resistant 
Pseudomonas aeruginosa. Antimicrob Agents Chemother., 26, 181 -186. 
GOERING, R.V., SANDERS, C.C., SANDERS, W.E.Jr., GUAY., R. & GUERIN, S. 
(1988). Heterogeneity in ampR -ampC gene interaction in Enterobacter cloacae. Rev 
Infect Dis., 10, 786 -792. 
GOOTZ, T.D., SANDERS, C.C. & GOERING, R.V. (1982). Resistance to 
cefamandole: derepression of ß- lactamases by cefoxitin and mutation in 
243 
Enterobacter cloacae. J Infect Dis., 146, 34 -42. 
GOOTZ, T.D. & SANDERS, C.0 (1983). Characterization of (3- lactamase induction 
in Enterobacter cloacae. Antimicrob Agents Chemother., 23, 91 -97. 
GOOTZ, T.D., JACKSON, D.B. & SHERRIS, J.C. (1984). Development of 
resistance to cephalosporins in clinical strains of Citrobacter spp. Antimicrob Agents 
Chemother., 25, 591 -595. 
GOOTZ, T.D. (1985). Determinatants of microbial resistance to 3- lactam antibiotics. 
Annu Rep Med Chem., 20, 137 -144. 
GRASSI, G.G. (1981). Combined activity of antibiotics. In New Trends in 
Antibiotics: Research and Therapy, Vol.10 (Grassi, G.G. & Sabath, L.D.), pp.203- 
220. Proceedings of the International Symposium on the New trends in Antibiotics 
Research and Therapy, Milan, Italy. Oxford. 
GREENWOOD, D. (1986). An overview of the response of bacteria to 13- lactam 
antibiotics. Rev Infect Dis., 8 (suppl 5), S487 -S495. 
GRUNEBERG, R.N. (1984). Antibiotic sensitivities of urinary pathogens, 1971 -82. J 
Antimicrob Chemother., 14, 17 -23. 
GUTMANN, L., WILLIAMSON, R., MOREAU, N., KITZIS, M -D., COLLATZ, E., 
ACAR, J.F. et al. (1985). Cros- resistance to nalidixic acid, trimethoprim, and 
chloramphenicol associated with alternations in outer membrane proteins of 
Klebsiella, Enterobacter and Serratia. J Infect Dis., 151, 501 -507. 
GUTMANN, L., KITZIS, M.D., BILLOT- KLEIN, D., GOLDSTEIN, F., TRAN 
VAN NHIEU, G., LU, T. et al. (1988). Plasmid- mediated 3- lactamase ('1'EM -7) 
involved in resistance to ceftazidime and aztreonam. Rev Infect Dis., 10, 860 -866. 
GUTMANN, L., FERRE, B., GOLDSTEIN, F.W., RISK, N., PINTO -SCHUSTER, 
E., ACAR, J.F. et al. (1989). SHV -5, a novel SHV- type ß- lactamase that hydrolyzes 
broad -spectrum cephalosporins and monobactams. Antimicrob Agents Chemother., 
33, 951 -956. 
GUTTMAN, D. (1970). Cephalexin in chronic and recurrent urinary infections: 
Laboratory and clinical studies. Postgrad Med J., 46 (Suppl), 75 -79. 
GWYNN, M.N. & ROLINSON, G.N. (1983). Selection of variants Gram -negative 
bacteria with elevated production of type I (3- lactamase. J Antimicrob Chemother., 
11, 577 -581. 
HAKENBECK, R., TARPAY, M. & TOMASZ, A. (1980). Multiple changes of 
penicillin -binding proteins in penicillin- resistant clinical isolates of Streptococcus 
pneumoniae. Antimicrob Agents Chemother. 17, 364 -371. 
HALE, T.L., OAKS, E.V. & FORMAL, S.B. (1985). Identification and antigenic 
Characterisation of virulence associated, plasmid -coded proteins of Shigella spp. and 
enteroinvasive Escherichia coli. Infect Immun., 50, 620 -629. 
HALL, C., CURRAN, F., BURDON, D.W. & KEIGHLEY, M.R.B. (1989). A 
randomized trial to compare amoxycillin/clavulanate with metronidazole plus 
genetamicin in prophylaxis in elective colorectal surgery. J Antimicrob Chemther., 
244 
24 (suppl B), 195 -202. 
HANNINEN, P. & ROSSI, T. (1986). Penetration of sulbactam into cerebrospinal 
fluid of patients with viral meningitis or without meningitis. Rev Infect Dis., 8 (suppl 
5), 5609 -S611. 
HARDER, K.J., NIKAIDO, H. & MATSUSHASHI, M. (1981). Mutants of 
Escherichia coli that are resistant to certain beta -lactam compounds lack the ompF 
porin. Antimicrob Agents Chemother., 20, 549 -552. 
HEDGES, R.W. & JACOB, A.E. (1974). Transposition of ampicillin resistance from 
RP4 to other replicons. MGG., 132, 31 -40. 
HEDGES, R.W., DATTA, N., KONTAMICHALOU, P. & SMITH, J.T. (1974). 
Molecular specificities of R factor -determined beta -lactamases: correlation with 
plasmid compatability. J Bacteriol., 117, 56 -62. 
HEDGES, R.W. & MATTHEW, M. (1979). Acquisition by Escherichia coli of 
plasmid -borne 13- lactamases normally confined to Pseudomonas spp. Plasmid, 2, 
269 -278. 
HEDGE, P.J. & SPRATT, B.G. (1985a). Amino acid substitutions that reduce the 
affinity for penicillin -binding protein 3 of Escherichia coli for cephalexin. Eur J 
Biochem., 151, 111 -121. 
HEDGE, P.J. & SPRATT, B.G. (1985b). Resistance to 0- lactam antibiotics by re- 
modelling the active site of an E.coli penicilin- binding proteins. Nature, 318, 478- 
480. 
HERZBERG, O. & MOULT, J. (1987). Bacterial resistance to 33- lactam antibiotics: 
Crystal structure of (3- lactamase from Staphylococcus aureus PC 1 at 2.5 A° 
resolution. Science, 236, 694 -701. 
HESSLEWOOD, S.R. (1973). Host cell regulation of enzyme production in bacteria 
harbouring R- factors. Ph.D Thesis, London (cited by Reid, A.J -Ph D Thesis, 
Edinburgh). 
HEYMES, R., LUTZ, A. & SCHRINNER, E. (1977). Experimental evaluation of 
HR756, a new cephalosporin derivative: Pre -clinical study. Infection, 5, 259 -260. 
HOLLAND, S. & DALE, J.W. (1985). Immunological comparison between OXA -2 
13- lactamase and those mediated by other R plasmids. Antimicrob Agents 
Chemother., 27, 989 -991. 
HOOVER, J.R.E. (1983). b- lactam antibiotics: structure- activity relationships. In 
Antibiotics Containing the Beta- lactam Structure. Part II. Handbook of Experimental 
Pharmacology, 67 /II (DEMAIN, A.L. AND SOLOMON, N.A. Eds), pp. 119 -246. 
Springer -Verlag. 
HUOVINEN, P., HUOVINEN, S. & JACOBY, G.A. (1988a). 
lactamase. Antimicrob Agents Chemother., 32, 134 -136. 
HUOVINEN, S., HUOVINEN, P. AND JACOBY, G.A. 
plasmid- mediated beta -lactamases with DNA probes. 
Chemother., 32, 175 -179. 
245 
Sequence of PSE -2 ß- 
(1988b). Detection of 
Antimicrob Agents 
IYER, R., DARBY, V. & HOLLAND, I.B. (1978). Alterations in the outer membrane proteins of Escherichia coli B/r associated with the presence of the R plasmid rRM 98. FEBS Lett., 85, 127 -132. 
JACK, G.W. & RICHMOND, M.H. (1970). A comparative study of eight distinct f3- 
lactamases synthesized by Gram- negative bacteria. J Gen Microbiol., 61, 43 -61. 
JACKSON, D., COOPER, D.L., HORTON, R., LANGLEY, P.F., STANIFORTH, 
D.S. & SUTTON, A.J. (1983). Absorption, pharmacokinetic and metabolic studies 
and augmentin. In Augmentin. Clavulanate Potential Amoxycillin (CROYDON, 
E.A.P. AND MICHEL, M.F. Eds), pp.83 -101. Proceedings of the European 
Symposium, Scheveningen, The Netherlands. Excerta Medica, Amsterdam. 
JACOBY, G.A. & SUTTON, L. (1985). f3-lactamases and ß- lactam resistance in 
Escherichia coli. Antimicrob Agents Chemother., 28, 703 -705. 
JACOBY, G.A. (1985). Genetics and epidemiology of resistance. In The Scientific 
Basis of Antimicrobial Chemotherapy (GREENWOOD, D. AND o'GRADY' F. Eds), 
pp.185 -218. Thirty- eighth Symposium for the Society for General Microbiology, 
Nottingham. Cambridge University Press, Cambridge. 
JACOBY, G.A., MEDEIROS, A.A., O'BRIEN, T.F., PINTO, M.E. & JIANG, H. J. 
(1988). Broad -spectrum, transmissible ß- lactamases. N Engl J Med., 319, 723 -724. 
JAFFE, A., CHABBERT, Y.A. & SEMONIN, O. (1982). Role of porin protein ompF 
and ompC in the permeation of 0- lactams. Antimicrob Agents Chemother., 22, 942- 
948. 
JARLIER, V., NICOLAS, M -H., FOURNIER, G. & PHILIPPON, A. (1988). 
Extended broad - spectrum ß- lactamases conferring transferable resistance to newer ß- 
lactam agents in Enterobacteriaceae: hospital prevalence and susceptibility patterns. 
Rev Infect Dis., 10, 867 -878. 
JAURIN, B. & GRUNDSTROM, T. (1981). amp C cephalosporinase of Escherichia 
coli K -12 has a different evolutionary origin from that of f3-lactamases of the 
penicillinase type. Pro Natl Acad Sci USA., 78, 4897 -4901. 
JOLY -GUILLO, M.L., VALLE, E., BERGOGNE -BEREZIN, E. & PHILIPPON, A. 
(1988). Distribution of b- lactamases and phenotype analysis in clinical strains of 
Acinetobacter calcoaceticus. J Antimicrob Chemother., 22, 597 -604. 
JOUVENOT, M., BONIN, P. & MICHEL- BRIAND, Y. (1983). Frequency of ß- 
lactamases that are markedly active against carbenicillin in the Pseudomonas 
aeruginosa strains isolated in a Medical School Hospital. J Antmicrob Chemother., 
12, 451 -458. 
JOUVENOT, M., DESCHASEAUX, M.L., ROYEZ, M., MOUGIN, C., COOKSEY, 
R.C., MICHEL- BRIAND, Y. et al. (1987). Molecular hybridization versus isoelectric 
focusing to determine TEM -type ß- lactamases in Gram- negative bacteria. 
Antimicrob Agents Chemother., 31, 300 -305. 
KASIK, J.E. (1979). Mycobacterial ß- lactamases. In Beta- lactamses (HAMILTON - 
MILLER, J.M.T. AND SMITH, J.T. Eds), pp.339 -350. Academic Press, London. 
KELLY, J.A., DIDEBERG, O., CHARLIER, P., WERY, J.P., LIBERT, M., 
246 
MOEWS, P.C. et al., (1986). On the origin of bacterial resistance to penicillin 
comparison of a 13- lactamase and a penicillin target. Science, 231, 1429 -1431. 
KIM, J -H., CHOI,K -H., KIM, Y -T. & YANG, I -S. (1986). Treatment of infections 
due to multiresistant Neisseria gonorrhoeae with sulbactam/ampicillin. Rev Infect 
Dis., 8 ( suppl 5), S599 -S603. 
KIRBY, W.M.M. (1944). Extraction of a highly potent penicillin inactivator from 
penicillin resistant Staphylococci. Science, 99, 452 -453. 
KIRBY, W.M.M. & AHERN, J.J. (1953). Changing patterns of resistance of 
Staphylococci to antibiotics. Antibiot Chemother., 3, 831 -835. 
KIRBY, W.M.M., ROSENFELD, L.S. & BRODIE, J. (1962). Oxacillin: laboratory 
and clinnical evaluation. JAMA., 181, 739 -744 
KITZIS, M.D., FERRE, B., COUTROT, A., ACAR, J.F. & GUTMANN, L. (1989). 
In vitro activity of combinations of beta -lactam antibiotics with beta -lactamase 
inhibitors against cephalosporinases -producing bacteria. Eur J Clin Microbiol Infect 
Dis., 8, 783 -785. 
KLIEBE, C., NIES, B.A., MEYER, J.F., TOLXDORFF- NEUTZLING, R.M. & 
WIEDEMANN, B. (1985). Evolution of plasmid -coded resistance to broad -spectrum 
cephalosporins. Antimicrob Agents Chemother., 28, 302 -307. 
KNOTHE, H., SHAH, P., KRCMERY, V., ANTAL, M. AND MITSUHASHI, S. 
(1983). Transferable resistance to cefotaxime, cefoxitin, cefamandole and 
cefuroxime in clinical isolates of Klebsiella pneumoniae and Serratia marcescens. 
Infection, 6, 315 -317. 
KNUDSEN, E.T., ROLINSON, G.N. & STEVENS, S. (1961). Absorption and 
excretion of "Penbritin ". Br Med J., 2, 198 -200. 
KNUDSEN, E.T., ROLINSON, G.N. & SUTHERLAND, R. (1967). Carbenicillin: a 
new semi- synthetic penicillin active against Peudomonas pyocyanea. Br Med J., iii, 
75 -78. 
KOBAYASHI, S., ARAI, S., HAYASHI, S. & SAKAGUCHI, T. (1988). Simple 
assay of 3- lactamase with agar medium containing a chromogenic cephalosporin, 
pyridinium- 2- azo- p- dimethylaniline chromophore (PADAC). Antimicrob Agents 
Chemother., 32, 1040 -1045. 
KOMATSU, Y., MURAKAMI, K. & NISHIKAWA, T. (1981). Penetration of 
moxalactam into its target proteins in Escherichia coli K -12: Comparison of a highly 
moxalactam- resistant mutant with its parent strain. Antimicrob Agents Chemother., 
20, 613 -619. 
KONTOMICHALOU, P., MITANI, M. & CLOWES, R.C. (1970). Circular R- factor 
molecules controlling penicillinase synthesis, replicating in Eschrichia coli under 
either relaxed or stringent control. J Bacteriol., 104, 34 -44. 
KORFMANN, G., KLIEBE, C. & WIEDEMANN, B. (1986). b- lactam antibiotics 
and selection of resistance: speculation on the evolution of R- plasmids. J Antimicrob 
Chemother., 18 (suppl C), 113 -121. 
247 
KORFMANN, G. & WIEDEMANN, B. (1988). Genetic control of ß- lactamase 
production in Enterobacter cloacae. Rev Infect Dis., 10, 793 -799. 
KRON, M.A., SHALES, D.M. CURRIE -McCUMBER, C. & MEDEIROS, A.A. 
(1987). Molecular epidemiology of OHI0-1 (3- lactamase. Antimicrob Agents 
CHemother., 31, 2007 -2009. 
LABIA, R., MORAND, A. & PEDUZZI, J. (1986). Timentin and ß- lactamases. J 
Antimicrob Chemother., 17 (suppl c), 17 -26. 
LABIA, R., MORAND, A., TIWARI, K., SIROT, J., SIROT., D. & PETIT, A. 
(1988a). Interactions of new plasmid- mediated ß- lactamases with third -generation 
cephalosporins. Rev Infect Dis., 10, 885 -891. 
LABIA, R., MORAND, A., TIWARI, K., CHANAL, C., SIROT, J. & PITTON, J.S. 
(1988b). Ceftazidimases: comparision of the kinetic properties of five such 3- 
lactamases. In Program and Abstracts of the Twenty -Eight Interscience Conference 
on Antimicribial Agents Chemotherapy, Abstract No 481. American Society for 
Microbiology, Los Angeles. 
LAMBERT, P.A. (1983). The (3- lactam surface and drug resistance. In Medical 
Microbiology, Vol.3 (EASMON, C.S.F., JELJASZEWICZ, J., BROWN, M.R.W. 
AND LAMBERT, P.A. Eds), pp.1 -19. Academic Press, London. 
LEES, L., MILSON., J.A., KNIRSCH, A.K. & GREENHALGH, K. (1986). 
Sulbactam plus ampicillin: Interim review of efficacy and safety for therapeutic and 
prophylactic use. Rev Infect Dis., 8 ( suppl 5), S644 -S650. 
LEIGH, D.A., JOY, G.E., TAIT, S., HARRIS, K. & WALSH, B. (1989). Treatment 
of acute uncomplicated urinary tract infections with single daily doses of cefuroxime 
axetil. J Antimicrob chemother., 23, 267 -273. 
LEVESQUE, R., ROY, P.H., LETARTE, R. & PECHERE, J -C. (1982). A plasmid- 
mediated cephalosporinase from Achromobacter species. J Infect dis., 145, 753 -761. 
LEVESQUE, R.C., MEDEIROS, A.A. & JACOBY, G.A. (1987). Molecular cloning 
and DNA homology of plasmid- mediated beta -lactamase genes. MGG., 206, 252- 
258. 
LEVY, S.B., HEDGES, R.W., SULLIVAN, F., MEDEIROS, A.A. AND 
SOSROSEPUTRO, H. (1985). Multiple antibiotic resistance plasmids in 
Enterobacteriaceae isolated from diarrhoeal specimens of hospitalized children in 
Indonesia. J Antimicrob Chemother., 16, 7 -16. 
LINDBERG, F. & NORMARK, S. (1986). Contribution of chromosomal ß- 
lactamases to ß- lactam resistance in Enterobacteria. Rev Infect Dis., 8 ( suppl 3), 
S292 -S304. 
LINDBERG, F., LINDQUIST, S. & NORMARK, S. (1988). Genetic basis of 
induction and overproduction of chromosomal class I ß- lactamase in nonfastidious 
Gram - negative bacilli. Rev Infect Dis., 10, 782 -785. 
LINEWEAVER, H. & BURK, D. (1934). The determination of enzyme dissociation 
constants. J AM Chem Soc., 56, 658 -666. 
248 
LIVERMORE, D.M., MASKELL, J.P. & WILLIAMS, J.D. (1984). Detection of 
PSE-2 ß-lactamase in Enterobacteria. Antimicrob Agents Chemother., 25, 268-272. 
LIVERMORE, D.M. (1985). Do (3-lactamases "trap" cephalosporins?. J Antimicrob 
Chemother., 15, 511-514. 
LIVERMORE, D.M., MOOSDEEN, F., LINDRIDGE, M.A., KHO, P. & 
WILLIAMS J.D. (1986). Behaviour of TEM -1 ß- lactamase as a resistance 
mechanism to ampicillin, mezlocillin, and azlocillin in Escherichia coli. J 
Antimicrob Chemother., 17, 139 -146. 
LIVERMORE, D..M. (1987a). Chromosomal beta -lactamase induction and stable 
derepression in relation to antibiotic resistance in Gram- negative bacteria. In Beta - 
lactamases: Current Perspectives (LIVERMORE, D.M. Ed), pp.13 -29. Third 
European Congress of Clinical Microbiology, Theracom. Winchester, UK. 
LIVERMORE, D.M. (1987b). Clinical significance of beta -lactamase induction and 
stable derepression in Gram- negative rods. Eur J Clin Microbiol., 6, 439 -445. 
LIVERMORE, D.M. (1987c). "Covalent trapping" and latamoxef resistance in ß- 
lactamase- derepressed Pseudomonas aeruginosa. J Antimicrob Chemother., 20, 7- 
13. 
LIVERMORE, D.M. & YANG, Y -J. (1987). ß- lactamase lability and inducer power 
of newer 13-lactam antibiotics in relation to their activity against ß- lactamase- 
inducibility mutants of Pseudomonas aeruginosa. J Infect Dis., 155, 775 -782. 
LIVERMORE, D.M. (1988). Permeation of ß- lactam antibiotics into Esherichia coli, 
Pseudomonas aeruginosa, and other Gram -negative bacteria. Rev Infect Dis., 10, 
691 -698. 
LIVERMORE, D.M., AKOVA, M., WU, P. & YANG, Y. (1989). Clavulanate and 
ß- lactamase induction. J Antimicrob Chemother., 24 (suppl B), 23 -33. 
LOFFLER, L., BAUERNFEIND, A., KEYL, W., HOFFSTEDT, B., PIERGIES, A. 
& LENZ, W. (1986). An open, comparative study of sulbactam plus ampicillin vs 
cefotaxime as initial therapy for serious soft tissue and bone and joint infections. Rev 
Infect Dis., 8 (suppl 5), 5593 -5598. 
LOWRY, O.H., ROSENBROUGH, N.J., FARR, A.L. & RANDALL, R.J. (1951). 
Protein measurement with the folin phenol reagent. J Biol Chem., 193, 265 -275. 
LYON, B.R. & SKURRAY, R. (1987). Antimicrobial resistance of Staphylococcus 
aureus: Genetic basis. Microbiol Rev., 51, 88 -134. 
MACHKA, K., BRAVENY, I., DABERNAT, H., DORNBUSCH, K., VAN 
DYCK,E., KAYSER, F.H. et al. (1988). Distribution and resistance patterns of 
Haemophilus influenzae: A European cooperative study. Eur J Clin Microbiol Infect 
Dis., 7, 14 -24. 
MALOUIN, F. & BRYAN, L. E. (1986). Modification of penicillin -binding proteins 
as mechanisms of ß- lactam resistance. Antimicrob Agents Chemother., 30, 1 -5. 
MARTINEZ, J.L., CERCENADO, E., RODRIGUEZ- CREIXEMS, M., VINCENTE- 
PEREZ, M.F., DELGADO- IRIBARREN, A. & BAQUERO, F. (1987). Resistance to 
249 
beta -lactam/clavulanate. Lancet, 2, 1473. 
MARTINEZ, J.L., REGUERA, J.A., PEREZ -DIAZ, J.C. & BAQUERO, F. (1988). 
Factors influencing the antibacterial activity of beta -lactams plus beta- lactamase 
inhibitors in Escherichia coli. In Abstracts of the Interscience Conference on 
Antimicrobial Agents Chemotherapy, Abstract no 490. American Society for 
Microbiology, Los Angeles. 
MARTINEZ, J.L., VINCENTE, M.F., DELGADO- IRIBARREN, A., PEREZ -DIAZ, 
J.C. & BAQUERO, F. (1989). Small plasmids are involved in amoxicillin- 
clavulanate resistance in Escherichia coli. Antimicrob Agents Chemother., 33, 595. 
MARUNAKA, T., MANIWA, M., MATSUHASHI, E & MINAMI, Y. (1988). High - 
performance liquid chromatographic determination of a new beta -lactamase inhibitor 
and its metabolite in combination therapy with piperacillin in biological meterials. J 
Chromatogr., 431, 87 -101. 
MATSUMOTO, Y., IKEDA, F., KAMIMURA, T., YOKOTO, Y. & MINE, Y. 
(1988). Novel plasmid- mediated f3- lactamase from Escherichia coli that inactivates 
oxyimino -cephalosporins. Antimicrob Agents Chemother., 32, 1243 -1246 
MATTHEW, M., HARRIS, A.M., MARSHALL., M.J. & ROSS, G.W. (1975). The 
use of analytical isoelectric focusing for detection and identification of 13- lactamases. 
J Gen Micrbiol., 88, 169 -178. 
MATTHEW, M. & HARRIS, A.M. (1976). Identification of ß- lactamases by 
analytical isoelectric focusing: correlation with bacterial taxonomy. J Gen 
Microbiol., 94, 55 -67. 
MATTHEW, M. & SYKES, R.B. (1977). Properties of the beta -lactamase specified 
by the Pseudomonas plasmid RPL11. J Bacteriol., 132, 341 -345. 
MATTHEW, M. (1978). Properties of the ß- lactamase specified by the Pseudomonas 
plasmid R151. FEMS Microbiol Lett., 4, 241 -244. 
MATTHEW, M. (1979). Plasmid- mediated ß- lactamases of Gram- negative bacteria: 
properties and distribution. J Antimicrob Chemother., 5, 349 -358. 
MATTHEW, M., HEDGES, R.W. & SMTTH, J.T. (1979). Types of ß- lactamases 
determined by plasmids in Gram -negative bacteria. J Bacteriol., 138, 657 -662. 
MEDEIROS, A.A., KENT, R.L. & O'BRIEN, T.F. (1974). Characterization and 
prevalence of the different mechanisms of resistance to beta -lactam antibiotics in 
clinical isolates of Escherichia coli. Antimicrob Agents Chemother., 6, 791 -801. 
MEDEIROS, A.A. & O'BRIEN, T. F. (1975). Ampicillin- resistant Haemophilus 
influenzae type B possessing a TEM -type 13- lactamase but little permeability barrier 
to ampicillin. Lancet, 1, 716 -718. 
MEDEIROS, A.A., XIMENEZ, J., BLICKSTEIN- GOLDWORM, K., O'BRIEN, 
T.F. & ACAR, J. (1980). ß- lactamases of ampicillin- resistant Escherichia coli from 
Brazil, France, and the United States. In Current Chemotherapy and Infectious 
Disease, Vol. 1 (NELSON, J. D. and GRASSI, C. Eds), pp.761 -762. American 
Society for Microbiology, Washington, Washington DC. 
250 
MEDEIROS, A.A., GILLEECE, E.S. & O'BRIEN, T.F.(1981). Distribution of plasmids type ß- lactamase from in ampicillin- resistant salmonellae from humans and 
animals in the United States. In Molecular Biology, Pathogenicity, and Ecologgy of Plasmids (LEVY, S.B., CLOWES R.C. and KOENING, E.L. Eds), pp.634. Plenum 
Press, New York. 
MEDEIROS, A.A., HEDGES, R.W. & JACOBY, G.A. (1982). Spread of a 
"Pseudomonas-specific" ß-lactamase to plasmids of Enterobacteria. J Bacteriol., 149, 
700-707. 
MEDEIROS, A.A. (1984). ß- lactamases. Br Med Bull., 40, 18 -27. 
MEDEIROS, A.A., COHENFORD, M. & JACOBY, G.A. (1985). Five novel 
plasmid- determined ß- lactamases. Antimicrob Agents Chemother., 27, 715 -719. 
MEDEIROS, A.A. & JACOBY, G.A. (1986). Beta -lactamase- mediated resistance. In 
Beta -lactam Antibiotics for Clinical Use (QUEENER S.F., WEBBER, J.A. & 
QUEENER, S.W. Eds), pp.49 -84. Dekker, New York. 
MEDEIROS, A.A., O'BRIEN, T.F., ROSENBURG, E.Y. & NIKAIDO, H. (1987). 
Loss of ompC porin in a strain of Salmonella typhimurium cause increased resistance 
to cephalosporins during therapy. J Infect Dis., 156, 751 -757. 
MEDEIROS, A.A. (1987). Beta -lactamases -past, present and future. In Beta - 
lactamases Current Perspectives (LIVERMORE, D.M. Ed), pp.1 -11. Third 
European Congress of Clinical Microbiology. Theracom, Winchester, UK. 
MEDEIROS. A.A., MARTINEZ -BELTRAN, J., PAPA, E.F. and O'GARA, C. 
(1988). Comparative efficacy of beta -lactamase inhibitor /antibiotic combinations 
against clinical isolates of E.coli producing different amounts of beta -lactamase. In 
Abstracts of the 28th Interscience Conference on Antimicrobial Chemotherapy, 
Abstract 491, American Society for Microbiology, Los Angeles. 
MEDEIROS, A.A. (1989). Plasmid- determind beta -lactamases. In Microbial 
Resistance to Drugs. Handbook of Experimental Pharmocology. Vol.91 (Bryan, L.E. 
Ed), pp.101 -127. Springer -Verlag. 
MEIER, H., ADAM, D. & HEILMANN, H -D. (1989). Penetration of 
ticarcillin/clavulanate into cartilage. J Antimicrob Chemother., 24 (suppl B), 101- 
105. 
MENZIES, D., GILBERT, J.M., SHEPHERD, M.J. & ROGERS, T.R. (1989). A 
comparison between amoxycillin/clavulanate and mezlocillin in abdominal surgical 
prophylaxis. J Antimicrob Chemother., 24 (suppl B), 203 -208. 
MEYERS, J.A., SANCHEZ, D., ELWELL, L.P. & FALKOW, S. (1976). Simple 
agarose gel electrophoretic method for the identifiation and characterisation of 
plasmid deoxyribonucleic acid. J Bacteriol., 171, 1529 -1537. 
MEYNELL, E & DATTA, N. (1966). The relation of resistance transfer factors to 
the F- factor (sex- factor) of Escherichia coli K12. Genet Res., 7, 134 -140. 
MILATOVIC, D. & BRAVENY, I (1987). Development of reistance during 
antibiotic therapy. Eur J Clin Microbiol., 6, 234 -244. 
251 
MOOSDEEN, F., WILLIAMS, J.D. & YAMABE, S. (1988). Antibacterial 
characteristics of YTR830, a sulfone 13- lactamase inhibitor, compared with those of 
clavulanic acid and sulbactam. Antimicrob Agents Chemother., 32, 925 -927. 
MOORHOUSE, E.C. (1969). Transferable drug resistance in Enterobacteria isolated 
from urban infants. Br Med J., 2, 405 -407. 
MORIN, C.J., PATEL, P.C., LEVESQUE, R.C. & LETARTE, R. (1987). 
Monoclonal antibodies to TEM -1 plasmid -mediated ß- lactamase. Antimicrob Agents 
Chemother., 31, 1761 -1767. 
MORFIN- OTERO, R., DIAZ, T., ATILANO, G., ESPARZA -AHUMADA, S., 
RODRIGUEZ CHAGOLLAN, J.J. & RODRIGEUZ- NORIEGA, E. (1990). Beta - 
lactamases producing bacteria in a developing country. In Abstracts of the 90th 
Annual Meeting of Soctiey of Microbiology, Abstract No A85. American Society for 
Microbiology, Anaheim, California. 
MOXON, E.R., MEDEIROS, A.A. & O'BRIEN, T.F. (1977). Beta -lactamase effect 
on ampicillin treatment of Haemophilus influenzae B bacteremia and meningitis in 
infant rats. Antimicrob Agents Chemother., 12, 461 -464. 
MUENCH, R., LUETHY R. & SIEGENTHALER, W. (1981). Beta -lactamase 
inhibition by clavulanic acid and other inhibitors with betalactam structure. 
Theoretical aspects and clinical application. In New Trends in Antibiotics: Research 
and Therapy, Vol.10 (GRASSI, G. & SABATH, L.D. EDs) pp.145 -164. Proceedings 
of the International Symposium on New Trends in Antibiotics: Research and 
Therapy. Oxford. 
MUGGLETON, P.W., O'CALLAGHAN, C.H. & STEVENS, W.K. (1964). 
Laboratory evaluation of a new antibiotic cephaloridine (Ceporin). Br Med J., 2, 
1234 -1237. 
MURPHY, D. & TODD, J. (1979). Treatment of ampicillin- resistant Haemophilus 
influenzae in soft tissue infections with high doses of ampicillin. J Pediatr., 94, 983- 
987. 
MURRAY, K. & MURRAY, N.E. (1975). Phage lambda receptor chromosomes for 
DNA fragments made with restriction endonuclease III of Haemophilus influenzae 
and restriction endonuclease I of Escherichia coli. J Mol Biol., 98, p551 -564. 
MURRAY, B.E. & MEDERISKI- SAMAROJ, B. (1983). Transferable ß- lactamase. 
A new mechanism for in vitro penicillin resistance in Streptococcus faecalis. J Clin 
Invest., 72, 1168 -1171. 
MURRAY, B.E., CHURCH, D.A., WANGER, A. ZSCHECK, K., LEVISON, M.E. 
INGERMAN, M.J. et al. (1986). Comparison of two ß- lactamase- producing strains 
of Streptococcus faecalis. Antimicrob Agents Chemother., 30, 861 -864. 
NABER, K.G. & WEI"l'ENBERGER, R. (1986). In vitro activity of aminopenicillins 
combined with sulbactam, clavulanic acid, or amdinocillin against bacteria isolated 
from patients with complicated urinary tract infections. Rev Infec Dis., 8 (suppl 5), 
S604-S608. 
NABER, K.G. (1989). Cefotaxime in urinary tract infections. Infection, 17, 425 -428. 
252 
NANDIVADA, L.S. & AMYES, S.G.B. ( 1989). SAR -2: Identification of a novel plasmid- encoded ß- lactamase from India. FEMS Microbiol Lett., 57, 219 -222. 
NANDIVADA, L.S. & AMYES, S.G.B. (1987). Transferabe resistance to beta - lactam antibiotics in Gram -negative bacteria isolated in India. J Pharm Pharmacol., 39 (suppl), 18P. 
NAYLER, J.H.C. (1987). Review: Resistance to 13- lactams in Gram -negative 
bacteria: relative contributions of ß- lactamase and permeablity limitations. J Antimicrob Chemother., 19, 713 -732. 
NEU, H.C. (1983). Structure -activity relations of new 3- lactam compounds and in 
vitro activity against commen bacteria. Rev Infect Dis., 5 (Suppl 2), S319 -S332. 
NEISS, E.S. (1973). Cephradine -a summery of pre- clinical studies and clinical 
pharmacology. J Irish Med Assoc., 66 (suppl), 1 -12. 
NEU, H.C. & FU, K.P. (1978). Clavulanic acid, a novel inhibitor of 13- lactamases. 
Antimicrob Agents Chemother. 14, 650 -655. 
NICAS, T.I. & HANKCOCK, R.E.W. (1983). Peudomonas aeruginosa outer 
membrane permeability: Isolation of a porin protein F- deficient mutant. J Bacteriol., 
153, 281 -285. 
NICOLAS, M -H., JARLIER, V., HONORE, N., PHILIPPON, A & COLE, S.T. 
(1989). Molecular characterization of the gene encoding SHV -3 [3- lactamase 
resistance in clinical isolates of Klebsiella pneumoniae. Antimicrob Agents 
Chemother.,33, 2096 -2100. 
NIKAIDO, H. & ROSENBERG, E.Y. (1983). Porin channels in Escherichia coli: 
studies with liposomes reconstituted from purified proteins. J Bacteriol., 153, 241- 
252. 
NIKAIDO, H, ROSENBERG, E.Y. & FOULDS, J. (1983). Porin channels in 
Escherichia coli: studies with ß- lactams and intact cells. J Bacteriol., 153, 232 -240. 
NIKAIDO, H. & VAARA, M. (1985). Molecular basis of bacterial outer membrane 
permeability. Microbiol Rev., 49, 1 -32. 
NIKAIDO, H. (1989). Role of the outer membrane of Gram- negative bacteria in 
antimicrobial resistance. In Microbial Resistance to Drugs. Handbook of 
Experimental Pharmacology, Vol. 91 (BRYAN, L.E. Ed), pp.1 -34. Springer -Verlag. 
NISHIDA, M., MATSUBARA, T., MURAKAWA, T., MINE, Y., YOKOTA, Y., 
KUWAHARA, S. et al. (1969). In vitro and in vivo evaluation of cefazolin, a new 
cephalosporin C derivative. Antimicrob Agents Chemother., 9, 236 -243. 
NORD, C.E. & OLSSON- LILJEQUIST. (1984). Anaerobic bacteria and beta -lactam 
antibiotics. Scand J Infect Dis., 42 (Suppl), 72 -82. 
NORD, C.E. (1986). Mechanisms of 13- lactam resistance in anaerobic bacteria. Rev 
Infect Dis., 8 (suppl 5), S543 -548. 
NORD, C.E., BERGAN, T. & THORSTEINSSON, S.B. (1989). Impact of 
ticarcillin /clavulanate on the intestinal microflora. J Antimicrob Chemother., 24 
253 
(suppl B), 221 -226. 
NORMARK, S. & BURMAN, L.G. (1977). Resistance of Escherichih coli to penicillins Fine -structure mapping and dominance of chromosomal beta -1a,,' mutations. J Bacteriol., 132, 1 -7. 
NORMARK, S. EDLUND, T., GRUNDSTROM, T., BERGSTROM, S. & WOLF- WATZ, H. (1977). Escherichla coli K -I2 mutants hyperproducing chromo of beta- lactamase by gene repetitions. J Bacteriol., 132, 912 -922. 
NUGENT, M.E. & HEDGES, R.W. (1979). The nature of the genetic determinant for the SHV -1 3- lactamase. MGG., 175, 239 -243. 
OBWEGESER, J. KUNZ, J., WUST, J., SCHAR, G., STEINER, R & BUCHI, W. (1989). Clinical efficacy of amoxycilllin+clavulanate in laparoscopically coned 
salpingitis. J Antimicrob Chemother., 24 (suppl B), 165 -176. 
O'CALLAGHAN, C.H. & MUGGLETON, P.W. (1963). The formation of 
metabolites from cephalosporin compounds. Biochem J., 89, 304 -308. 
O'CALLAGHAN, C.H., MUGGLETON, P.W. & ROSS, G.W. (1968). Effects of 0- 
lactamase from Gram -negative organisms on cephalosporins and penicillins_ 
Antimicrob Agents Chemother., (HOBBY, G. ED), pp.57 -63. American Society for 
Microbiology. Bethesda. 
O'CALLAGHAN, C.H., MORRIS, A., KIRBY, S.M. & SHINGLER, AIL (1972). 
Novel method for detection of 3- lactamases by using a chromogenic cephalosporin 
substrate. Antimicrob Agents Chemother., 1, 283 -288. 
O'CALLAGHAN, C.H. (1975). Classification of cephalo i e ' 3 by their antibacterial 
activity and pharmacokinetic properties. J Antimicrob Chemother., 1 (suppl), 1 -12. 
O'CALLAGHAN, C.H., SYKES, R.B., GRIFFITHS, A. & THORNTON, J.E. 
(1976). Cefuroxime, a new cephalosporin antibiotic: Activity in vitro. Antimicrob 
Agents Chemother., 9, 511 -519. 
O'CALLAGHAN, C.H. (1979). Description and classification of the newer 
cephalosporins and their relationships with the establihed compounds. J An II taob 
Chemother., 5, 635 -671. 
O'CALLAGHAN, C.H., ACRED, P., HARPER, P.B., RYAN, D.M., KIRBY, SM. 
& HARDING, S.M. (1980). GR20263 a new broad -spectrum cephalosporin with 
anti- pseudomonal activity. Antimicrob Agents Chemother., 17, 876-883 
OLSON, R.H. (1978). Evolution of Pseudornonas R- plasmids: Consequences of Tnl 
insertion and resultant partial diploidy to chromosome and Tra- R- plasmid 
mobilization. J Bacteriol., 133, 210 -216. 
OLSON, B., WEINSTEIN, R.A., NATHAN, C. & KABINS, S.A.(1983). ':'road- 
spectrum 3- lactam resistance in Enterobacter: Emergence during treatment and 
mechanisms of resistance. J Antimicrob Chemother., 11, 299 -310. 
ONISHI, H.R. DAOUST, D.R., ZIMMERMAN, S.B., HENDLIN, D. & STAPLEY, 
E.O. (1974). Cefoxitin, a semi- synthetic cephamycin antibiotic: resistance to beta- 
lactamase inactivation. Antimicrob Agents Chemother., 5, 38-48. 
254 
OUELLE'I "lE, M. & ROY, P.H. (1986). Analysis by using DNA probes of the OXA- 
1 13- lactamase gene and its transposon. Antimicrob Agents Chemother., 30, 46 -51. 
OUELLEFIE, M., BISSONNE'1"1'E, L. & ROY, R.H. (1987). Precise insertion of antibiotic resistance determinants into Tn21 -like transposons: Nucleotide sequence of the OXA -1 ß- 1actamase gene. Pro Natl Acad Sci USA., 84, 7378 -7382. 
OUELLE 11E, M., ROSSI, J.J., BAZIN, R. & ROY, P.H. (1987). Oligonucleotide probes for the detection of TEM -1 and TEM -2 3- lactamase genes and their transposons. Can J Microbiol., 33, 205 -211. 
PARRY, M.F. (1989). Epidemiology and mechanisms of antimicrobial resistance. 
Am J Infect Control., 17, 286 -294. 
PA'1"1'ERSON, J.E., MASECAR, B.L. & ZERVOS, M.L. (1988). Characterization 
and comparison of two penicillinase- producing strains of Streptococcus 
(Enterococcus) faecalis. Antimicrob Agents Chemother., 32, 122 -124. 
PAUL, G., PHILIPPON, A., BARTHELEMY, M., LABIA, R. & NEVOT, P. (1981). 
Immunological distinction between constitutive beta -lactamases of gram- negative 
rods with antisera TEM -1 and CARB -3. In Program and Abstracts of the 21st 
Interscience Conference on Antimicrobial Agents and Chemotherapy. Abstract No. 
681. American Society for Microbiology, Chicago. 
PAUL, G., PHILIPPON, A. & NEVOT, P. (1985). Immunological identification of 
beta -lactamases: specificity of an immune serium anti- OXA -2. Chemioterapia, 4, 31- 
33. 
PAUL, G., GERBAUD, G., BURE, A., PHILIPPON, A., PANGON, B. & 
COURVALIN, P. (1987). Transferable resistance to third- generation cephalosporins 
in Escherichia coli. In Program and Abstracts of the 27th Interscience Conference 
on Antimicrobial Agents and Chemotherapy. Abstract No. 520. American Society for 
Microbiology, New York. 
PAULL, A. & MORGAN, J.R. (1986). Emergence of ceftriaxone- resistant strains of 
Pseudomonas aeruginosa in cystic fibrosis patients. J Antimicrob Chemother., 18, 
635 -639. 
PAYNE, D.J., MARRIOTT, M.S. & AMYES, S.G.B. (1989). TEM-El: a novel ß- 
lactamase conferring resistance to ceftazidime. FEMS Microbiol Lett., 59, 97-100. 
PAYNE, D.J., BLAKEMORE, P.H., DRABU, Y.J. & AMYES, S.G.B. (1989). 
Comparison of TEM-E3 and TEM-5 ß-lactamases. J Antimicrob Chemother., 24, 
615-617. 
PAYNE, D.J., MARRIOTT, M.S. & AMYES, S.G.B. (1990). Characterisation of a 
unique ceftazidime-hydrolysing ß-lactamase, l'EM-E2. J Med Microbiol., 32, 131- 
134. 
PEDERSON, S.S. KOCH, C., HOIBY, N. & ROSENDAL., K. (1986). An epidemic 
spread of multiresistant Pseudomonas aeruginosa in a cystic fibrosis centre. J 
Antimicrob Chemother., 17, 505-516. 
PEDU7.7,I, J., BARTHELEMY, M., TIWARI, K., MATTIONI, D. & LABIA, R. 
255 
(1989). Structural features related to hydrolytic activity against ceftazidime of plasmid- mediated SHV -type CAZ -5 13- lactamase. Antimicrob Agents Chemother., 33, 2160 -2163. 
PERINE, P.L., SCHALLA, W., SIEGAL, M.S., THRONSBERRY, C., BIDDLE, J., WONG, K -H. et al. (1977). Evidence for distinct types of penicillinase- producing 
Neisseria gonorrhoeae. Lancet, 2, 993 -995. 
PETER, K., KORFMANN, G. & WIEDEMANN, B. (1988). Impact of the ampD 
gene and its product on ß- lactamase production in Enterobacter cloacae. Rev Infect 
Dis., 10, 800 -805. 
PETIT, A., SIROT, D.L., CHANAL, C.M., SIROT, J.L., LABIA, R., GERBAUD, G. 
et al. (1988). Novel plasmid- mediated ß- lactamase in clinical isolates of Klebsiella 
pneumoniae more resistant to ceftazidime than to other broad -spectrum 
cephalosporins. Antimicrob Agents Chemother., 32, 626 -630. 
PETROCHEILOU, V., SYKES, R.B. & RICHMOND, M.H. (1977). Novel R- 
plasmid- mediated beta -lactamase from Klebsiella aerugenes. Antimicrob Agents 
Chemother., 12, 126 -128. 
PHILIPPON, A.M., PAUL, G.C. & JACOBY, G.A. (1986). New plasmid- mediated 
oxacillin- hydrolyzing ß- lactamase in Pseudomonas aeruginosa. J Antimicrob 
Chemother., 17, 415 -422. 
PHILIPPON, A., LABIA, R. & JACOBY, G. (1989). Extended -spectrum 13- 
lactamases. Antimicrob Agents Chemother., 33, 1131 -1136. 
PHILIPPON, A., BEN REDJEB, S., FOURNEIR, G. & BEN HASEEN, A. (1989). 
Epidemiology of extended spectrum ß- lactamases. Infection, 17, 347 -354. 
PIDDOCK, L.J.V. & WISE, R. (1985). Newer mechanisms of resistance to (3- lactam 
antibiotics in Gram - negative bacteria. J Antimicrob Chemother., 16, 279 -284. 
POLLLOCK, M.R. (1964). Stimulating and inhibiting antibodies for bacterial 
penicillinase. Immunology, 7, 707 -723. 
POLLOCK, M.R. (1967). Origin and function of penicillinase; a problem in 
biochemical evolution. Br Med J., 4, 71 -77. 
QUINN, J.P., DUDEK, E.J., DiVINCENZO, D.A., LUCKS, D.A. & LERNER, S.A. 
(1986). Emergence of resistance to imipenem during therapy for Pseudomonas 
aeruginosa infections. J Infect Dis., 154, 289 -294. 
QUINN, J.P., DIVINCENZO, D.A. & FOSTER, J. (1987). Emergence of resistance 
to ceftazidime during therapy of Enterobacter cloacae infection. J Infect Dis., 155, 
942 -947. 
QUINN, J.P., MIYASHIRO, D., SAHM, D., FLAMM, R. & BUSH, K. (1989). 
Novel plasmid- mediated 13- lactamase (TEM -10) conferring selective resistance to 
ceftazidime and aztreonam in clinical isolates of Klebsiella pneumoniae. Antimicrob 
Agents Chemother., 33, 1451 -1456. 
READING, C. & COLE, M. (1977). Clavulanic acid: a beta -lactamase- inhibiting 




READING, C. & SLOCOMBE, B. (1986). Augmentin: clavulanate- potentiated amoxicillin. In ß- lactam Antibiotics for Clinical Use. (QUEENER, S.F., WEBBER, J.A. & QUEENER, S.W. EDs), pp.527 -589. Marcel Dekker, New York. 
REID, A.J. (1986). Resistance to beta -lactam antibiotics in Gram -negative bacteria. Ph.D., Thesis. Edinburgh. 
REID, A.J. & AMYES, S.G.B. (1986). Plasmid penicillin resistance in Vibrio cholerae: identification of a new (3- lactamase SAR -1. Antimicrob Agents 
Chemother., 30, 245 -247. 
REID, A.J., SIMPSON, I.N., HARPER, P.B. & AMYES, S.G.B. (1987a). Ampicillin 
resistance in Haemophilus influenzae: Identification of resistance mechanisms. J 
Antimicrob Chemother., 20, 645 -656. 
REID, A.J., SIMPSON, I.N., HARPER, P.B. & AMYES, S.G.B. (1987b). 
Identification and charactrisation of a novel 3- lactamase TLE -2, encoded by plasmid 
pUK702. FEMS Microbiol Lett., 44, 125 -128. 
REID, A.J., SIMPSON, I.N., HARPER, P.B. & AMYES, S.G.B. (1988a). The 
differential expression of genes for the PSE -4 ß- lactamase in Pseudomonas 
aeruginosa and the Enterobacteriaceae. J Antimicrob Chemother., 21, 525 -533. 
REID, A.J., SIMPSON, I.N., HARPER, P.B. & AMYES, S.G.B. (1988b). 
Cephaloridine resistance in Gram- negative bacteria isolated in Scotland. J Pharm 
Pharmacol., 40, 571 -573. 
REINER, R. (1982a). Mechanism of action of antibiotics. In Antibioitcs. An 
Introduction. pp.57 -60. Georg Thieme Verlag, France. 
REINER, R, (1982b). Chemotherapeutic properties of antibiotics. In Antibiotics. An 
Introduction. p67 -91. Georg Thieme Verlag, France. 
RETSEMA, J.A., ENGLISH, A.G. & GIRARD, A.E.(1980). CP- 45,899 in 
combination with penicillin or ampicillin against penicillin- resistant Staphylococcus, 
Haemophilus influenzae and Bacteroides. Antimicrob Agents Chemother., 17, 615- 
622. 
RICHMOND, M.H. (1965). Wild -type variants of exopenicillinase from 
Staphylococcus aureus. Biochem J., 94, 584 -593. 
RICHMOND, M. H. & SYKES, R. (1972). The chromosomal integration of a 0- 
lactamase gene derived from the p -type R- factor RPI in Escherichia coli. Genet Res., 
20, 231 -237. 
RICHMOND, M.H. & SYKES, R.B. (1973). The beta -lactamases of Gram -negative 
bacteria and their possible physiological role. In Advances in Microbial Physiology, 
Vo1..9 (ROSE, A.H. & TEMTPEST, D.W. Eds), pp.31 -38. Academic Press, London. 
RICHMOND, M.H. & CURTIS, N.A. (1974). The interplay of ß- lactamases and 
intrinsic factors in the resistance of Gram -negative bacteria to penicillins and 
cephalosporins. Ann NY Acad Sci., 235, 553 -568. 
257 
ROBERTS, M., ELWELL, L.P. & FALKOW, S. (1977). Molecular characterization of two beta -lactamase- specifying plasmids isolated from Neisseria gonorrhoeae. J Bacteriol., 131, 557 -563. 
RODRIGUEZ, W.J., KHAN, W.N., PUIG, J. FERIS, J., HARMON, S., GOLD, B.G. et al. (1986). Sulbactam/ampicillin vs chloramphenicol/ampicillin for the treatment of meningitis in infants and children. Rev Infect Dis., 8 ( suppl 5), S620 -S629. 
RODRIGUEZ -CREIXEMS, M., CERCENADO, E., NIETO, P., GARCIA, J., RIVERA, M. & BOUZA, E. (1988). Hyperproduction of ß- lactamase as mechanism of E. coli resistance to the combination of amoxicillin +clavulanic acid. In the Abstracts of 28th Interscience Conference on Antimicrobial Agents and Chemotherapy, Abstarct No 489. American Society for Microbiology, Los Angeles. 
ROLINSON. G.N. & STEVENS, S. (1961). Microbiological studies on a new broad - 
spectrum penicillin, "Penbritin ". Br Med J., 2, 191 -198. 
ROSDAHL, V.T. (1973). Naturally occurring constitutive ß- lactamase of novel 
serotype in Staphylococcus aureus. J Gen Microbiol., 77, 229 -231. 
ROSDAHL, V.T., JARLOV, J.O. & KNUDSEN, A.M. (1986). Beta -lactamase 
production in coagulase- negative Micrococcaceae. Acta Pathol Microbiol Scand., 94 
B, 423 -427. 
ROSELLE, G.A., BODE, R., HAMILTON, B., BIBLER, M., SULLIVAN, R., 
DOUCE, R. et al. (1985). Clinical trail of the efficacy and safety of ticarcillin and 
clavulanic acid. Antimicrob Agents Chemother., 27, 291 -296. 
ROSSOUW, F.T. & ROWBURY, R.J. (1984). Effects of the resistance plasmid 
R124 on the level of the OmpF outer membrane protein and on the response of 
Escherichia coli to environmental agents. J Appl Bacteriol., 56, 63 -79. 
ROY, C., FOZ, A., SEGURA, C., TIRADO, M., FUSTER, C. & REIG, R. (1983). 
Plasmid- determined ß- lactamases identified in a group of 204 ampicillin- resistant 
Enterobacteriaceae. J Antimicrob Chemother., 12, 507 -510. 
ROY, C., SEGURA, C., TIRADO, M., REIG, R., HERMIDA, M., TERUEL, D. et 
al. (1985). Frequency of plasmid- determined beta -lactamases in 680 consecutively 
isolated strains of Enterobacteriaceae. Eur J Clin Microbiol., 4, 146 -147. 
ROY, C., SEGURA, C., TORRELLAS, A., REIG, R., TERUEL, D. & HERMIDA, 
M. (1989). Activity of amoxycillin/clavulanate against ß- lactamase producing 
Escherichia coli and Klebsiella spp. J Antimicrob Chemother., 24 (suppl B), 41 -47. 
RUBIN, L.G., MEDEIROS, A.A., YOLKEN, R.H. & MOXON, E.R. (1981). 
Ampicillin treatment failure of apparently ß- lactamase negative Haemophilus 
influenzae type b meningitis due to novel ß- lactamase. Lancet, 2, 1008 -1010. 
RUBIO, M.C., GIL, J., CASTILLO, J., OTAL, I., GOMEZ -LUS, M.L., RUBIO, E. 
et al. (1989). The susceptibility to amoxycillin/ clavulanate of Enterobacteriaceae 
with plasmid- mediated ampicillin resistance: a twelve -year study of strains in one 
Spanish hospital. J Antimicrob Chemother., 24 (suppl B), 35 -40. 
SABATH, L.D. & ABRAHAM, E.P. (1966). Zinc as a cofactor for cephalosporinase 
from Bacillus cereus 569. Biochem J., 98, 11c -13c. 
258 
SAMRAOUI, B., SUTTON, B.J., TODD, R.J., ARTYMIUK, P.J., WALEY, S.G. & PHILLIPS, D.C. (1986). Tertiary structural similarty between a class A ß- lactamase and a penicillin- sensitive L- alanyl carboxypeptidase- transpeptidase. Nature, 320, 378 -380. 
SANDERS C.C. (1983). Novel resistance selected by the new expanded- spectrum cephalosporins: A concern. J Infect Dis., 147, 585 -589. 
SANDERS, C.C. & SANDERS, W.E. Jr. (1985). Microbial resistance to newer generation 13- lactam antibiotics: Clinical and laboratory implications. J Infect Dis., 151, 399 -405. 
SANDERS, C.C. & SANDERS, W.E. Jr. (1986). Trapping and hydrolysis are not mutually exclusive mechanisms for (3- lactamase- mediated resistance. J Antimicrob 
Chemother., 17, 121 -122. 
SANDERS, C.C., SANDERS, W.E. Jr. & MOLAND, E.S. (1986). Characterization 
of 13- lactamases in situ on polyacrylamide gels. Antimicrob Agents Chemother., 30, 
951 -952. 
SANDERS, W.E. JR & SANDERS, C.C. (1988). Inducible ß- lactamases: Clinical 
and epidemiological implications for use of newer cephalosporins. Rev Infect Dis., 
10, 830 -838. 
SANDERS, C.C., IACONIS, J.P., BODEY, G.P. & SAMONIS, G. (1988). 
Resistance to ticarcillin- potassium clavulanate among clinical isolates of the family 
Enterobacteriaceae: role of PSE -1 beta -lactamase and high levels of TEM -1 and 
SHV -1 and problems with false susceptibility in disk diffusion tests. Antimicrob 
Agents Chemother., 32, 1365 -1369. 
SANDERS, C.C. (1989). The chromosomal beta -lactamases. In Microbial Resistance 
to Drugs. Handbook of Experimental Pharmacology, Vol.91 (BRYAN, E.L. Ed), 
pp.129 -149. Springer -Verlag. 
SAUNDERS, J.R. DOCHERTY, A. & HUMPHREYS, G.O. (1984). Transformation 
of bacteria by plasmid DNA. In Methods in Microbiology. Plasmid Technology, 
Vol.17 (BENNETT, P.M. & GRINSTED, J. EDs), pp.61 -97. Academic Press, 
London. 
SAUNDERS, J.R., HART, C.A. & SAUNDERS, V.A. (1986). Plasmid- mediated 
resistance to 13- lactam antibiotics in Gram -negative bacteria: the role of in -vivo 
recyclization reactions in plasmid evolution. J Antimicrob Chemother., 18 (suppl C)., 
57 -66. 
SAWADA, Y., YAGINUMA, S., TAI, M., IYOBE, S. & MITSUHASHI, S. (1974). 
Resistance to 13- lactam antibiotics in Pseudomonas aeruginosa. In Microbial Drug 
Resistance, (MITSUHASHI, S. & HASHIMOTO, H Eds), pp.39. University of 
Tokyo Press, Tokyo. 
SAWAI, T., YAMAGISHI, S. & MITSUHASHI, S. (1973). Penicillinases of 
Klebsiella pneumoniae and their phylogenetic relationship to penicillinase mediated 
by R factors. J Bacteriol., 115, 1045 -1054. 
SAWAI, T., KANNO, M. & TSUKAMOTO, K. (1982). Characterization of eight ß- 
259 
lactamases of Gram -negative bacteria. J Bacteriol., 152, 567 -571. 
SAWAI, T., HIRUMA, R., KAWANA, N., KANEKO, M., TANIYASU, F. & INAMI, A. (1982). Outer membrane permeation of 13-lactam antibiotics in Escherichia coli, Proteus mirabilis and Enterobacter cloacae. Antimicrob Agenta 
Chemother., 22, 585 -592. 
SAWAI, T., YAMAGUCHI, A. & TSUKAMOTO, K. (1988). Amino acid sequence, 
active -site residue, and effect of suicide inhibitors on cephalosporinase of 
Citrobacter freundii GN 346. Rev Infect Dis., 10, 721 -725. 
SAZ, A.K. & LOWERY, D.L. (1979). Do 13-lactamases have a biological function ?. 
In Beta - lactamases (HAMILTON- MILLER, J.M.T. & SMITH, JT. EDs) pp.465- 
479. Academic Press, London. 
SCHMIDT, E.W., ZIMMERMANN, I., RITZERFELD, W., VOSS, E. & ULMER, 
W.T. (1989). Controlled prospective study of oral amoxycillin/ clavulanate versus 
ciprofloxacillin in acute exacerbations of chronic bronchitis. J Antimicrob 
Chemother., 24 ( suppl B), 185 -193. 
SCHMITT, M., BONDONNY, J.M., DELMAS, P. GALIFER, R.B., REVILLON, 
Y., ROBERT, M. et al. (1989). Antibiotic therapy of perforated appendicitis in 
children: A comparison of amoxycillin/ clavulanate with a combination of 
benzylpenicillin, netilmicin and metronidazole. J Antimicrob Chemother., 24 (suppl 
B), 157 -163. 
SEEBERG, A.H., TOLXDORFF -NEUTZLING, R.M. & WIEDEMANN, B. (1983). 
Chromosomal ß- lactamases of Enterobacter cloacae are responsible for resistance to 
third- generation cephalosporins. Antimicrob Agents Chemother., 23, 918 -925. 
SEEBERG, A,H. & WIEDEMANN, B. (1984). Transfer of the chromosomal bla 
gene from Enterobacter cloaceae to Escherichia coli by RP4: Mini Mu. J Bacteriol., 
157, 89 -94. 
SERFASS, D,A., MENDELMAN, P.M., CHAFFIN, D.O. & NEEDHAM, C.A. 
(1986). Ampicillin resistance and penicillin - binding proteins of Haemophilus 
influenzae. J Gen Microbiol., 132, 2855 -2861. 
SHARMA, P.L., SHARMA, K.B. & PRAKASH, K. (1984). Incidence of 
conjugative plasmids amongst multidrug resistant Salmonella typhimurium strains 
isolated from different parts of India (1979- 1982). Indian J Med Res., 79, 473. (cited 
by Young et al., 1986). 
SHALES, D.M., MEDEIROS, A.A., KRON, M.A., CURRIE -McCUMBER, C., 
PAPA, E. & VARTIAN, C.V. (1986). Novel plasmid- mediated ß.lactamase in 
members of the family Enterobacteriaceae from Ohio. Antimicrob Agents 
Chemother., 30, 220 -224. 
SHALES, D.M. & CURRIE- McCUMBER, C.A. (1989). 
The molecular 
epidemiology of antimicrobial resistance. In Microbial Resistance 
to8 
4 s . 
Handbook of Experimental Pharmacology, Vol.91 (BRYAN, L.E. Ed), pp. 
Springer -Verlag. 
SHAOKAT, S., OUELLEFIE, M., SIROT, D., JOLY, 
B. & CLUZEL, R. (1987). 
Spread of SHV -1 13-lactamase in Escherichia coli 
isolated from fecal samples in 
260 
Africa. Antimicrob Agents Chemother., 31, 943 -945. 
SIMONET, M., MOITTIE, D., PHILIPPON, A., DESCAMPS, Ph. & VERON, M. (1989). Synergy of clavulanic acid, sulbactam and tazobactam (YTR 830) with amoxycillin against fifty (3- lactamase- producing strains of Haemophilus influnzae. J Antimicrob Chemother., 23, 798 -800. 
SIMPSON, I.N., HARPER, P.B. & O'CALLAGHAN, C.H. (1980). Principle (3- lactamases responsible for resistance to ß- lactam antibiotics in urinary tract infections. Antimicrob Agents Chemother., 17, 926 -936. 
SIMPSON, I.N., PLESTED, S.J., BUDIN -JONES, M.J., LEES, J., HEDGES, R.W. 
& JACOBY, G.A. (1983). Characterization of a novel plasmid- mediated beta - 
lactamase and its contribution to beta -lactam resistance in Pseudomonas aeruginosa. 
FEMS Microbiol Lett., 19, 23 -27. 
SIMPSON, I.N., KNOTHE, H., PLESTED, S.J. & HARPER, P.B. (1986). 
Qualitative and quantitative aspects of beta -lactamase as mechanisms of beta -lactam 
resistance in a survey of clinical isolates from faecal samples. J Antimicrob 
Chemother., 17, 725 -737. 
SIROT, J., LABIA, R. & THABAUT, A. (1987). Klebsiella pneumoniae strains more 
resistant to ceftazidime than to other third generation cephalosporins. J Antimicrob 
Chemother., 20, 611 -612. 
SIROT, D., SIROT, J., LABIA, R., MORAND, A., COURVALIN, P., 
DARFEUILLE-MICHAUD, A. et al. (1987). Transferable resistance to third- 
generation cephalosporins in clinical isolates of Klebsiella pneumoniae: 
identification of CTX-1, a novel -lactamase. J Antimicrob Chemother., 20, 323-334. 
SIROT, J., CHANAL, C., PETIT, A., SIROT, D., LABIA, R. & GERBAUD, G. 
(1988). Klebsiella pneumoniae and other Enterobacteriacae producing novel 
plasmid- mediated ß- lactamases markedly active against third -generation 
cephalosporins: Epidemiologic studies. Rev Infect Dis., 10, 850 -859. 
SIROT, D., CHANAL, C., LABIA, R., MEYRAN, M., SIROT, J. & CLUZEL, R. 
(1989). Comparative study of five plasmid -mediated ceftazidimases isolated in 
Klebsiella pneumoniae. J Antimicrob Chemother., 24, 509 -521. 
SLACK, M.P.E. & NICHOLS. W.W. (1982). Antibiotic penetration through 
bacterial capsules and exopolysaccharides. J Antimicrob Chemother., 10, 368 -372. 
SMITH, H.W. & HALLS, S (1966). Observation on infective drug resistance in 
Britain. Br Med J., 1, 266 -269. 
SORBELLO, A.F., ECHOLS, R.M. & CONDOLUCI, D.V. (1988). Clinical efficacy 
of one -daily ceftriaxone therapy. Infect Med., 4, 69 -78. 
SOUGAKO! -F, W., GOUSSARD, S., GERBAUD, G. & COURVALIN, P. (1988). 
Plasmid- mediated resistance to third -generation cephalosporins caused by point 
mutations in TEM -type penicillin genes. Rev Infect Dis., 10, 879 -884. 
SPENCER, R.C., WHEAT, P.E., WINSTANLEY, T.G., COX, D.M. & 
PLESTED, 
S.J. (1987). Novel 13-lactamase in a clinical isolate of Klebsiella pneumoniae 




SPRAYT, B.G. & PARDEE, A.B. (1975). Penicillin -binding proteins and cell shape in E.coli. Nature, 254, 516 -517. 
SPRAYT, B.G. (1983). Penicillin- binding proteins and the future of ß- lactam antibiotics. J Gen Microbiol., 129, 1247 -1260. 
SPRAYT, B.G. & CROMIE, K.D. (1988). Penicillin -binding proteins of Gram - negative bacteria. Rev Infect Dis., 10, 699 -711. 
SPRAYT, B.G. (1989). Resistance to ß- lactam antibiotics mediated by alterations of penicillin- binding proteins. In Microbial Resistance to Drugs. Handbook of Experimental Pharmacology, Vol. 91 (BRYAN, L.E. ED), pp.77 -100. Springer - Verlag. 
STAHL, J -P., BRU, J -P., FREDJ, G., BRAMMER, K -W., MALLERET, M -R. & MICOUD, M. (1986). Penetration of sulbactam into the cerebrospinal fluid of 
patients with bacterial meningitis receiving ampicillin therapy. Rev Infect Dis., 8 
(suppl 5), S612 -S616. 
STEWART, G.T. (1960). Microbiological studies on sodium 6 -(2,6 
dimethoxybenzamido) penicillinate monohydrate (BRL 1241) in vitro and in 
patients. Br Med J., 2, 694 -699. 
STOBBERINGH, E.E., HOUBEN, A.W. & VAN BOYEN, C.P.A. (1985). In Recent 
Advances in Chemotherapy (Antimicrobial Section), (ISHIGAMI, J. Ed), pp.423 -424. 
University of Tokyo Press, Tokyo. 
STOBBERINGH, E.E. (1988). Induction of chromosomal beta -lactamases by 
different concentrations of clavulanic acid in combination with ticarcillin. J 
Antimicrob Chemother., 21, 9 -16. 
STUDY GROUP OF INTRAABDOMINAL INFECTIONS. (1986). A randomized 
controlled trail of ampicillin plus sulbactam vs genatamicin plus clindamycin in the 
treatment of intraabdominal infections: A preliminary report. Rev Infect Dis., 8 
(suppl 5), S583 -5588. 
SUGARMAN, B. & PESANTI, E. (1980). Treatment failures secondary to in vivo 
development of drug resistance by microorganisms. Rev Infect Dis., 2, 153 -168. 
SUTCLIFFE, J.G. (1978). Nucleotide sequence of the ampicillin resistance gene of 
Escherichia coli plasmid pBR 322. Proc natl Acad Sci USA., 75, 3737 -3741. 
SUTHERLAND, R., CROYDON, E.A.P. & ROLINSON, G.N. (1970). 
Flucloxacillin, a new isoazolyl penicillin, compared with oxacillin, cloxacillin, and 
dicloxacillin. Br Med J., 4, 455 -460. 
SUTHERLAND, R., CROYDON, E.A.P. & ROLINSON, G.N. (1972). Amoxycillin: 
A new semi - synthetic penicillin. Br Med J., 3, 13 -21. 
SYKES, R.B. & MATTHEW, M. (1976). The ß- lactamases of Gram -negative 
bacteria and their role in resistance to (3- lactam antibiotics. J Antimicrob Chemother., 
2, 115 -157. 
262 
SYKES, R.B. & SMITH, J.T. (1979). Biochemical aspects of 13- lactamases from Gram- negative organisms. In Beta -lactamases, (HAMILTON- MILLER, J.M.T.& SMITH, J.T. EDs), pp.369 -401. Academic Press, London. 
SYKES, R.B. & MATTHEW, M. (1979). Detection, assay and immunology of ß- lactamases. In Beta -lactamases (HAMILTON- MILLER, J.M.T. & SMITH, J.T. EDs), pp.17 -49. Academic Press, London. 
SYKES, R.B., BONNER, D.P., BUSH, K. & GEORGOPAPADAKOU, N.H. (1982). Azthreonam (SQ 26,776), a synthetic monobactam specifically active against aerobic Gram- negative bacteria. Antimicrob Agents Chemother., 21, 85 -92. 
TAKAHASHI, I., TSUKAMOTO, K., HARADA, M. & SAWAI, T. (1983). 
Carbenicillin- hydrolyzing penicillinases of Proteus mirabilis and the the PSE -type 
penicillinases of Pseudomonas aeruginosa. Microbiol Immunol., 27, 995 -1004. 
TAKAHASHI, S. & NAGANO, Y. (1984). Rapid procedure for isolation of plasmid 
DNA and application to epidemiological analysis. J Clin Microbiol., 20, 608 -613. 
TAYLER, D.E. (1989). General properties of resistance plasmids. In Microbial 
Resistance to Drugs. Handbook of Experimental Pharmacology, Vol. 91 (BRYAN, 
L.E. ED), p325 -357. Springer -Verlag. 
THEN, R.L. & ANGEHRN, P. (1982). Trapping of non -hydrolyzable cephalosporins 
by cephalosporinases in Enterobacter cloaceae and Pseudomonas aeruginosa as a 
possible resistance mechanism. Antimicrob Agents Chemother., 21, 711 -717. 
THEN, R.L., CHARNAS, R.L., KOCHER, H.P., MANNEBERG, M., 
ROTHLISBERGER, U. & STOCKER, J. (1988). Biochemical characterization of 
type A and type B ß- lactamase from Enterobacter cloacae. Rev Infect Dis., 10, 714- 
720. 
THORNSBERRY, C. & McDOUGAL., L.K. (1982). Ampicillin- resistant 
Haemophilus influenzae: Incidence, mechanism, and detection. Post Grad Med J., 71, 
133 -145. 
TIMMIS, K.N., GONZALEZ -CARRERO, M.I., SEKIZAKI, T. & ROJO, F. (1986). 
Biological activities specified by antibiotic resistance plasmids. J Antimicrob 
Chemother., 18 (suppl C), 1 -12. 
TOMASZ, A. (1983). Mode of action of (3- lactam antibiotics- A microbiologist's 
view. In Antibiotics Containing the Beta -lactam structure, Part I. Handbook of 
Experimental Pharmacology, Vol.67/I ( DEMAIN, A.L. & SOLOMON, N.A. Eds), 
pp.15 -96. Spinger -Verlag. 
TOMASZ, A. (1986). Penicillin -binding proteins and the antibacterial effectiveness 
of 13- lactam antibiotics. Rev Infect dis., 8 (suppl 3), S260 -S278. 
TSURUOKA, T., YAMADA, Y., GOI, H., MIYAUCHI, K., MIYATA, A. & 
INOUYE, S. (1985). The Bacteriolytic action of MT -141, a new cephamycin 
antibiotic, on Gram -negative bacteria. J Antimicrob Chemother., 15, 159 -171. 
TUAMANEN, E. & SCHWARTZ, J. (1987). Penicillin- binding protein, 7 and 
its 
relationship to lysis of nongrowing Escherichia coli. J Bacteriol., 169, 4912 -4915. 
263 
TURCK, M. (1988). Clinical application of the newer beta -lactam antibiotics. J Antimicrob Chemother., 22 (suppl A), 45 -62. 
UBUKATA, K., YAMASHITA, N. & KONNO, M. (1985). Occurrence of a ß- lactam- inducible penicillin- binding protein in methicillin -resistant Staphylococci. Antimicrob Agents Chemother., 27, 851 -857. 
VECOLI, C., PREVOST, F. E., VERVERIS, J.J., MEDEIROS, A.A. & O'LEARY, G.P.Jr. (1983). Comparison of polyacrylamide and agarose gel thin -layer focusing for the characterization of (3- lactamases. Antimicrob Agents Chemother., 24, 186- 189. 
VEDEL,G., PAUL, G. & PICARD, B. (1988). Electrophoretic behaviour of beta - lactamases in Gram -negative bacteria. Pathol Biol., 36, 250 -254. 
VEDEL, G., PICARD, B., PAUL, G., PHILIPPON, A., GILLY, L., 
KRISHNAMOORTHY, R. et al. (1989). Analysis of the molecular relatedness of 
four extended spectrum (3- lactamases (SHV -2, SHV -3, SHV -4 and SHV -5) by 
comparative protein titration curves. J Antimicrob Chemother., 24, 9 -17. 
VU, H. & NIKAIDO, H. (1985). Role of ß- lactam hydrolysis in the mechanism of 
resistance of a ß- lactamase -constitutive Enterobacter cloacae strain to expanded - 
spectrum (3- lactams. Antimicrob Agents Chemother., 27, 393 -398. 
VUYE, A., VERSCHRAEGEN, G. & CLAEYS, G. (1989). Plasmid- mediated beta - 
lactamases in clinical isolates of Klebsiella pneumoniae and Escherichia coli 
resistant to ceftazidime. Antimicrob Agents Chemother., 33, 757 -761. 
WADDELL, W.J. (1956). A sample ultraviolet spectrophotometric method for the 
determination of protein. J Lab Clin Med., 48, 311 -314. 
WALD, E., REILLY, J.S., BLUESTONE, C.D. & CHIPONIS, D. (1986). 
Sulbactam/ampicillin in the treatment of acute epiglottitis in children. Rev Infect 
Dis., 8 (suppl 5), S617 -S619. 
WANG, P -Z. & NOVICK, R.P. (1987). Nucleotide sequence and expression of the 
(3- lactamase gene from Staphylococcus aureus plasmid pI258 in Escherichia coli, 
Bacillus subtilis, and Staphylococcus aureus. J Bacteriol., 169, 1763 -1766. 
WATANABE, T., FURUSE, C. & SAKAIZUMI, S. (1968). Transduction of various 
R factors by phage PI in Escherichia coli and by phage P22 in Salmonella 
typhimurium. J Bacteriol., 96, 1791 -1795. 
WAXMAN, D.J., AMANUMA, H. & STROMINGER, J.L. (1982). Amino acid 
sequence homologies between Escherichia coli penicillin- binding protein 5 and class 
Ap- lactamases. FEBS Lett., 139, 159 -163. 
WAXMAN, D.J. & STROMINGER, J.L. (1983). Penicillin -binding proteins and the 
mechanisms of action of (3- lactam antibiotics. Annu Rev Biochem., 52, 825 -869. 
WEINSTEIN, R.A. (1985). Occurrence of cefotaxime -resistant Enterobacter during 
therapy of cardiac surgery patients. Chemioterapia, 4, 110 -112. 
WEISMEIER, K., ADAM, D., HEILMANN, H -D. & KOEPPE, P. 
(1989). 
Penetration of amoxycillin /clavulanate into human bone. J Antimicrob 
Chemother., 
264 
24 (suppl B), 93 -100. 
WERNER, V., SANDERS, C.C., SANDERS, W.E. Jr. & GOERING, R.V. (1985). Role of ß- lactamases and outer membrane proteins in multiple ß- lactam resistance of Enterobacter cloacae. Antimicrob Agents Chemother., 27, 455 -459. 
WERNER, H., HEIZMANN, W.R., FREUER, G., MITINIS, N. & HEILMANN, F. (1989). Efficacy of clavulanate- potentiated antibiotics against Bacteroides species 
and artificially associated cultures of aerobes and anaerobes. J Antimicrob 
Chemother., 24 (suppl B), 55 -61. 
WICK, W.E. & PRESTON, D.A. (1972). Biological properties of 3- heterocyclic- 
thiomethyl cephalosporin antibiotics. Antimicrob Agents Chemother., 1, 221 -234. 
WIEDEMANN, B. (1981). Development of bacterial resistance to antibiotics. In New 
Trends in Antibiotics: Research and Therapy, Vol.10 (GRASSI, G.G. & SABATH, 
L.D. EDs), pp.179 -202. Proceedings of the International Symposium on New Trends 
in Antibiotics: Research and Therapy . Oxford. 
WIEDEMANN, B. (1986). Genetic and biochemical basis of resistance of 
Enterobacteriaceae to P- lactam antibiotics. J Antimicrob Chemother., 18 (suppl B), 
31 -38. 
WIEDEMANN, B., KLIEBE, C. & KRESKEN, M. (1989). The epidemiology of ß- 
lactamases. J Antimicrob Chemother., 24 (suppl B), 1 -22. 
WTI J JAMS, J.D. & ANDREWS, J. (1974). Sensitivity of Haemophilus influenzae to 
antibiotics. Br Med J., 1, 134 -137. 
WILLIAMS, H., KING, A., SHANNON, K. & PHILLIPS, I. (1988). 
Amoxycillin/clavulanate resistant Escherichia coli. Lancet, 1, 304 -305. 
WISE, R., ANDREWS, J.M. & BEDFORD, K.A. (1980). Clavulanic acid and CP- 
45,899: A comparison of their in vitro activity in combination with penicillins. J 
Antimicrob Chemother., 6, 197 -206. 
WOODRUFF, W.A., PARR., T.R.Jr., HANCOCK, R.E.W., HANNE, L.F., NICAS, 
T.I. & IGLEWSKI, B.H. (1986). Expression in Escherichia coli and function of 
Pseudomonas aeruginosa outer membrane porin protein F. J Bacteriol., 167, 473- 
479. 
YAMAGUCHI, A., HIRUMA, R. & SAWAI, T. (1982). Phospholipid bilayer 
permeability of beta -lactam antibiotics. J Antibiot (Tokyo), 35, 1692 -1699. 
YAMAGUCHI, A., TOMIYAMA, N., HIRUMA., R. & SAWAI, T. (1985). 
Difference in pathways of Escherichia coli outer membrane permeation between 
penicillins and cephalosporins. FEBS Lett., 181, 143 -148. 
YANG, Y.J., JACOBY, G.A. & LIVERMORE, D.M. (1988). 
LXA -1: a new 
plasmid- mediated ß- lactamase giving low -level resistance, FEMS 
Microbiol Lett., 
52, 97 -102. 
YOSHIMURA, F. & NIKAIDO, H. (1985). Diffusion of ß- lactam 
antibiotics through 
the porin channels of Escherichia coli K -12. Antimicrob Agents 
chemother., 27, 84- 
92. 
265 
YOUNG, H -K., JESUDASON, M.V., KOSHI, G. & AMYES, S.G.B. (1986). 
Trimethoprim resistance amongst urinary bacteria in South India. J Antimicrob 
Chemother., 17, 615 -621. 
YOUNG, H -K., NANDIVADA, L.S. & AMYES, S.G.B. (1989). Antibiotics 
resistance in the tropics. The genetics of bacterial ampicillin resistance in tropical 
areas. Trans R Soc Trop Med Hyg., 83, 38 -41. 
ZIMMERMANN, W. & ROSSELET, A. (1977). Function of the outer membrane of 
Escherichia coli as a permeability barrier to beta -lactam antibiotics. Antimicrob 
Agents Chemother., 12, 368 -372. 
266 
